0001437749-23-005222.txt : 20230302 0001437749-23-005222.hdr.sgml : 20230302 20230302161547 ACCESSION NUMBER: 0001437749-23-005222 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 103 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230302 DATE AS OF CHANGE: 20230302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASENSUS SURGICAL, INC. CENTRAL INDEX KEY: 0000876378 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 112962080 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19437 FILM NUMBER: 23699112 BUSINESS ADDRESS: STREET 1: 1 TW ALEXANDER DRIVE STREET 2: SUITE 160 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-765-8400 MAIL ADDRESS: STREET 1: 1 TW ALEXANDER DRIVE STREET 2: SUITE 160 CITY: DURHAM STATE: NC ZIP: 27703 FORMER COMPANY: FORMER CONFORMED NAME: TRANSENTERIX, INC. DATE OF NAME CHANGE: 20190712 FORMER COMPANY: FORMER CONFORMED NAME: TRANSENTERIX INC. DATE OF NAME CHANGE: 20131210 FORMER COMPANY: FORMER CONFORMED NAME: SafeStitch Medical, Inc. DATE OF NAME CHANGE: 20080211 10-K 1 asxc20221231_10k.htm FORM 10-K asxc20221231_10k.htm
0000876378 ASENSUS SURGICAL, INC. false --12-31 FY 2022 0.001 0.001 750,000,000 750,000,000 236,895,440 236,895,440 235,218,552 235,218,552 0.01 0.01 25,000,000 25,000,000 0 0 0 0 1.1 1 3 2 3 10 1 10 1 6 15.0 25.0 5 4 1 1 4 0 0 436 0 10 4.5 Includes investments that are readily convertible to cash with original maturities of 90 days or less. 00008763782022-01-012022-12-31 iso4217:USD 00008763782022-06-30 xbrli:shares 00008763782023-02-24 thunderdome:item 00008763782022-12-31 00008763782021-12-31 0000876378us-gaap:IntellectualPropertyMember2022-12-31 0000876378us-gaap:IntellectualPropertyMember2021-12-31 iso4217:USDxbrli:shares 0000876378us-gaap:ProductMember2022-01-012022-12-31 0000876378us-gaap:ProductMember2021-01-012021-12-31 0000876378us-gaap:ServiceMember2022-01-012022-12-31 0000876378us-gaap:ServiceMember2021-01-012021-12-31 0000876378asxc:LeaseMember2022-01-012022-12-31 0000876378asxc:LeaseMember2021-01-012021-12-31 00008763782021-01-012021-12-31 0000876378us-gaap:CommonStockMember2020-12-31 0000876378us-gaap:TreasuryStockMember2020-12-31 0000876378us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000876378us-gaap:RetainedEarningsMember2020-12-31 0000876378us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 00008763782020-12-31 0000876378us-gaap:CommonStockMember2021-01-012021-12-31 0000876378us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-31 0000876378us-gaap:RetainedEarningsMember2021-01-012021-12-31 0000876378us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-31 0000876378us-gaap:TreasuryStockMember2021-01-012021-12-31 0000876378us-gaap:CommonStockMember2021-12-31 0000876378us-gaap:TreasuryStockMember2021-12-31 0000876378us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000876378us-gaap:RetainedEarningsMember2021-12-31 0000876378us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0000876378us-gaap:CommonStockMember2022-01-012022-12-31 0000876378us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0000876378us-gaap:RetainedEarningsMember2022-01-012022-12-31 0000876378us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-31 0000876378us-gaap:TreasuryStockMember2022-01-012022-12-31 0000876378us-gaap:CommonStockMember2022-12-31 0000876378us-gaap:TreasuryStockMember2022-12-31 0000876378us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000876378us-gaap:RetainedEarningsMember2022-12-31 0000876378us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 xbrli:pure 0000876378us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberasxc:OneCustomerMember2022-01-012022-12-31 0000876378us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberasxc:ThreeCustomersMember2021-01-012021-12-31 0000876378us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberasxc:CustomerOneMember2021-01-012021-12-31 0000876378us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberasxc:CustomerTwoMember2021-01-012021-12-31 0000876378us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberasxc:CustomerThreeMember2021-01-012021-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberasxc:OneCustomerMember2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberasxc:TwoCustomersMember2021-01-012021-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberasxc:CustomerOneMember2021-01-012021-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberasxc:CustomerTwoMember2021-01-012021-12-31 utr:Y 0000876378us-gaap:PatentsMember2022-01-012022-12-31 0000876378us-gaap:DevelopedTechnologyRightsMembersrt:MinimumMember2022-01-012022-12-31 0000876378us-gaap:DevelopedTechnologyRightsMembersrt:MaximumMember2022-01-012022-12-31 0000876378us-gaap:IntellectualPropertyMember2022-01-012022-12-31 0000876378asxc:OperatingLeaseAssetsMember2022-01-012022-12-31 0000876378asxc:MachineryManufacturingAndDemonstrationEquipmentMembersrt:MinimumMember2022-01-012022-12-31 0000876378asxc:MachineryManufacturingAndDemonstrationEquipmentMembersrt:MaximumMember2022-01-012022-12-31 0000876378us-gaap:ComputerEquipmentMember2022-01-012022-12-31 0000876378us-gaap:FurnitureAndFixturesMember2022-01-012022-12-31 0000876378us-gaap:LeaseholdImprovementsMembersrt:MinimumMember2022-01-012022-12-31 0000876378us-gaap:LeaseholdImprovementsMembersrt:MaximumMember2022-01-012022-12-31 0000876378srt:MinimumMember2022-12-31 0000876378srt:MaximumMember2022-12-31 0000876378asxc:PaycheckProtectionProgramCaresActMember2021-06-102021-06-10 0000876378us-gaap:LetterOfCreditMember2022-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMember2022-12-31 iso4217:EUR 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMember2022-01-012022-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMembersrt:MinimumMember2022-01-012022-12-31 0000876378asxc:SystemsMembercountry:US2022-01-012022-12-31 0000876378asxc:SystemsMembercountry:US2021-01-012021-12-31 0000876378asxc:InstrumentsAndAccessoriesMembercountry:US2022-01-012022-12-31 0000876378asxc:InstrumentsAndAccessoriesMembercountry:US2021-01-012021-12-31 0000876378us-gaap:ServiceMembercountry:US2022-01-012022-12-31 0000876378us-gaap:ServiceMembercountry:US2021-01-012021-12-31 0000876378asxc:LeaseMembercountry:US2022-01-012022-12-31 0000876378asxc:LeaseMembercountry:US2021-01-012021-12-31 0000876378country:US2022-01-012022-12-31 0000876378country:US2021-01-012021-12-31 0000876378asxc:SystemsMemberus-gaap:NonUsMember2022-01-012022-12-31 0000876378asxc:SystemsMemberus-gaap:NonUsMember2021-01-012021-12-31 0000876378asxc:InstrumentsAndAccessoriesMemberus-gaap:NonUsMember2022-01-012022-12-31 0000876378asxc:InstrumentsAndAccessoriesMemberus-gaap:NonUsMember2021-01-012021-12-31 0000876378us-gaap:ServiceMemberus-gaap:NonUsMember2022-01-012022-12-31 0000876378us-gaap:ServiceMemberus-gaap:NonUsMember2021-01-012021-12-31 0000876378asxc:LeaseMemberus-gaap:NonUsMember2022-01-012022-12-31 0000876378asxc:LeaseMemberus-gaap:NonUsMember2021-01-012021-12-31 0000876378us-gaap:NonUsMember2022-01-012022-12-31 0000876378us-gaap:NonUsMember2021-01-012021-12-31 0000876378asxc:SystemsMember2022-01-012022-12-31 0000876378asxc:SystemsMember2021-01-012021-12-31 0000876378asxc:InstrumentsAndAccessoriesMember2022-01-012022-12-31 0000876378asxc:InstrumentsAndAccessoriesMember2021-01-012021-12-31 00008763782023-01-012022-12-31 0000876378srt:MinimumMember2023-01-012022-12-31 0000876378srt:MaximumMember2023-01-012022-12-31 0000876378us-gaap:CommercialPaperMember2022-12-31 0000876378us-gaap:CorporateDebtSecuritiesMember2022-12-31 0000876378us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-31 0000876378us-gaap:CommercialPaperMember2021-12-31 0000876378us-gaap:CorporateDebtSecuritiesMember2021-12-31 0000876378us-gaap:FairValueInputsLevel1Member2022-12-31 0000876378us-gaap:FairValueInputsLevel2Member2022-12-31 0000876378us-gaap:FairValueInputsLevel3Member2022-12-31 0000876378us-gaap:FairValueInputsLevel1Member2021-12-31 0000876378us-gaap:FairValueInputsLevel2Member2021-12-31 0000876378us-gaap:FairValueInputsLevel3Member2021-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2022-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2021-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2022-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2021-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberasxc:MeasurementInputCurrencyExchangeRateMember2022-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberasxc:MeasurementInputCurrencyExchangeRateMember2021-12-31 0000876378us-gaap:WarrantMember2020-12-31 0000876378us-gaap:WarrantMember2021-01-012021-12-31 0000876378us-gaap:WarrantMember2021-12-31 0000876378us-gaap:WarrantMember2022-01-012022-12-31 0000876378us-gaap:WarrantMember2022-12-31 0000876378asxc:MachineryManufacturingAndDemonstrationEquipmentMember2022-12-31 0000876378asxc:MachineryManufacturingAndDemonstrationEquipmentMember2021-12-31 0000876378asxc:OperatingLeaseAssetsMember2022-12-31 0000876378asxc:OperatingLeaseAssetsMember2021-12-31 0000876378us-gaap:ComputerEquipmentMember2022-12-31 0000876378us-gaap:ComputerEquipmentMember2021-12-31 0000876378us-gaap:FurnitureAndFixturesMember2022-12-31 0000876378us-gaap:FurnitureAndFixturesMember2021-12-31 0000876378us-gaap:LeaseholdImprovementsMember2022-12-31 0000876378us-gaap:LeaseholdImprovementsMember2021-12-31 0000876378us-gaap:ConstructionInProgressMember2022-12-31 0000876378us-gaap:ConstructionInProgressMember2021-12-31 0000876378us-gaap:DevelopedTechnologyRightsMember2022-12-31 0000876378us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-31 0000876378us-gaap:DevelopedTechnologyRightsMember2021-12-31 0000876378us-gaap:TechnologyBasedIntangibleAssetsMember2021-12-31 0000876378us-gaap:DevelopedTechnologyRightsMembersrt:WeightedAverageMember2022-01-012022-12-31 0000876378us-gaap:TechnologyBasedIntangibleAssetsMembersrt:WeightedAverageMember2022-01-012022-12-31 0000876378us-gaap:DevelopedTechnologyRightsMembersrt:WeightedAverageMember2021-01-012021-12-31 0000876378us-gaap:TechnologyBasedIntangibleAssetsMembersrt:WeightedAverageMember2021-01-012021-12-31 0000876378us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-31 0000876378us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-31 0000876378srt:MinimumMember2021-12-31 0000876378srt:MaximumMember2021-12-31 0000876378asxc:StartupCostsAndOtherIntangiblesMember2022-12-31 0000876378asxc:StartupCostsAndOtherIntangiblesMember2021-12-31 0000876378us-gaap:ResearchMember2022-12-31 0000876378us-gaap:ResearchMember2021-12-31 0000876378us-gaap:DomesticCountryMemberasxc:ImpactOf382OwnershipChangesMember2022-01-012022-12-31 0000876378us-gaap:StateAndLocalJurisdictionMemberasxc:ImpactOf382OwnershipChangesMember2022-01-012022-12-31 0000876378us-gaap:DomesticCountryMember2022-12-31 0000876378us-gaap:DomesticCountryMember2022-01-012022-12-31 0000876378us-gaap:StateAndLocalJurisdictionMember2022-12-31 0000876378us-gaap:DomesticCountryMemberus-gaap:ResearchMember2022-12-31 0000876378us-gaap:DomesticCountryMemberus-gaap:ResearchMember2022-01-012022-12-31 0000876378us-gaap:ForeignCountryMemberus-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember2022-12-31 0000876378us-gaap:ForeignCountryMemberus-gaap:LuxembourgInlandRevenueMember2022-12-31 0000876378us-gaap:ForeignCountryMemberus-gaap:SwissFederalTaxAdministrationFTAMember2022-12-31 0000876378us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMember2022-12-31 0000876378asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember2021-07-222021-07-22 0000876378asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember2022-12-31 0000876378asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember2022-01-012022-12-31 0000876378srt:MinimumMember2022-01-012022-12-31 0000876378srt:MaximumMember2022-01-012022-12-31 0000876378srt:MinimumMember2021-01-012021-12-31 0000876378srt:MaximumMember2021-01-012021-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2021-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2022-12-31 0000876378us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0000876378us-gaap:EmployeeStockOptionMember2021-01-012021-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-31 0000876378asxc:PerformanceRestrictedStockUnitMember2022-01-012022-12-31 0000876378asxc:PerformanceRestrictedStockUnitMember2021-01-012021-12-31 0000876378us-gaap:EmployeeStockOptionMember2022-12-31 0000876378asxc:The2020ATMOfferingMember2020-10-09 0000876378asxc:PublicOfferingMember2021-01-292021-01-29 0000876378asxc:PublicOfferingMember2021-01-29 0000876378asxc:RegisteredDirectOfferingMember2021-01-122021-01-12 0000876378asxc:RegisteredDirectOfferingMember2021-01-12 0000876378asxc:The2021ATMOfferingMember2021-05-19 0000876378asxc:The2021And2020ATMOfferingMember2021-01-012021-12-31 0000876378asxc:The2021And2020ATMOfferingMember2021-12-31 0000876378asxc:The2022AtmOfferingMember2022-03-18 0000876378asxc:The2022AtmOfferingMember2022-01-012022-12-31 0000876378us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0000876378us-gaap:EmployeeStockOptionMember2021-01-012021-12-31 0000876378us-gaap:WarrantMember2022-01-012022-12-31 0000876378us-gaap:WarrantMember2021-01-012021-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberasxc:LicenseAndSupplyAgreementMember2022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembercountry:US2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:US2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembercountry:CH2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:CH2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembercountry:IT2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:IT2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMemberasxc:OtherCountriesInEmeaMember2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMemberasxc:OtherCountriesInEmeaMember2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMemberasxc:EuropeMiddleEastAndAfricaMember2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMemberasxc:EuropeMiddleEastAndAfricaMember2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembercountry:US2021-01-012021-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:US2021-01-012021-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembercountry:CH2021-01-012021-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:CH2021-01-012021-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembercountry:IT2021-01-012021-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:IT2021-01-012021-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMemberasxc:OtherCountriesInEmeaMember2021-01-012021-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMemberasxc:OtherCountriesInEmeaMember2021-01-012021-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMemberasxc:EuropeMiddleEastAndAfricaMember2021-01-012021-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMemberasxc:EuropeMiddleEastAndAfricaMember2021-01-012021-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2021-01-012021-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2021-01-012021-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2021-01-012021-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2021-01-012021-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2021-01-012021-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2021-01-012021-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2021-01-012021-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2021-01-012021-12-31 0000876378asxc:AsensusSurgicalEuropeSrlMemberasxc:ServiceSupplyAgreementMemberasxc:OneMedSaMember2022-01-012022-12-31 0000876378asxc:AsensusSurgicalEuropeSrlMemberasxc:ServiceSupplyAgreementMemberasxc:OneMedSaMember2021-01-012021-12-31
 

Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

OR

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                     

 

Commission File Number 0-19437

_____________________________________________________________

ASENSUS SURGICAL, INC.

(Exact name of registrant as specified in its charter)

_____________________________________________________________

 

Delaware

11-2962080

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

 

1 TW Alexander Drive, Suite 160, Durham, NC 27703

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (919) 765-8400

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange where registered

Common Stock
$0.001 par value per share

 

ASXC

 

NYSE American

 

Securities registered pursuant to Section 12(g) of the Act:

 

None

(Title of class)

___________________________________________

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒.

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  ☒.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐.

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐.

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

 

Accelerated filer

☐

Non-accelerated filer

☒

 

Smaller reporting company

☒

   

Emerging growth company

☐

 

 
Table of Contents

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b) ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)    Yes  ☐    No  ☒.

 

On June 30, 2022, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value (based on the average bid and asked price of its common stock on that date) of the voting stock held by non-affiliates of the registrant was $93.1 million.

 

The number of shares outstanding of the registrant’s common stock as of February 24, 2023 was 239,279,746.

 

Documents Incorporated By Reference: Part III of this Annual Report on Form 10-K is incorporated by reference to our proxy statement to be filed in respect of our 2023 Annual Meeting of Stockholders

 

 
Table of Contents
 

 

ASENSUS SURGICAL, INC.

ANNUAL REPORT ON FORM 10-K

 

DECEMBER 31, 2022

 

Table of Contents

 

   

Page

PART I

    

ITEM 1.

BUSINESS

5

ITEM 1.A.

RISK FACTORS

22

ITEM 1.B.

UNRESOLVED STAFF COMMENTS

 36

ITEM 2.

PROPERTIES

 36

ITEM 3.

LEGAL PROCEEDINGS

 37

ITEM 4.

MINE SAFETY DISCLOSURES

 37
     

PART II

    

ITEM 5.

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 38

ITEM 6.

RESERVED

 38

ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 39

ITEM 7.A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 48

ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 49

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 76

ITEM 9.A.

CONTROLS AND PROCEDURES

 76

ITEM 9.B.

OTHER INFORMATION

 77

ITEM 9.C.

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 77
     

PART III

    

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

 78

ITEM 11.

EXECUTIVE COMPENSATION

 79

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 80

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 81

ITEM 14.

PRINCIPAL ACCOUNTING FEES AND SERVICES

 82
     

PART IV

    

ITEM 15.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

83

ITEM 16.

FORM 10-K SUMMARY

85

 

i
Table of Contents
 

 

FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K, or Annual Report, contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 21E of the Securities Exchange Act of 1934, as amended or the Exchange Act. Such forward-looking statements contain information about our expectations, beliefs or intentions regarding our product development and commercialization efforts, business, financial condition, results of operations, strategies or prospects. You can identify forward-looking statements by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.

 

Many factors could cause our actual operations or results to differ materially from the operations and results anticipated in forward-looking statements. These factors include, but are not limited to:

 

 

•

our history of operating losses;

 

 

•

our ability to continue as a going concern within one year from the date that these financial statements are issued as a result of anticipated capital needs, in conjunction with past recurring losses and an accumulated deficit;

 

 

•

our ability to successfully develop, clinically test and commercialize new products and services;

 

 

•

our ability to successfully finalize collaboration agreements;

 

 

•

our ability to successfully implement our Performance-Guided Surgery™ strategy and grow our business as a result;

 

 

•

our ability to successfully grow the sales and distribution of our products;

 

 

•

our ability to increase use of our products by existing and new customers;

 

 

•

competition from existing and new market entrants;

 

 

•

our ability to identify and pursue development of additional products;

 

 

•

the timing and outcome of the regulatory review process for our products and product candidates;

 

 

•

the impact of foreign currency fluctuations on our financial results;

 

 

•

our ability to attract and retain key management, marketing and scientific personnel;

 

 

•

our ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights;

 

 

•

changes in the healthcare regulatory environments of the United States, Europe and other jurisdictions in which the Company operates; and

 

 

•

other factors contained in the section entitled “Risk Factors” contained in this Annual Report.

 

We do not undertake any obligation to update our forward-looking statements, except as required by applicable law.

 

In February 2021, we changed our name from TransEnterix, Inc. to Asensus Surgical, Inc. In this Annual Report we refer to Asensus Surgical, Inc. and its subsidiaries collectively as the “Company,” “it,” “we,” “our” or “us.”  The Company’s subsidiaries are: Asensus Surgical US, Inc., Asensus International, Inc.; Asensus Surgical Italia S.r.l.; Asensus Surgical Europe S.à r.l.; Asensus Surgical Taiwan Ltd; Asensus Surgical Japan K.K.; Asensus Surgical Israel Ltd.; Asensus Surgical Netherlands B.V.; and Asensus Surgical Canada, Inc.

 

ii
Table of Contents

 

 

PART I

 

ITEM 1.

BUSINESS

 

Introduction

 

We are a medical device company that is digitizing the interface between the surgeon and patient to reimagine surgery and pioneer a new era of surgery that we refer to as, Performance-Guided Surgery™ (PGS), by unlocking clinical intelligence to enable surgeons to deliver consistently superior outcomes to patients and establish a new standard of surgery. Built upon the foundation of laparoscopic minimally invasive surgery, that remains the gold standard of surgery today, with the Senhance Surgical System, combined with the Intelligent Surgical Unit™ (ISU™), the Company is pioneering this new standard of surgery, PGS, to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience delivered via the ISU, we intend to holistically address the current clinical, surgeon performance (fatigue and ergonomics), and the economic shortcomings that drive surgical outcomes in a value-based healthcare environment.

 

Our mission is focused on leveraging robotic technologies, in combination with real time computer vision and machine learning capabilities, or Augmented Intelligence, to: reduce variability in surgery, drive more predictable outcomes, optimize resources and costs, and work with hospital systems that strive to employ innovative healthcare strategies. By leveraging advanced digital technologies, we aim to enable surgeons to take the best surgical practices and techniques from everywhere and utilize them to help improve outcomes, reduce variability, control the unexpected, reduce costs, as well as reduce cognitive and physical fatigue for surgeons, and provide patients with the best care possible. We believe that by digitizing the interface between the surgeon and patient, we can unlock clinical intelligence to pioneer Performance-Guided Surgery, and believe that it is the missing element in surgery today.

 

Recent Developments

 

On February 21, 2023, we held an investor day to describe our focus on developing a next generation robotic system we call the LUNA™ Surgical System and the ongoing developments in our Performance-Guided Surgery platform. Performance-Guided Surgery is comprised of three strategic pillars:

 

 

●

enhanced robotic precision and manipulation capabilities, via the Senhance System today and, when developed and approved, the LUNA System;

 

 

●

expanded intra-operative Augmented Intelligence clinical decision support guidance for the surgeon via the ISU; and

 

 

●

integration of cloud and big data to harness best practices across pre-, intra- and post-operative settings, and make it available to surgeons around the world via the Asensus Cloud.

 

In the LUNA System we are developing a “best in class” robot that will use 3mm and 5mm instruments (as contrasted with current systems available that use 8mm instruments), TrueWrist™ fully wristed 5mm instruments, monopolar and bipolar electrosurgery capabilities, rapid instrument exchange with our proprietary instrument drive system, an open platform with a smaller footprint in the OR, as compared to the Senhance System, up to four-arm configuration with enhanced manipulation and dexterity, a surgeon console with 4K-3D capabilities without the need to wear 3D glasses, and unconstrained handles with improved digital features while retaining haptic feedback.

 

The LUNA System will continue our tradition of providing instruments that are reusable and can be re-sterilized and re‑processed, and, with improvements in manufacturing, are expected to have lower costs per procedure.

 

We also clarified our focus areas for our future development efforts with the ISU, including:

 

 

●

an analytical feature set, which includes intra-operative surgical planning that will allow surgeons to map out and plan for specific surgical actions intraoperatively using the ISU’s Augmented Intelligence;

 

 

●

a safety feature set, which includes real-time notifications that will enable the identification and marking of potential hazards during the operation, and optionally restrict access to these structures or areas by simultaneously controlling the robotic arm; and

 

 

●

a training and education set, allowing multiple team members to work together in real-time by annotating, highlighting and drawing on a shared visual display of the surgical field to communicate and provide expert support in real-time.

 

5
Table of Contents

 

The Asensus Cloud is being designed to assist in pre-operative surgical planning, post-surgical performance analytics and best practices guidance, and enable the extraction and aggregation of insights from surgical data. We believe that the collection and analysis of surgical data transformed into insights, and when shared with our physicians, will enhance surgical planning, surgeon education and training, and promote better patient outcomes.

 

We anticipate that, although we have been working on aspects of the LUNA System for four years, we will spend the rest of 2023 refining and finalizing the design builds, and conducting testing on the ISU enhancements for standalone use.  We anticipate reaching design freeze on the LUNA System in the first quarter of 2024 and making regulatory notices and submissions by the end of 2024.  For the ISU enhancements and standalone configuration, we anticipate making regulatory notices and submissions in the first quarter of 2024 and beginning commercial activities by mid-2024.  We anticipate a commercial pilot launch of the LUNA System in the second half of 2025. 

 

On February 16, 2023, we announced that we had entered into a memorandum of understanding with KARL STORZ VentureONE Pte. Ltd, a wholly owned subsidiary of KARL STORZ SE & Co. KG (KARL STORZ), a global leader in the medical technologies industry. Under the definitive agreements to be developed:

 

 

●

KARL STORZ will market and sell the ISU as a standalone device together with their IMAGE1 S™ imaging system and OR 1™ integrated OR offering;

 

 

●

KARL STORZ and Asensus will work on an ISU product that will integrate with KARL STORZ’ laparoscopic vision systems; and

 

 

●

KARL STORZ and Asensus will collaborate on developing next-generation instrumentation to be used with their respective surgical product offerings.

 

KARL STORZ will, under the definitive agreements once negotiated, be assisting in the development of the instrument and machine vision portions of our LUNA System development program.

 

Performance‑Guided Surgery - current

 

Historical advances in surgery have largely focused on incremental advancements in surgical tools and techniques targeted at reducing the invasiveness of procedures. When we introduced the Senhance digital laparoscopy platform, our intention was to help surgeons minimize surgical variability in a cost-effective manner while also helping to offset the increasing physical and cognitive demands on surgeons. The next logical step in the progression is looking for ways to deliver real-time Augmented Intelligence and actionable analytics which we believe will take us from digital laparoscopy to Performance-Guided Surgery.

 

Performance-Guided Surgery builds upon our foundation of digital laparoscopy by adding Augmented Intelligence enabled by our machine vision, and deep learning capabilities through all surgical phases to help guide improved decision making, enriched collaboration, and enhanced predictability for all surgeons (independent of skill level and experience). Our Performance-Guided Surgery strategy leverages our capabilities across robotics, Augmented Intelligence and cloud/big data and is executed across all 3 phases of surgery, including:

 

 

●

Pre-operative - in what we call “intelligent preparation,” our machine learning models will take data from procedures done utilizing our current Senhance System with the ISU, such as tracking surgical motion and team interaction, to create a large and constantly expanding database of surgeries and their outcomes to enable surgeons to best inform their surgical approach and setup.
 

●

Intra-operative – we believe the Senhance System provides “perceptive real-time guidance” for intra-operative tasks, allowing surgeons performing a procedure with the Senhance System and ISU to execute multiple tasks while benefitting from the collective knowledge of other successful Senhance-based procedures delivered through Augmented Intelligence in real time. Not only will this provide the surgeon with a pathway to better outcomes, but we also believe it will ultimately help reduce the cognitive load of the surgeons, enabling more sustained peak performance over time and reducing risk of burn-out.
 

●

Post-operative – finally, by tapping into the vast amount of data captured during procedures, surgeons and operating room staff will have access to “performance analytics” with actionable assessments of their performance giving them the information needed to constantly and consistently improve. We intend to establish a new standard of descriptive, diagnostic, predictive and prescriptive analytics to improve not only the skills of surgeons but move towards accessible best-practice-sharing that bridges the global surgeon community.

 

6
Table of Contents

 

We believe that future outcomes of minimally invasive surgery will be enhanced through our combination of more advanced tools such as Augmented Intelligence solutions and robotic functionality which are designed to:

 

 

•

empower surgeons with improved precision, ergonomics, dexterity, visualization, perceptive real-time guidance and surgical decision support;
 

•

offer high patient satisfaction and enable a more predictable post-operative recovery; and
 

•

provide a cost-effective robotic system, compared to existing alternatives today, for a wide range of clinical applications and operative sites within the healthcare system.

 

From our inception, we devoted a substantial percentage of our resources to research and development and start-up activities, consisting primarily of product design and development, clinical studies, manufacturing, recruiting qualified personnel and raising capital.  We are a data driven company that expects to continue to invest in research and development, market development, and generation and analysis of clinical evidence as we implement our strategy. As a result, we will need to generate significant revenue in order to achieve profitability. The Company operates in one business segment.

 

2022 Market Development Activities

 

In 2022 we continued to focus our resources and efforts on market development activities to increase awareness of:

 

 

•

our growing body of real-world clinical data through the utilization of our TRUST™ registry
 

•

the expanded global ISU machine vision capabilities
 

•

the digitization of high volume procedures using the Senhance System
 

•

the collection of surgical data on the Asensus Cloud
 

•

the benefits of the use of the Senhance System in laparoscopic surgery;
 

•

the technical advancement of digital surgical tools to lead to the realization of Performance-Guided Surgery;
 

•

the indications for use, including pediatric indications for use in CE Mark territories; and
 

•

the overall cost efficiency of the Senhance System.

 

We are a healthcare driven organization, focused on building a strong and collaborative surgeon community to develop collaborations to collect data to inform the Augmented Intelligence engine of our robotic applications for our robotic and ISU product offerings and elevate surgical practice and training. We are focusing on markets with high utilization of laparoscopic techniques, including Japan, Western Europe and the United States. Our focus in 2022 was on (1) increasing the number of placements of the Senhance System, not necessarily through sales, but through leasing arrangements, (2) increasing the number of procedures conducted using the Senhance System quarter over quarter, and (3) solidifying key opinion leader support and publications related to the value of the Senhance System in laparoscopic procedures. We are not focusing on revenue targets, especially in the United States.

 

2022 Senhance Surgical System Programs

We define the initiation of a Senhance Surgical program as entering into an agreement to purchase or lease, and subsequently utilizing a Senhance System. Throughout 2022, we initiated nine Senhance System programs, four in Germany, three in Japan and two in the CIS region. We initiated five Senhance System programs in the fourth quarter of 2022 alone.

 

Training Sites

In February 2021, we announced an agreement with the Amsterdam Skills Centre establishing the second European surgical training site for Senhance System digital laparoscopy. This site serves surgeons and staff throughout Europe with basic and advanced training on the Senhance System. The Amsterdam Skills Centre also provides Asensus with a world-class facility to engage European surgeons in technology and clinical development studies.

 

We now have six global training sites, including three in the United States at the Advent Health Nicholson Center in Celebration, Florida, at LSU Health Sciences Center, New Orleans, and our office in Research Triangle Park North Carolina; two in Europe at Amsterdam Skills Centre, and our office in Milan, Italy; and one in Asia at our office in Tokyo, Japan.

 

Procedure Volumes

In 2022, surgeons performed 3,137 procedures utilizing the Senhance System, representing a 29% increase over the previous year, despite the continued impact of the COVID-19 pandemic on elective surgeries and hospital operations. These procedures included general surgery, gynecology, urology, colorectal, bariatric and pediatric surgical procedures. Beginning with reporting the results for the year ended December 31, 2022, we have re-analyzed our data and are reporting the surgical procedures performed using the Senhance System, rather than surgical cases, where multiple procedures may take place in a single surgical setting or surgical case. For the comparable period in 2021, surgeons performed 2,434 surgical procedures, within the 2,106 surgical cases previously reported.

 

7
Table of Contents

 

Clinical Validation

 

During 2022, there were 16 peer-reviewed clinical papers published providing further support for the clinical utility of the Senhance Surgical System across gynecology, general surgery, urology, and colorectal procedures demonstrating the utility breadth and the complexity of procedures being performed with the device. In particular, there was a milestone paper published in October 2022 describing comparable intra-operative and short-term post-operative complications outcomes between DaVinci robots and the Senhance Surgical System, with significantly lower procedure costs with use of the Senhance Surgical System when accounting for operative time, estimated blood loss and other equipment usage.

 

Impact of COVID-19

 

The COVID-19 pandemic continued to have a significant impact on our operations in 2022, primarily due to the continued repeated temporary cessation of elective surgical procedures in many markets, implementation of time limitations for certain surgeries by certain hospitals, and the challenges and restrictions caused by stay-at-home orders, social distancing requirements and travel restrictions. Our business and customers were negatively impacted by the COVID‑19 pandemic, which suspended many elective surgical procedures globally, curtailed travel and necessarily diverted the attention of hospital customers. A variety of travel restrictions have caused delays in product installation and training activities. This has significantly impacted our ability to implement our market development activities to place our Senhance Surgical Systems, provide training, and increase the use of the Senhance Systems in place. Given the dynamic nature of this health emergency, the full impact of the COVID-19 pandemic on ongoing business, results of operations and overall financial performance cannot be reasonably estimated at this time.

 

Market Overview

 

Over the past three decades, laparoscopic surgery has emerged as a minimally invasive alternative to open surgery. In laparoscopic surgery, multiple incisions are necessary to provide surgical access ports. Carbon dioxide gas insufflation is then used to create room in the body cavity, and long rigid instruments are introduced through ports placed in the incisions to perform surgical tasks. Millions of laparoscopic surgical procedures across a broad range of clinical applications are now performed each year worldwide, though many surgeries are still performed in an open fashion.

 

While laparoscopy has improved upon the invasive nature of many previously open procedures, it still has many limitations. Traditional, or rigid, laparoscopy still requires multiple incisions to achieve the visualization and instrument triangulation required to perform successful surgery. Rigid laparoscopy also creates physical challenges by forcing the surgeon’s hands and arms into awkward angles, requiring the surgeon to hold instruments in fixed positions for long periods of time and requiring an assistant to stabilize and move a laparoscopic camera. Another challenge associated with rigid laparoscopic surgery is the creation of a cumbersome and potentially tissue-damaging fulcrum at the patient’s abdominal wall where instruments are manipulated. Nearly all laparoscopic instruments are rigid instruments that lack internal articulation to enhance dexterity in complex tasks. Most laparoscopic surgeries are performed with two-dimensional, or 2-D, visualization of the operative field, making depth perception difficult.

 

Despite such limitations, traditional laparoscopy remains the prevalent technique in minimally invasive surgery. We believe that robotic devices that replicate laparoscopic motion are more ergonomic for surgeons to adopt. Our Senhance System is designed to mimic laparoscopic surgery. We are uniquely focused on the laparoscopic surgical market as we believe it separates us from our competitors and allows surgeons to perform minimally invasive surgery which provide improved patient outcomes compared to open surgery, while utilizing fully reusable tools, smaller instruments to broaden applicability of the laparoscopic method, including in pediatric cases, and the additional Senhance System technology such as the ISU with its Augmented Intelligence capabilities.

 

Robotic and computer-controlled assistance have developed as technologies that offer the potential to improve upon many aspects of the laparoscopic surgical experience. According to DRG Global Market’s Laparoscopic Surgical Robotic Devices (September 2022), the existing laparoscopic market for soft tissue abdominal surgery is up to 19 million procedures annually. Initial widespread adoption of robotic-assisted surgery was focused on urologic and gynecologic procedures that were primarily performed in an open fashion prior to robotics, but more recently developed robotic approaches like the Senhance System have been applied to many other clinical applications, particularly in general surgery.

 

Despite recent advances and new entrants into the market, we believe there remain many limitations associated with current robotic-assisted surgery systems.

 

8
Table of Contents

 

We digitize the surgical interface between the surgeon and the patient by providing a computer controller interface for the surgeon to manipulate surgical instruments and move the visualization system.  We believe image analytics technology will help accelerate and drive meaningful adoption of the Senhance System and allow us to continue to expand the Senhance System capabilities adding new Augmented Intelligence and decision support capabilities. In addition, we believe our focus on expanding surgical data to include pre- and post-operative intelligence will help in surgical planning, review and overall evaluation.

 

The historical advances in surgery have largely focused on bringing tools and techniques into the operating room to reduce the invasiveness of procedures. When we introduced the Senhance digital laparoscopy platform, our intention was to help surgeons minimize surgical variability in a cost-effective manner. The next step in our progress is looking for ways to deliver superior outcomes, which we believe can be enabled by Performance-Guided Surgery.

 

Factors plaguing the healthcare industry that amplify the urgency for Performance-Guided Surgery include:

 

 

●

Value-based care is shifting a greater responsibility for poor quality and inefficiency to hospitals and physicians;
 

●

COVID-19 exposed the financial frailty of the hospital system as well as capacity and resource constraints, which must be bolstered and requires an acceleration of innovation; and
 

●

Patients are presenting with more complex conditions and treating them becomes more complicated. The absolute number of patients seeking care is increasing, and many more patients have multiple chronic conditions than they did a generation, or even a decade, ago.

 

These factors make it the ideal time to integrate advanced technology in the operating room.

 

Product Overview

 

We are addressing the challenges in laparoscopy and robotic-assisted surgery with technologically advanced products and product candidates that leverage the best features of both approaches to minimally invasive surgery, or MIS. We are also addressing the need for clinically relevant data and analysis through our PGS offerings.

 

The Senhance Surgical System

On September 18, 2015, the Company entered into a Membership Interest Purchase Agreement, or the Purchase Agreement, with Sofar S.p.A., or Sofar, as seller, pursuant to which the Company acquired the Senhance System and related assets and personnel, or the Senhance Acquisition. The closing occurred on September 21, 2015.

 

The Senhance System addresses key challenges for laparoscopic surgeons and hospitals by delivering the benefits of robotics with improved control of the surgical field, enhanced visualization and camera control and improved ergonomics, coupled with the familiarity of laparoscopic motion and consistent per-procedure costs.

 

The Senhance System is available for sale in Europe, the United States, Japan, Taiwan, the Commonwealth of Independent States, or CIS, and select other countries.

 

 

•

The Senhance System has a CE Mark in Europe for adult and pediatric laparoscopic abdominal and pelvic surgery, as well as limited thoracic surgeries excluding cardiac and vascular surgery, and surgeries in direct contact with central nervous systems.
 

•

In the United States, we have 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of the Senhance System in general laparoscopic surgical procedures and laparoscopic gynecologic surgery in a total of 31 indicated procedures, including benign and oncologic procedures, laparoscopic inguinal, hiatal and paraesophageal hernia, sleeve gastrectomy and laparoscopic cholecystectomy (gallbladder removal) surgery.
 

•

In Japan, we have received regulatory approval and reimbursement for 124 laparoscopic procedures.
 

•

The Senhance System received its registration certificate by the Russian medical device regulatory agency, Roszdravnadzor, allowing for its sale and utilization throughout the Russian Federation.

 

We also enter into lease arrangements with certain qualified customers. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System during or at the end of the lease term (which we refer to as a Lease Buyout).

 

Our focus over the last few years has been on seeking regulatory approvals and clearances for the Senhance System and related product offerings and instruments and pursuing commercialization of our products. The following chart describes our success in achieving regulatory clearances and approvals to date.

 

9
Table of Contents

 

Product/Indications

FDA Clearance

CE Mark

Other Approvals

Senhance System

October 2017

January 2012

Taiwan – April 2018

Japan – May 2019

Russian Federation – December 2020

Indications for Use of Senhance System

●     Initial general surgery indications for laparoscopic colorectal and gynecologic surgery procedures

October 2017

N/A

N/A

●     Extended to cholecystectomy and inguinal hernia repair

May 2018

N/A

N/A

●     Extended to hiatal and paraesophageal hernia, sleeve gastrectomy, and sacrocolpopexy

March 2021

N/A

N/A

●     General surgery indications

General laparoscopic surgical procedures and laparoscopic gynecologic surgery including a total of 31 indicated procedures, including benign and oncologic procedures, laparoscopic inguinal, hiatal and paraesophageal hernia, sleeve gastrectomy and laparoscopic cholecystectomy

For adult and pediatric laparoscopic abdominal and pelvic surgery, as well as limited thoracic surgeries excluding cardiac and vascular surgery and surgeries in direct contact with central nervous systems

Japan – regulatory approval and reimbursement for 98 laparoscopic procedures – July 2019

 

Additional 26 laparoscopic procedures approved for reimbursement in Japan during 2022

●     Pediatric indications

Applied for during third quarter 2022

February 2020

N/A

●     Inelligent Surgical Unit, or ISU

Initial - March 2020

 

Expansion of Augmented Intelligence in August 2021

January 2021

 

Expansion of Augmented Intelligence in January 2023

Japan - December 2020

Instruments and Other Products

●     5mm articulating instruments

July 2021

September 2018

Japan - October 2022

●     3mm diameter instruments

October 2018

July 2017

Taiwan - November 2018

Japan - October 2019

●     Senhance ultrasonic system

January 2019

September 2018

Japan - October 2020

●     3mm and 5mm hooks

5mm July 2019

3mm November 2019

December 2019

Japan - December 2020

 

On July 28, 2021, we announced that we received FDA clearance for 5mm diameter articulating instruments, offering better access to difficult-to-reach areas of the anatomy by providing two additional degrees of freedom. These instruments previously received CE Mark for use in the EU.

 

We also focused on expanding the indications for use of the Senhance System. As of March 2021, the Senhance System is FDA cleared for use in general laparoscopic surgical procedures and laparoscopic gynecologic surgery including a total of 31 indicated procedures, including benign and oncologic procedures, laparoscopic inguinal, hiatal and paraesophageal hernia, sleeve gastrectomy and laparoscopic cholecystectomy. We continue to make additional submissions for clearance or approval for enhancements to the Senhance System and related instruments and accessories, including additional filings and approvals sought in Japan.

 

The Senhance System is a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera. The system builds on the success of laparoscopy by enhancing the traditional features that surgeons have come to expect from existing products and by addressing some of the limitations associated with robotic surgery systems for laparoscopic procedures. The Senhance System also offers responsible economics to hospitals through its robotic technology coupled with reusable standard instruments that yield minimal additional costs per surgery when compared to laparoscopy. The Senhance System has a CE Mark in Europe for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, and surgeries in direct contact with central nervous systems.

 

10
Table of Contents

 

Key features of the Senhance System are:

 

 

•

Fully Reusable, Autoclavable Instrumentation: The Senhance System offers standard instrumentation that is cleaned and sterilized using current autoclave technology that does not require additional, non-standard sterilization methods, and that has no pre-set limitation on number of uses that require them to be disposed. Exceptions to this are ultrasonic disposals and articulating instruments.
 

•

Enhanced Vision, Eye-Tracking Camera Control: The Senhance System is compatible with 3DHD, vision technology, which provides the surgeon with additional depth and spatial relation of organs; and a tremor free view of the surgical field and is centered in the surgeon’s field of vision. Eye-tracking camera control, allows hands free, surgeon-controlled visualization.
 

•

Intelligent Surgical Unit or ISU: The ISU enables machine vision capabilities providing the ability to recognize certain objects and locations in the surgical field. This capability enhances visualization and camera control over previously available surgical technologies, and provides the foundation for additional Augmented Intelligence capabilities, with a number of enhancements added and FDA-cleared in 2021 and CE Marked in early 2023. Additionally, the ISU improves surgical team collaboration by seamlessly sharing the surgeon’s console view in real-time across the entire operating room. The most recently cleared Augmented Intelligence features available in the U.S., Japan and the EU include 3D point-to-point measurement, advanced endoscopic control modalities, image enhancement, and intra-operative surgeon digital tagging.
 

•

Articulating Instruments: These instruments improve accessibility and reach around critical structures, providing two additional degrees of freedom, when working in deep anatomical spaces. They optimize efficiency for the surgeon.
 

•

Haptic Feedback: The Senhance System’s haptic feedback feature heightens the surgeon’s sensing of pressure/tension throughout the surgical procedure; haptics provides the surgeon with the ability to feel the tissue response of the body during a procedure.
 

•

Laparoscopic Motion: Digital laparoscopy maintains familiar motions, tools, and techniques that are similar to the motion used during traditional laparoscopic surgeries.
 

•

Improved Ergonomics: Ergonomic seating for the surgeon throughout the procedure helps to reduce fatigue and risk of musculoskeletal injuries.
 

•

E-Fulcrum: A digital fulcrum, setting a dynamic virtual pivot point, helps to potentially minimize incision trauma.
 

•

Open-Platform Architecture: The Senhance System allows the use and integration of existing OR technologies to maximize benefit from capital investments and support surgeon preference (e.g., trocars, electrosurgical units, insufflators, select vision systems, etc.).
 

•

View of the Sterile Field: The Senhance System offers the user an open view of the operating room and sterile field from the ergonomically-designed console.

 

The Senhance System is manufactured for us by third-party contract manufacturers. We or our manufacturers acquire raw materials and components of the Senhance System from vendors, some of which are sole suppliers. We believe our relationships with our vendors and manufacturing contractors are good. We further believe that we have the manufacturing capacity and inventory reserves to meet our anticipated Senhance System sales for the foreseeable future.

 

ISU and Digital Solutions

Our ISU is a real-time intra-operative surgical image analytics platform that leverages Augmented Intelligence to help reduce surgical variability and provides tools to reduce a surgeon’s cognitive fatigue. It is currently used to enable machine vision capabilities on the Senhance System and collect clinical data related to surgical procedures. The ISU was developed using image analytics technology that we acquired as part of our October 2018 acquisition of the assets, intellectual property and highly experienced multidisciplinary personnel of Medical Surgical Technologies, Inc., or MST, an Israeli-based medical technology company. On March 13, 2020, we announced that we had received FDA clearance for the ISU. On September 23, 2020, we announced the first surgical procedures successfully completed using the ISU. On January 19, 2021, we announced that we received CE Mark for the ISU, allowing us to expand our Augmented Intelligence capabilities to all global areas accepting the CE Mark.

 

The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical fields and allows a surgeon to change the visualized field of view using the movement of their instruments. In September 2021 we received FDA clearance for additional Augmented Intelligence features of the ISU, and received CE Mark for such additional features in January 2023. The newest ISU features expand upon these capabilities and introduce additional advanced features including 3D measurement, digital tagging, image enhancement, and enhanced camera control based on real-time data while performing surgery. The regulatory review of such expanded capabilities, which included a review of the Senhance System platform, made Senhance one of the first robotic surgical systems to be approved through the new, more rigorous EU Medical Device Regulation, or MDR, process.

 

11
Table of Contents

 

We are continuing to advance the utility of the ISU for the Senhance System while also adding such capabilities to the standalone ISU and the LUNA System.

 

Our digital solutions are the features, products and platforms that are enabled by data, generated through the digitization of the interface between the surgeon and the patient, and deployed via software. Our digital solutions are a foundational component of our PGS strategy enabling the delivery of insights in pre-operative and post-operative settings, while continuously enhancing our real-time, intra-operative Augmented Intelligence offerings. Given the criticality of this part of our business, in 2022 we reorganized our R&D structure to establish a dedicated engineering team focused on digital solutions and established an additional cross-functional team to advance efforts in data collection, connectivity, needs definition and solution development. Currently, commercially available digital solutions are largely deployed via the ISU in the form of Augmented Intelligence applications including automatic camera control, digital tagging, and digital measurement. To develop these and future digital solutions, we designed and deployed the Asensus Cloud, which has been architected to efficiently manage unique surgical data automatically transferred via connected ISUs and additional sources. The Asensus Cloud provides a secure, scalable, and efficient platform for data storage, data use and computing in machine learning model development, business model innovation and future analytics delivery via portals and dashboards. We believe these analytics solutions will address numerous challenges in the pre-operative planning and post-operative assessment phases of surgery, enhancing training as well as continuing education, to help advance Performance-Guided Surgery and promote consistently superior outcomes.

 

Senhance Connect

Senhance Connect is a telesurgical platform that allows surgeons in an operating room to connect with and communicate with other Senhance surgeons in other locations.  The process allows for streaming of multiple operating room camera views and an endoscopic view simultaneously, and allows for two-way screen sharing and annotation.  This product is part of our PGS, enabling the ability to provide real-time digital collaboration capabilities to surgeons enabling best practice sharing and surgical proctoring to a wider audience.  Additionally, this expands surgeon flexibility and is more cost effective, enabling broader global access to clinical excellence.

 

Clinical Registry (TRUST)

We believe TRUST is the largest multi-specialty robotic-assisted laparoscopic registry in the industry. In 2022, we continued to leverage the growing body of real-world clinical data through the utilization of our TRUST clinical registry, which is aimed at providing a research tool that enables physicians to monitor safety, efficacy, and feasibility of robotic assisted surgical interventions in a variety of abdominal, thoracic, urologic and gynecologic surgical cases using the Senhance System. In 2022, we continued to drive enrollment as well as support peer-reviewed publications through this registry.

 

Instruments and Other Products

Instruments

We successfully obtained FDA clearance and CE Mark for a number of instruments, including, our 3mm diameter instruments, our 3mm and 5mm hooks, and articulating instruments. The 3mm instruments enable the Senhance System to be used for microlaparoscopic surgeries, allowing for tiny incisions. We currently offer approximately 80 instruments and accessories in our portfolio.  We also have designed the Senhance System so that third-party manufactured instruments can be easily adapted for use.

 

Our articulating instruments were commercially launched in the U.S. and Japan in the fourth quarter of 2022.

 

Other Products

The Senhance ultrasonic system is an advanced energy device used to deliver controlled energy to ligate and divide tissue, while minimizing thermal injury to surrounding structures.

 

Indications for Use

 

We continue to work on expanding the indications for use of the Senhance System and our instruments and other products. The most notable recent advances are:

 

 

●

We received CE Mark approval for an expanded indication to treat pediatric patients.
 

●

In 2020, we submitted a notice to the FDA for 510(k) clearance for expanded General Surgery indications for use for the Senhance System. In March 2021, we received such clearance which allows for hiatal and paraesophageal hernia, and sleeve gastrectomy procedures. These additional indications helped to increase procedure volume in 2022.
 

●

We submitted a 510(k) notice to the FDA for expanding the indications for use of the Senhance System to pediatric patients.

 

12
Table of Contents

 

Business Strategy

 

Our strategy is to focus on the realization of Performance-Guided Surgery through the continued collection of surgical data via the ISU and Asensus Cloud leveraging the Senhance System and by other means of non-robotic laparoscopic surgery, while completing the design and development of the LUNA System and its capabilities. We anticipate that the definitive agreements with KARL STORZ will lead to an increase the sales of our ISU standalone configuration and also grant us greater access to surgical video and surgical data via non-robotic laparoscopic surgical towers.  We believe that:   

 

 

•

the LUNA System, if successfully developed and approved for use, will dramatically improve our ability to offer digital solutions to surgeons to promote better patient outcomes;
 

•

the ISU and Asensus Cloud will enable the structured acquisition, processing and analysis of surgical video and data and glean insights to better inform our Augmented Intelligence engines to help reduce surgical variability and drive consistently superior outcomes for patients;
 

•

laparoscopic robotic surgery will need to continue to evolve given the pressures of value-based healthcare and existing operating room inefficiencies, surgical variability, and workforce challenges;
 

•

with our robotic surgery products, surgeons can benefit from the haptic feedback for better connection to the patient, enhanced three-dimensional, high definition, or 3DHD, vision, and open console design to better connect the surgeon with the operating room; and
 

•

patients will continue to benefit from minimally invasive options, offering better overall patient outcomes than other MIS surgical techniques.

 

We continue the market development for and commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance System is the first and only multi-port, digital laparoscopy platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, improved ergonomics, advanced instrumentation including 3mm microlaparoscopic instruments, 5mm articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.

 

Our strategy is to focus our resources on the market development of digital surgery to create a new and unique market segment for Performance-Guided Surgery using the standalone ISU and the LUNA System in the future and the Senhance System, the ISU and currently offered instruments to generate procedural data to inform and elevate practice in real time.

 

We believe that:

 

 

•

our Performance-Guided Surgery framework, which focuses on leveraging robotic technologies, Augmented Intelligence and machine learning capabilities will assist in reducing variability in surgery, drive more predictable outcomes, optimize resources and costs, and resonate with hospital systems that seek to employ innovative healthcare strategies;
 

•

the Senhance System is easier to use in MIS, particularly for surgeons well versed in laparoscopic technique;
 

•

markets outside of the United States, particularly where laparoscopic surgery is more heavily utilized, such as Japan, may more readily adopt the use of the Senhance System;
 

•

because of the capital-intensive nature of the purchase of a robotic system, our strategy to lease the Senhance System to additional hospitals will increase our placements and use of our systems;
 

•

there are a number of hospitals and an increasing number of ambulatory surgery centers internationally and in the United States that can benefit from the addition of robotic-assisted MIS and, through the Senhance System, lower operational costs as contrasted with other robotic systems;
 

•

with the Senhance System, surgeons can benefit from the security of haptic feedback, enhanced 3DHD vision and open-platform architecture consistent with current laparoscopic surgery procedures;
 

•

the addition of advanced energy instruments, 3mm instruments and 5mm articulating instruments for the Senhance System will help to increase adoption of our products in the laparoscopic surgery market;
 

•

leveraging haptic feedback, 3mm instruments, independent arms and lower operating cost, the Senhance system is well suited for pediatric surgeries;
 

•

a standalone ISU will enable much broader access to Augmented Intelligence solutions, providing better surgeon experience and clinical outcomes in laparoscopic procedures, compared to if all ISUs needed to be part of a robotic system; and
 

•

the enablement of image analytics technology, Augmented Intelligence and machine vision capabilities, enabled by the ISU, will help accelerate and drive meaningful adoption of our robotic systems into the future and help clearly differentiate our offering in surgical robotics.

 

13
Table of Contents

 

Sales and Marketing

 

We utilize distributors in jurisdictions where we do not sell directly.  Our distribution agreements typically provide exclusivity in a specific territory or jurisdiction.

 

We are dependent on growing the number of hospital customers and increasing the number of customers with installed Senhance Systems. Throughout 2022, we initiated nine Senhance surgical programs, four in Germany, three in Japan and two in the CIS region. We define the initiation of a Senhance Surgical program as entering into an agreement to purchase or lease, and subsequently utilizing a Senhance System.

 

Intellectual Property

 

We believe that our intellectual property and expertise is an important competitive resource. Our experienced research and development team has created a substantial portfolio of intellectual property, including patents, patent applications, trade secrets and proprietary know-how. We maintain an active program of intellectual property protection, both to assure that the proprietary technology developed by us is appropriately protected and, where necessary, to assure that there is no infringement of our proprietary technology by competitive technologies.

 

The following summarizes our current patent and patent application portfolio.

 

As of December 31, 2022, the Company’s patent portfolio includes approximately 75 issued or allowed United States patents, over 100 patents issued outside the United States, and more than 130 patent applications filed in the United States and internationally.  We own all right, title and interest in all but the approximately 38 of our patents and patent applications that are exclusively licensed to us and the approximately 25 patents and patent applications that are non-exclusively licensed to us.

 

Several of our issued patents resulted from filings related to the Senhance System.  These include 8 United States patents, and approximately 40 patents outside the United States. The earliest to expire U.S. and non-U.S. patents within this part of our portfolio will remain in force until 2027.  The patent applications include over 120 that relate to the Senhance System, the LUNA System, the ISU or other features, instruments, or components for robotic-assisted surgery. Our patents and applications that we acquired from MST relate to image analytics, our digital solutions and robotic surgery, among other things. We intend to continue to seek further patent and other intellectual property protection in the United States and internationally, where available and when appropriate, as we continue our product development efforts.

 

Some of our issued patents and pending applications for the Senhance System, as well as associated technology and know-how, are exclusively licensed to Asensus Surgical Italia from the European Union. The license agreement with the European Union has a term which runs until the final licensed patent expires unless the agreement is terminated earlier by mutual consent of the parties, for the Company’s convenience, or for breach. The Company is currently in compliance with the terms of this license agreement.

 

Competition

 

Our industry is highly competitive, subject to change and significantly affected by new product introductions and other activities of industry participants. Many of our competitors have significantly greater financial and human resources than we do and have established reputations with our target customers, as well as worldwide distribution channels that are more established and developed than ours.

 

There were new entrants in the market for robotic surgery in 2022 and 2021, and some forward steps by a number of existing entrants, such as the CE Mark attained by Medtronic for its Hugo™ robot, and the enrollment of the first patient in its U.S. clinical trial. We believe that our focus on the laparoscopic market and our Performance-Guided Surgery initiative help us to remain competitive in this growing field.

 

There are many competitive offerings in the field of minimally invasive surgery. Several companies have launched devices that enable reduced incision or single incision laparoscopic surgery with or without robotic assistance.  Our surgical competitors include, but are not limited to: Medtronic plc, Intuitive Surgical Inc., Vicarious Surgical, Inc., Momentis Surgical, Distalmotion SA, and CMR Surgical Ltd. We are aware that more entrants anticipate introducing additional robotic-based instruments in the next few years.

 

There are also a number of existing and emerging competitors in the digital surgery space. Some well-established players have and are expanding their digital offerings, such as Medtronic’s post acquisition of Digital Surgery with their Touch Surgery offerings and Intuitive Surgical with their My Intuitive app. Several smaller companies that are exclusively focused on digital surgery solutions are currently in, or are expected to enter in the near future, the market including, but not limited to Theator Surgical, Activ Surgical and CareSyntax.

 

14
Table of Contents

 

In addition to surgical device manufacturer competitors, there are many products and therapies designed to reduce the need for or attractiveness of surgical intervention. These products and therapies may impact the overall volume of surgical procedures and negatively impact our business.

 

Our ability to compete may be affected by the failure to fully educate physicians in the use of our products and products in development, or by the level of physician expertise. This may have the effect of making our products less attractive. We believe the Senhance System can be distinguished from other currently available robotic systems on the basis of (1) overall attractiveness to laparoscopic surgeons due to its ability to provide robotic benefits while leveraging their laparoscopic training and experience, (2) the additions we have made, including the ISU, (3) lower per procedure costs and (4) increasing indications for use, including pediatric indications. We further expect the Senhance System to differentiate in its ability to provide the surgeon with valuable tactile feedback and real-time clinical intelligence to help guide better outcomes. Several medical device companies are actively engaged in research and development of robotic systems or other medical devices and tools used in minimally invasive surgery procedures. We cannot predict the basis upon which we will compete with new products marketed by others.

 

Government Regulation of our Product Development Activities

 

The U.S. government and foreign governments regulate the medical device industry through various agencies, including but not limited to, the FDA, which administers the Federal Food, Drug and Cosmetic Act, or the FDCA. The design, testing, manufacturing, storage, labeling, distribution, advertising, and marketing of medical devices are subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar agencies in other countries, including in the European Union. Any device product that we develop must receive all requisite regulatory approvals or clearances, as the case may be, before it may be marketed in a particular country.

 

Device Development, Marketing Clearance and Approval

 

Medical devices are subject to varying levels of pre-market regulatory requirements. The FDA classifies medical devices into one of three classes: (i) Class I devices are relatively simple and can be manufactured and distributed with general controls; (ii) Class II devices are somewhat more complex and have heightened regulatory requirements, typically including clearance of a 510(k) notice prior to marketing; and (iii) Class III devices are new, high-risk devices, and frequently are permanently implantable or help sustain life, and generally require approval of a Pre-Market Approval application, or PMA, by the FDA.

 

Our current products are subject to premarket notification and clearance under section 510(k) of the FDCA, and the 510(k) process is normally used for products of the type that we are developing and propose to market and sell. To obtain 510(k) clearance, we must submit to the FDA a premarket notification (510(k) notice) demonstrating that the proposed device is “substantially equivalent” to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to PMA, generally either a Class I or Class II device. A 510(k) notice must provide information supporting a claim of substantial equivalence to a single medical device, the predicate device, or multiple predicates in certain circumstances. If clinical data are required to support the 510(k) notice, these data must be gathered in compliance with the investigational device exemption, or IDE, regulations for investigations performed in the United States.

 

If the FDA agrees that the device is substantially equivalent to a predicate device, it will grant 510(k) clearance, which permits the company to commercially distribute the device for its intended use. If the FDA determines that the device is “not substantially equivalent” to a previously cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the “de novo” process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. Review times for de novo requests vary widely, and may take in excess of one year. 

 

The FDA review process for premarket notifications submitted pursuant to Section 510(k) of the FDCA takes, pursuant to statutory requirements, 90 days, but it can take substantially longer if the FDA has questions regarding the regulatory submission. It is possible for a 510(k) review process to take from six to twelve months, depending on the concerns raised by the FDA and the complexity of the device. There is no guarantee that the FDA will “clear” a medical device for marketing; if clearance is not granted, the device cannot be distributed in the United States. There is also no guarantee that the FDA will deem the applicable device subject to the 510(k) process, as opposed to the more time-consuming and resource-intensive de novo process escribed above or PMA process described below.

 

15
Table of Contents

 

A new device that is high-risk and not substantially equivalent to a predicate device must obtain approval of a PMA prior to commercial distribution in the U.S. These devices are normally Class III devices. Before a company can market a product in the United States that is subject to PMA approval, it typically must collect clinical data to support the intended use of the device, and must comply with IDE regulations in connection with any human clinical investigation of the device conducted in the United States. Prior express FDA approval of an IDE application is required if the device is a significant risk device (as opposed to a “non-significant risk”, or NSR, device), which is typically the case for Class III devices. The FDA must subsequently approve the company’s PMA application, which typically contains, among other things, clinical information acquired under the IDE. Additionally, devices subject to PMA approval may be subject to an Advisory Panel review and are required to pass a manufacturing facility inspection in accordance with the current “good manufacturing practices” standards prior to obtaining marketing approval. The FDA will approve the PMA application if it determines that the data and information in the PMA constitute valid scientific evidence and finds that there is reasonable assurance that the device is safe and effective for its intended use. The PMA process takes substantially longer than the 510(k) process, approximately one to two years or more.

 

The Company believes the Senhance System and many related products are Class II devices as evidenced by our cleared 510(k) notices. The Company intends to further develop the product line by adding additional instrumentation to and expanding the capabilities of the Senhance System.  At this time, the Company believes that the items under development are Class II devices subject to 510(k) clearance. The FDA might find that the 510(k) submission does not provide the evidence required to prove that the additional instruments or accessories for use with the Senhance System are substantially equivalent to legally-marketed Class II devices. If that were to occur, the Company would be required to undertake either the de novo reclassification process or the even more complex and costly PMA process. For either the 510(k), de novo, or the PMA process, the FDA could require the Company to conduct clinical trials, which would take more time, cost more money, and pose other risks and uncertainties. The Company does not believe it has any need to, and is not currently planning to conduct, any clinical trials.

 

If needed in the future, clinical studies conducted in the United States or used in any U.S. application on an unapproved medical device that presents a significant risk require approval from the FDA prior to initiation. Even when a clinical study has been approved by the FDA or deemed approved, the study is subject to factors beyond a sponsor's control, including, but not limited to, the fact that the institutional review board, or IRB, at a specified clinical site might not approve the study, might decline to renew approval, or might suspend or terminate the study before its completion. There is no assurance that a clinical study at any given site will progress as anticipated. In addition, there can be no assurance that the clinical study will provide sufficient evidence to assure the FDA that the product is safe and effective, a prerequisite for FDA approval of a PMA, or substantially equivalent in terms of safety and effectiveness to a predicate device, a prerequisite for 510(k) clearance. Even if the FDA approves or clears a device, it may limit its intended uses in such a way that manufacturing and distribution of the device may not be commercially feasible.

 

After clearance or approval to market is given, the FDA and foreign regulatory agencies, upon the occurrence of certain serious adverse events, are authorized under various circumstances to withdraw the clearance or approval of the device, or require changes to a device, its manufacturing process, or its labeling, or require additional proof that regulatory requirements have been met.

 

A manufacturer of a device approved through the PMA process is not permitted to make changes to the device which affect its safety or effectiveness, including changes to the intended use/indications for use, without first submitting a PMA Supplement application and obtaining FDA approval for that supplement. In some instances, the FDA may require clinical trials to support a PMA Supplement. A manufacturer of a device cleared through the 510(k) process must submit an additional premarket notification if it intends to modify the device in a manner that could significantly affect the safety or effectiveness of the device, such as a significant change or modification in design, material, chemical composition, energy source, labeling or manufacturing process, or that represents a major change in the intended use.

 

Exported devices are subject to the regulatory requirements of each country to which the device is exported, as well as certain FDA export requirements.

 

16
Table of Contents

 

Continuing Regulation

 

After a device is placed on the market, numerous FDA and other regulatory requirements continue to apply. These include:

 

 

•

establishment registration and device listing with the FDA;
 

•

quality system regulations that require manufacturers to follow stringent design, testing, process control, documentation and other quality assurance procedures;
 

•

labeling regulations that prohibit the promotion of products for unapproved, i.e. “off label,” uses and impose other restrictions on labeling and promotional activities;
 

•

Medical Device Reporting regulations that require manufacturers to report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur;
 

•

corrections and removal reporting regulations that require manufacturers to report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; and
 

•

in some cases, requirements to conduct post-market surveillance studies to establish continued safety data.

 

We are required to, and have, registered with the FDA as a medical device manufacturer and listed the products that we currently commercialize in the U.S. We must obtain all necessary permits and licenses to operate our business in all regions in which we do business. As manufacturers, we and our suppliers are subject to announced and unannounced inspections by the FDA to determine our compliance with the Quality System Regulation, or QSR (21 CFR Part 820), and other regulations.

 

In Europe, we comply with the requirements of the 93/42/EEC Medical Devices Directive, or MDD, and appropriately affix the CE Mark on our products to attest to such compliance. Asensus Surgical Italia S.r.l. is the legal manufacturer in the European Union. Our products marketed in the EU meet the “Essential Requirements” of the MDD relating to safety and performance. We have undergone verification of our regulatory compliance, or conformity assessment, by a Notified Body duly authorized by an EU country and must continue to do so as new products and changes to the products arise. The level of scrutiny of such assessment depends on the regulatory class of the product. We are subject to continued surveillance by our Notified Body and are required to report any serious adverse incidents to the appropriate authorities. We also must comply with additional requirements of individual countries in which our products are marketed. In the European Union, we are required to maintain certain quality system certifications in order to sell products. These regulations require us or our manufacturers to manufacture products and maintain documents in a prescribed manner with respect to design, manufacturing, testing, labeling and control activities.  As legal manufacturers, we and our suppliers are subject to announced and unannounced inspections by the European Notified Bodies and Competent Authorities.

 

In May 2021, the Medical Device Directive was replaced by the updated European Medical Device Regulation, or 2017/745 (MDR), after an initial four-year transition period, which has been extended to a seven-year period.   Any of our products that were certified to comply with the MDD have been or will have to be re-evaluated by a designated Notified Body according to the new regulations after their certificates expire or in case of a substantial change.  To date, the Senhance System (with the ISU included) and articulating instruments have been certified under the MDR process The new regulations place new requirements regarding labeling, post-market surveillance, and technical documentation on all medical device manufacturers.  In addition, Notified Bodies underwent the transition as well, leading to reduced capacity to take on new clients or review new medical devices for CE Mark approvals or existing medical devices for substantial changes.  The transition extensions are until 2027 for class IIb devices and 2028 for class IIa devices under the following conditions: (1) devices do not present any unacceptable risk to health and safety, (2) devices have not undergone significant changes in design or intended purpose, and (3) the manufacturers have already undertaken the necessary steps to launch the certification process under the MDR, such as adaptation of their quality management system to the MDR and submission to a notified body. Some of our legacy devices in class IIb and IIa still require MDR transition (instruments and ultrasonic). Full transition to the new regulations will take time and resources from our internal personnel and external consultants to gain compliance, which may reduce the resources available for market expansion and new product introductions.

 

Failure to comply with the applicable regulatory requirements can result in enforcement action by the FDA and other international regulatory bodies, which may include, among other things, any of the following sanctions:

 

 

•

warning letters, fines, injunctions, consent decrees and civil penalties;
 

•

repair, replacement, refund or seizure of our products;
 

•

operating restrictions, partial suspension or total shutdown of production;
 

•

refusing our request for market access approvals of new products or modifications to existing products;
 

•

withdrawing or suspending clearances or approvals that are already granted;
 

•

criminal prosecution; and
 

•

disgorgement of profits.

 

Further, the levels of revenues and profitability of medical device companies like us may be affected by the continuing efforts of government and third-party payors to contain or reduce the costs of healthcare through various means. For example, in certain foreign markets, pricing or profitability of products is subject to governmental control. In the United States, there have been, and we expect that there will continue to be, a number of federal and state proposals to implement similar governmental controls.

 

17
Table of Contents

 

Therefore, we cannot assure you that any of our products will be considered cost effective, or that, following any commercialization of our products, coverage and reimbursement will be available or sufficient to allow us to manufacture and sell them competitively and profitably.

 

Health Care Regulation

 

Our business activities are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. These laws include the following:

 

 

●

The U.S. Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving anything of value to induce (or in return for) the referral of business, including the purchase of a particular medical device reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between medical device manufacturers on one hand and purchasers on the other. A violation of the Anti-Kickback Statute may be established without proving actual knowledge of the statute or specific intent to violate it. The government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly and practices that involve remuneration to those who purchase medical devices, including certain discounts, or engaging such individuals as consultants, speakers or advisors, may be subject to scrutiny if they do not fit squarely within the exception or safe harbor.

 

 

●

The federal civil False Claims Act, or FCA, which prohibits, among other things, any person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of federal funds, or knowingly making, or causing to be made, a false statement material to a false claim. Actions under the False Claims Act may be brought by private individuals known as qui tam relators in the name of the government and relators may share in any monetary recovery.

 

 

●

The Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (collectively “HIPAA”) prohibits, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors. HIPAA also prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. We may obtain health information from third parties that are subject to privacy and security requirements under HIPAA and we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.

 

 

●

The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.

 

 

●

The U.S. Physician Payment Sunshine Act, or Sunshine Act, requires tracking of payments and transfers of value to physicians and teaching hospitals and ownership interests held by physicians and their families, and reporting to the federal government and public disclosure of these data. As of last year, manufacturers must also report transfers of value made to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician payment transparency laws. If our operations are found to be in violation of any of such laws that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results. We have provided reports under the Open Payments Act to the Centers for Medicare & Medicaid Services since 2014. Amendments to the Open Payments Act expanded the categories of healthcare providers for which reporting is required.  The failure to report appropriate data accurately, timely, and completely could subject us to significant financial penalties. Other countries and several states currently have similar laws and more may enact similar legislation.

 

18
Table of Contents

 

If our operations are found to be in violation of any of such laws that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.

 

Health Care Reform

 

In the United States, there have been, and we expect there to continue to be, a number of legislative and regulatory initiatives, at both the federal and state government levels, to change the healthcare system in ways that, if approved, could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.

 

For example, in March 2010, the Patient Protection and Affordable Care Act was enacted. The ACA is a sweeping measure generally designed to expand access to affordable health insurance, control healthcare spending, and improve healthcare quality. Several provisions of the ACA specifically affect the medical equipment industry. Among other things, the ACA established enhanced Medicare and Medicaid program integrity provisions, including expanded documentation requirements, and new disclosure requirements regarding manufacturer payments to physicians and teaching hospitals, along with broader expansion of federal fraud and abuse authorities. It is unclear how efforts to modify or invalidate the ACA or its implementing regulations, or portions thereof, will affect our business. Additional legislative changes, regulatory changes, and judicial challenges related to the ACA remain possible. We cannot predict what effect further changes related to the ACA would have on our business.

 

Other legislative changes have been proposed since the ACA was enacted such as the Budget Control Act of 2011 which, among other things and in concert with subsequent legislation, resulted in reductions in payments to Medicare providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect into 2031. Sequestration is currently set at 2% and will increase to 2.25% for the first half of fiscal year 2030, to 3% for the second half of fiscal year 2030, and to 4% for the remainder of the sequestration period that lasts through the first six months of fiscal year 2031. As long as these cuts remain in effect, they could adversely impact payment for the procedures performed with our products.

 

We expect there will continue to be reforms to healthcare legislation, regulation, and policy guidance at the federal and state level. Any such reform could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of existing products or to successfully commercialize product candidates.

 

International Regulation and Potential Impact

 

The Company has market development and commercial activities in a number of international markets and intends to focus on such markets in the near term. Some of these markets maintain unique regulatory requirements outside of or in addition to those of the FDA and the European Union. The Senhance System is CE Marked, which is the basis to allow us to offer the product for sale in a number of jurisdictions, including select countries in Europe, the Middle East and Asia.  Due to the variations in regulatory requirements within territories, the Company may be required to perform additional safety or clinical testing or fulfill additional agency requirements for specific territories. The Company may also be required to apply for registration using third parties within those territories and may be dependent upon the third parties’ successful regulatory processes to file, register and list the product applications and associated labeling, which could lead to significant investments and resource use. These additional requirements may result in delays in international registrations and commercialization of our products in certain countries.

 

Additionally, the General Data Protection Regulation (the GDPR) in effect across the EEA, imposes many stringent requirements for controllers and processors of  personal data, including imposing strict standards when obtaining consent from individuals to process their personal data, requiring detailed disclosures to individuals, providing individual data rights, imposing short time lines for data breach notifications, limiting retention periods and secondary use of information, imposing certain requirements pertaining to health data, as well as additional obligations when we contract third-party processors to process personal data.

 

Global laws are increasingly restricting and regulating the cross-border transfer of personal data, which may require us to undertake additional obligations in order to receive personal data from overseas customers or transfer such data, including to our vendors. For example, the GDPR restricts the ability of companies to transfer personal data from the EEA to the United States and other countries, which may adversely affect our ability to transfer or receive personal data or otherwise may cause us to incur significant costs to undertake data transfer impact assessments and implement lawful data transfer mechanisms.

 

In addition, we are utilizing distributors and sales agents in various territories throughout Europe, the Middle East, Africa, and the CIS, and need to ensure that our activities, and the activities of our distributors and sales agents, are compliant with local law and U.S. laws governing the sales of medical devices.  We have also established subsidiaries and contracted with third parties in Asia, including Japan and Taiwan, to seek regulatory approvals to offer our products in Asia.  The laws governing the registration, approval, clearance, and sales of medical devices, such as the Senhance System, in multiple jurisdictions are complex, and the failure to comply with such laws in any given jurisdiction could subject us to financial penalties or suspension or termination of our ability to sell our products in the applicable jurisdiction.

 

19
Table of Contents

 

Environmental, Social and Governance

 

Environmental

 

As a company, we are committed to encouraging and fostering sustainable practices to support the global environment. We comply with environmental regulations in each of our locations. We have a corporate goal of limiting the use of plastic with paper cups and recyclable materials and, prior to COVID, adopted a no plastic policy in our Milan office, which was interrupted due to the need for single-use packaging for health concerns during COVID. Our employees located in our European facilities are encouraged to travel by train rather than aircraft, and some employees benefit from local government incentives to use electric cars. We also put safety first in our locations. Our employees at our manufacturing facility in Italy follow mandatory safety training and take mandatory vision tests and a check-up by the occupational doctor every five years; we also have safety procedures which are drafted with assistance from a third-party safety consultant and updated twice a year. 

 

Social

 

Company Culture

Our employees are passionate about the work they do and thrive in a collaborative environment that fosters creative solutions to complex problems. The Company fosters a significant amount of collaboration and synergy among employees. Team members at any level are encouraged to provide suggestions and input to enable the Company’s success.

 

Employee Demographics

As of December 31, 2022, we had 197 employees, including 183 full-time employees, of whom 71 were in the R&D Department, 16 were in Quality and Regulatory Affairs, 38 were in Marketing and Sales, 32 were in Corporate Administration, and 26 were in Customer Care. As of December 31, 2022, approximately 32% of the Company’s workforce were female, and minorities represented approximately 19% of the Company’s workforce. As of December 31, 2022, approximately 57% of the Company’s employees were in the United States and 43% were outside of the United States. In 2022, our turnover rate was approximately 15% and we hired 53 full-time employees. We believe the improvement in our turnover rate, from 18% in 2021, is primarily attributed to our increased hiring in 2022 and the implementation of our DEI programs discussed below. 

 

Diversity, Equity & Inclusion (DEI)

We believe in contributing to a society that welcomes diverse voices and values differences in lived experiences, culture, religion, age, gender identity, sexual orientation, race, ethnicity, and neurodiversity. We are committed to ensuring this same environment for our employees – a culture where individuals feel safe, heard, and respected. We celebrate the uniqueness of our global workforce, especially in a company of our size, and appreciate that only through inclusion, ongoing learning, and partnership can we succeed.

 

In 2020, we created an internal webpage dedicated to DEI resources for our employees, kicked off a DEI committee and partnered with a DEI alliance to further evolve our DEI efforts. In 2022, we held biweekly meetings of the DEI committee, attended the Raleigh Chamber ‘Diversity, Equity & Inclusivity Conference in July, shared information on our social media pages about relevant events and holidays, and held various education events including DEI focused movie watch parties with follow-up discussion groups. We are also focused on incorporating DEI principles into our governance structure and believe having mix of backgrounds and experience in our Board composition is essential to understanding and reflecting the needs of our diverse stakeholders. Currently, one of eight board members self-identifies as a woman, and two of our eight Board members self-identify as individuals from underrepresented communities (defined as an individual who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, or Alaska Native, or who self-identifies as gay, lesbian, bisexual, or transgender).

 

COVID-19 Pandemic

Throughout the COVID-19 pandemic, employee safety is of top priority. Until August 2021, most of our employees globally worked from home since the beginning of the pandemic, except for those with a business need to engage in work onsite. Beginning in August 2021, we encouraged a return to the office on a hybrid basis, while monitoring the ongoing impact of the pandemic on our office locations. During 2022, our employees returned to the office three days per week. Ongoing safety measures remain in place at each of our locations including implementing pre-screening and social distancing requirements in addition to providing PPE. Our Global Prevention Team continues to monitor the impact of the pandemic on our global workforce and to carry out our ongoing planning and response efforts. We increased our employee communications to ensure frequent connections while working remotely across the company including regular all-hands meetings and employee newsletters.

 

Health & Wellness

Throughout 2022, health and wellness was a key focus of the Company, especially in light of the ongoing pandemic and new variants. Many of our employee communications focused on the physical and mental health of our employees. We remain committed to providing our workforce with flexible remote working schedules to suit their personal needs through this challenging time. We also continue to benchmark all of our health insurance offerings to ensure plan competitiveness.

 

20
Table of Contents

 

People Strategy

Our People Strategy is to create and maintain a culture of high performance and accountability through the attraction, retention and development of expert talent. To enhance our employees’ satisfaction and retention, we offer ongoing training opportunities that support professional growth. We have an annual performance review process for all employees worldwide to review performance and inform compensation recommendations. We compete for top talent with effective recruitment strategies, well defined roles and attractive total compensation packages. We keep talent engaged through appreciation, communication and creation of a great work environment. We support employee growth professionally and personally through formal and informal opportunities and leadership support.

 

Employee Engagement

We partner with Gallup, Inc., a global analytics and advice firm, to monitor and improve the engagement of our workforce. Gallup’s Q12 survey measures employee engagement based on twelve key needs of employees. We utilize survey results to identify strengths and weaknesses and create action plans to improve engagement and ultimately team performance. In 2022, we continued to see an improvement in our engagement score over the prior year. We continue to incorporate Gallup’s programs into our overall People Strategy.  

 

Compensation

In addition to competitive base salaries, we offer incentive-based compensation programs tied to the performance of key objectives. We also provide compensation in the form of retention grants of restricted stock units and/or stock options, which we believe help align longer term employee incentives with our company performance. Ensuring fair and equitable pay is also an important commitment we make to our employees.

 

Governance

 

Our Board of Directors, through its Nominating and Corporate Governance Committee, evaluates the governance and management practices of the Company. We believe our corporate governance guidelines and structure provide our stockholders with a dedicated, qualified and skilled board of directors and management team. Our governance structure includes:

 

 

●

annual elections of all board members;
 

●

an independent Board chair and separation of the CEO/Chair role;
 

●

diversity in skills, gender and ethnicity in our board and management team; and
 

●

the ability of stockholders to propose candidates for potential nomination to the board and proposals for consideration by stockholders at annual meetings.

 

Corporate Information

On February 23, 2021, we changed our corporate name to Asensus Surgical, Inc. Effective March 10, 2021, our principal executive offices are located at 1 TW Alexander Drive, Suite 160, Durham, NC 27703. The Company was originally incorporated on August 19, 1988 as a Delaware corporation.

 

The active subsidiaries of the Company are Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc.

 

Available Information

 

The Company maintains a website at www.asensus.com. We are not incorporating our website by reference into this Annual Report. Our Code of Business Conduct and Ethics, as reviewed and updated on October 26, 2022, is available on our website. Our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, are available free of charge on our website as soon as practicable after electronic filing of such material with, or furnishing it to, the U.S. Securities and Exchange Commission, or the SEC.

 

21
Table of Contents

 

ITEM 1.A.

RISK FACTORS

 

Our risk factors are grouped into the following categories: (1) Risks Related to the Operation of our Business; (2) Risks Related to Our Status as a Public Company; (3) Risks Related to Protection of our Intellectual Property; (4) Risks Related to the Regulation of our Business; and (5) General Risk Factors.

 

Risks Related to the Operation of our Business

 

We have a history of operating losses, and we may not be able to achieve or sustain profitability.

We have a limited operating history. We are not profitable and have incurred losses since our inception. Our accumulated deficit was $860.9 million and our working capital was $76.5 million as of December 31, 2022. We expect to continue to incur losses for the foreseeable future, and these losses will likely increase as we continue to develop and commercialize our products. We will continue to incur research and development and general and administrative expenses related to our operations, and sales and marketing expenses to support our commercial activities, as restructured. Even if we are successful in reducing our expenses or achieving profitability in the future, we may not be able to sustain profitability in subsequent periods. 

 

Our recurring operating losses and negative cash flows raise substantial doubt about our ability to continue as a going concern. We will need additional financing to execute our business plan and fund our operations.

Since inception, we have experienced recurring operating losses and negative cash flows and we expect to continue to generate operating losses and consume significant cash resources in the foreseeable future, particularly as we increase our research and development spending as we develop and seek regulatory approval for the LUNA System and enhancements to our digital surgery and Performance-Guided Surgery product offerings. Management has concluded that substantial doubt exists about our ability to continue as a going concern as a result of anticipated capital needs in conjunction with past recurring losses and an accumulated deficit. Our independent registered public accounting firm also included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended December 31, 2022 with respect to this uncertainty. We believe that our existing cash, cash equivalents, short-term investments and long-term investments, together with cash received from product, service, and lease sales will be sufficient to meet our anticipated cash needs into the first quarter of 2024. We will need additional financing to implement our next generation products strategy. We believe we have cash on hand to sustain our operations into the first quarter of 2024, and also believe we will need to raise capital in order to implement the LUNA System program. Substantial doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock and we may have a more difficult time obtaining financing.

 

Our strategic focus, on delivering tools and assistance to provide Performance-Guided Surgery opportunities, may not result in the growth of our business in the timeline we envision or at all.

On February 23, 2021, we announced a strategic focus on providing clinical intelligence to surgeons to provide Performance-Guided Surgery opportunities. We believe that the Senhance System, which digitizes the interface between the surgeon and the patient in laparoscopic surgery, can also be used, with our Augmented Intelligence offerings, to provide real-time clinical data throughout the entire surgical experience, assist in removing elements and factors that contribute to surgical variability and reduce complications. Our efforts to communicate and implement this strategy with hospitals, surgery centers and surgeons may take longer than we anticipate, may not be as successful as we contemplate, and may not result in a meaningful increase in our business or financial condition.

 

In order to compete successfully within the surgical robotics industry, we need to continue to evolve our robotic surgery products, including the innovations associated with assets we acquired.  Failure to develop, obtain regulatory approval for and commercialize such developments could have a material adverse effect on our business and financial position.

In order to compete successfully within the highly competitive surgical robotics industry, we need to continue to advance and innovate our robotic surgery products, including the innovations associated with the assets we acquired from MST in 2018.  Our focus currently is on harnessing the image technology acquired in the MST acquisition to advance the intelligence of our products through the ISU to provide meaningful real-time Augmented Intelligence to surgeons.  We have developed and received CE Mark in Europe and FDA clearance in the U.S. for articulating instruments. These assets are also vital to our Performance-Guided Surgery strategy. If we fail to continue to develop such innovations, or fail to obtain regulatory approval or clearance for or to successfully commercialize such innovations, such failure could have a material adverse effect on our business and financial position. 

 

We are also focused on commercializing our ISU as a vital part of our Performance-Guided Surgery initiative. If we are not successful in commercializing the ISU, our business could be materially adversely affected. Companies such as us rely on innovation and new product development to attract and retain customers. Such development efforts take time, are expensive, and there is no certainty that we will be successful in commercializing the ISU, developing the LUNA System, or receiving regulatory clearances and approvals, on a timely basis, if at all. If we are not successful in our development efforts, such failure will have a material adverse effect on our business and financial position.

 

22
Table of Contents

 

We may not be successful in realizing benefits from our collaboration agreements.

We are collaborating with Google on further developing the Asensus Cloud as a key component of our LUNA System product offerings, and have signed an MOU with KARL STORZ to increase sales of our ISU and to develop instruments and other technologies with them. We may not be successful in completing the definitive agreements with KARL STORZ or realizing the benefits of these collaborative programs. If we are not successful, our reputation and our operations and financial condition may be harmed.

 

The coronavirus (COVID-19) pandemic has negatively impacted our operations.

We have facilities located in the United States, Israel, Japan, and Italy. All of our facilities are in locations that are subject to, or have been subject to, travel restrictions, stay-at-home or shelter-in-place orders, or return-to-work on a hybrid basis. Our Senhance Systems are manufactured at a contract manufacturing facility in Milan. A variety of travel restrictions, caused delays in our product installation and training activities in 2022. Elective surgeries have also been curtailed a number of times during variant surges in 2022 in various parts of the globe. Although such procedures have recommenced in large part, the limits on elective procedures significantly impacted our ability to place our Senhance Systems, provide training, and increase the use of the Senhance Systems in place. It is uncertain whether elective surgeries will continue to be negatively impacted or halted again in the future by a resurgence of COVID-19 cases in any of these jurisdictions.

 

The global spread of COVID-19 and the various attempts to contain it continue to create significant volatility, uncertainty and economic disruption. The full extent to which the COVID-19 pandemic and the various responses to it impacts our business, operations and financial results continues to depend on numerous factors that we may not be able to accurately predict, including: the duration and scope of the pandemic, including new variants; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; the availability and cost to access the capital markets; the decline in elective surgical procedures; the effect on our customers and customer demand for Senhance Systems and the ability to provide training services; disruptions or restrictions on our employees’ ability to work and travel; and shortages of certain supplies and materials. In addition, any preventative or protective actions that governments implement or that we take in respect of COVID-19, such as travel restrictions or stay-at-home orders, may interfere with the ability of our employees, vendors and contract manufacturers to perform their respective responsibilities and obligations relative to the conduct of our business. Such results could have a material adverse effect on our operations, business, financial condition, results of operations, or cash flows.

 

We believe the COVID-19 pandemic, including emerging variant strains of the virus, will continue to negatively impact our operations and our ability to implement our market development efforts, which will have a negative effect on our financial condition. There is a risk that government actions will not be effective at containing further COVID-19 outbreaks, including from variants, and that government actions, including the orders and restrictions described above, that are intended to contain the spread of COVID-19 will have a devastating negative impact on the world economy at large, in which case the risks to our sales, operating results and financial condition described herein would be elevated significantly.

 

We are currently highly dependent on a single product, the Senhance System.  We cannot give any assurance that the Senhance System can be successfully commercialized.

We are currently highly dependent on the Senhance System, which is FDA cleared for sale in the United States, CE Marked for sale in the European Union and other countries, registered for sale in the Russian Federation, and approved for sale and reimbursement in Japan. We began our selling efforts for the Senhance System in the fourth quarter of 2015 in Europe, in the fourth quarter of 2017 in the United States, in the second quarter of 2018 in Asia and, through distributors in the Russian Federation in 2021.  We have had limited commercial success to date, particularly in 2019 and 2020. We have determined to focus our energies on market development and increased usage of the Senhance Systems that have been purchased and placed, as well as on our Performance-Guided Surgery strategy. We cannot assure you that we will be able to successfully improve the commercialization of the Senhance System, for a number of reasons, including, without limitation, failure in our market development and sales efforts, the long sales cycle associated with the purchase of capital equipment, and the potential introduction by our competitors of more clinically effective or cost-effective alternatives.  In addition, we are now more focused on developing the LUNA System than focusing on continued commercial success with the Senhance System.

 

We cannot assure you that we will be successful in continuing to grow utilization of the Senhance System and the ISU year over year.

While we believe Performance-Guided Surgery and our other tools available to assist the laparoscopic surgeon perform successful surgeries, it is time-consuming to educate and train physicians and educate hospitals on the benefits of use of the Senhance System with the ISU. If we cannot continue to grow our procedure volume year over year, our business and financial condition will be adversely affected.

 

23
Table of Contents

 

We have de-emphasized sales of the Senhance System, which occurs now only in areas in which our distributors and certain areas in Europe and Japan.

Purchase of a surgical robotic system such as the Senhance System represents a capital purchase by hospitals and other potential customers, which is a time-intensive process involving adoption by surgeons and approval of the capital purchase by administration. We are also expanding the potential market for robotic surgical systems with our focus on laparoscopic surgery.  Such expansion requires a different sales and marketing approach than a focus on open procedures.  We have found that sales are extremely difficult and take substantial effort. In late 2019, we began leasing Senhance Systems to hospitals with lease terms ranging from twelve to twenty-four months or more. We cannot assure you that these lease arrangements will lead to longer term placements or result in sales of our Senhance System.

 

We use distributors and sales agents in a number of geographic locations where we do not have sales personnel. We have procedures in place to require our distributors and sales agents to comply with applicable laws and regulations governing the sales of medical devices in the jurisdictions where they operate.  Failure to meet such requirements could subject us to financial penalties or the suspension or termination of the ability to sell our products in such jurisdiction.  

 

The surgical robotics and digital surgery industries are increasingly competitive, which can negatively impact our commercial opportunities.

The medical device industry is highly competitive, and we face significant competition from many companies that are researching and marketing products designed to address minimally invasive and robotic-assisted surgery, including new entrants in the competitive market. We are currently commercializing the Senhance System in the United States with FDA 510(k) clearance, in Europe which accepts a CE Mark, the Middle East, the Commonwealth of Independent States, and selected countries in Asia. We face significant competition in such markets. Many of our competitors, including Intuitive Surgical, have significantly greater financial, manufacturing, marketing and product development resources than we do. Some of the medical device companies we compete with or expect to compete with include Medtronic plc, Intuitive Surgical Inc., Vicarious Surgical, Inc., Momentis Surgical, Distalmotion SA, and CMR Surgical Ltd., Activ Surgical, Inc., Theator Surgical, CareSyntax Inc. and a number of minimally invasive surgical device and robotic surgical device manufacturers and providers of products and therapies that are designed to reduce the need for or attractiveness of surgical intervention. In addition, many other universities and private and public research institutions are or may become active in research involving surgical devices for minimally invasive and robotic-assisted surgery.

 

We are also expanding the potential market for robotic surgical systems with our focus on laparoscopic surgery. Such expansion may lead to additional competition with companies with sufficiently higher resources than ours. We believe that our ability to successfully compete will depend on, among other things: the efficacy, safety and reliability of our products; our ability to commercialize and market our cleared or approved products; the completion of our development efforts and receipt of regulatory clearance or approval for instruments and accessories to support the use of the Senhance System; the cost of ownership and use of our products in relation to alternative devices; the timing and scope of regulatory clearances or approvals, including any expansion of the indications for use for our products; whether our competitors substantially reduce the cost of ownership and use of an alternative device; our ability to protect and defend intellectual property rights related to our products; our ability to have our partners manufacture and sell commercial quantities of any cleared or approved products to the market; our ability to adapt to changes in the regulatory environment; the effectiveness of our sales and marketing efforts; and acceptance of future products by physicians and other healthcare providers.

 

If our competitors market products that are more effective, safer, easier to use or less expensive than our products or future products, or that reach the market sooner than our products, we may not achieve commercial success. In addition, the medical device industry is characterized by rapid technological change. It may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or products obsolete or less competitive.

 

We anticipate that the highly competitive surgical robotics environment can lead our competitors to attempt to slow or derail our commercial progress. We are using our best efforts to enter the commercial markets effectively and efficiently while maintaining compliance with all regulatory and legal requirements. Responding to the actions of our competitors will require the attention of our management and may distract the management team from its focus on our commercial operations and lead to increased costs of commercialization, which could have a negative impact on our financial position.

 

We also anticipate that the competitive surgical robotics and digital surgery environments will become more intense because of increased consolidation by companies in the healthcare industry looking to achieve cost reductions. Such consolidation may have an adverse effect on our business operations.

 

24
Table of Contents

 

Use of our Senhance System requires training for surgeons, and inadequate training may lead to negative patient outcomes, which could harm our business, financial condition, and results of operations.

The successful use of our Senhance System depends in part on the training and skill of the surgeon performing the procedure and his or her comfort level with the use of a robotic device. We provide training and proctoring, as well as Senhance Connect, that allows us to provide real-time guidance as desired. We cannot be certain that all of the surgeons that use our Senhance System have received and completed sufficient training. If a surgeon uses our Senhance System incorrectly, or without adhering to or completing all relevant training, their patients could be negatively affected. Adverse safety outcomes that arise from improper or incorrect use of our Senhance System may limit adoption of our Senhance System, which could harm our sales, business, financial condition, and results of operations.

 

We will require substantial additional funding to advance our current plans.

We are focused on our development efforts for our products, including the LUNA System and enhanced digital solutions, and commercialization of the Senhance System, ISU and other products, as well as market development for our products and other research and development activities. We expect increased research and development spend associated with the development of the LUNA System, next generation versions of the ISU and enhanced digital solutions, putting additional pressure on funding requirements as we advance through regulatory processes and commercialization, if our R&D efforts are successful. We intend to advance multiple additional products through clinical and pre-clinical development in the future. We will need to raise additional capital in the future in order to fund these priorities and achieve our business objectives. We cannot assure you that we will be successful in obtaining additional financing in the future on terms acceptable to the Company or at all.

 

Until we generate a sufficient amount of revenue to finance our cash requirements, which may never occur, we expect to finance future cash needs primarily through public or private equity offerings, debt financings or strategic collaborations. We do not know whether additional funding will be available on acceptable terms, or at all. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more of our research and development programs. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution; and debt financing, if available, may involve restrictive covenants that limit our operations. To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our products or grant licenses on terms that may not be favorable to us.

 

Negative publicity, whether true or not, concerning us or our products could reduce market acceptance of our products and could result in decreased demand for the Senhance System.

There have been social media and other publications regarding us and the Senhance System published from time to time since we started selling the Senhance System. Negative media and social media coverage, whether true or not, concerning our products or us could reduce market acceptance of the Senhance System and increase volatility in our stock price.

 

We are subject to risk as a result of our international manufacturing operations.

Because most of our products are manufactured at third-party facilities located in Europe, Israel and Singapore, our operations are subject to risk inherent in doing business internationally. Such risks include the adverse effects on operations from corruption, war, international terrorism, civil disturbances, political instability, government activities such as border taxes and renegotiation of treaties, deprivation of contract and property rights and currency valuation changes. Countries may adopt other measures, such as controls on imports or exports of goods, technology, or data, that could adversely impact the Company’s operations and supply chain and limit the Company’s ability to offer our products and services as designed. These measures could require us to take various actions, including changing suppliers and restructuring business relationships. Changing our operations in accordance with new or changed trade restrictions can be expensive, time-consuming, disruptive to our operations and distracting to management. Such restrictions can be announced with little or no advance notice, and we may not be able to effectively mitigate all adverse impacts from such measures. Any of these events could increase the cost of our products and services, or otherwise have a materially adverse impact on our or our suppliers’ businesses and results of operations.

 

Fluctuations in foreign currency exchange rates may adversely affect our financial results.

We conduct operations in several different countries, including the United States and throughout Europe, and portions of our revenues, expenses, assets and liabilities are denominated in U.S. dollars, Euros, and other currencies. Since our consolidated financial statements are presented in U.S. dollars, we must translate revenues, income and expenses, as well as assets and liabilities, into U.S. dollars at exchange rates in effect during or at the end of each reporting period. We have not historically hedged our exposure to foreign currency fluctuations.  Accordingly, increases or decreases in the value of the U.S. dollar against the Euro and other currencies could materially affect our net operating revenues, operating income and the value of balance sheet items denominated in foreign currencies.

 

25
Table of Contents

 

Our global operations expose us to additional risks and challenges associated with conducting business internationally.

The international nature of our business, particularly in Europe, Israel, Asia and the Russian Federation, may expose us to risks inherent in conducting foreign operations. These risks include: challenges associated with managing geographically diverse operations, which require an effective organizational structure and appropriate business processes, procedures and controls; the high cost of doing business in foreign jurisdictions, including compliance with international and U.S. laws and regulations that apply to our international operations; currency exchange and interest rate fluctuations and the resulting effect on our revenue and expenses, and the cost and risk of entering into hedging transactions, if we chose to do so in the future; changes in a specific country’s or region’s political or economic environment; trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments; potentially adverse tax consequences; complexities and difficulties in obtaining protection and enforcing our intellectual property; compliance with additional regulations and government authorities in a highly regulated business; difficulties associated with staffing and managing foreign operations, including differing labor relations; and general economic and political conditions outside of the U.S.

 

The risks that we face in our international operations may continue to intensify as we further develop and expand our international operations.

 

We expect our gross margins to vary over time, and changes in our gross margins could adversely affect our financial condition or results of operations.

We began selling the Senhance System in 2015.  Our gross margins have fluctuated from period to period, and we expect that they will continue to fluctuate in the future. Our gross margins have been and may continue to be adversely affected by numerous factors, including: service costs, changes in customer, geographic or product mix; the number of Senhance Systems sold vs. placed, our ability to maintain or reduce production costs, changes in production volume driven by demand for our products, changes in material, labor or other manufacturing-related costs, including increases in costs relating to global supply shortages and inflation, and the impact of foreign exchange rate fluctuations for foreign-currency denominated costs, fluctuations in foreign currency exchange rates and changes to U.S. and foreign trade policies, including the enactment of tariffs on goods imported into the U.S., inventory obsolescence and product recall charges and market conditions.

 

If we are unable to offset the unfavorable impact of the factors noted above by increasing the volume of products shipped, reducing product manufacturing costs or otherwise, our business, financial condition, results of operations or cash flows may be materially adversely affected.

 

We face risks arising from sole suppliers of components and our ability to meet delivery schedules for sales of our products.

The Senhance System is manufactured for us under contract by a third-party manufacturer. We or our manufacturer acquire raw materials and components of the Senhance System from vendors, some of which are sole suppliers. Although we believe that we have the manufacturing capacity and inventory reserves to meet our anticipated Senhance System sales for the foreseeable future, we are currently taking steps to develop redundant manufacturing and supply alternatives. We cannot assure you that we will be successful in developing these redundant supply and manufacturing capabilities. If we are not successful, our business operations could suffer.

 

Our products require precise, high-quality manufacturing. We and our contract manufacturers will be subject to ongoing periodic unannounced inspection by the FDA and non-U.S. regulatory authorities to ensure strict compliance with the quality systems regulations, current “good manufacturing practices” and other applicable government regulations and corresponding standards. If we or our contract manufacturers fail to achieve and maintain high manufacturing standards in compliance with QSR, we may experience manufacturing errors resulting in patient injury or death, product recalls or withdrawals, delays or interruptions of production or failures in product testing or delivery, delay or prevention of filing or approval of marketing applications for our products, cost overruns or other problems that could seriously harm our business.

 

Global supply shortages may prevent or restrict our ability to purchase adequate supplies of materials, parts and components at acceptable prices, which could result in delivery delays for our products or increases in our manufacturing costs.

A disruption or termination in the supply of components could result in our inability to meet demand for our products, which could harm our ability to generate revenues, lead to customer dissatisfaction, and damage our reputation and our brand. Furthermore, if we are required to change the manufacturer of a key component of our products, we may be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The time and processes associated with the verification of a new manufacturer could delay our ability to manufacture our products on schedule or within budget, which may have a material adverse impact on our business, financial condition, results of operations, or cash flows. In addition, our ability to meet customers’ demands depends, in part, on our ability to timely obtain an adequate delivery of quality materials, parts, and components from our suppliers. Any such supply shortage could adversely impact our business, financial condition, results of operations, or cash flows.

 

Labor shortages may disrupt our operations and result in delays in the manufacture and delivery of our products.

Increased labor shortages globally, including staff burnout and attrition, could also impact our ability to hire and retain personnel critical to our manufacturing, logistics, and commercial operations. We are also highly dependent on the principal members of our management and scientific staff. Attracting and retaining qualified personnel is critical to our success, and competition for them has become more intense. The loss of critical members of our team, or our inability to attract and retain qualified personnel, could significantly harm our operations, business, and ability to compete. In addition, hospitals are also experiencing staffing shortages and supply chain issues that could impact their ability to provide patient care.

 

26
Table of Contents

 

The inflationary environment could materially adversely impact our business and results of operations.

Changes in economic conditions and supply chain constraints and steps taken by governments and central banks, particularly in response to the COVID-19 pandemic as well as other stimulus and spending programs, could lead to higher inflation than previously experienced or expected, which could, in turn, lead to an increase in costs. An inflationary environment could have a negative impact on our expenses, increase our labor costs and reduce our available cash flow.

 

Because our design, development and manufacturing capabilities are limited, we rely on third parties to design, develop, manufacture or supply some of our products. An inability to find additional or alternate sources for these services and products could materially and adversely affect our financial condition and results of operations.

We have used third-party design and development sources to assist in the design and development of our medical device products. In the future, we may choose to use additional third-party sources for the design and development of our products. If these design and development partners are unable to provide their services in the timeframe or to the performance level that we require, we may not be able to establish a contract and obtain a sufficient alternative supply from another supplier on a timely basis and in the manner that we require.

 

Natural disasters and the effects of climate change could disrupt our business and harm our financial condition.

The effects of climate change, weather or other events could adversely impact our supply chain, including our ability to manufacture our products, source materials or components or services from suppliers (including sole-source suppliers) that are needed for such manufacturing (including sterilization), or provide products to our customers, including events that impact key distributors. Natural disasters, including the impacts of climate change, hurricanes, tornadoes, windstorms, fires, earthquakes and floods and other extreme weather events, global health pandemics, war, terrorism, labor disruptions and international conflicts that could cause significant economic disruption and political and social instability, could result in decreased demand for our products, or adversely affect our manufacturing and distribution capabilities or cause interruptions in our supply chain.

 

Our operations, and the activities of our customers, vendors or distributors, could be disrupted by climate change. The physical changes caused by climate change may prompt changes in regulations or consumer preferences which in turn could have negative consequences for our and our customers’ businesses. Potential physical risks from climate change may include altered distribution and intensity of rainfall, prolonged droughts or flooding, increased frequency of wildfires and other natural disasters, rising sea levels, and a rising heat index, any of which could cause negative impacts to our and our customers’ businesses. If such events affect our customers’ businesses, they may purchase fewer of our products, and our revenues may be negatively impacted.

 

There has been a broad range of proposed and promulgated state, national and international regulations aimed at reducing the effects of climate change. Such regulations could result in additional costs to maintain compliance and additional income or other taxes. Climate change regulations continue to evolve, and it is not possible to accurately estimate potential future compliance costs.

 

Risks Related to Our Status as a Public Company

 

Our stock price has been volatile and may experience additional volatility and fluctuation in the future. 

The market price of our common stock has been, and may continue to be, volatile, and the market price of our common stock could decrease and could cause you to lose some or all of your investment in our common stock.  During the two-year period ended December 31, 2022, the market price of our common stock fluctuated from a high of $6.95 per share to a low of $0.28 per share. The market price of our common stock may continue to fluctuate significantly in response to numerous factors, some of which are beyond our control, such as

 

 

•

the announcement of favorable or unfavorable news regarding us, including our product development efforts and regulatory clearance activities;
 

•

the achievement of lease placements or commercial sales of our products;
 

•

the announcement of new products or product enhancements or collaborations by us or our competitors;
 

•

variations in our and our competitors’ results of operations;
 

•

future issuances of common stock or other securities;
 

•

the addition or departure of key personnel;
 

•

announcements by us or our competitors of acquisitions, investments or strategic alliances; and
 

•

general market conditions and other factors, including factors unrelated to our operating performance.

 

27
Table of Contents

 

We are currently a smaller reporting company, which may limit our ability to raise sufficient capital to advance our LUNA System and Performance-Guided Surgery development efforts.

Our stock price was below $1.00 per share during much of 2022. If our stock price continues to remain under a $1.00 per share for an extended period, we will be subject to the SEC’s “baby shelf” rules, which may limit the amount of capital we can raise over a twelve month period under a Form S-3 registration statement. Such rules may make our capital financing transactions more difficult or expensive.

 

Our stockholders have experienced dilution of their percentage ownership of our stock and may experience additional dilution in the future.

We have raised significant capital through the issuance of our common stock and warrants and anticipate that we may need to raise substantial additional capital in order to continue our operations and achieve our business objectives. We cannot assure you that we will be able to sell shares or other securities in any offering at a price per share that is equal to or greater than the price per share paid by investors in previous offerings, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in previous offerings. The future issuance of the Company’s equity securities will further dilute the ownership of our outstanding common stock.  The market price of our common stock has been, and may continue to be, highly volatile, and such volatility could cause the market price of our common stock to decrease and could cause stockholders to lose some or all of their investment in our common stock.

 

We do not currently intend to pay dividends on our common stock, and any return to investors is expected to come, if at all, only from potential increases in the price of our common stock.

At the present time, we intend to use available funds to finance our operations. Accordingly, while payments of dividends is within the discretion of our board of directors, no cash dividends on our common stock have been declared or paid by us, and we have no intention of paying any such dividends in the foreseeable future. Any return to investors is expected to come, if at all, only from potential increases in the price of our common stock.  

 

Risks Related to Protection of our Intellectual Property

 

Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.

Other entities may have or obtain patents or proprietary rights that could limit our ability to manufacture, use, sell, offer for sale or import products or impair our competitive position. In addition, to the extent that a third-party develops new technology that covers our products, we may be required to obtain licenses to that technology, which licenses may not be available or may not be available on commercially reasonable terms, if at all. If licenses are not available to us on acceptable terms, we will not be able to market the affected products or conduct the desired activities, unless we challenge the validity, enforceability or infringement of the third-party patent or circumvent the third-party patent, which would be costly and would require significant time and attention of our management. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing products using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations.

 

If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts, any of which could materially adversely affect our liquidity, business prospects and results of operations.

 

Third parties may sue us for infringing their patent rights. Likewise, we may need to resort to litigation to enforce a patent issued or licensed to us or to determine the scope and validity of proprietary rights of others. In addition, a third-party may claim that we have improperly obtained or used its confidential or proprietary information. Furthermore, in connection with our third-party license agreements, we generally have agreed to indemnify the licensor for costs incurred in connection with litigation relating to intellectual property rights. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and the litigation would divert our management’s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than us because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue our operations.

 

If any parties successfully claim that our creation or use of proprietary technologies infringes upon their intellectual property rights, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties’ patent rights. In addition to any damages we might have to pay, a court could require us to stop the infringing activity or obtain a license. Any license required under any patent may not be made available on commercially acceptable terms, if at all. In addition, such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and products, which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations.

 

28
Table of Contents

 

For our Senhance System, we rely on our license from the European Union, and any loss of our rights under such license agreement, or failure to properly prosecute, maintain or enforce the patent applications underlying such license agreement, could materially adversely affect our business prospects for the Senhance System.

Some of the patents and patent applications in our patent portfolio related to the Senhance System are licensed to Asensus Surgical Italia S.r.l. under a license agreement with the European Union. Presently, we rely on such licensed technology for our Senhance System products and may license additional technology from the European Union or other third parties in the future. The EU license agreement gives us rights for the commercial exploitation of the licensed patents, patent applications and know-how, subject to certain provisions of the license agreement. Failure to comply with these provisions could result in the loss of our rights under the EU license agreement. Our inability to rely on these patents and patent applications which are the basis of certain aspects of our Senhance System technology would have an adverse effect on our business.

 

Further, our success will depend in part on the ability of us, the European Union and other third-party licensors to obtain, maintain and enforce patent protection for our licensed intellectual property and, in particular, those patents to which we have secured exclusive rights. We, the European Union or other third-party licensors may not successfully prosecute the patent applications which are licensed to us, may fail to maintain these patents, and may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than necessary to obtain an acceptable outcome from any such litigation. Without protection for the intellectual property we have licensed, other companies might be able to offer substantially identical products for sale, which could materially adversely affect our competitive business position, business prospects and results of operations.

 

If we or our licensors are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.

In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, know-how and confidential and proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we will seek to enter into confidentiality agreements with our employees, consultants and collaborators upon the commencement of their relationships with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees also generally provide and will generally provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations.

 

If we are unable to obtain and enforce patent protection for our products, our business could be materially harmed.

Our success depends, in part, on our ability to protect proprietary methods and technologies that we develop or license under the patent and other intellectual property laws of the United States and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. However, we may not hold proprietary rights to some patents required for us to commercialize our proposed products. Because certain U.S. patent applications are confidential until patents issue, such as applications filed prior to November 29, 2000, or applications filed after such date which will not be filed in foreign countries, third parties may have filed patent applications for technology covered by our pending patent applications without our being aware of those applications, and our patent applications may not have priority over those applications. For this and other reasons, we or our third-party collaborators may be unable to secure desired patent rights, thereby losing desired exclusivity. If licenses are not available to us on acceptable terms, we will not be able to market the affected products or conduct the desired activities, unless we challenge the validity, enforceability or infringement of the third-party patent or otherwise circumvent the third-party patent.

 

Our strategy depends on our ability to promptly identify and seek patent protection for our discoveries. In addition, we may rely on third-party collaborators to file patent applications relating to proprietary technology that we develop jointly during certain collaborations. The process of obtaining patent protection is expensive and time-consuming. If our present or future collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business will be adversely affected. Despite our efforts and the efforts of our collaborators to protect our proprietary rights, unauthorized parties may be able to develop and use information that we regard as proprietary.

 

29
Table of Contents

 

The issuance of a patent provides a presumption, but does not guarantee that it is valid. Any patents we have obtained, or obtain in the future, may be challenged or potentially circumvented. Moreover, the United States Patent and Trademark Office, or the USPTO, may commence interference proceedings involving our patents or patent applications. Any such challenge to our patents or patent applications would be costly, would require significant time and attention of our management and could have a material adverse effect on our business. In addition, future court decisions may introduce uncertainty in the enforceability or scope of any patent, including those owned by medical device companies.

 

Our pending patent applications may not result in issued patents. The patent position of medical device companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in medical device patents. Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Therefore, the enforceability or scope of our owned or licensed patents in the United States or in foreign countries cannot be predicted with certainty, and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection for our pending patent applications, those we may file in the future, or those we may license from third parties.

 

We cannot assure you that any patents that will issue, that may issue or that may be licensed to us will be enforceable or valid or will not expire prior to the commercialization of our products, thus allowing others to more effectively compete with us. Therefore, any patents that we own or license may not adequately protect our future products.

 

Certain software being developed for the LUNA System and the ISU may include third-party open source software. Any failure to comply with the terms of one or more open source software licenses could adversely affect our business, subject us to litigation, or create potential liability.

Certain software being developed for the LUNA System and for the ISU may include third-party open source software and we expect to continue to incorporate open source software in the future. The use of open source software involves a number of risks, many of which cannot be eliminated and could negatively affect our business. For example, we cannot ensure that we have effectively monitored our use of open source software or that we are in compliance with the terms of the applicable open source licenses or our current policies and procedures. There have been claims against companies that use open source software asserting that the use of such open source software infringes the claimants’ intellectual property rights. As a result, we could be subject to suits by third parties claiming infringement on such third parties’ intellectual property rights. Litigation could be costly for us to defend, have a negative effect on our business, financial condition and results of operations, or require us to devote additional research and development resources to modify our computational drug discovery platform.

 

Use of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties, controls on the origin of the software or other contractual protections regarding infringement claims or the quality of the code, including with respect to security vulnerabilities. In addition, certain open source licenses require that source code for software programs that interact with such open source software be made available to the public at no cost and that any modifications or derivative works to such open source software continue to be licensed under the same terms as the open source software license. The terms of various open source licenses have not been interpreted by courts in the relevant jurisdictions, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to market our solutions. By the terms of certain open source licenses, if portions of our proprietary software are determined to be subject to an open source license or if we combine our proprietary software with open source software in a certain manner, we could be required to release the source code of our proprietary software and to make our proprietary software available under open source licenses, each of which could reduce or eliminate the effectiveness of our computational discovery efforts. We may also face claims alleging noncompliance with open source license terms or misappropriation or other violation of open source technology. Any of these events could create liability for us and damage our reputation, which could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.

 

Risks Related to Regulation of our Business

 

Even if we obtain regulatory clearances or approvals for our products, the terms thereof and ongoing regulation of our products may limit how we manufacture and market our products, which could materially impair our ability to generate anticipated revenues.

Once regulatory clearance or approval has been granted, the cleared or approved product and its manufacturer are subject to continual review. Any cleared or approved product may be promoted only for its intended uses. In addition, if the FDA or other non-U.S. regulatory authorities clear or approve any of our products, the labeling, packaging, adverse event reporting, storage, advertising and promotion for the product will be subject to extensive regulatory oversight. We and any outsourced manufacturers of our products are also required to comply with the FDA’s QSR, or similar requirements of non-U.S. regulatory authorities which includes requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation as well as other quality system requirements and regulations from non-U.S. regulatory authorities. Further, all manufacturing facilities are subject to routine regulatory inspection.

 

30
Table of Contents

 

If we fail to comply with the regulatory requirements of the FDA, either before or after clearance or approval, or other non-U.S. regulatory authorities, or if previously unknown problems with our products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions, including: restrictions on our products, manufacturers or manufacturing process; adverse inspectional observations (Form 483), Warning Letters, letters incorporating inspectional observations, or consent decrees; civil or criminal penalties or fines; injunctions; product seizures, detentions or import bans; voluntary or mandatory product recalls and publicity requirements; suspension or withdrawal of regulatory clearances or approvals; total or partial suspension of production; imposition of restrictions on operations, including costly new manufacturing requirements; refusal to clear or approve pending applications or premarket notifications; and import and export restrictions.

 

Any of these sanctions could have a material adverse effect on our reputation, business, results of operations and financial condition. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all. In addition, the FDA and other non-U.S. regulatory authorities may change their policies and additional regulations may be enacted that could prevent or delay regulatory clearance or approval of our products. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are not able to maintain regulatory compliance, we would likely not be permitted to market our future products and we may not achieve or sustain profitability. 

 

Once our products are cleared or approved, modifications to our products may require new 510(k) clearances, de novo clearance, premarket approvals or new or amended CE Certificates of Conformity, and may require us to cease marketing or recall the modified products until clearances, approvals or the relevant CE Certificates of Conformity are obtained.

Any modification to a 510(k)-cleared or CE marked device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use requires a new 510(k) clearance or, possibly, PMA approval or de novo authorization or review by the Notified Body for CE marked devices. The FDA or Notified Body requires every manufacturer to make this determination in the first instance, but the FDA/Notified Body may review such determinations. The FDA/Notified Body may not agree with our decisions regarding whether new clearances or approvals are necessary. If the FDA/Notified Body disagrees with our determinations for any future changes, or prior changes to previously marketed products, we may be required to cease marketing or to recall the modified products until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties.

 

Furthermore, the FDA’s review of the 510(k) program may make it more difficult for us to make modifications to our products, either by imposing more strict requirements on when a new 510(k) for a modification to a previously cleared product must be submitted, or applying more onerous review criteria to such submissions. In October 2017, the FDA issued guidance documents addressing when to submit a new 510(k) notice for modifications to cleared products and the criteria for evaluating substantial equivalence. The interpretation of the guidance documents by the FDA staff could lead to instances where the FDA disagrees with the Company’s decision regarding a change, and could result in Warning Letters and other enforcement actions.

 

Our future success depends on our ability to develop, receive regulatory clearance or approval for, and introduce new products that will be accepted by the market in a timely manner. There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future products on a timely basis, if at all, and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.

When a 510(k) notice, de novo request, or PMA is submitted for a new product or for a change to an existing product, there is no guarantee that it will receive FDA authorization. Failure to receive clearance or approval for our new products or indications for use would have an adverse effect on our ability to expand our business. For example, the FDA review process is ongoing for our 510(k) notice to expand the Senhance System indications to pediatric use. If we do not receive clearance for this expanded indication, we will not be able to market the device for pediatric procedures in the U.S. until such clearance is obtained.

 

31
Table of Contents

 

Our products are subject to international regulatory processes and approval or certification requirements. If we do not obtain and maintain the necessary international regulatory approvals or certifications, we will not be able to sell our products in other countries.

To be able to sell our products in other countries, we must obtain regulatory approvals or certifications and comply with the regulations of those countries, which may differ substantially from those of the U.S. These regulations, including the requirements for approvals or certifications and the time required for regulatory review, vary from country to country. Obtaining and maintaining foreign regulatory approvals or certifications is complex, and timing to obtain clearances or certifications in those countries varies; therefore, we cannot be certain that we will receive regulatory approvals or certifications in any other country in which we plan to market our products or obtain such approvals or certifications on a favorable schedule. The time required to obtain marketing authorization in other countries might differ from that required to obtain FDA authorization. If we fail to obtain or maintain regulatory approval or certification in any other country in which we plan to market our products, our ability to generate revenue will be harmed. Regulatory authorization of a product in one country does not ensure regulatory authorization in another, but a failure or delay in obtaining marketing authorization in one country may negatively impact the regulatory process in others.

 

One of the most significant moving targets related to the regulatory landscape is in the EU; more specifically, the medical devices regulation has recently evolved. Regulation (EU) 2017/745 on medical devices became applicable in the European Union on May 26, 2021. The MDR, which replaced the MDD in May 2021 after a four-year transition period, which has now been extended to a seven-year transition period for some class IIb and class IIa, imposes significant additional premarket and post-market certification requirements on medical devices marketed in the EU. European Economic Area (EEA) Member State legislation may also restrict or impose limitations on our ability to advertise our products directly to the general public. In addition, voluntary EU and national codes of conduct provide guidelines on the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare providers harming our business, operating results and financial condition.  If we are unable to obtain timely, updated post-market certifications for our products under the MDR, or experience difficulty scheduling with a Notified Body, our business prospects in the EU could be materially adversely affected, which could have a material adverse effect on our financial results.

 

Even after clearance or approval for our products is obtained, we are subject to extensive post-market regulation by the FDA and other regulators. Our failure to meet strict regulatory requirements could require us to pay fines, incur other costs or even close our facilities.

Even after we have obtained the proper regulatory clearance or approval to market a product, the FDA has the power to require us to conduct post-market studies. These studies can be very expensive and time-consuming to conduct. Failure to complete such studies in a timely manner could result in the revocation of clearance or approval and the recall or withdrawal of the product, which could prevent us from generating sales from that product in the United States. The FDA has broad enforcement powers, and any regulatory enforcement actions or inquiries, or other increased scrutiny on us, could dissuade some surgeons from using our products and adversely affect our reputation and the perceived safety and efficacy of our products.

 

We are also required to comply with the FDA’s QSR, which covers the methods used in, and the facilities and controls used for, the design, manufacture, quality assurance, labeling, packaging, sterilization, storage, shipping, installation and servicing of our marketed products. The FDA enforces the QSR through periodic announced and unannounced inspections of manufacturing facilities. In addition, in the future, regulatory authorities and/or customers may require specific packaging of sterile products, which could increase our costs and the price of our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as the QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.

 

If one of our products, or a malfunction of one of our products, causes or contributes to a death or a serious injury, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.

Under the FDA’s regulations, we are required to report to the FDA any incident in which our product may have caused or contributed to a death, serious health threat or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. Repeated product malfunctions may result in a voluntary or involuntary product recall, which could divert managerial and financial resources, impair our ability to manufacture our products in a cost-effective and timely manner, and have an adverse effect on our reputation, results of operations and financial condition. We are also required to follow detailed recordkeeping requirements for all firm-initiated medical device corrections and removals, and to report such corrective and removal actions to the FDA if they are carried out in response to a risk to health and have not otherwise been reported under the regulations.

 

All manufacturers bringing medical devices to market in the EEA are legally bound to report any incident that led or might have led to the death or serious deterioration in the state of health of a patient, user or other person, and which the manufacturer’s device is suspected to be a contributory cause, to the competent authority in whose jurisdiction the incident occurred. In such case, the manufacturer must file an initial report with the relevant competent authority, which would be followed by further evaluation or investigation of the incident and a final report indicating whether further action is required.  Any adverse event involving our products could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Adverse events involving our products have been reported to us in the past, and we cannot guarantee that they will not occur in the future. Any corrective action, whether voluntary or involuntary, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.

 

32
Table of Contents

 

A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us.

The FDA and similar foreign governmental authorities such as the competent authorities of the EEA countries have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture or in the event that a product poses an unacceptable risk to health. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design or labeling defects or other deficiencies and issues.

 

Any future recalls of any of our products would divert managerial and financial resources and could have an adverse effect on our reputation, results of operations and financial condition, which could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers’ demands. We may also be required to bear other costs or take other actions that may have a negative impact on our future sales and our ability to generate profits.

 

Our employees, consultants, third-party vendors and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk of employee, consultant, third-party vendor or collaborator fraud or other misconduct. Misconduct by our employees, consultants, third-party vendors or collaborators could include, among other things, intentional failures to comply with FDA, EU or other regulations, provide accurate information to the FDA or other regulators, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commissions, customer incentive programs and other business arrangements. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business, financial condition and results of operations, and result in the imposition of significant fines or other sanctions against us.

 

U.S. legislative, FDA regulatory reforms or global regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained.

Legislative changes could significantly alter the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products. In addition, FDA regulations and guidance could be revised or reinterpreted by the FDA in ways that could significantly affect our business and our products. Any new regulations or revisions, or reinterpretations of existing regulations, may impose additional costs or lengthen review times of future products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations will be changed, and what the impact of such changes, if any, may be. We anticipate that future regulatory requirements may focus on artificial intelligence or clinical decision support products, such as our ISU, which may subject our products to additional regulations.

 

Disruptions at the FDA and other government agencies or notified bodies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent products from being developed, cleared, certified, approved, or commercialized in a timely manner or at all, which may adversely affect our business.

The delivery of healthcare by hospitals, health systems, and physicians depends on a number of government agencies and services. Further prolonged government shutdowns or restrictions could impact inspections, regulatory review and certifications, grants or approvals, or could cause other situations that could impede their ability to effectively deliver healthcare, including attempts to reduce payments and other reimbursements to hospitals by federal healthcare programs. These situations could adversely affect our customers’ ability to perform procedures with our devices and/or their decisions to purchase additional products from us. In addition, the review and clearance, approval, or certification of new products can be affected by a variety of factors globally, including government budget and funding levels, global health concerns, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. In addition, government funding of other government agencies that fund research and development activities is subject to unpredictable and ever-changing political processes. Disruptions at the FDA and other agencies or notified bodies for any of these or other reasons may cause significant regulatory delays and, therefore, delay our efforts to seek clearances, approvals, or certifications from the FDA, foreign authorities, and notified bodies and adversely affect business travel and import and export of products, all of which could have a material adverse effect on our business, financial condition, results of operations, or cash flows. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.

 

33
Table of Contents

 

We may be subject, directly or indirectly, to federal and state anti-kickback, fraud and abuse, false claims, privacy and security and physician payment transparency laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

Our business activities are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician payment transparency laws further described under “Business” above. Some such laws, including privacy laws, may include private rights of action and can lead to class action litigation. If our operations are found to be in violation of any of such laws that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.

 

We are subject to an evolving set of complex laws and regulations relating to privacy, data protection and information collection matters.

There are numerous state, federal, and foreign laws, regulations, decisions, and directives regarding privacy rights and the collection, storage, transmission, use, processing, disclosure, and protection of different types of personal data and personal information and other customer or other data, the scope of which is continually evolving and subject to differing interpretations. We also must comply with the policies, procedures and business requirements of our customers relating to data privacy and security, which can vary based upon the customer, the customer’s industry or location, and the product the customer selects, and which may be more restrictive than the privacy and security measures required by law or regulation. Around the world, the privacy and data protection legal landscape is rapidly changing, which may require us to adjust aspects of our operations or expend significant time and resources to come into compliance with new laws or regulatory obligations. In particular, the European Union and many countries in Europe have stringent privacy laws and regulations, which may impact our ability to profitably operate in certain European countries or to offer products that meet the needs of customers subject to European Union privacy laws and regulations.

 

For example, the GDPR provides that EEA Member States may make their own further laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to use and share personal data or could cause our costs to increase and harm our business and financial condition. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EEA member states may result in fines of up to 4% of the total worldwide annual turnover of the preceding financial year and other administrative penalties. Compliance with the new data protection rules imposed by GDPR may be onerous and adversely affect our business, financial condition, and results of operations.

 

Global laws are increasingly restricting and regulating the cross-border transfer of personal data, which may require us to undertake additional obligations in order to receive personal data from overseas customers or transfer such data, including to our vendors. For example, the GDPR restricts the ability of companies to transfer personal data from the EEA to the United States and other countries, which may adversely affect our ability to transfer or receive personal data or otherwise may cause us to incur significant costs to undertake data transfer impact assessments and implement lawful data transfer mechanisms. Some available lawful transfer mechanisms are under scrutiny and in flux, such as the European Commission’s Standard Contractual Clauses, or the Model Clauses and the recently invalidated Privacy Shield Frameworks. The Model Clauses may continue to be subject to scrutiny as a result of the European Court of Justice’s judgement in July 2020, though they remain the most common authorized procedure to transfer personal data out of the EU. The European Commission and U.S. regulators are expected to revive a version of the EU-US Privacy Shield Framework, which may ease the burden of these cross-border transfers. Still, any approved transfer framework likely will face scrutiny and lawsuits from privacy advocacy groups, which may result in the invalidation of a transfer mechanism on which we or our customers rely, which may impede our ability to transfer or receive data from the EEA. Our continued monitoring of and reactions to these legal developments can affect our customer base, business operations, and costs of doing business abroad. Other countries are implementing data localization requirements or restrictions or obstacles on the cross-border transfers of personal data, such as requiring express consent, notification to local authorities, or assessments and contractual amendments similar to the GDPR requirements.

 

34
Table of Contents

 

In addition to the laws specifically discussed, numerous other federal and state laws and regulations govern privacy and security, including state data breach notification laws, state health information and/or genetic privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act, new state consumer protection laws), many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Compliance with these laws is difficult, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future. Federal regulators, state attorneys general, and plaintiffs’ attorneys have been and will likely continue to be active in this space.

 

The costs of compliance with, and other burdens imposed by, our customers’ own requirements and the privacy and security laws and regulations that are applicable to our customers’ businesses may limit the use and adoption of our products and reduce overall demand. Non-compliance with our customers’ specific requirements may lead to termination of contracts with these customers or liabilities to the customers; non-compliance with applicable laws and regulations may lead to significant fines, penalties or liabilities.

 

In addition to government activity, privacy advocacy groups and the technology and other industries are considering various new, additional or different self-regulatory standards that may place additional burdens on our software products. Complying with these varying requirements could cause us to incur substantial costs or require it to change our business practices in a manner adverse to our business. Any failure, or perceived failure, on our part to comply with any regulatory requirements or international privacy or consumer protection-related laws and regulations could result in proceedings or actions against it by governmental entities or others, subject it to significant penalties or fines and negative publicity and adversely affect us.

 

Significant disruptions of our information technology systems or data security incidents could harm our reputation, cause us to modify our business practices, and otherwise adversely affect our business and subject us to liability.

We are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store, process, and transmit sensitive corporate, personal, and other information, including intellectual property, proprietary business information, customer data, and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity, and availability of such information. Our obligations under applicable laws, regulations, contracts, industry standards, self-certifications, and other documentation may include maintaining the confidentiality, integrity, and availability of personal information in our possession or control, maintaining reasonable and appropriate security safeguards as part of an information security program. These obligations create potential legal liability to regulators, our business partners, our customers, and other relevant stakeholders, and also impact the attractiveness of our products and services to existing and potential customers.

 

We rely on sophisticated information technology systems to operate our business. Our systems are subject to cyber-attacks, viruses, worms, malicious software programs, outages, equipment malfunction or constraints, software deficiencies, human error, hacking and other malicious intrusions, which may materially disrupt our business and compromise our data. We may not be able to anticipate and prevent such disruptions or intrusions, and we may not be able to mitigate them when and if they occur. Any failure, breach or unauthorized access to our or third-party systems could result in the loss of confidential, sensitive or proprietary information, interruptions in service or production or otherwise our ability to conduct business operations and could result in potential reductions in revenue and profits, damage to its reputation or liability. Furthermore, we may incur significant costs in responding to any such disruption or intrusion and remedying our systems. In such event we may also be subject to litigation and other potential liability, which could materially impact our business and financial condition. Moreover, a breach or disruption of our information technology systems could damage our reputation. Further, as regulatory focus on privacy and data security issues continues to increase and worldwide laws and regulations concerning the protection of information become more complex, the potential risks and costs of compliance to the company’s business will intensify.

 

Although we have implemented remote working protocols for some employees and offer work-issued devices to employees, the actions of our employees while working remotely may have a greater effect on the security of our systems and the data we process, including by increasing the risk of compromise to our systems, intellectual property, or data arising from employees’ combined personal and private use of devices, accessing our systems or data using wireless networks that we do not control, or the ability to transmit or store company-controlled data outside of our secured network. These risks have been heightened by the dramatic increase in the numbers of our employees who have been and are continuing to work from home.

 

We maintain insurance policies to cover certain losses relating to our information technology systems. However, there may be exceptions to our insurance coverage such that our insurance policies may not cover some or all aspects of a security incident. Insurance policies will also not protect against the reputational harms caused by a major security incident. Even where an incident is covered by our insurance, the insurance limits may not cover the costs of complete remediation and redress that we may be faced with in the wake of a security incident. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.

 

35
Table of Contents

 

In addition, any actual or perceived failure by us, our vendors, or our business partners to comply with our privacy, confidentiality, or data security-related legal or other obligations to customers or other third parties, or any further security incidents or other unauthorized access events that result in the unauthorized access, release, or transfer of sensitive information (which could include personal data), may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us by advocacy groups or others, and could cause third parties, including current and potential partners, to lose trust in us (including existing or potential customers’ perceiving our products or services as less desirable), or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related obligations, which could materially and adversely affect our business and prospects. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages.

 

General Risk Factors

 

If we fail to attract and retain key management and professional personnel, we may be unable to successfully commercialize or develop our products.

We will need to effectively manage our operational, sales and marketing, development and other resources in order to successfully pursue our commercialization and research and development efforts for our existing and future products. Our success depends on our continued ability to attract, retain and motivate highly qualified personnel.  If we are not successful in retaining and recruiting highly qualified personnel, our business may be harmed as a result.

 

We may become subject to potential product liability claims, and we may be required to pay damages that exceed our insurance coverage.

Our business exposes us to potential product liability claims that are inherent in the design, testing, manufacture, sale and distribution of our products and each of our product candidates that we are seeking to introduce to the market. Surgical medical devices involve significant risks of serious complications, including bleeding, nerve injury, paralysis, infection, and even death. Any product liability claim brought against us, with or without merit, could result in the increase of our product liability insurance rates or in our inability to secure coverage in the future on commercially reasonable terms, if at all. In addition, if our product liability insurance proves to be inadequate to pay a damages award, we may have to pay the excess of this award out of our cash reserves, which could significantly harm our financial condition. If longer-term patient results and experience indicate that our products or any component of a product causes tissue damage, motor impairment or other adverse effects, we could be subject to significant liability. A product liability claim, even one without merit, could harm our reputation in the industry, lead to significant legal fees, and result in the diversion of management’s attention from managing our business.

 

ITEM 1.B.

UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2.

PROPERTIES

 

Effective March 10, 2021, our principal corporate office is located at 1 TW Alexander Drive, Suite 160, Durham, North Carolina. We lease this facility, which consists of 27,807 square feet, for a ten year and five month term ending in August 2031.

 

Our Italian research and development and demonstration facilities are located at Viale dell'Innovazione 3, 20126 Milan, Italy. We lease these facilities, which consist of 11,733 square feet, for a seven-year and three month term ending on December 31, 2028, under a lease that commenced on October 1, 2021.

 

Our Israeli research and development facilities are located at Ha Kadima 9, Fibernet Building, 4th Floor, Yokne'am Illit, Israel. We lease these facilities, which consist of 8,471 square feet, for a five-year term ending on June 30, 2026, under a lease that commenced on July 1, 2021.

 

Our Japanese office is located at Gotenyama Trust Tower 12F, 4 Chome-7-35 Kitashinagawa, Shinagawa City, Toyko 140-0001, Japan. We lease this facility, which consists of 911 square feet, for a three-year term ending on August 31, 2025, under a lease that commenced on September 1, 2022.

 

Our Swiss administrative office is located at Via Serafino Balestra 12, Lugano, Switzerland. We lease this facility, which consists of 3,208 square feet, for a five-year term ending on June 30, 2023, under a lease that commenced on July 1, 2018.

 

36
Table of Contents

 

ITEM 3.

LEGAL PROCEEDINGS

 

None.

 

ITEM 4.

MINE SAFETY DISCLOSURES

 

Not applicable.

 

37
Table of Contents

 

PART II

 

ITEM 5.

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information

 

Since April 2, 2014, our common stock has been listed on the NYSE American. Our trading symbol is “ASXC,” which changed from “TRXC” on March 5, 2021 when we changed our name from TransEnterix Surgical, Inc. to Asensus Surgical, Inc.

 

Holders

 

As of February 24, 2023, there were approximately 63 record holders of our common stock (counting all shares held in single nominee registration as one stockholder).

 

Dividends

 

We have never declared or paid any cash dividends on our common stock. We intend to retain earnings for use in the operation and expansion of our business.

 

Recent Sales of Unregistered Securities and Use of Proceeds.

 

None.

 

Issuer Purchases of Equity Securities

 

None.

 

ITEM 6.

RESERVED

 

38
Table of Contents

 

ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of our financial condition and results of operations should be read in conjunction with our “Risk Factors” and our consolidated financial statements and the related notes to our consolidated financial statements included in this Annual Report. The following discussion contains forward-looking statements. See cautionary note regarding “Forward-Looking Statements” at the beginning of this Annual Report.

 

Overview

 

We are a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of digital laparoscopy (our combination of more advanced tools and robotic functionality) with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of Augmented Intelligence, enabled by our machine vision, and deep learning capabilities leveraged throughout the surgical experience, we intend to holistically address the clinical, cognitive and economic shortcomings to allow surgeons to deliver consistently superior surgical outcomes and realize the benefits of value-based healthcare.

 

The Company is focused on the market development for and commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance System is the first and only digital, multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including 3mm microlaparoscopic instruments, 5mm articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.

 

The Senhance System is available for sale in Europe, the United States, Japan, Taiwan, Russia (to the extent lawful), and select other countries.

 

 

•

The Senhance System has a CE Mark in Europe for adult and pediatric laparoscopic abdominal and pelvic surgery, as well as limited thoracic surgeries excluding cardiac and vascular surgery.

 

 

•

In the United States, the Company has received 510(k) clearance from the FDA for use of the Senhance System in general laparoscopic surgical procedures and laparoscopic gynecologic surgery in a total of 31 indicated procedures, including benign and oncologic procedures, laparoscopic inguinal, hiatal and paraesophageal hernia, sleeve gastrectomy and laparoscopic cholecystectomy surgery.

 

 

•

In Japan, the Company has received regulatory approval and reimbursement for 124 laparoscopic procedures.

 

 

•

The Senhance System received its registration certificate by the Russian medical device regulatory agency, Roszdravnadzor, in December 2020, allowing for its sale and utilization throughout the Russian Federation.

 

We also enter into lease arrangements with certain qualified customers. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System during or at the end of the lease term ("Lease Buyout").

 

On February 23, 2021, we changed our name from TransEnterix, Inc. to Asensus Surgical, Inc. as part of our strategy to utilize the Senhance System and ISU capabilities, along with our other Augmented Intelligence related offerings and instrumentation to unlock clinical intelligence to enable consistently superior outcomes and a new standard of surgery we are calling Performance-Guided Surgery. We believe our product offerings, and our digitization of the interface between the surgeon and the patient allows us to assist the surgeon in all aspects of laparoscopic surgery including:

 

 

●

Pre-operative - in what we call “intelligent preparation,” our machine learning models will take data from procedures done utilizing our current Senhance System with the ISU, such as tracking surgical motion and team interaction, to create a large and constantly expanding database of surgeries and their outcomes to enable surgeons to best inform their surgical approach and setup.
 

●

Intra-operative – we believe the Senhance System provides “perceptive real-time guidance” for intra-operative tasks, allowing surgeons performing a procedure with the Senhance System and ISU to execute multiple tasks while benefitting from the collective knowledge of other successful Senhance-based procedures delivered through Augmented Intelligence in real time. Not only will this provide the surgeon with a pathway to better outcomes, but we also believe it will ultimately help reduce the cognitive load of the surgeons, enabling more sustained peak performance over time and reducing risk of burn-out.

 

39
Table of Contents

 

 

●

Post-operative – finally, by tapping into the vast amount of data captured during procedures, surgeons and operating room staff will have access to “performance analytics” with actionable assessments of their performance giving them the information needed to constantly and consistently improve. We intend to establish a new standard of descriptive, diagnostic, predictive and prescriptive analytics to improve not only the skills of surgeons but move towards best-practice-sharing that bridges the global surgeon community.

 

We received FDA clearance in March 2020 for our ISU. We believe it is the only FDA cleared device for machine vision technology in abdominal robotic surgery. On September 23, 2020, we announced the first surgical procedures successfully completed using the ISU. In January 2021, we received CE Mark for the ISU. In 2022 we received FDA clearance for advanced features of the ISU, and received CE Mark for such enhancements in January 2023.

 

In February 2020, we received CE Mark for the Senhance System and related instruments for pediatric use indications in CE Mark territories.

 

In 2020, we obtained regulatory clearance for the Senhance ultrasonic system in both Taiwan and Japan. We also received clearance for the ISU in both the U.S. and Japan. Finally, in the EU, we expanded our claims for the Senhance System to include pediatric patients, allowing accessibility to more surgeons and patients, as well as expanding our potential market to include pediatric hospitals in Europe. We anticipate the robotic precision provided by the Senhance System, coupled with the already available 3mm instruments will prove to be an effective tool in surgery with smaller patients.

 

On July 28, 2021, the Company announced that it received FDA clearance for 5mm diameter articulating instruments, offering better access to difficult-to-reach areas of the anatomy by providing two additional degrees of freedom. These instruments have previously received CE Mark for use in the EU.

 

The Company believes that future outcomes of minimally invasive laparoscopic surgery will be enhanced through its combination of more advanced tools and robotic functionality, which are designed to: (i) empower surgeons with improved precision, dexterity and visualization; (ii) improve patient satisfaction and enable a desirable post-operative recovery; and (iii) provide a cost-effective robotic system, compared to existing alternatives today, for a wide range of clinical indications.

 

From our inception, we devoted a substantial percentage of our resources to research and development and start-up activities, consisting primarily of product design and development, clinical studies, manufacturing, recruiting qualified personnel and raising capital.  We expect to continue to invest in research and development and market development as we implement our strategy.

 

Since inception, we have been unprofitable. As of December 31, 2022, we had an accumulated deficit of $860.9 million, and there is substantial doubt about our ability to continue as a going concern. We operate in one business segment.

 

Recent Financing Transactions

 

At-the -Market Offerings

 

On March 18, 2022, the Company entered a Controlled Equity Offering Sales Agreement (the “2022 Sales Agreement”), with Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc. The Company commenced an at-the-market offering (the “2022 ATM Offering”) pursuant to which the Company could sell from time to time, at its option, up to an aggregate of $100.0 million shares of the Company’s common stock. No sales of common stock were made under the 2022 ATM Offering during the year ended December 31, 2022.

 

During late 2020 and 2021, the Company engaged in a number of equity financing transactions to fund its operations and extend its cash reach to provide capital to progress its strategy. These financings included:

 

 

●

October 2020 At-the-Market Offering. On October 9, 2020, the Company filed a prospectus supplement relating to an at-the-market offering with Cantor Fitzgerald & Co., or Cantor, pursuant to which the Company could sell from time to time, at its option, up to an aggregate of $40.0 million of shares of the Company’s common stock through Cantor as sales agent, referred to as the “2020 ATM Offering”. The Company terminated this agreement in January 2021. 

 

 

●

January 2021 Public Offering. On January 29, 2021, the Company completed an underwritten public offering of 26,545,832 shares of its common stock, including the underwriter’s full exercise of an over-allotment option on February 1, 2021, at the public offering price of $3.00 per share, generating net proceeds of approximately $73.4 million.

 

40
Table of Contents

 

 

●

January 2021 Registered Direct Purchase Agreement. On January 12, 2021, the Company sold in a registered direct offering 25,000,000 shares of common stock at a purchase price per share of $1.25 for aggregate gross proceeds of $31.25 million, and net proceeds of $28.6 million.

 

 

●

2021 At-the-Market Offering. On May 19, 2021, we entered into a Controlled Equity OfferingSM Sales Agreement with Cantor, Robert W. Baird & Co. Incorporated and Oppenheimer & Co. Inc., as our sales agents, relating to an at-the-market offering of up to an aggregate of $100,000,000 of shares of our common stock, referred to as the “2021 ATM Offering”.

 

Sales during the year ended December 31, 2021, under the 2020 and 2021 ATM Offerings are as follows (in thousands except for share and per share amounts):

 

   

Year Ended December 31, 2021

  
         

Total shares of common stock sold

     20,237,045  

Average price per share

   $ 1.53  

Gross proceeds

   $ 30,943  

Commisssion earned by Sales Agents

   $ 928  

Net proceeds

   $ 30,015  

 

 

 

●

2021 Exercise of Warrants. During 2021, certain holders of our Series B, C and D warrants to purchase shares of our common stock exercised such warrants for aggregate proceeds to the Company of $30.6 million.

 

Paycheck Protection Program

 

During 2020, the Company received an unsecured non-recourse loan of $2.8 million under the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The Company accounted for the PPP promissory note as debt within notes payable on the consolidated balance sheet. As of December 31, 2020, $1.6 million of the promissory note was classified as long-term and $1.2 million was classified as current. On June 10, 2021, the Company received notification from the Small Business Administration that the principal amount of $2.8 million and related interest had been forgiven. Gain on extinguishment of debt of $2.8 million was recognized for the year ended December 31, 2021 on the consolidated statement of operations and comprehensive loss.

 

Results of Operations for the Years Ended December 31, 2022 and 2021

 

Revenue

Both in 2022 and 2021, our revenue consisted of the sale of two Senhance Systems, ongoing System leasing payments, sales of instruments and accessories, and services revenue for Systems sold or placed in Europe, Asia, and the U.S. in prior periods.

 

Product revenue for the year ended December 31, 2022 decreased to $4.3 million compared to $5.4 million for the year ended December 31, 2021. The $1.1 million decrease was primarily the result of a Lease Buyout in the prior period.

 

Service revenue for the year ended December 31, 2022 decreased to $1.4 million compared to $1.5 million for the year ended December 31, 2021.

 

Lease revenue for the year ended December 31, 2022 and 2021 remained consistent at approximately $1.4 million.

 

Cost of Revenue

Cost of revenue consists of contract manufacturing, materials, labor, and manufacturing overhead incurred internally to produce the products. Shipping and handling costs incurred by the Company are included in cost of revenue. We expense all inventory excess and obsolescence provisions as cost of revenue. The manufacturing overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment depreciation and operations supervision and management. We expect overhead costs as a percentage of revenues to decline as our production volume increases.

 

41
Table of Contents

 

Product cost for the year ended December 31, 2022 decreased to $5.3 million as compared to $5.7 million for the year ended December 31, 2021. The $0.4 million decrease primarily relates to a $0.7 million decrease in materials costs, which is primarily related to a Lease Buyout in the prior period. This decrease is partially offset by a $0.2 million increase in supplies cost and $0.1 million increase in consulting costs.

 

Service cost for the year ended December 31, 2022 increased to $2.2 million as compared to $1.8 million for the year ended December 31, 2021. The $0.4 million increase primarily relates to an increase in personnel-related costs of $0.4 million. Cost of revenue exceeds revenue primarily due to part replacements under maintenance plans, which are expensed when incurred, along with salaries for the field service teams.

 

Lease cost for the year ended December 31, 2022 decreased to $3.4 million as compared to $3.6 million for the year ended December 31, 2021. The $0.2 million decrease primarily relates to a decrease in materials costs.

 

Research and Development

Research and development, or R&D, expenses primarily consist of engineering, product development and regulatory expenses incurred in the design, development, testing and enhancement of our products and legal services associated with our efforts to obtain and maintain broad protection for the intellectual property related to our products. In future periods, we expect R&D expenses to continue to substantially increase as we invest in the LUNA™ Surgical System and our digital laparoscopy platform. R&D expenses are expensed as incurred.

 

R&D expenses for the year ended December 31, 2022 increased 50% to $28.9 million as compared to $19.3 million for the year ended December 31, 2021 as we continue to invest in basic research, clinical studies, and product development in the areas of robotics and digital technologies supporting the LUNA System and our digital laparoscopy platform. All activities are in the effort of building the future for Performance-Guided Surgery. The $9.6 million increase primarily relates to increased contract engineering services, consulting, and other outside services of $5.4 million. The change was also driven by increased personnel costs of $2.5 million, driven by additional headcount, increased supplies costs of $1.5 million and increased travel costs of $0.2 million.

 

Sales and Marketing

Sales and marketing expenses include costs for sales and marketing personnel, travel, demonstration product, market development, physician training, tradeshows, marketing clinical studies and consulting expenses.

 

Sales and marketing expenses for the year ended December 31, 2022 increased 10% to $14.8 million compared to $13.4 million for the year ended December 31, 2021. The $1.4 million increase was primarily related to increased employee related costs of $1.1 million due to an increase in headcount, increased consulting costs of $0.6 million, increased travel costs of $0.5 million, partially offset by decreased supplies costs of $0.5 million and decreased depreciation expense of $0.3 million.

 

General and Administrative

General and administrative expenses consist of personnel costs related to the executive, finance, legal and human resource functions, as well as professional service fees, legal fees, accounting fees, insurance costs, and general corporate expenses.

 

General and administrative expenses for the year ended December 31, 2022 increased 5% to $20.2 million compared to $19.3 million for the year ended December 31, 2021. The $0.9 million increase was primarily related to increased software costs of $0.6 million and increased travel costs of $0.3 million.

 

Amortization of Intangible Assets

Amortization of intangible assets for the year ended December 31, 2022 decreased to $7.7 million compared to $11.3 million for the year ended December 31, 2021. The $3.6 million decrease is primarily related to the developed technologies intangibles that fully depreciated during the year ended December 31, 2022 with no offset.

 

Change in Fair Value of Contingent Consideration

The change in fair value of contingent consideration in connection with the Senhance Acquisition was a $1.1 million decrease for the year ended December 31, 2022 compared to a $1.6 million decrease for the year ended December 31, 2021. The decrease was primarily due to changes in the Company’s forecast of future product revenue, including changes in market assumptions and discount rate utilized.

 

Property and Equipment Impairment

During the year ended December 31, 2022, the Company recorded an impairment charge of $1.4 million to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are not expected to generate future cash flows sufficient to recover their net book value. No impairment charge was recognized for the year ended December 31, 2021.

 

42
Table of Contents

 

Other Income (Expense), net

The Company recognized $0.4 million other income for the year ended December 31, 2022, compared to $2.4 million other income for the year ended December 31, 2021. Other income for the year ended December 31, 2021 primarily related to the gain on extinguishment of debt of $2.8 million and $1.3 million refund for the Employee Retention Credit (ERTC), partially offset by the change in the fair value of Series B Warrants of $2.0 million. No related income or expense was recorded in the year ended December 31, 2022.

 

Income Tax Expense

The Company recognized $0.3 million income tax expense for the year ended December 31, 2022, compared to $0.2 million income tax expense for the year ended December 31, 2021. Income tax expense consisted primarily of current income taxes related to profitable foreign jurisdictions in Japan, Israel, and the Netherlands.

 

Liquidity and Capital Resources

 

Going Concern

The Company’s consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $860.9 million and working capital of $76.5 million as of December 31, 2022. The Company has not established sufficient revenues to cover its operating costs and will require additional capital to continue as a going concern. As of December 31, 2022, the Company had cash, cash equivalents, short-term investments and long-term investments, excluding restricted cash, of approximately $74.4 million. We believe that our existing cash, cash equivalents, short-term investments and long-term investments, together with cash received from product, service, and lease sales will be sufficient to meet our anticipated cash needs into the first quarter of 2024.

 

The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. If sufficient funds are not received on a timely basis, the Company would then need to purse a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date that these financial statements are issued. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

The Company believes the COVID-19 pandemic and other geopolitical factors will continue to negatively impact its operations and ability to implement its market development efforts, which will have a negative effect on its financial condition.

 

The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: negative impacts on the Company's operations caused by the COVID-19 pandemic and other geopolitical factors; the historical lack of profitability; the Company’s ability to grow its placements and increase utilization of the Senhance System by customers, the Company’s ability to raise additional capital; the success of its market development efforts; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution concern; competition in the market for robotic and digital surgical devices; and its ability to identify and pursue development of additional products.

 

Sources of Liquidity

Our principal sources of cash to date have been proceeds from public offerings of common stock, incurrence of debt, the sale of equity securities held as investments and asset sales.

 

43
Table of Contents

 

Consolidated Cash Flow Data

 

   

Year Ended December 31,

  

(In millions)

  

2022

    

2021

  

Net cash (used in) provided by

                

Operating activities

   $ (58.9 )   $ (40.7 )

Investing activities

     47.5       (119.7 )

Financing activities

     (0.3 )     161.7  

Effect of exchange rate changes on cash and cash equivalents

     (0.1 )     0.4  

Net (decrease) increase in cash, cash equivalents and restricted cash

   $ (11.8 )   $ 1.7  

 

Operating Activities

For the year ended December 31, 2022, cash used in operating activities of $58.9 million consisted of a net loss of $75.6 million, changes in operating assets and liabilities of $4.7 million, offset by non-cash items of $21.4 million. The non-cash items primarily consisted of $8.4 million of stock-based compensation expense, $7.7 million of amortization of intangible assets, $3.4 million of depreciation, $1.4 million of property and equipment impairment, $0.6 million change in inventory reserves, $0.6 million net amortization of discounts and premiums on investments, $0.3 million deferred tax expense, and $0.1 million loss on disposal of property and equipment, offset by $1.1 million of change in fair value of contingent consideration. The decrease in cash from changes in operating assets and liabilities primarily relates to a $3.9 million decrease in accrued expenses, $2.3 million increase in inventory net of transfers to property and equipment, $2.1 million increase in other current and long-term assets, $1.5 million increase in accounts receivable, and $0.4 million increase in prepaid expenses, offset by $4.5 million increase in accrued employee compensation and benefits, $0.8 million decrease in employee retention tax credit receivable, and $0.2 million decrease in operating lease right-of-use assets.

 

For the year ended December 31, 2021, net cash used in operating activities of $40.7 million consisted of a net loss of $62.5 million and cash provided by working capital of $0.4 million, offset by non-cash items of $21.4 million. The non-cash items primarily consisted of $11.3 million of net amortization of intangible assets, $9.4 million of stock-based compensation expense, $2.9 million of depreciation, $2.8 million gain on extinguishment of debt, $2.0 million change in fair value of warrant liabilities, $1.6 million change in fair value of contingent consideration, $0.5 million change in inventory reserves, $0.4 million of accretion of discounts and amortization of premiums on investments, net, $0.2 million deferred tax expense and $0.1 million bad debt expense. The decrease in cash from changes in working capital included a $4.5 million increase in operating lease liabilities, a $4.3 million increase in operating lease right-of-use assets, $0.9 million decrease in accrued employee compensation and benefits, $0.6 million increase in inventories net of transfers to property and equipment, a $1.6 million increase in accounts payable, a $1.3 million increase in tax credit receivable, a $0.9 million increase in other current and long-term assets, a $0.4 million increase in accrued expenses, a $0.2 million decrease in accounts receivable, a $0.2 million decrease in deferred revenue, and a $0.1 million decrease in prepaid expenses.

 

Investing Activities

For the year ended December 31, 2022, net cash provided by investing activities was $47.5 million. This amount consists of $82.7 million of proceeds from maturities of available-for-sale investments, offset by $33.9 million of purchases of available-for-sale investments and $1.3 million purchases of property and equipment.

 

For the year ended December 31, 2021, net cash used in investing activities was $119.7 million. This amount primarily consists of $122.3 million in purchases of available-for-sale investments, $1.4 million in purchases of property and equipment, offset by $4.0 million proceeds from maturities of available-for-sale securities.

 

Financing Activities

For the year ended December 31, 2022, net cash used in financing activities was $0.3 million, primarily related to taxes paid for the net share settlement of vesting of restricted stock units.

 

For the year ended December 31, 2021, net cash provided by financing activities was $161.7 million. The net change primarily related to $131.9 million in proceeds from the issuance of shares of our common stock in equity financings, net of issuance costs, $30.9 million in proceeds from the exercise of stock options and warrants, partially offset by $1.1 million in taxes paid related to the net share settlement of vesting of restricted stock units.

 

44
Table of Contents

 

Operating Capital and Capital Expenditure Requirements

 

We intend to spend substantial amounts on research and development activities, including product development, regulatory and compliance, and clinical studies in support of the development of the LUNA System and our digital solutions platform. We intend to use financing opportunities strategically to continue to strengthen our financial position.

 

Cash and cash equivalents held by our foreign subsidiaries totaled $3.2 million as of December 31, 2022, including restricted cash. We do not intend or currently foresee a need to repatriate cash and cash equivalents held by our foreign subsidiaries. If these funds are needed in the United States, we believe that the potential U.S. tax impact to repatriate these funds would be immaterial.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2022, we did not have any off-balance sheet arrangements.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations set forth above under the headings “Results of Operations” and “Liquidity and Capital Resources” have been prepared in accordance with U.S. GAAP and should be read in conjunction with our consolidated financial statements and notes thereto appearing in Item 8 of this Annual Report. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our critical accounting policies and estimates, including identifiable intangible assets, contingent consideration, stock-based compensation, inventory, revenue recognition and income taxes. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. A more detailed discussion on the application of these and other accounting policies can be found in Note 2 in the Notes to the Consolidated Financial Statements which are included in Item 8 of this Annual Report. Actual results may differ from these estimates under different assumptions and conditions.

 

While all accounting policies impact the consolidated financial statements, certain policies may be viewed as critical. Critical accounting policies are those that are both most important to the portrayal of financial condition and results of operations and that require management’s most subjective or complex judgments and estimates. Our management believes the policies that fall within this category are the policies on accounting for identifiable intangible assets, contingent consideration, stock-based compensation, inventory, revenue recognition and income taxes.

 

Identifiable Intangible Assets

 

Identifiable intangible assets consist of purchased patent rights recorded at cost and developed technology acquired as part of business acquisitions recorded at estimated fair value. Intangible assets are amortized over 5 to 10 years. We periodically evaluate identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.  

 

Contingent Consideration

 

Contingent consideration is recorded as a liability and measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration at each reporting date will be updated by reflecting the changes in fair value in our consolidated statements of operations and comprehensive loss.

 

45
Table of Contents

 

Stock-Based Compensation

 

We recognize as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. We use the Black-Scholes-Merton model to estimate the fair value of our stock-based payments. The volatility assumption used in the Black-Scholes-Merton model is based on the calculated historical volatility based on the Company’s historical volatility. The expected term of options granted by us has been determined based upon the simplified method, because we do not have sufficient historical information regarding our options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. We have not paid and do not anticipate paying cash dividends on our shares of common stock; therefore, the expected dividend yield is assumed to be zero. We estimate forfeitures based on our historical experience and adjust the estimated forfeiture rate based upon actual experience.

 

Inventories

 

Inventory, which includes material, labor and overhead costs, is stated at the lower of cost, determined on a first-in, first-out basis, or net realizable value. We record reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

 

Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires us to estimate the portion of on-hand inventory that can be realized over the upcoming twelve months.

 

Revenue Recognition

 

The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements generally include a five-year service period; the first year of service is generally free and included in the Senhance System sale arrangement and the remaining four years are generally included at a stated service price.

 

The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements may include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.

 

For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services; however due to limited sales to date, standalone selling prices may not be directly observable. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer, and market conditions. The Company regularly reviews estimated standalone selling prices and updates these estimates if necessary.

 

The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows: 

 

 

•

System sales. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when we receive an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do not provide a right of return. The Senhance Systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.

 

46
Table of Contents

 

 

•

Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.

 

 

•

Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.

 

We enter into lease arrangements for our Senhance Systems with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, we consider the following terms at lease commencement: (1) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (3) whether the lease term is for the major part of the remaining economic life of the leased Senhance System, (4) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (5) whether the underlying Senhance System is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. All such arrangements through December 31, 2022, are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage and is presented as lease revenue. 

 

We invoice our customers based on the billing schedules in its sales arrangements. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue for the periods presented was primarily related to service obligations, for which the service fees are billed up-front, generally annually. The associated deferred revenue is generally recognized ratably over the service period.

 

In connection with assets recognized from the costs to obtain a contract with a customer, we have determined that sales incentive programs for our sales team do not meet the requirements to be capitalized as we do not expect to generate future economic benefits from the related revenue from the initial sales transaction.

 

Income Taxes

 

We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of our assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. Determination of the realizability of deferred tax assets requires management’s judgment. Valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the estimated amounts expected to be realized. 

 

U.S. shareholders are subject to tax on global intangible low-taxed income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred. As of December 31, 2022 and 2021, no GILTI tax has been recorded.

 

Recent Accounting Pronouncements

 

See “Note 2. Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this Annual Report for a full description of recent accounting pronouncements including the respective expected dates of adoption and effects on our Consolidated Balance Sheets and Consolidated Statements of Operations and Comprehensive Loss.

 

47
Table of Contents

 

ITEM 7.A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are exposed to changes in foreign currency exchange rates. Operations outside of the United States accounted for 89% and 87% of revenue for year ended December 31, 2022 and 2021, respectively, and are concentrated principally in Europe. We translate the revenue and expenses of our foreign operations using average exchange rates prevailing during the period. The effect of a 10% change in the average foreign currency exchange rates among the U.S. dollar versus the Euro for the year ended December 31, 2022, would result in revenue changing by $0.6 million. This change would not be material to our cash flows and our results of operations.

 

48
Table of Contents
 

 

49
Table of Contents

 

Report of Independent Registered Public Accounting Firm

 

Shareholders and Board of Directors

Asensus Surgical, Inc.

Durham, North Carolina

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Asensus Surgical, Inc. (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern Uncertainty

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and has not generated positive cash flows from operations which raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

50
Table of Contents

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Inventories Valuation

 

Inventories totaled approximately $13.8 million at December 31, 2022, including approximately $5.5 million classified as noncurrent. As described in Note 2 to the Company’s consolidated financial statements, inventories are stated at the lower of cost or net realizable value. Management considers historical consumption and forecasted demand in relation to inventories on hand, competitiveness of product offerings, and product life cycles when estimating net realizable value.

 

We identified management’s estimation of the net realizable value of inventories as a critical audit matter. The Company’s limited sales history requires management to make significant judgments and assumptions with respect to future demand for the Company’s products and product life cycles that affect the estimation of the net realizable value of inventories. Auditing such assumptions required a high degree of auditor judgment and an increased auditor effort.

 

The primary procedures we performed to address this critical audit matter included:

 

 

●

Evaluating the reasonableness of management’s assumption that future consumption of raw materials and sale of instruments and accessories approximates actual consumption and sales of identical items in historical periods and evaluating the time period over which management expects future consumption and sales to occur.
 

●

Evaluating the reasonableness of management’s forecasted demand for Senhance Systems based on the results of historical sales and leasing efforts, expectations with respect to future sales and lease placements, and expectations with respect to product life cycles.
 

●

Testing management’s estimation of the net realizable value of completed Senhance Systems and system components, included in finished goods inventories, by evaluating the Company’s assumptions with respect to selling prices and lease terms.

 

/s/ BDO USA, LLP

 

We have served as the Company's auditor since 2013.

 

Raleigh, North Carolina

March 2, 2023

 

51
Table of Contents
 

 

Asensus Surgical, Inc.

Consolidated Balance Sheets

(in thousands, except share amounts)

 

  

December 31, 2022

  

December 31, 2021

 

Assets

        

Current Assets:

        

Cash and cash equivalents

 $6,329  $18,129 

Short-term investments, available-for-sale

  64,195   80,262 

Accounts receivable, net

  2,256   749 

Inventories

  8,284   8,634 

Prepaid expenses

  3,584   3,255 

Employee retention tax credit receivable

  554   1,311 

Other current assets

  1,671   957 

Total Current Assets

  86,873   113,297 
         

Restricted cash

  1,141   1,154 

Long-term investments, available-for-sale

  3,865   37,435 

Inventories, net of current portion

  5,469   7,074 

Property and equipment, net

  9,542   10,971 

Intellectual property, net

  1,576   9,892 

Net deferred tax assets

  174   288 

Operating lease right-of-use assets, net

  4,950   5,348 

Other long-term assets

  2,463   1,014 

Total Assets

 $116,053  $186,473 
         

Liabilities and Stockholders' Equity

        

Current Liabilities:

        

Accounts payable

 $3,348  $3,448 

Accrued employee compensation and benefits

  4,508   3,559 

Accrued expenses and other current liabilities

  1,293   1,617 

Operating lease liabilities - current portion

  800   683 

Deferred revenue

  465   543 

Total Current Liabilities

  10,414   9,850 
         

Long-Term Liabilities:

        

Contingent consideration

  1,256   2,371 

Noncurrent operating lease liabilities

  4,738   5,006 

Total Liabilities

  16,408   17,227 
         

Commitments and Contingencies (Note 16)

          
         

Stockholders' Equity:

        

Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2022 and December 31, 2021; 236,895,440 and 235,218,552 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively

  237   235 

Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and December 31, 2021

  -   - 

Additional paid-in capital

  962,731   954,649 

Accumulated deficit

  (860,935)  (785,374)

Accumulated other comprehensive loss

  (2,388)  (264)

Total Stockholders' Equity

  99,645   169,246 

Total Liabilities and Stockholders' Equity

 $116,053  $186,473 

 

 

See accompanying notes to consolidated financial statements.

 

52
Table of Contents
 

 

Asensus Surgical, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands except per share amounts)

 

   

Year Ended

 
   

December 31,

 
   

2022

    

2021

  

Revenue:

                

Product

   $ 4,327     $ 5,399  

Service

     1,373       1,520  

Lease

     1,387       1,313  

Total revenue

     7,087       8,232  
                 

Cost of revenue:

                

Product

     5,303       5,741  

Service

     2,174       1,799  

Lease

     3,395       3,556  

Total cost of revenue

     10,872       11,096  
                 

Gross loss

     (3,785 )     (2,864 )

Operating Expenses:

                

Research and development

     28,942       19,348  

Sales and marketing

     14,756       13,395  

General and administrative

     20,172       19,323  

Amortization of intangible assets

     7,708       11,254  

Change in fair value of contingent consideration

     (1,115 )     (1,565 )

Property and equipment impairment

     1,431       -  

Total Operating Expenses

     71,894       61,755  
                 

Operating Loss

     (75,679 )     (64,619 )

Other Income (Expense), net

                

Gain on extinguishment of debt

     -       2,847  

Change in fair value of warrant liabilities

     -       (1,981 )

Interest income

     1,141       590  

Interest expense

     (410 )     (370 )

Employee retention tax credit

     -       1,311  

Other expense, net

     (295 )     (15 )

Total Other Income (Expense), net

     436       2,382  
                 

Loss before income taxes

     (75,243 )     (62,237 )

Income tax expense

     (318 )     (225 )

Net loss

     (75,561 )     (62,462 )
                 

Comprehensive loss:

                

Net loss

     (75,561 )     (62,462 )

Foreign currency translation loss

     (1,867 )     (2,985 )

Unrealized loss on available-for-sale investments

     (257 )     (247 )

Comprehensive loss

   $ (77,685 )   $ (65,694 )
                 

Net loss per common share attributable to common stockholders - basic and diluted

   $ (0.32 )   $ (0.28 )

Weighted average number of shares used in computing net loss per common share - basic and diluted

     236,492       226,960  

 

 

See accompanying notes to consolidated financial statements.

 

53
Table of Contents
 

 

Asensus Surgical, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

(in thousands)

 

   

Common Stock

    

Treasury Stock

                                  
   

Shares

    

Amount

    

Shares

    

Amount

    

Additional Paid-in Capital

    

Accumulated Deficit

    

Accumulated Other

Comprehensive

Income (Loss)

    

Total Stockholders' Equity

  

Balance, December 31, 2020

     116,231     $ 116       -     $ -     $ 781,397     $ (722,912 )   $ 2,968     $ 61,569  

Stock-based compensation

     -       -       -       -       9,429       -       -       9,429  

Issuance of common stock, net of issuance costs

     71,787       72       -       -       131,857       -       -       131,929  

Exercise of stock options and warrants

     45,630       46       -       -       33,029       -       -       33,075  

Award of restricted stock units

     1,571       1       -       -       -       -       -       1  

Return of common stock to pay withholding taxes on restricted stock

     -       -       320       -       (1,063 )     -       -       (1,063 )

Cancellation of treasury stock

     -       -       (320 )     -       -       -       -       -  

Other comprehensive loss

     -       -       -       -       -       -       (3,232 )     (3,232 )

Net loss

     -       -       -       -       -       (62,462 )     -       (62,462 )

Balance, December 31, 2021

     235,219     $ 235       -     $ -     $ 954,649     $ (785,374 )   $ (264 )   $ 169,246  

Stock-based compensation

     -       -       -       -       8,416       -       -       8,416  

Exercise of stock options

     43       -       -       -       18       -       -       18  

Award of restricted stock units

     1,633       2       -       -       -       -       -       2  

Return of common stock to pay withholding taxes on restricted stock

     -       -       443       -       (352 )     -       -       (352 )

Cancellation of treasury stock

     -       -       (443 )     -       -       -       -       -  

Other comprehensive loss

     -       -       -       -       -       -       (2,124 )     (2,124 )

Net loss

     -       -       -       -       -       (75,561 )     -       (75,561 )

Balance, December 31, 2022

     236,895     $ 237       -     $ -     $ 962,731     $ (860,935 )   $ (2,388 )   $ 99,645  

 

 

See accompanying notes to consolidated financial statements.

 

54
Table of Contents
 

 

Asensus Surgical, Inc.

Consolidated Statements of Cash Flows

(in thousands)

 

   

Year Ended December 31,

  
   

2022

    

2021

  
 Operating Activities:                

Net loss

   $ (75,561 )   $ (62,462 )

Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:

                

Depreciation

     3,368       2,857  

Amortization of intangible assets

     7,708       11,254  

Amortization of discounts and premiums on investments, net

     565       409  

Stock-based compensation

     8,416       9,429  

Gain on extinguishment of debt

     -       (2,847 )

Deferred tax expense

     318       225  

Change in inventory reserves

     620       (492 )

Bad debt expense

     9       144  

Property and equipment impairment

     1,431       -  

Loss on disposal of property and equipment

     122       -  

Change in fair value of warrant liabilities

     -       1,981  

Change in fair value of contingent consideration

     (1,115 )     (1,565 )
                 

Changes in operating assets and liabilities:

                

Accounts receivable

     (1,528 )     174  

Inventories

     (2,302 )     (611 )

Operating lease right-of-use assets

     232       (4,254 )

Prepaid expenses

     (450 )     146  

Employee retention tax credit receivable

     757       (1,311 )

Other current and long-term assets

     (2,101 )     902  

Accounts payable

     35       1,614  

Accrued employee compensation and benefits

     4,523       (859 )

Accrued expenses

     (3,955 )     384  

Deferred revenue

     (55 )     (229 )

Operating lease liabilities

     26       4,452  

Net cash and cash equivalents used in operating activities

     (58,937 )     (40,659 )
                 

Investing Activities:

                

Purchase of available-for-sale investments

     (33,886 )     (122,330 )

Proceeds from maturities of available-for-sale investments

     82,702       4,030  

Purchase of property and equipment

     (1,279 )     (1,368 )

Net cash and cash equivalents provided by (used in) investing activities

     47,537       (119,668 )
                 

Financing Activities:

                

Proceeds from issuance of common stock, net of issuance costs

     -       131,929  

Taxes paid related to net share settlement of vesting of restricted stock units

     (350 )     (1,063 )

Proceeds from exercise of stock options and warrants

     18       30,839  

Net cash and cash equivalents (used in) provided by financing activities

     (332 )     161,705  
                 

Effect of exchange rate changes on cash and cash equivalents

     (81 )     376  

Net (decrease) increase in cash, cash equivalents and restricted cash

     (11,813 )     1,754  

Cash, cash equivalents and restricted cash, beginning of period

     19,283       17,529  

Cash, cash equivalents and restricted cash, end of period

   $ 7,470     $ 19,283  
                 

Supplemental Disclosure for Cash Flow Information

                

Cash paid for leases

   $ 984     $ 1,490  

Cash paid for taxes

   $ 165     $ 170  
                 

Supplemental Schedule of Non-cash Investing and Financing Activities:

                

Transfer of inventories to property and equipment

   $ 2,693     $ 3,244  

Reclass of warrant liability to common stock and additional paid-in-capital

   $ -     $ 2,236  

Lease liabilities arising from obtaining right-of-use assets

   $ 577     $ 5,119  

 

 

See accompanying notes to consolidated financial statements.

 

55
Table of Contents

 

Asensus Surgical, Inc.

Notes to Consolidated Financial Statements

 

 

1.

Description of the Business

 

Asensus Surgical, Inc. (formerly known as TransEnterix, Inc.) (the "Company") is a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The Company is focused on the market development for and commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance System is the first and only digital, multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including 3mm microlaparoscopic instruments, 5mm articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.

 

 

2.

Summary of Significant Accounting Policies

 

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its direct and indirect wholly owned subsidiaries.

 

Going Concern

The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $860.9 million and working capital of $76.5 million as of December 31, 2022. The Company has not established sufficient sales revenues to cover its operating costs and requires additional capital to proceed with its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.

 

The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to meet its existing obligations, and to continue as a going concern within one year from the date that these financial statements are issued. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

Principles of Consolidation and Foreign Currency Considerations

The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.

 

The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive loss as a separate component of stockholders’ equity.

 

The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 were not material.

 

56
Table of Contents
 

Reclassifications

Certain amounts reported previously have been reclassified to conform to the current year presentation, with no effect on stockholders’ equity or net loss as previously reported. Revenue and cost of revenue for leases were historically included in product and service revenue and corresponding cost of revenue on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. Accrued employee compensation and benefits were historically included in accrued expenses and other current liabilities on the consolidated balance sheets for the year ended December 31, 2021.

 

Revision of Previously Disclosed Amounts

During the course of preparing the Company’s unaudited consolidated financial statements as of and for the six months ended June 30, 2022, the Company determined that its December 31, 2021 inventory footnote presentation overstated raw materials and understated finished goods by $2.5 million.  For comparative purposes, Note 7 – Inventories, has been revised to reflect the adjustment to raw materials and finished goods as of December 31, 2021.  The revision had no effect on the previously reported total gross and net carrying value of inventory.  The revision also had no effect on the previously reported consolidated balance sheets, statements of operations and comprehensive loss, cash flows and stockholders’ equity. 

 

Risk and Uncertainties

The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: negative impacts on the Company's operations caused by the COVID-19 pandemic and other geopolitical factors; the historical lack of profitability; the Company’s ability to raise additional capital; the success of its market development efforts; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan, and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic surgical devices; and its ability to identify and pursue development of additional products.

 

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, short-term and long-term investments, excess and obsolete inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use (“ROU”) assets, and deferred tax asset valuation allowances.

 

Cash and Cash Equivalents, Restricted Cash, and Investments

The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents.

 

Restricted cash as of December 31, 2022 and 2021 includes $1.1 million in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, and automobile leases.

 

The Company’s investments as of December 31, 2022 consisted of commercial paper, corporate bonds, and United States government agencies and were classified as available-for-sale. Investments classified as available-for-sale are measured at fair value, and net unrealized gains and losses are recorded as a component of accumulated other comprehensive loss on the consolidated balance sheets until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization and accretion is included in interest expense, net. There were no gross realized gains or loss for the year ended December 31, 2022. The Company recognized an immaterial amount of gross realized losses for the year ended December 31, 2021. There were no gross realized gains for the year ended December 31, 2021.

 

Investments with remaining maturities at date of purchase greater than 90 days and remaining maturities as of the reporting period less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. 

 

57
Table of Contents
 

There have been no credit losses for the years ended December 31, 2022 and 2021, and no allowance for credit losses as of December 31, 2022. Factors considered in determining whether a credit loss exists include credit ratings and other qualitative factors for each security type in the portfolio.

 

Fair Value Measurements

The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper and corporate notes and bonds without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy. The Company measures contingent consideration at fair value using a Monte-Carlo simulation utilizing Level 3 inputs. These inputs include the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones.

 

Concentrations and Credit Risk

The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents (including restricted cash), and investments, including amounts held in money market funds, commercial paper, and corporate bonds. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits may at times exceed the Federal Deposit Insurance Corporation’s insured limit. Balances in excess of federally insured limitations may not be insured. The Company has not experienced losses on these accounts, and management believes that the Company is not exposed to significant risks on such accounts. Investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investments consist of various major corporations, financial institutions, and government agencies of high credit standing.

 

The Company’s accounts receivable are derived from sales and leases to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no collateral from its customers. The Company had one customer that accounted for 69% of the Company’s net accounts receivable as of December 31, 2022. The Company had three customers that accounted for 26%, 20%, and 14%, respectively, of the Company’s net accounts receivable as of December 31, 2021. The Company had one customer who accounted for 47% of revenue in 2022, and two customers who accounted for 36% and 16% of revenue in 2021, respectively.

 

Accounts Receivable

Accounts receivable are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses is based on the Company’s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The allowance for expected credit losses was $1.6 million and $1.7 million as of December 31, 2022, and December 31, 2021, respectively. The Company recorded an immaterial amount for expected credit losses during the year ended December 31, 2022 and $0.1 million during the year ended December 31, 2021.          

 

Inventories

Inventories are stated at the lower of cost (determined on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers historical consumption and forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

 

Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming twelve months.

 

58
Table of Contents
 

 

Definite-Lived Intangible Assets - Intellectual Property

Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified in-process research and development (“IPR&D”) assets related to (i) the Senhance System acquired in 2015 and reclassified in 2017 and (ii) a 2018 acquisition and reclassified in 2020. Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed technology is recorded using the straight-line method over the estimated useful life of 5 to 7 years.

 

The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To determine the recoverability, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the assets, then such assets are written down to their fair value. No impairment of intellectual property was identified during the years ended December 31, 2022 and 2021.

 

Property and Equipment

Property and equipment consists primarily of operating lease Senhance System assets, machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

 

  

Years

 

Operating lease assets – Senhance System leasing

   5  

Machinery, manufacturing, and demonstration equipment

  3-5 

Computer equipment

   3  

Furniture

   5  

Leasehold improvements

 

Lesser of lease term or 3 to 10

 

 

The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value.

 

During the year ended December 31, 2022, the Company recorded a non-cash asset impairment charge of $1.4 million to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are not expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the consolidated statements of operations and comprehensive loss. No such impairment charges were recorded during the year ended December 31, 2021.

 

Operating Leases

We have operating leases for our corporate office buildings, vehicles, and machinery and equipment. At inception, we determine whether an agreement represents a lease and, at commencement, we evaluate each lease agreement to determine whether the lease constitutes an operating or financing lease.

 

The Company accounts for lease components and non-lease components as a single component. Non-lease components consist of common area maintenance payments for most real estate leases, which are determined based on costs incurred by the lessor. Many of the Company’s leases include base rental periods coupled with options to renew or terminate the lease, generally at the Company’s discretion.  In evaluating the lease term, the Company considers whether renewal is reasonably certain.  To the extent a significant economic incentive exists to renew the lease, the option is included within the lease term.  Based on the Company’s leases, renewal options generally do not provide a significant economic incentive and are therefore excluded from the lease term. While our operating leases range from one year to ten years, some may include options to extend the lease generally between one year and six years, and some may include options to terminate the leases within one year.

 

The interest rate implicit in our lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.

 

59
Table of Contents
 

Implementation Costs in a Cloud Computing Arrangement

The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract. These capitalized implementation costs are recorded within other current and long-term assets, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis and included within operating expenses.

 

Employee Retention Tax Credit Receivable

The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages. During the year ended December 31, 2021, we submitted an ERTC refund for $1.3 million and recorded the amount into Other Income (Expense) on the consolidated statements of operations and comprehensive loss. The Company received notification from the IRS that the relevant conditions of the employee retention credit provision were met and that it will receive the credit. The Company received $0.7 million of the ERTC refund during the year ended December 31, 2022. The remaining $0.6 million is recorded as a current asset on the consolidated balance sheets as of December 31, 2022.

 

Notes Payable 

The Company’s policy is to account for forgivable loans received through the U.S. Small Business Administration (the “SBA”) under the CARES Act Payroll Protection Program (“PPP”), as debt in accordance with ASC 470, Debt, and other related accounting pronouncements. The forgiveness of debt, in whole or part, is recognized once the debt is extinguished, which occurs when the Company is legally released from the liability by the SBA. Any portion of debt forgiven, adjusted for accrued interest forgiven and unamortized debt issuance costs, is recorded as a gain on extinguishment of debt, and presented in the consolidated statements of operations and comprehensive loss. On June 10, 2021, the Company received notification from the SBA that the principal amount of its PPP loan of $2.8 million and related interest had been forgiven.

 

As of December 31, 2022, the Company has $0.6 million available under a letter of credit. No amounts have been utilized by the Company as of December 31, 2022.

 

Contingent Consideration

Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, revenue volatility and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

 

On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar S.p.A., an Italian company (“Sofar”), an Italian company, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System. Under the terms of the Purchase Agreement, as amended in 2016, as of December 31, 2022, the Company has accrued $1.3 million of estimated fair value of remaining contingent consideration related to a milestone of €15.0 million which shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least €25.0 million over a calendar quarter or in the event that (i) the Company or Asensus International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. In 2022, Sofar assigned its right to receive the contingent payment to Three Heads Investment S.r.l.

 

Warrant Liabilities

The Company’s Series B Warrants were measured at fair value using a simulation model which considered, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant. The warrant liability was revalued at each reporting period and changes in fair value were recognized in the consolidated statements of operations and comprehensive loss. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. All remaining outstanding Series B Warrants were exercised in the first quarter 2021.

 

60
Table of Contents
 

Revenue Recognition

The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements generally include a five-year service period; the first year of service is generally free and included in the Senhance System sale arrangement and the remaining four years are generally included at a stated service price.

 

The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements may include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.

 

For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services; however due to limited sales to date, standalone selling prices generally are not directly observable. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer, and market conditions. The Company regularly reviews estimated standalone selling prices and updates these estimates if necessary.

 

The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows:

 

•  System sales. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from Senhance System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when the Company receives an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do not provide a right of return. The Senhance Systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.

 

•  Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.

 

•  Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.

 

The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements, and are included in accounts receivable.

 

In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do not meet the requirements to be capitalized as the Company does not expect to generate future economic benefits from the related revenue from the initial sales transaction and such costs are expensed as incurred.

 

61
Table of Contents
 

Senhance System Leasing

The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. For the years ended December 31, 2022 and 2021, variable lease revenue related to usage-based arrangements was not material.  

 

In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, the Company considers the following terms at lease commencement: (1) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (3) whether the lease term is for the major part of the remaining economic life of the leased System, (4) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (5) whether the underlying Senhance System is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. All such arrangements through December 31, 2022 are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage. As of December 31, 2022 future minimum lease payments due from customers was $2.2 million, which is expected to be received over the next one to three years.

 

Cost of Revenue

Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Depreciation expense related to leased systems is included in the cost of revenue. Shipping and handling costs incurred by the Company are included in the cost of revenue.  We expense all inventory obsolescence provisions as cost of revenue.

 

Research and Development Costs

Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.

 

Stock-Based Compensation

The Company recognizes expenses for share-based awards exchanged for services rendered equal to the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of stock options. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimates forfeitures based on its historical experience and adjust the estimated forfeiture rate based upon actual experience. For performance-based restricted stock awards with performance conditions, we begin recognizing compensation expense when it becomes probable that the performance condition will be attained.

 

The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. See “Note 13 – Stock-Based Compensation,” for a detailed discussion of the Company’s stock plans and stock-based compensation expense.

 

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred.

 

62
Table of Contents
 

The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than not sustain the position following audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.

 

Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company may be subject to examination by authorities for all previously filed income tax returns.

 

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

 

Segments

The Company operates in one business segment—the research, development and sale of medical device robotics to improve minimally invasive surgery. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

 

Impact of Recently Issued Accounting Standards

 

The Company has evaluated issued ASUs not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.

 

 

3.

Revenue Recognition

 

The following table presents revenue disaggregated by type and geography:

 

     

Years Ended December 31,

 
     

2022

    

2021

  
     

(in thousands)

  

U.S.

                  

Systems

   $ -     $ -  

Instruments and accessories

     211       273  

Services

     300       383  

Leases

     256       377  

Total U.S. revenue

     767       1,033  
                   

Outside of U.S. ("OUS")

                

Systems

     2,551       3,286  

Instruments and accessories

     1,565       1,840  

Services

     1,073       1,137  

Leases

     1,131       936  

Total OUS revenue

     6,320       7,199  
                   

Total

                  

Systems

     2,551       3,286  

Instruments and accessories

     1,776       2,113  

Services

     1,373       1,520  

Leases

     1,387       1,313  
Total revenue   $ 7,087     $ 8,232  

 

Remaining Performance Obligations

The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to service obligations performed under the Company's system sales contracts that will be invoiced and recognized as revenue in future periods. Transaction price allocated to remaining performance obligations as of December 31, 2022 was $1.1 million, which is expected to be recognized over one to four years. 

 

63
Table of Contents
 

Contract Assets and Liabilities

Deferred revenue for the periods presented was primarily related to service obligations, for which the service fees are billed up-front, generally annually. The associated deferred revenue is generally recognized ratably over the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2022 and 2021 that was included in the deferred revenue balance at the beginning of each reporting period was $0.5 million and $0.6 million, respectively.

 

The following information summarizes the Company’s contract assets and liabilities:

 

   

December 31, 2022

    

December 31, 2021

  
   

(in thousands)

  

Contract Assets

   $ 116     $ 91  

Deferred Revenue

   $ 465     $ 543  

 
 

4.

Cash, Cash Equivalents, and Restricted Cash

 

Cash, cash equivalents and restricted cash consist of the following:

 

   

December 31,

    

December 31,

  
   

2022

    

2021

  
   

(in thousands)

  

Cash

   $ 3,473     $ 8,343  

Money Market

     2,856       5,287  

Commerical Paper

     -       4,499  

Total cash and cash equivalents

   $ 6,329     $ 18,129  

Restricted Cash

     1,141       1,154  

Total

   $ 7,470     $ 19,283  

 

 

Restricted cash at December 31, 2022 and 2021 includes $1.1 million and $1.2 million, respectively, in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, automobile leases, and a performance guarantee required by the government of a country in which a Senhance System was sold in 2018.

 

64
Table of Contents

 

 

5.

Investments, available-for-sale

 

The aggregate fair values of investment securities along with cumulative unrealized gains and losses determined on an individual investment security basis and included in other comprehensive loss are as follows:

 

  

December 31, 2022

 
  

(in thousands)

 
                         
  

Amortized

Cost

  

Unrealized

Gain

  

Unrealized

Loss

  

Fair Value

  

Short-term

investments

  

Long-term

investments

 

Commercial Paper

 $12,364  $-  $(49) $12,315  $12,315  $- 

Corporate Bonds

  55,201   -   (447)  54,754   50,889   3,865 

U.S. Government Agencies

  999   -   (8)  991   991   - 

Total Investments

 $68,564  $-  $(504) $68,060  $64,195  $3,865 

 

 

  

December 31, 2021

 
  

(in thousands)

 
                         
  

Amortized

Cost

  

Unrealized

Gain

  

Unrealized

Loss

  

Fair Value

  

Short-term

investments

  

Long-term

investments

 

Commercial Paper

 $50,705  $-  $(46) $50,659  $50,660  $- 

Corporate Bonds

  67,239   1   (202)  67,038   29,602   37,435 

Total Investments

 $117,944  $1  $(248) $117,697  $80,262  $37,435 

 

 

The following table summarizes the contractual maturities of the Company’s available-for-sale investments:

 

  

December 31, 2022

 
  

(in thousands)

 
  

Amortized

Cost

  

Fair Value

 

Mature in less than one year

 $64,662  $64,195 

Mature in one to two years

  3,902   3,865 

Total

 $68,564  $68,060 

 

Actual maturities may differ from contractual maturities because certain borrowers have the right to call or prepay certain obligations. There were no sales of investments for the years ended December 31, 2022 or 2021, respectively. There were no realized gains or losses for the years ended December 31, 2022. The company recorded an immaterial amount of gross realized losses for the year ended December 31, 2021 related to the maturity of investments.

 

65
Table of Contents

 

 

6.

Fair Value

 

The following are categories of assets and liabilities measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):

 

   

December 31, 2022

  
   

(in thousands)

  
                                 

Description

  

Quoted Prices in

Active Markets for

Identical Assets

(Level 1)

    

Significant Other

Observable Inputs

(Level 2)

    

Significant

Unobservable

Inputs (Level 3)

    

Total

  

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 6,329     $ -     $ -     $ 6,329  

Restricted cash

     1,141       -       -       1,141  

Short-term investments

     -       64,195       -       64,195  

Long-term investments

     -       3,865       -       3,865  

Total assets measured at fair value

   $ 7,470     $ 68,060     $ -     $ 75,530  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 1,256     $ 1,256  

Total liabilities measured at fair value

   $ -     $ -     $ 1,256     $ 1,256  

 

 (1) Includes investments that are readily convertible to cash with original maturities of 90 days or less.

 

   

December 31, 2021

  
   

(in thousands)

  
                                 

Description

  

Quoted Prices in

Active Markets for

Identical Assets

(Level 1)

    

Significant Other

Observable Inputs

(Level 2)

    

Significant

Unobservable

Inputs (Level 3)

    

Total

  

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 18,129     $ -     $ -     $ 18,129  

Restricted cash

     1,154       -       -       1,154  

Short-term investments

     -       80,262       -       80,262  

Long-term investments

     -       37,435       -       37,435  

Total assets measured at fair value

   $ 19,283     $ 117,697     $ -     $ 136,980  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 2,371     $ 2,371  

Total liabilities measured at fair value

   $ -     $ -     $ 2,371     $ 2,371  

 

 (1) Includes investments that are readily convertible to cash with original maturities of 90 days or less.

 

The carrying values of accounts receivable, prepaid expenses, employee retention tax credit receivables, other current assets, accounts payable, accrued employee compensation and benefits, accrued expenses, deferred revenue, and other current liabilities as of December 31, 2022, and December 31, 2021, approximate their fair values due to the short-term nature of these items.

 

The Company’s financial liabilities consisted of contingent consideration payable to Three Heads Investment S.r.l., related to the Company’s 2015 acquisition of the Senhance Surgical System from an assignor to Three Heads Investment S.r.l. (the “Senhance Acquisition”). Adjustments associated with the change in fair value of contingent consideration are included in the Company’s consolidated statements of operations and comprehensive loss.

 

The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements for contingent consideration utilizing a Monte-Carlo simulation as of December 31, 2022 and December 31, 2021:

 

 

Valuation

Methodology

  

Significant Unobservable

Input

  

December 31, 2022

    

December 31, 2021

  
                   

Contingent consideration

Probability weighted

income approach

  

Milestone dates

  

2032

    

2031

  
     

Discount rate

   16.5%     9.5%  
     

Revenue volatility

   45.0%     39.0%  
     

EUR-to-USD exchange rate

   1.07     1.14  

 

66
Table of Contents
 

The following table presents the current and long-term portion of the contingent consideration for the year ended December 31, 2022 and summarizes the change in fair value, as determined by Level 3 inputs for the contingent consideration for the year ended December 31, 2022 and 2021:

 

  

Fair Value

Measurement at

Reporting Date

(Level 3)

 
  

(in thousands)

 
  

Contingent

consideration

 

Balance at December 31, 2020

 $3,936 

Change in fair value

  (1,565)

Balance at December 31, 2021

 $2,371 

Change in fair value

  (1,115)

Balance at December 31, 2022

 $1,256 
     

Current portion

 $- 

Long-term portion

  1,256 

Balance at December 31, 2022

 $1,256 

 
 

7.

Inventories

 

The components of inventories are as follows:

 

   

December 31, 2022

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Reserve Balance

    

Net

Carrying

Amount

  

Finished goods

   $ 15,337     $ (4,129 )   $ 11,208  

Raw materials

     4,718       (2,173 )     2,545  

Total inventories

   $ 20,055     $ (6,302 )   $ 13,753  
                         

Current Portion

   $ 9,399     $ (1,115 )   $ 8,284  

Long-term portion

     10,656       (5,187 )     5,469  

Total inventories

   $ 20,055     $ (6,302 )   $ 13,753  

 

   

December 31, 2021

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Reserve Balance

    

Net

Carrying

Amount

  

Finished goods

   $ 13,066     $ (2,987 )   $ 10,079  

Raw materials

     8,324       (2,695 )     5,629  

Total inventories

   $ 21,390     $ (5,682 )   $ 15,708  
                         

Current Portion

   $ 9,931     $ (1,297 )   $ 8,634  

Long-term portion

     11,459       (4,385 )     7,074  

Total inventories

   $ 21,390     $ (5,682 )   $ 15,708  

 
67
Table of Contents

 

 

8.

Property and Equipment

 

Property and equipment consisted of the following:

 

   

December 31,
2022

    

December 31,
2021

  
   

(In thousands)

  

Machinery, manufacturing, and demonstration equipment

   $ 8,450     $ 8,289  

Operating lease assets - Senhance System leasing

     10,251       10,143  

Computer equipment

     600       325  

Furniture

     831       644  

Leasehold improvements

     1,654       1,259  

Construction in process

     436    

‑

  

Total property and equipment

     22,222       20,660  

Accumulated depreciation and amortization

     (12,680

)

     (9,689

)

Property and equipment, net

   $ 9,542     $ 10,971  

 

Depreciation expense was approximately $3.4 million and $2.9 million for the years ended December 31, 2022 and 2021, respectively. 

 

 

9.

Intellectual Property

 

The components of gross intellectual property, accumulated amortization, and net intellectual property are as follows:

 

   

December 31, 2022

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Accumulated Amortization

    

Foreign

Currency

Translation

Impact

    

Net

Carrying

Amount

  

Developed technology

   $ 68,838     $ (66,562 )   $ (874 )   $ 1,402  

Technology and patents purchased

     400       (239 )     13       174  

Total intellectual property

   $ 69,238     $ (66,801 )   $ (861 )   $ 1,576  

 

   

December 31, 2021

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Accumulated

Amortization

    

Foreign

Currency

Translation

Impact

    

Net

Carrying

Amount

  

Developed technology

   $ 68,838     $ (58,912 )   $ (262 )   $ 9,664  

Technology and patents purchased

     400       (199 )     27       228  

Total intellectual property

   $ 69,238     $ (59,111 )   $ (235 )   $ 9,892  

 

The weighted average remaining useful life of the developed technology and technology and patents purchased was 4.2 years and 4.3 years, respectively, as of December 31, 2022. The weighted average remaining useful life of the developed technology and technology and patents purchased was 1.6 years and 5.3 years, respectively as of December 31, 2021.

 

68
Table of Contents
 

The estimated future amortization expense of intellectual property as of December 31, 2022 is as follows (in thousands):

 

  

Year Ending
December 31, 2022

 

2023

 $377 

2024

  377 

2025

  377 

2026

  377 

2027

  68 

Total

 $1,576 

 

 
 

10.

Leases

 

Lessee Information

Components of operating lease expense are primarily recorded in general and administrative on the consolidated statements of operations and comprehensive loss were as follows:

 

   

Years Ended December 31,

  
   

2022

    

2021

  
   

(in thousands)

  

Long-term Operating

   $ 1,557     $ 1,826  

Short-term Operating

     -       -  

Total Operating lease expense

   $ 1,557     $ 1,826  

 

Supplemental balance sheet information related to operating leases was as follows:

 

   

December 31, 2022

    

December 31, 2021

  

Weighted-average remaining lease term (in years)

  

6.8

    

7.8

  

Weighted-average discount rate

   8.4%     7.8%  

Incremental borrowing rate

   6.1% - 14.5%     6.1% - 8.5%  

 

Maturities of operating lease obligations as of December 31, 2022 were as follows (in thousands):

 

Fiscal Year

        

2023

   $ 1,222  

2024

     1,136  

2025

     1,058  

2026

     837  

2027

     775  

Thereafter

     2,195  

Total minimum lease payments

   $ 7,223  

Less: Amount of lease payments representing interest

     (1,685 )

Present value of future minimum lease payments

   $ 5,538  

 
 

11.

Accrued Expenses

 

The following table presents the components of accrued expenses:

 

   

December 31,
2022

    

December 31,
2021

  
   

(In thousands)

  

Consulting and other vendors

   $ 155     $ 128  

Other

     —       124  

Royalties

     24       247  

Legal and professional fees

     275       503  

Taxes and other assessments

     839       615  

Total

   $ 1,293     $ 1,617  

 
69
Table of Contents

 

 

12.

Income Taxes

 

The components for the income tax expense are as follows for the years ended December 31 (in thousands):

 

  

2022

  

2021

 

Current income taxes

        

Federal

 $-  $- 

State

  -   - 

Foreign

  239   232 

Deferred income taxes

        

Federal

  -   - 

State

  -   - 

Foreign

  79   (7)

Total income tax expense

 $318  $225 

 

The United States and foreign components of loss from operations before taxes are as follows for the years ended December 31 (in thousands):

 

  

2022

  

2021

 
         

United States

 $(44,802) $(32,094)

Foreign

  (30,441)  (30,143)

Total loss from operations before taxes

 $(75,243) $(62,237)

 

 

 

Significant components of the Company’s deferred tax assets consist of the following at December 31 (in thousands):

 

  

2022

  

2021

 
         

Deferred Tax assets:

        

Stock-based compensation

 $2,840  $2,440 

Accrued expenses and other

  2,538   2,423 

Research credit carryforward

  1,341   564 

Fixed Assets

  162   101 

Capitalized start-up costs and other intangibles

  921   1,109 

Capitalized research costs

  4,382   - 

Net operating loss carryforwards

  83,908   75,237 
   96,092   81,874 

Valuation Allowance

  (94,704)  (78,294)

Net deferred tax asset

  1,388   3,580 

Deferred tax liabilities

        

Fixed assets and other

  (1,214)  (1,176)

Purchase accounting intangibles

  -   (2,116)

Net deferred tax liability

  (1,214)  (3,292)

Net deferred tax asset (liability)

 $174  $288 

 

During 2021, the Company completed an assessment of the available net operating loss and tax credit carryforwards under Section 382 and Section 383 of the Internal Revenue Code, respectively. The Company determined that it underwent multiple ownership changes throughout its history as defined under Section 382, including most recently in 2020. As a result of the identified ownership changes, the portion of net operating loss and tax credits carryforwards attributable to the pre-ownership change periods are subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code. The Company has adjusted its net operating loss and tax credit carryforwards to address the impact of the 382 ownership changes. This resulted in a reduction of available Federal and State NOLs of $253 million and $204 million, respectively.

 

70
Table of Contents
 

At December 31, 2022 and 2021, the Company has provided a full valuation allowance against its net deferred assets in the U.S., Canada, Italy, Luxembourg, Switzerland, and Taiwan tax jurisdictions, since realization of these benefits is not more likely than not. The valuation allowance increased approximately $16.4 million from the prior year. At December 31, 2022, the Company had U.S. federal net operating loss carryforwards of $419.4 million, of which $253 million are expected to expire unused under the limitations imposed by Internal Revenue Code Section 382 (as discussed above). Of the total amount of Federal NOLs (notwithstanding the 382 limitation), $254.5 million begin to expire in 2027, while the remaining $164.9 million carry forward indefinitely. At December 31, 2022, the Company had U.S. state net operating loss carryforwards of $328.9 million, of which $204 million are expected to expire unused under the state tax law equivalents of Internal Revenue Code Section 382. Of this amount (notwithstanding the 382 limitations), $317.4 million of state NOLs begin to expire in 2022, while the remaining $11.5 million carry forward indefinitely. At December 31, 2022, the Company had federal research credit carryforwards in the amount of $10.2 million. These carryforwards begin to expire in 2027. However, under the limitations of Internal Revenue Code Section 383, it is expected that $8.8 million of this carryforward will expire unused. The utilization of the federal net operating loss carryforwards and credit carryforwards will depend on the Company’s ability to generate sufficient taxable income prior to the expiration of the carryforwards.

 

At December 31, 2022, the Company had foreign operating loss carryforwards in Italy of approximately $24.6 million, which can be carried forward indefinitely; foreign operating loss carryforwards in Luxembourg of approximately $95.9 million, which will begin to expire in 2034; foreign operating loss carryforwards in Switzerland of approximately $116.5 million, which begin to expire in 2023, and foreign operating loss carryforwards in Canada of approximately $0.9 million, which begin to expire in 2040.

 

The Company has evaluated its tax positions to consider whether it has any unrecognized tax benefits. As of December 31, 2022, the Company had gross unrecognized tax benefits of approximately $0.3 million. Of the total, none would reduce the Company’s effective tax rate if recognized. The Company does not anticipate a significant change in total unrecognized tax benefits or the Company’s effective tax rate due to the settlement of audits or the expiration of statutes of limitations within the next twelve months. Furthermore, the Company does not expect any cash settlement with the taxing authorities as a result of these unrecognized tax benefits as the Company has sufficient unutilized carryforward attributes to offset the tax impact of these adjustments.

 

The following is a tabular reconciliation of the Company’s change in gross unrecognized tax positions at December 31 (in thousands):

 

  

2022

  

2021

 
         

Beginning balance

 $141  $- 

Gross increases for tax positions related to current periods

  194   141 

Gross decreases related to 382 limitations

  -   - 

Ending balance

 $335  $141 

 

 

The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes. As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions.

 

The Company has analyzed its filing positions in all significant federal, state, and foreign jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, the Company is no longer subject to United States Federal, state, and local tax examinations by tax authorities for years before 2019, although carryforward attributes that were generated prior to 2019 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.

 

Taxes computed at the then-current statutory federal income tax rate of 21% are reconciled to the provision for income taxes as follows for the years ended December 31:

 

  

2022

  

2021

 
  

Amount

  

Percent

of

Pretax

Earnings

  

Amount

  

Percent

of

Pretax

Earnings

 

United States federal tax at statutory rate

 $(15,801)  21.0% $(13,070)  21.0%

State taxes (net of deferred benefit)

  (2,912)  3.9%  (2,205)  3.5%

Nondeductible expenses

  1,077   (1.4%)  (440)  0.7%

Change in fair market value of contingent consideration

  (283)  0.4%  (397)  0.6%

Warrant remeasurment and financing costs

  -   -   502   (0.8%)

Research & Development

  (970)  1.3%  (705)  1.1%

Change in unrecognized tax benefits

  194   (0.3%)  141   (0.2%)

Foreign tax rate differential

  2,676   (3.6%)  1,911   (3.1%)

True-up to Stock Compensation - Cancellations

  49   (0.1%)  2,832   (4.6%)

Change in enacted tax rates and other, net

  (96)  0.2%  731   (1.0%)

Change in valuation allowance

  16,384   (21.8%)  10,925   (17.6%)

Income tax expense (benefit)

 $318   (0.4%) $225   (0.4%)

 

71
Table of Contents

 

 

13.

Stock-Based Compensation

 

Overview

 

On July 22, 2021, at the 2021 Annual Meeting of Stockholders, stockholders voted to approve the Company’s Amended and Restated Incentive Compensation Plan (the “Plan”) to increase the number of shares reserved for issuance under the Plan by 22,000,000 shares. As of December 31, 2022, there were 32,072,308 shares authorized for issuance, and 11,038,824 shares available for future issuance under the Plan. To date all equity awards under the Plan have consisted of nonqualified stock options, incentive stock options, and restricted stock units.

 

Under the Plan, which is administered by the Compensation Committee, the Company may grant stock options, stock appreciation rights, restricted stock and/or deferred stock to employees, officers, directors, consultants, and vendors. The exercise price of stock options or stock appreciation rights may not be less than the fair market value of the Company’s shares at the date of grant. Additionally, no stock options or stock appreciation rights granted under the Plan may have a term exceeding ten years.

 

Stock Options

The following table summarizes the Company’s stock option activity, including grants to non-employees, for the year ended December 31, 2022:

 

   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average

Remaining

Contractual Term

(Years)

  

Balance at December 31, 2021

     4,640,660     $ 6.64       5.66  

Granted

     3,153,881       0.70          

Forfeited

     (129,134 )     1.60          

Cancelled

     (36,987 )     21.11          

Exercised

     (43,453 )     0.41          

Balance at December 31, 2022

     7,584,967     $ 4.22       5.31  

 

 

The aggregate intrinsic value of stock options exercised under the Company’s stock plans was not material during the year ended December 31, 2022.

 

The following table summarizes information about stock options outstanding at December 31, 2022:

 

   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average

Remaining

Contractual Term

(Years)

    

Aggregate

Intrinsic Value

(Millions)

  

Exercisable at December 31, 2022

     3,524,473     $ 7.40       4.75     $ -  

Vested or expected to vest at December 31, 2022

     7,350,141     $ 4.32       5.28     $ -  

 

 

The fair value of options granted were estimated using the Black-Scholes-Merton option pricing model based on the assumptions in the table below:

 

  Years Ended December 31,
  2022  2021

Expected dividend yield

 0%  0%

Expected volatility

 126%-133%  118%-139%

Risk-free interest rate

 1.25%-4.40%  0.33%-1.11%

Expected life (in years)

 3.8-4.5  3.8-4.5 

 

72
Table of Contents
 

Restricted Stock Units

The following is a summary of the restricted stock units activity, including performance restricted stock units, for the year ended December 31, 2022:

 

   

Number of

Restricted

Stock Units

Outstanding

    

Weighted-

Average Grant

Date Fair

Value

  

Unvested December 31, 2021

     3,839,030     $ 2.36  

Granted

     6,996,822       0.71  

Vested

     (2,076,663 )     2.34  

Forfeited

     (275,698 )     1.19  

Unvested December 31, 2022

     8,483,491     $ 1.04  

 

Performance Restricted Stock Units

In 2022 and 2021, the Company granted performance-based restricted stock units with vesting terms based on our attainment of certain operational targets by October 1, 2023 and October 1, 2022, respectively. The number of shares earnable under the 2022 and 2021 awards are based on achieving designated corporate goals. These operational targets were achieved for 2022 and 2021, therefore the performance-based restricted stock units are fully earned and remain subject to three-year time-based vesting requirements.

 

Stock-based Compensation Expense

The following table summarizes non-cash stock-based compensation expense by award type for the years ended December 31, 2022, and 2021:

 

   

Years Ended December 31,

 
   

2022

    

2021

  
   

(in thousands)

  

Stock options

   $ 3,654     $ 4,535  

Restricted stock units

     3,319       3,954  

Performance restricted stock units

     1,443       940  
    $ 8,416     $ 9,429  

 

As of December 31, 2022, the Company had future employee stock-based compensation expense of approximately $2.1 million related to unvested stock options, which is expected to be recognized over an estimated weighted-average period of 1.5 years. As of December 31, 2022, the unrecognized stock-based compensation expense related to unvested restricted stock units and performance restricted stock units was approximately $4.2 million, which is expected to be recognized over a weighted average period of approximately 1.4 years.

 

 

14.

Equity Offerings

 

Equity financing transactions for the years ended December 31, 2022 and 2021, include:

 

2020 ATM Offering. On October 9, 2020, the Company filed a prospectus supplement relating to an at-the-market offering with Cantor pursuant to which the Company could sell from time to time, at its option, up to an aggregate of $40.0 million of shares of the Company’s common stock (the “2020 ATM Offering”). The Company terminated this agreement in January 2021. 

 

January 2021 Public Offering. On January 29, 2021, the Company completed an underwritten public offering of 26,545,832 shares of its common stock, including the underwriter’s full exercise of an over-allotment option on February 1, 2021, at the public offering price of $3.00 per share, generating net proceeds of approximately $73.4 million.

 

January 2021 Registered Direct Purchase Agreement. On January 12, 2021, the Company sold in a registered direct offering 25,000,000 shares of common stock at a purchase price per share of $1.25 for aggregate net proceeds of $28.6 million.

 

2021 ATM Offering. On May 19, 2021, we entered into a Controlled Equity OfferingSM Sales Agreement with Cantor, Robert W. Baird & Co. Incorporated and Oppenheimer & Co. Inc., as our sales agents, relating to an at-the-market offering of up to an aggregate of $100,000,000 of shares of our common stock, referred to as the “2021 ATM Offering”.

 

73
Table of Contents
 

Sales during the year ended December 31, 2021, under the 2021 and 2020 ATM Offering are as follows (in thousands, except for share and per share amounts):

 

  

Year Ended

December 31, 2021

 
     

Total shares of common stock sold

  20,237,045 

Average price per share

 $1.53 

Gross proceeds

 $30,943 

Commisssion earned by Sales Agents

 $928 

Net proceeds

 $30,015 

 

 

2021 Exercise of Warrants. During the year ended December 31, 2021, certain holders of our Series B, C and D warrants to purchase shares of our common stock exercised such warrants for aggregate proceeds to the Company of $30.6 million.

 

2022 ATM Offering. On March 18, 2022, the Company entered a Controlled Equity Offering Sales Agreement (the “2022 Sales Agreement”), with Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc. The Company commenced an at-the-market offering (the “2022 ATM Offering”) pursuant to which the Company could sell from time to time, at its option, up to an aggregate of $100.0 million shares of the Company’s common stock. No sales of common stock were made under the 2022 ATM Offering during the year ended December 31, 2022.

 

 

15.

Basic and Diluted Net Loss per Share

 

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all potential dilutive common shares that were outstanding during the period when the effect is dilutive. Potential dilutive common shares consist of incremental shares issuable upon exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding common shares figures for the years ended December 31, 2022 or 2021 as the assumed exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.

 

Potential common shares not included in calculating diluted net loss per share are as follows:

 

 

   

December 31,

 
   

2022

    

2021

  

Stock options

     7,584,967       4,640,660  

Stock warrants

     1,021,076       1,120,300  

Nonvested restricted stock units

     8,483,491       3,839,030  

Total

     17,089,534       9,599,990  

 

 
 

16.

Commitments and Contingencies

 

License and Supply Agreements

As part of the Company’s acquisition of the Senhance System in 2015, the Company assumed certain license and supply agreements. The Company has purchase orders with various suppliers for certain tooling, supplies, contract engineering and research services. Commitments related to license agreements and purchase orders are as follows (in thousands):

 

Fiscal Year

        

2023

   $ 5,976  

2024

     407  

2025

     313  

2026

     303  

Total commitments

   $ 6,999  

 
74
Table of Contents

 

 

17.

Segments and Geographic Areas

 

The following table presents consolidated assets and long-lived assets by geographic area, which includes property and equipment, intellectual property, and operating lease assets:

 

   

December 31, 2022

  
   

Long-Lived Assets

    

Total Assets

  

U.S.

     35 %     72 %
                 

EMEA

                

Switzerland

     46 %     24 %

Italy

     8 %     2 %

Other

     8 %     1 %

Total EMEA

     62 %     27 %
                 

Asia

     3 %     1 %

Total

     100 %     100 %

 

 

   

December 31, 2021

  
   

Long-Lived Assets

    

Total Assets

  

U.S.

     26 %     77 %
                 

EMEA

                

Switzerland

     34 %     16 %

Italy

     36 %     5 %

Other

     4 %     1 %

Total EMEA

     74 %     22 %
                 

Asia

     0 %     1 %

Total

     100 %     100 %

 

 

The following table presents sales by geographic area based on the country in which the customer is based.

 

 

   

Years Ended December 31,

 
   

2022

    

2021

  
                 
                 

US

     11 %     13 %

EMEA

     77 %     62 %

Asia

     12 %     25 %

Total

     100 %     100 %

 

 

18.

Related Party Transactions

 

In March 2018, Asensus Surgical Europe S.à r.l. entered into a Service Supply Agreement with 1 Med S.A. for certain regulatory consulting services. Andrea Biffi, a current member of the Company’s Board of Directors, owns a non-controlling interest in 1 Med S.A. Expenses under the Service Supply Agreement were approximately $290,000 and $186,000 for the years ended December 31, 2022 and 2021, respectively.

 

75
Table of Contents
 

 

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9.A.

CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2022. We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2022, our disclosure controls and procedures were not effective due to ongoing remediation efforts described below.

 

Material Weakness in Internal Control over Financial Reporting

 

During the year ended December 31, 2022, management identified a deficiency constituting a material weakness related to the design and implementation of information technology general controls (“ITGCs”) related to the implementation of our new global enterprise resource planning system (“ERP”) utilized in the preparation of our consolidated financial statements. Specifically, we did not design and maintain user access controls to adequately restrict user and privileged access to the financial application and data to appropriate Company personnel.

 

The material weakness identified above did not result in any identified misstatements to our consolidated financial statements, and our management has concluded that the consolidated financial statements present fairly, in all material respects, our financial position, results of operations, and cash flows in conformity with U.S. GAAP. Based on this material weakness, management concluded that as of December 31, 2022, our internal control over financial reporting was not effective.

 

Remediation Efforts

 

We have commenced measures to remediate the identified material weakness. Management has been and will continue designing and implementing an improved process for requesting, authorizing, and reviewing user access to key systems which impact our financial reporting, including identifying access to roles where manual business process controls may be required. This implementation will include the addition of detection controls which will include the review of user access and activity logs related to systems that were accessed. We will also enhance the training of our personnel regarding their roles and responsibilities within the information technology general controls objectives and activities. The material weakness will not be considered remediated until management designs and implements effective controls that operate for a sufficient period of time for management to conclude, through testing, that the controls are operating effectively. The material weakness is not considered remediated as of December 31, 2022 as remediation efforts are ongoing.

 

Management’s Report on Internal Control Over Financial Reporting

 

We are responsible for establishing and maintaining adequate internal control over financial reporting. As defined in the securities laws, internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officer and effected by our Board of Directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the acquisitions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

76
Table of Contents

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

For the year ended December 31, 2022, pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, management (with the participation of our principal executive officer and principal financial officer) conducted an evaluation of the effectiveness of our internal control over financial reporting, based on the original framework established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, management concluded that, as of December 31, 2022, our internal control over financial reporting was not effective.

 

Changes in Internal Controls Over Financial Reporting

 

There were no changes in the Company’s internal control over financial reporting during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

ITEM 9.B.

OTHER INFORMATION

 

None.

 

ITEM 9.C.

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

77
Table of Contents

 

PART III

 

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE.

 

The information required by this item is incorporated by reference from the information contained in our proxy statement for the Annual Meeting of Stockholders expected to be filed with the SEC on or prior to May 1, 2023.

 

78
Table of Contents

 

ITEM 11.

EXECUTIVE COMPENSATION.

 

The information required by this item is incorporated by reference from the information contained in our proxy statement for the Annual Meeting of Stockholders expected to be filed with the SEC on or prior to May 1, 2023.

 

79
Table of Contents

 

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 

The information required by this item is incorporated by reference from the information contained in our proxy statement for the Annual Meeting of Stockholders expected to be filed with the SEC on or prior to May 1, 2023.

 

Securities Authorized for Issuance Under Equity Compensation Plans 

 

The Company currently has one equity compensation plan under which it makes awards, the Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan (the “Plan”). The Plan was originally approved by the Board of Directors of the Company, or the Board, and adopted by the majority of stockholders on November 13, 2007. The Plan was subsequently amended, approved by the Board, and approved by stockholders as follows:

 

No.

Amendment Purpose

Date of Stockholders’ approval

1

increase the number of shares of common stock authorized under the Plan to 918,462 shares, and to make other changes

May 7, 2015

2

increase the number of shares reserved for issuance under the Plan to 1,456,923 shares, and to make other changes

June 8, 2016

3

increase the number of shares reserved for issuance under the Plan to 1,995,385 shares

May 25, 2017

4

increase the number of shares reserved for issuance under the Plan to 3,149,231 shares

May 24, 2018

5

increase the number of shares reserved for issuance under the Plan to 4,072,308 shares, and to make other changes

April 24, 2019

6

increase the number of shares reserved for issuance under the Plan to 10,072,307 shares, and to make other changes

June 8, 2020

7

Increase the number of shares reserved for issuance under the Plan to 32,072,307 shares.

July 22, 2021

 

The Plan is used for plan-based awards for officers, other employees, consultants, advisors and non-employee directors. In connection with the 2013 merger transaction with SafeStitch Medical, Inc., or the Merger, we assumed all of the options that were issued and outstanding immediately prior to the Merger as issued by Asensus Surgical US, Inc., and adjusted based on the Merger at the exchange ratio, which are now exercisable for approximately 32,590 shares of common stock. Such options were granted under the TransEnterix, Inc. 2006 Stock Plan (the “2006 Plan”) which was assumed by the Company in the Merger. The 2006 Plan is maintained solely for the purpose of the stock options granted under such 2006 Plan that remain outstanding; no future awards are authorized to be made under the 2006 Plan.

 

80
Table of Contents

 

The following table gives information about the Company’s common stock that may be issued upon the exercise of options and other equity awards as of December 31, 2022:

 

Plan Category

  

Number of
securities to

be
issued upon
exercise of
outstanding
options and

other

equity

awards (1)

    

Weighted
average

exercise
price of
outstanding
options

    

Number of
securities
remaining
available
for future
issuance (2)

  

Equity compensation plans approved by security holders

    

15,901,792

      

4.30

      

11,038,824

  

Equity compensation plans not approved by security holders (3)

    

166,666

      

0.42

      

0

  

Total

    

16,068,458

              

11,038,824

  

 

(1)

Includes 7,434,967 shares underlying outstanding stock options awarded under the Plan and 8,466,825 restricted stock units awarded under the Plan.

 

(2)

These shares are all available for future awards under the Plan.

 

(3)

Represents 150,000 shares underlying outstanding stock options awarded prior to the Merger under the 2006 Plan and assumed in the Merger and ‐‐‐16,666 shares underlying outstanding stock options, restricted stock units, and performance-based restricted stock units issued as an employment inducement grant as an exception to the NYSE American stockholder approval rules.

 

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

The information required by this item is incorporated by reference from the information contained in our proxy statement for the Annual Meeting of Stockholders expected to be filed with the SEC on or prior to May 1, 2023.

 

81
Table of Contents

 

ITEM 14.

PRINCIPAL ACCOUNTING FEES AND SERVICES.

 

The information required by this item is incorporated by reference from the information contained in our proxy statement for the Annual Meeting of Stockholders expected to be filed with the SEC on or prior to May 1, 2023.

 

82
Table of Contents

 

PART IV

 

ITEM 15.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a).

 

 

(1)

The following consolidated financial statements are filed as a part of this Annual Report:

 

 

Page

Consolidated Financial Statements :

  
   

Reports of Independent Registered Public Accounting Firm

50

Consolidated Balance Sheets as of December 31, 2022 and 2021

52

Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022, 2021 and 2020

53

Consolidated Statements of  Stockholders’ Equity for the years ended December 31, 2022, 2021 and 2020

54

Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020

55

 

 

(2)

Consolidated Financial Statement Schedules: The information required by this item has been omitted in this report because they are not applicable, not required under these instructions, or included in the consolidated financial statements or related notes thereto contained in Item 8 of this Annual Report.

 

 

(3)

Exhibits: The following exhibits are filed as part of, or incorporated by reference into, this Annual Report.

 

Exhibit
No.

  

Description

2.1

  

Membership Interest Purchase Agreement, dated September 18, 2015, by and among Sofar S.p.A., Vulcanos S.r.l., the Registrant and TransEnterix International, Inc. filed as Exhibit 2.1 to our Current Report on Form 8-K, filed with the SEC on September 21, 2015 and incorporated by reference herein).

2.1(a)

  

Amendment to Membership Interest Purchase Agreement by and among TransEnterix, Inc., TransEnterix International, Inc., and Sofar, S.p.A., dated December 30, 2016 (filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on January 5, 2017 and incorporated by reference herein).

3.1.1

  

Amended and Restated Certificate of Incorporation of Asensus Surgical, Inc. (filed as Exhibit 3.1 to our Current Report on Form 8-K, filed with the SEC on February 25, 2021 and incorporated by reference herein).

3.2

  

Amended and Restated Bylaws of Asensus Surgical, Inc. (filed as Exhibit 3.2 to our Current Report on Form 8‑K, filed with the SEC on February 25, 2021 and incorporated by reference herein).

4.1

  

Specimen Certificate for Common Stock of Asensus Surgical, Inc. (incorporated by reference to Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2020).

4.2

  

Form of Service Warrant to purchase common stock for warrants issued to third party vendor (filed as Exhibit 4.4 to our Quarterly Report on Form 10-Q, filed with the SEC on November 9, 2017 and incorporated by reference herein).

4.3

  

Form of Common Stock Purchase Warrant (Series C and Series D Warrants) (filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on March 6, 2020 and incorporated herein by reference).

4.4

  

Form of Warrant Agency Agreement by and between the Registrant and Continental Stock Transfer & Trust Company (filed as Exhibit 4.2 to our Current Report on Form 8-K, filed with the SEC on March 6, 2020 and incorporated herein by reference).

4.5

  

Description of Listed Securities (filed as Exhibit 4.8 to our Annual Report on Form 10-K, filed with the SEC on March 11, 2021 and incorporated herein by reference). 

 

83
Table of Contents

 

10.1 +

  

Employment Agreement, dated March 6, 2018, and effective as of March 1, 2018, by and between the Registrant and Anthony Fernando (filed as Exhibit 10.7 to our Annual Report on Form 10-K, filed with the SEC on March 8, 2018 and incorporated by reference herein).

10.2+

  

Employment Agreement, dated August 14, 2020, by and between Asensus Canada, Inc., on behalf of the Registrant, and Shameze Rampertab (filed as Exhibit 10.1 to our Current Report on Form 8-K/A, filed with the SEC on August 14, 2020 and incorporated by reference herein).

10.2.1+

  

Amendment to Employment Agreement, dated September 16, 2020, by and between Asensus Canada, Inc., on behalf of the Registrant, and Shameze Rampertab (filed as Exhibit 10.1.2 to our Registration Statement on Form S-8, filed with the SEC on November 6, 2020 and incorporated by reference herein).

10.3 +

  

TransEnterix, Inc. 2006 Stock Plan, as amended on November 29, 2011 (filed as Exhibit 4.4 to the Registrant’s Registration Statement on Form S-8 (File No. 333-191011), filed with the SEC on September 5, 2013 and incorporated by reference herein).

10.4 +

  

Asensus Surgical Amended and Restated Incentive Compensation Plan, as amended and restated July 22, 2021 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on July 23, 2021).

10.4.1 + 

   Form of Employee Stock Option Award Notice (incorporated by reference to Exhibit 10.4.1 to our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022).

10.4.2 + 

   Form of Employee Restricted Stock Unit/Performance Restricted Stock Unit Award Notice (incorporated by reference to Exhibit 10.4.2 to our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022).

10.4.3 +

   Form of Non-Employee Director Stock Option Agreement pursuant to the Plan (filed as Exhibit 10.4.5 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021 and incorporated herein by reference).

10.4.4 +

   Form of Non-Employee Director Restricted Stock Unit Agreement pursuant to the Plan (filed as Exhibit 10.4.6 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021 and incorporated herein by reference).

10.4.5 +

   Form of Non-Employee Director Other Stock Award Agreement (filed as Exhibit 10.4.7 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021 and incorporated herein by reference).

10.4.6 +

   Form of Non-Employee Director Stock Option Grant in Lieu of Cash Retainer (filed as Exhibit 10.4.8 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021 and incorporated herein by reference).

10.5+

   Non-Qualified Deferred Compensation Plan, adopted December 8, 2021 (incorporated by reference to Exhibit 10.5 to our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022).

10.6 ++

  

License Contract between the European Union and Vulcanos S.r.l. (now known as Asensus Surgical Italia S.r.l.), dated September 18, 2015 (filed as Exhibit 10.5 to our Quarterly Report on Form 10-Q, filed with the SEC on November 9, 2015 and incorporated by reference herein).

10.6.1 +++

   Amendment to License Contract between the European Union and Asensus Surgical Italia S.r.l., effective July 2, 2021 (incorporated by reference to Exhibit 10.6.1 to our Annual Report on Form 10K for the year ended December 31, 2021, filed with the SEC on February 28, 2022).

10.7 +

  

Asensus Surgical Non-Employee Director Compensation Plan effective July 1, 2021 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on April 30, 2021).

10.8

  

Promissory Note, dated April 18, 2020, by and between TransEnterix, Inc. and City National Bank, a national banking association (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 28, 2020 and incorporated by reference).

21.1 *

  

Subsidiaries of the Registrant.

23.1 *

  

Consent of BDO USA, LLP.

31.1 *

  

Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).

31.2 *

  

Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).

32.1 *

  

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 *

  

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS *

  

Inline XBRL Instance Document.

101.SCH *

  

Inline XBRL Taxonomy Extension Schema Document.

101.CAL *

  

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF *

  

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB *

  

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE *

  

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104

  

The cover page from the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, formatted in Inline XBRL (included in Exhibit 101).

 

+

A management contract, compensatory plan or arrangement required to be separately identified.

 

84
Table of Contents

 

++

Confidential treatment has been granted for certain portions of the agreement pursuant to a confidential treatment request filed with the Commission on November 9, 2015. Such provisions have been filed separately with the Commission.

+++

Portions of this exhibit have been omitted because the information is not material and would likely cause competitive harm if publicly disclosed.

*

Filed herewith.

 

ITEM 16.

FORM 10-K SUMMARY.

 

Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.

 

85
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

March 2, 2023

Asensus Surgical, Inc.
     
 

By:

/s/ Anthony Fernando
   

Anthony Fernando
   

President, Chief Executive Officer
   

and a Director
   

(principal executive officer)

 

POWER OF ATTORNEY

 

We, the undersigned officers and directors of Asensus Surgical, Inc., hereby severally constitute and appoint Anthony Fernando and Shameze Rampertab, our true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution in him for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

 

Signature

  

Title(s)

  

Date
     

/s/ Anthony Fernando

  

President, Chief Executive Officer and a Director

  

March 2, 2023

Anthony Fernando

  

(principal executive officer)

    
     

/s/ Shameze Rampertab

  

Executive Vice President and Chief Financial Officer

  

March 2, 2023

Shameze Rampertab

  

(principal financial officer and principal accounting officer)

    
         

/s/ David B. Milne

  

Chairman of the Board and a Director

  

March 2, 2023

David B. Milne

        
     

/s/ Andrea Biffi

  

Director

  

March 2, 2023

Andrea Biffi

        
     

/s/ Kevin Hobert

  

Director

  

March 2, 2023

Kevin Hobert

        
     

/s/ Elizabeth Kwo, M.D.

 Director

 March 2, 2023

Elizabeth Kwo, M.D.

    
     

/s/ Richard C. Pfenniger, Jr.

  

Director

  

March 2, 2023

Richard C. Pfenniger, Jr.

        
     

/s/ William N. Starling, Jr.

  

Director

  

March 2, 2023

William N. Starling, Jr.

        

 

86
EX-21.1 2 ex_480515.htm EXHIBIT 21.1 ex_480515.htm

Exhibit 21.1

 

Subsidiaries

 

(As of February 24, 2023)

 

 

Name of Subsidiary

 Jurisdiction of Incorporation
   

Asensus Surgical US, Inc.

Delaware
   

Asensus International, Inc.

Delaware
   

Asensus Surgical Italia, S.r.l.

Italy
   

Asensus Surgical Europe S.à r.l.

Luxembourg
   

Asensus Surgical Netherlands B.V.

 Netherlands
   

Asensus Surgical Israel Ltd

Israel
   

Asensus Surgical Canada, Inc.

Ontario, Canada
   

Asensus Surgical Japan K.K.

Japan
   

Asensus Taiwan Ltd.

 Taiwan

 

 
 EX-23.1 3 ex_481819.htm EXHIBIT 23.1 ex_481819.htm

Exhibit 23.1

 

 

Consent of Independent Registered Public Accounting Firm

 

 

Asensus Surgical, Inc.

Durham, North Carolina

 

We hereby consent to the incorporation by reference in the Registration Statements on Forms S-1 (No. 333-238471), Form S-3 (No. 333-263711 and No. 333-224049), and Form S-8 (No. 333-161291, No. 333-190184, No. 333-191011, No. 333-193234, No. 333-203950, No. 333-211972, No. 333-219111, No. 333-225231, No. 333-231078, No. 333-239018, No. 333-249895 and 333-258160)  of Asensus Surgical, Inc. of our report dated March 2, 2023, relating to the consolidated financial statements which appear in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

 

 

/s/ BDO USA, LLP

 

 

Raleigh, North Carolina

March 2, 2023

 

 
 EX-31.1 4 ex_480516.htm EXHIBIT 31.1 ex_480516.htm

Exhibit 31.1

 

SECTION 302 CERTIFICATION

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

I, Anthony Fernando, certify that:

(1) I have reviewed this Annual Report on Form 10-K of Asensus Surgical, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its unconsolidated investments, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

     

Date: March 2, 2023

  

By: /s/ Anthony Fernando
 

Anthony Fernando

President and Chief Executive Officer (Principal Executive Officer)

 

 
 EX-31.2 5 ex_480517.htm EXHIBIT 31.2 ex_480517.htm

Exhibit 31.2

 

SECTION 302 CERTIFICATION

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

I, Shameze Rampertab, certify that:

(1) I have reviewed this Annual Report on Form 10-K of Asensus Surgical, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its unconsolidated investments, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

     

Date: March 2, 2023

  

By: /s/ Shameze Rampertab
 

Shameze Rampertab

Executive Vice President and Chief Financial Officer (Principal Financial Officer)

 

 
 EX-32.1 6 ex_480518.htm EXHIBIT 32.1 ex_480518.htm

Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Annual Report on Form 10-K of Asensus Surgical, Inc. for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Asensus Surgical, Inc.

 

Date: March 2, 2023

By:

  

/s/ Anthony Fernando
   

Anthony Fernando
   

President and Chief Executive Officer (Principal Executive Officer)

 

 

The certification set forth above is being furnished as an Exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate disclosure document of Asensus Surgical, Inc. or the certifying officers.

 

 
 EX-32.2 7 ex_480519.htm EXHIBIT 32.2 ex_480519.htm

Exhibit 32.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Annual Report on Form 10-K of Asensus Surgical, Inc. for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Asensus Surgical, Inc.

 

Date: March 2, 2023

By:

  

/s/ Shameze Rampertab
   

Shameze Rampertab
   

Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

 

The certification set forth above is being furnished as an Exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate disclosure document of Asensus Surgical, Inc. or the certifying officers.

 
 EX-101.SCH 8 asxc-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Description of the Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Revenue Recognition link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Investments, Available-for-sale link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Fair Value link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Inventories link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Intellectual Property link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Leases link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Equity Offerings link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 16 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 17 - Segments and Geographic Areas link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 18 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 3 - Revenue Recognition (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 5 - Investments, Available-for-sale (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 6 - Fair Value (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 7 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 8 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 9 - Intellectual Property (Tables) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 10 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 11 - Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 12 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 13 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 14 - Equity Offerings (Tables) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 16 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 17 - Segments and Geographic Areas (Tables) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 3 - Revenue Recognition 1 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 3 - Revenue Recognition 2 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 5 - Investments, Available-for-sale (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 5 - Investments, Available-for-sale - Contractual Maturities (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 7 - Inventories - Components of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 8 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 8 - Property and Equipment - Summary of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 9 - Intellectual Property (Details Textual) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 9 - Intellectual Property - Intellectual Property (Details) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 10 - Leases - Components of Operating Lease Expense (Details) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 10 - Leases -Supplemental Balance Sheet Information (Details) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 10 - Leases - Minimum Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 11 - Accrued Expenses - Components of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 12 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note 12 - Income Taxes - Deferred Tax Assets (Details) link:calculationLink link:definitionLink link:presentationLink 069 - Disclosure - Note 12 - Income Taxes - Unrecognized Tax Positions (Details) link:calculationLink link:definitionLink link:presentationLink 070 - Disclosure - Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) link:calculationLink link:definitionLink link:presentationLink 071 - Disclosure - Note 13 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 072 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 073 - Disclosure - Note 13 - Stock-based Compensation - Stock Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 074 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 075 - Disclosure - Note 13 - Stock-based Compensation - RSU Activity (Details) link:calculationLink link:definitionLink link:presentationLink 076 - Disclosure - Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 077 - Disclosure - Note 14 - Equity Offerings (Details Textual) link:calculationLink link:definitionLink link:presentationLink 078 - Disclosure - Note 14 - Equity Offerings - Summary of Sales Under Offering (Details) link:calculationLink link:definitionLink link:presentationLink 079 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 080 - Disclosure - Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details) link:calculationLink link:definitionLink link:presentationLink 081 - Disclosure - Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 082 - Disclosure - Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 083 - Disclosure - Note 18 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 9 asxc-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 asxc-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 asxc-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Expected dividend yield Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies United States federal tax at statutory rate, amount Mature in less than one year, amortized cost Note 3 - Revenue Recognition us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Risk-free interest rate Note 4 - Cash, Cash Equivalents, and Restricted Cash Mature in less than one year, fair value Note 5 - Investments, Available-for-sale Note 6 - Fair Value Note 7 - Inventories Long-Term Liabilities: Note 8 - Property and Equipment Note 9 - Intellectual Property Income Tax Disclosure [Text Block] Note 10 - Leases Note 11 - Accrued Expenses Unrealized loss on available-for-sale investments Note 12 - Income Taxes Note 13 - Stock-based Compensation us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Expected volatility Note 14 - Equity Offerings us-gaap_LiabilitiesCurrent Total Current Liabilities Note 15 - Basic and Diluted Net Loss Per Share Note 16 - Commitments and Contingencies Note 17 - Segments and Geographic Areas Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Expected life (in years) (Year) Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details) Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details) Note 5 - Investments, Available-for-sale - Contractual Maturities (Details) Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details) Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) Note 7 - Inventories - Components of Inventories (Details) Note 8 - Property and Equipment - Summary of Property and Equipment (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 9 - Intellectual Property - Intellectual Property (Details) Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details) Restricted stock units, Granted, weighted average grant date fair value (in dollars per share) Note 10 - Leases - Components of Operating Lease Expense (Details) Note 10 - Leases -Supplemental Balance Sheet Information (Details) Restricted stock units, Vested, weighted average grant date fair value (in dollars per share) Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Note 10 - Leases - Minimum Lease Payments (Details) Restricted stock units, Forfeited, weighted average grant date fair value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Beginning of period, Restricted stock units, Unvested, weighted average grant date fair value (in dollars per share) Unvested December 31, 2022 (in dollars per share) Note 11 - Accrued Expenses - Components of Accrued Expenses (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Restricted stock units, Forfeited (in shares) Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Beginning of period, Restricted stock units, Unvested (in shares) Unvested (in shares) Foreign currency translation loss Note 12 - Income Taxes - Deferred Tax Assets (Details) us-gaap_DeferredRentCreditCurrent Taxes and other assessments Note 12 - Income Taxes - Unrecognized Tax Positions (Details) us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-Sale Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term (Year) Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) Note 13 - Stock-based Compensation - Stock Option Activity (Details) US Government Agencies Debt Securities [Member] Note 13 - Stock-based Compensation - Stock Options Outstanding (Details) Restricted stock units, Granted (in shares) Proceeds from maturities of available-for-sale investments us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Restricted stock units, Vested (in shares) Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details) Corporate Debt Securities [Member] Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Note 13 - Stock-based Compensation - RSU Activity (Details) Options, Vested and Expected to Vest, Exercisable, Number of Shares (in shares) Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details) Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price (in dollars per share) Note 14 - Equity Offerings - Summary of Sales Under Offering (Details) Options, Vested or Expected to Vest, Aggregate Intrinsic Value Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block] Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details) Other comprehensive loss Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details) Notes To Financial Statements Options, Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares (in dollars per share) Notes To Financial Statements [Abstract] Options, Exercisable, Weighted Average Remaining Contractual Term (Year) Options, Exercisable, Aggregate Intrinsic Value Options, Exercisable, Number of Shares (in shares) Options, Outstanding, Weighted Average Remaining Contractual Term (Year) us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Purchase of available-for-sale investments Contingent consideration, measurement input Financial Instruments [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options, Outstanding, Weighted Average Exercise Price (in dollars per share) Options, Outstanding, Weighted Average Exercise Price (in dollars per share) Options, Forfeitures in Period, Weighted Average Exercise Price (in dollars per share) Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share) Deferred revenue Financial Instrument [Axis] Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share) us-gaap_AccruedLiabilitiesCurrent Total Accrued employee compensation and benefits Lessee, Operating Leases [Text Block] us-gaap_AccountsPayableCurrent Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options, Outstanding, Number of Shares (in shares) Options, Outstanding, Number of Shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Options, Cancelled, Number of Shares (in shares) Credit Facility [Axis] Credit Facility [Domain] us-gaap_OtherAccruedLiabilitiesCurrent Other us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) us-gaap_AccruedProfessionalFeesCurrent Legal and professional fees us-gaap_AccruedMarketingCostsCurrent Consulting and other vendors us-gaap_AccruedRoyaltiesCurrent Royalties us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Cash paid for taxes Current Liabilities: Developed Technology Rights [Member] Operating lease liabilities Product [Member] us-gaap_Assets Total Assets Patents [Member] Technology-Based Intangible Assets [Member] Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Intellectual Property [Member] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Net deferred tax assets Finite-Lived Intangible Assets by Major Class [Axis] Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Return of common stock to pay withholding taxes on restricted stock Contract Assets Award Type [Domain] Restricted cash us-gaap_RestrictedCashAndCashEquivalents Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Award Type [Axis] Net loss Net loss us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-Lived Intangible Assets, Accumulated Amortization Intellectual property, net Total Restricted Stock Units (RSUs) [Member] Finite-Lived Intangible Assets, Gross Share-Based Payment Arrangement, Option [Member] Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization Property and equipment, net Property and equipment, net Property, plant and equipment, gross Canada Revenue Agency [Member] Investing Activities: Fair Value Total, fair value Earnings Per Share [Text Block] us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty Related Party Transaction, Expenses from Transactions with Related Party Letter of Credit [Member] us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Accrued employee compensation and benefits Related Party Transactions Disclosure [Text Block] us-gaap_IncomeTaxExpenseBenefit Total income tax expense Income tax expense SWITZERLAND Accounts payable us-gaap_OperatingExpenses Total Operating Expenses us-gaap_RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent, Total us-gaap_RestrictedCash Restricted Cash, Total General and administrative us-gaap_DebtInstrumentDecreaseForgiveness Debt Instrument, Decrease, Forgiveness us-gaap_Cash Cash Cash and cash equivalents Total cash and cash equivalents us-gaap_AllocatedShareBasedCompensationExpense Share-based compensation us-gaap_CommercialPaperAtCarryingValue Commerical Paper us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Change in fair value us-gaap_MoneyMarketFundsAtCarryingValue Money Market Amendment Flag Comprehensive loss: us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss City Area Code Use of Estimates, Policy [Policy Text Block] us-gaap_TreasuryStockSharesRetired Cancellation of treasury stock (in shares) New Accounting Pronouncements, Policy [Policy Text Block] Reclassification, Comparability Adjustment [Policy Text Block] us-gaap_GainLossOnSaleOfPropertyPlantEquipment Loss on disposal of property and equipment us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred revenue us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Exercise of stock options and warrants Value of stock issued during period for stock options and warrants exercised. Public Offering [Member] Represents the public offering of securities. ITALY us-gaap_IncreaseDecreaseInOtherOperatingAssets Other current and long-term assets Current Fiscal Year End Date Accrued expenses and other current liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered, excluding employee related liabilities. Exercise of stock options and warrants (in shares) Number of shares issued for the stock options and warrants exercised during period. Lease [Member] Represents Lease. us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-Sale, Realized Gain (Loss), Total Weighted-average discount rate Document Fiscal Period Focus Proceeds from exercise of stock options and warrants The cash inflow from stock options and warrants exercised. us-gaap_OperatingLeaseCost Total Operating lease expense Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Transfer of inventories to property and equipment Amount of inventory transferred to property and equipment. Short-term Operating Lease, Cost [Table Text Block] Document Period End Date Lease liabilities arising from obtaining right-of-use assets Weighted-average remaining lease term (in years) (Year) us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expenses Measurement Input, Currency Exchange Rate [Member] Measurement input using currency exchange rate. Entity File Number asxc_WorkingCapital Working Capital The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities. Other Countries in EMEA [Member] Other Countries in EMEA. Europe, Middle East, and Africa [Member] Europe, Middle East, and Africa. Entity Emerging Growth Company asxc_ProceedsFromIssuanceOfEquityNet Net proceeds The cash inflow from issuance of equity, net of issuance cost. All Countries [Member] Represents all countries. Document Type Gain on extinguishment of debt Gain on extinguishment of debt Performance Restricted Stock Unit [Member] Represents performance restricted stock unit. Entity Small Business Entity Shell Company Long-term Operating Amount of long-term lease cost. Incremental borrowing rate Incremental borrowing rate for operating lease. Document Information [Line Items] Document Information [Table] Service [Member] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Entity Public Float Paycheck Protection Program CARES Act [Member] Represents loan designed to provide funds for small businesses to keep their employees on the payroll. Lessee, Operating Lease, Disclosure [Table Text Block] Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status asxc_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. Debt Instrument, Name [Domain] Entity Voluntary Filers Entity Well-known Seasoned Issuer us-gaap_ImpairmentOfIntangibleAssetsFinitelived Impairment of Intangible Assets, Finite-lived Two Customers [Member] Represents the two major customers of the company. us-gaap_LessorOperatingLeasePaymentsToBeReceived Lessor, Operating Lease, Payments to be Received, Total asxc_PeriodOfServiceSaleArrangement Period Of Service Sale Arrangement (Year) Represents the period of service sale arrangement. Senhance Surgical Robotic System Acquisition[Member] Represents Senhance Surgical Robotic System acquisition. Concentration risk, percent Percentage Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Stock-based compensation Entity Tax Identification Number asxc_PeriodOfServiceSaleArrangementAtStatedServicePrice Period of Service Sale Arrangement at Stated Service Price (Year) Represents the period of service sale arrangement at stated service price. Property and equipment impairment Entity Central Index Key Entity Registrant Name Liability Class [Axis] Substantial Doubt about Going Concern [Policy Text Block] Disclosure of accounting policy for substantial doubt about going concern. Fair Value by Liability Class [Domain] Contingent Consideration [Policy Text Block] Disclosure accounting policy for contingent consideration. Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] us-gaap_TreasuryStockRetiredCostMethodAmount Cancellation of treasury stock Entity Address, Address Line One Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Systems [Member] Represents the systems, a product of the company. Amortization of intangible assets Instruments and Accessories [Member] Represents instruments and accessories, a type of products of the company. Entity Address, City or Town Geographic Concentration Risk [Member] Entity Address, Postal Zip Code Warrant Liabilities [Policy Text Block] Disclosure of accounting policy warrant liabilities. Supplemental Disclosure for Cash Flow Information Schedule of Property Plant and Equipment Useful Life [Table Text Block] Tabular disclosure of the useful life of property, plant and equipment during the reporting period. Entity Address, State or Province Concentration Risk Type [Axis] Machinery, Manufacturing and Demonstration Equipment [Member] Represents machinery, manufacturing and demonstration equipment. Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss, Ending Balance Entity Common Stock, Shares Outstanding asxc_BusinessCombinationContingentConsiderationArrangementsTargetRevenue Business Combination Contingent Consideration Arrangements Target Revenue The target revenue to be achieved pursuant to the business combination agreement. Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Revenue Benchmark [Member] Accounts Receivable [Member] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Assets, Total [Member] Finite-Lived Intangible Assets, Foreign Currency Translation Impact The accumulated impact of foreign currency translation for finite-lived intangible assets. Current portion asxc_FairValueMeasurementWithUnobservableInputsRecurringBasisLiabilityValueCurrent Current portion of liability measurement with unobservable inputs on recurring basis. Concentration Risk Benchmark [Axis] Long-term portion asxc_FairValueMeasurementWithUnobservableInputsRecurringBasisLiabilityValueNonCurrent Noncurrent portion of liability measurement with unobservable inputs on recurring basis. Concentration Risk Benchmark [Domain] asxc_InventoryCurrentAndNoncurrentNet Total inventories, net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Local Phone Number us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Line of Credit Facility, Remaining Borrowing Capacity Exercise of stock options (in shares) Options, Exercised, Number of Shares (in shares) us-gaap_TableTextBlock Notes Tables Award of restricted stock units (in shares) Exercise of stock options Award of restricted stock units Related Party [Axis] Related Party [Domain] Bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Options, Granted, Number of Shares (in shares) Schedule of Sales Under Sales Agency Agreement [Table Text Block] Schedule of sales under sales agency agreement. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Options, Forfeited, Number of Shares (in shares) Sales and marketing Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Total shares of common stock sold (in shares) Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues (in shares) Raw materials, net us-gaap_LiabilitiesAndStockholdersEquity Total Liabilities and Stockholders' Equity Finished goods, net Issuance of common stock, net of issuance costs UNITED STATES Related Party Transaction [Axis] Related Party Transaction [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit), Total Research and development Accumulated other comprehensive loss Measurement Input, Discount Rate [Member] us-gaap_InterestExpense Interest expense Measurement Input, Price Volatility [Member] Changes in operating assets and liabilities: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Inventory Disclosure [Text Block] Noncurrent operating lease liabilities Schedule of Inventory, Current [Table Text Block] Restricted cash Present value of future minimum lease payments us-gaap_OperatingLeaseLiability Deferred tax expense Operating lease liabilities - current portion Operating lease right-of-use assets, net us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total minimum lease payments Capitalization of Internal Costs, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: Amount of lease payments representing interest us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2025 Measurement Input Type [Axis] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2026 Measurement Input Type [Domain] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive 2027 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Thereafter Fair Value Measurement, Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2024 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2025 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour 2026 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2023 Debt Securities, Available-for-Sale [Table Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive 2027 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2024 Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Segment Reporting, Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths 2023 Lessor, Leases [Policy Text Block] Change in fair value of warrant liabilities Change in fair value of warrant liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Other long-term assets us-gaap_ShareBasedCompensation Stock-based compensation Lessee, Leases [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Finite-Lived Intangible Assets, Remaining Amortization Period (Year) us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) Comprehensive Income, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Total assets measured at fair value us-gaap_AssetsFairValueDisclosure us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Amortization of discounts and premiums on investments, net Schedule of Finite-Lived Intangible Assets [Table Text Block] us-gaap_LesseeOperatingLeaseTermOfContract Lessee, Operating Lease, Term of Contract (Year) us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) Research and Development Expense, Policy [Policy Text Block] Long-term investments Long-term investments, available-for-sale Depreciation Depreciation, Total Total liabilities measured at fair value us-gaap_LiabilitiesFairValueDisclosure Return of common stock to pay withholding taxes on restricted stock (in shares) Intangible Assets Disclosure [Text Block] Average price per share (in dollars per share) us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) Inventories, net of current portion us-gaap_AssetsCurrent Total Current Assets Cash and cash equivalents us-gaap_CashAndCashEquivalentsFairValueDisclosure Share-Based Payment Arrangement [Policy Text Block] Stockholders' Equity Note Disclosure [Text Block] Change in fair value of contingent consideration Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2022 and December 31, 2021; 236,895,440 and 235,218,552 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: Common stock, shares authorized (in shares) Commercial Paper [Member] Common stock, shares issued (in shares) Common stock, par value (in dollars per share) us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Asia [Member] Deferred Tax Asset [Domain] asxc_OverstatedRawMaterialsAndUnderstatedFinishedGoodsAmount Overstated Raw Materials, Amount Represents the amount related to overtstsaed raw materials. us-gaap_DeferredTaxAssetsValuationAllowance Valuation Allowance Statistical Measurement [Domain] Cash paid for leases Maximum [Member] Supplemental Schedule of Non-cash Investing and Financing Activities: Minimum [Member] Weighted Average [Member] Valuation Allowance by Deferred Tax Asset [Axis] Other current assets Product and Service [Axis] Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Net deferred tax asset Statistical Measurement [Axis] Debt, Policy [Policy Text Block] Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and December 31, 2021 us-gaap_DeferredTaxAssetsLiabilitiesNet Net deferred tax asset (liability) Preferred stock, shares issued (in shares) The 2022 ATM Offering [Member] Represents the 2022 ATM offering. Prepaid expenses Property, Plant and Equipment Disclosure [Text Block] Geographical [Axis] Goodwill and Intangible Assets, Policy [Policy Text Block] Property, Plant and Equipment [Table Text Block] Geographical [Domain] us-gaap_DeferredTaxAssetsGross Deferred Tax Assets, Gross, Total Preferred stock, shares authorized (in shares) us-gaap_DeferredIncomeTaxLiabilities Net deferred tax liability Inventories Preferred stock, par value (in dollars per share) EMEA [Member] us-gaap_InventoryValuationReserves Current Portion, reserve Fair Value, Inputs, Level 3 [Member] Finished goods, gross Customer One [Member] Related to customer one. Fair Value Hierarchy and NAV [Domain] Customer [Axis] Customer Two [Member] Related to customer two. Customer [Domain] Customer Three [Member] Related to customer three. Current Portion, gross Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fixed Assets asxc_IncreaseDecreaseInAccruedLiabilitiesNotIncludingEmployeeRelatedLiabilities Accrued expenses The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid, not including employee related liabilities. Fair Value Hierarchy and NAV [Axis] Raw materials, gross Property and equipment, estimated useful lives (Year) Construction in Progress [Member] Operating Activities: Error Correction and Revisions [Policy Text Block] Disclosure of the accounting policies for error correction and revisions. Revenue [Policy Text Block] Statement [Line Items] us-gaap_NumberOfOperatingSegments Number of Operating Segments Furniture and Fixtures [Member] Accounts receivable, net Stock-based compensation us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Revenue: Additional paid-in capital AOCI Attributable to Parent [Member] asxc_ProceedsFromEmployeeRetentionTaxCredit Proceeds From Employee Retention Tax Credit The amount of cash inflow from employee retention tax credit. Stockholders' Equity: Capitalized costs Leasehold Improvements [Member] Short-term investments Short-term investments, available-for-sale Property, Plant and Equipment, Policy [Policy Text Block] Other expense, net Start-up Costs and Other Intangibles [Member] Related to start-up costs and other intangibles. Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total Other Income (Expense), net Segment Reporting Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Net operating loss carryforwards Research credit carryforward Cash, Cash Equivalents, and Restricted Cash Disclosure [Text Block] The complete disclosure for cash, cash equivalents, and restricted cash. Registered Direct Offering [Member] Represents information regarding a registered direct offering. Current Assets: Long-lived Assets [Member] Represents information regarding long-lived assets. Fair Value Disclosures [Text Block] Risk And Uncertainties, Policy [Policy Text Block] Disclosure of accounting policy for risk and uncertainties for the reporting period. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Total Inventory, Policy [Policy Text Block] Contractual Obligation, Fiscal Year Maturity [Table Text Block] Schedule of Cash, Cash Equivalents, and Restricted Cash [Table Text Block] Tabular disclosure of cash, cash equivalents, and restricted cash. Interest income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net (decrease) increase in cash, cash equivalents and restricted cash us-gaap_Liabilities Total Liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash and cash equivalents (used in) provided by financing activities Commitments and Contingencies (Note 16) Sale of Stock [Axis] Sale of Stock [Domain] Effect of exchange rate changes on cash and cash equivalents us-gaap_OperatingIncomeLoss Operating Loss us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash and cash equivalents used in operating activities Other Income (Expense), net us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash and cash equivalents provided by (used in) investing activities us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets Purchase accounting intangibles asxc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets Operating lease right-of-use assets The amount of increase (decrease) in right-of-use assets. us-gaap_GrossProfit Gross loss Cost of revenue asxc_OperatingLossCarryforwardsSubjectToExpiration Operating Loss Carryforwards, Subject to Expiration Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. asxc_OperatingLossCarryforwardsNotSubjectToExpiration Operating Loss Carryforwards, Not Subject to Expiration Amount of operating loss carryforward that are not subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. Accrued expenses and other Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities classified as noncurrent. Deferred Revenue The 2021 ATM Offering [Member] Represents the 2021 at the market offering. asxc_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent Change in unrecognized tax benefits, percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefits. us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total asxc_EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationPercent Change in fair market value of contingent consideration, percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in the fair market value of contingent consideration. asxc_EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsPercent Warrant remeasurment and financing costs, percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant remeasurement and financing costs. Accrued Liabilities [Text Block] The entire disclosure for accrued liabilities at the end of the reporting period. Change in fair market value of contingent consideration, amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in fair market value of contingent consideration. . Warrant remeasurment and financing costs, amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant remeasurement and financing costs. Change in unrecognized tax benefits, amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefits. Commisssion earned by Sales Agents us-gaap_PaymentsOfStockIssuanceCosts Concentration Risk, Credit Risk, Policy [Policy Text Block] Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan [Member] Information related to the "Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan". us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Taxes paid related to net share settlement of vesting of restricted stock units us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Fixed assets and other us-gaap_LettersOfCreditOutstandingAmount Letters of Credit Outstanding, Amount The 2020 ATM Offering [Member] Represents information pertaining to the 2020 ATM Offering. License and Supply Agreement [Member] Represents license and supply agreement. Asensus Surgical Europe S.à.R.L [Member] Represents Asensus Surgical Europe S.à.R.L . Cost of revenue: Gross proceeds us-gaap_ProceedsFromIssuanceOrSaleOfEquity Operating Expenses: Cost of Goods and Service [Policy Text Block] 1 Med S.A. [Member] Represents 1 Med S.A. us-gaap_ProceedsFromWarrantExercises Proceeds from Warrant Exercises Service Supply Agreement [Member] Represents the service supply agreement. Retained Earnings [Member] Revenue State Treasury Stock [Member] us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit State Foreign us-gaap_DeferredForeignIncomeTaxExpenseBenefit Foreign Additional Paid-in Capital [Member] Common Stock [Member] Federal us-gaap_DeferredFederalIncomeTaxExpenseBenefit Federal Equity Components [Axis] Equity Component [Domain] us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) us-gaap_RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Foreign us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income taxes us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic United States Luxembourg Inland Revenue [Member] ICFR Auditor Attestation Flag Ministry of Economic Affairs and Finance, Italy [Member] Swiss Federal Tax Administration (FTA) [Member] State and Local Jurisdiction [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority [Axis] Income Tax Authority [Domain] Disaggregation of Revenue [Table Text Block] Domestic Tax Authority [Member] Foreign Tax Authority [Member] Revenue from Contract with Customer [Text Block] Document Annual Report Computer Equipment [Member] Receivable [Policy Text Block] Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits, Ending Balance Beginning balance Ending balance asxc_InventoryCurrentAndNoncurrentGross Total inventories, gross The value of gross inventory before allowance, both current and noncurrent. General and Administrative Expense [Member] Accounting Policies [Abstract] Long-term portion, gross The amount of inventory before valuation allowance classified as noncurrent. Significant Accounting Policies [Text Block] asxc_InventoryFinishedGoodsValuationAllowance Finished goods, reserve Amount of valuation reserve for finished goods. Document Transition Report Basis of Accounting, Policy [Policy Text Block] asxc_InventoryRawMaterialsValuationAllowance Raw materials, reserve Amount of valuation reserve for raw materials. asxc_IncreaseDecreaseInInventoryReserve Change in inventory reserves Represents the changes in inventory reserve. us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations Gross decreases related to 382 limitations Entity Interactive Data Current asxc_IncreaseDecreaseInTaxCreditCarryforward Increase (Decrease) in Tax Credit Carryforward The amount of increase (decrease) in tax credit carryforward. asxc_InventoryValuationReservesCurrentAndNoncurrent Total inventories, reserve Amount of valuation reserve for inventory classified as current and noncurrent. Security Exchange Name asxc_InventoryValuationReservesNoncurrent Long-term portion, reserve Amount of valuation reserve for inventory classified as noncurrent. asxc_IncreaseDecreaseInOperatingLossCarryforwards Increase (Decrease) in Operating Loss Carryforwards The amount of increase (decrease) in operating loss carryforwards. Gross increases for tax positions related to current periods Title of 12(b) Security Three Customers [Member] Related to three customers. Income Statement Location [Axis] Income Statement Location [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Auditor Name Auditor Firm ID Auditor Location us-gaap_ContractualObligation Total commitments us-gaap_TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount us-gaap_ContractualObligationDueInFourthYear 2026 us-gaap_ContractualObligationDueInNextTwelveMonths 2023 Research Tax Credit Carryforward [Member] us-gaap_ContractualObligationDueInSecondYear 2024 Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) us-gaap_ContractualObligationDueInThirdYear 2025 Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Non-US [Member] us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards Operating Lease Assets [Member] Related to operating lease assets. Statement [Table] Statement of Financial Position [Abstract] Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares) us-gaap_EffectiveIncomeTaxRateContinuingOperations Income tax expense (benefit), percent asxc_StockOfferingAgreementMaximumShareValue Stock Offering Agreement, Maximum Share Value The maximum share value issuable under a stock offering agreement. Business Acquisition [Axis] us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Change in enacted tax rates and other, net, percent Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share) Business Acquisition, Acquiree [Domain] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Change in valuation allowance, percent Statement of Cash Flows [Abstract] The 2021 and 2020 ATM Offering [Member] Related to the 2021 and 2020 ATM offering. Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Revenue from External Customers by Geographic Areas [Table Text Block] Contingent consideration us-gaap_BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability, Total Long-Lived Assets by Geographic Areas [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense Nondeductible expenses, percent us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Research & Development, percent Mature in one to two years, fair value Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year to second fiscal year following current fiscal year. Mature in one to two years, amortized cost Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year to second fiscal year following current fiscal year. Contingent consideration us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes State taxes (net of deferred benefit), percent asxc_IncreaseDecreaseInTaxCreditReceivable Employee retention tax credit receivable Amount of increase (decrease) during the period in tax credit receivable. us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Foreign tax rate differential, percent Fair Value, Assets Measured on Recurring Basis [Table Text Block] Financing Activities: Employee retention tax credit Other Income, Employer Retention Tax Credit Represents the amount recorded in other income in connection with the Employer Retention Tax Credit under the CARES Act. Employee retention tax credit receivable Employer Retention Tax Credit Receivable Represents the amount of employer retention tax credit receivable as of the specified date. us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Cash and Cash Equivalents, Restricted Cash, and Investments, Policy [Policy Text Block] Disclosure of accounting policy for cash and cash equivalents, restricted cash, and investments. Change in enacted tax rates and other, net, amount Change in valuation allowance, amount Employer Retention Tax Credit, Policy [Policy Text Block] Disclosure of accounting policy related to the Employer Retention Tax Credit under the CARES Act. Reclass of warrant liability to common stock and additional paid-in-capital Amount of warrant liability reclassified to common stock and additional paid-in-capital. One Customer [Member] Represents one of the major customers. Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock, Net The cash inflow from issuance of common stock, net of issuance cost. Impact of 382 Ownership Changes [Member] Represents the impact of 382 ownership changes. asxc_PropertyPlantAndEquipmentIncludingPurchasedSoftwareImpairmentCharges Property, Plant and Equipment, Including Purchased Software, Impairment Charges Represents the amount of impairment charges associated with property, plant and equipment (including purchased software) during the period. asxc_BusinessCombinationContingentConsiderationLiabilityRelatedMilestone Business Combination, Contingent Consideration, Liability, Related Milestone Represents the milestone amount associated with the specified liability arising from contingent consideration in a business combination. asxc_EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsPercent True-up to Stock Compensation - Cancellations, percent Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to true-up to stock compensation cancellations. True-up to Stock Compensation - Cancellations, amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to true-up to stock compensation cancellations. us-gaap_StockholdersEquity Total Stockholders' Equity Balance Balance Nondeductible expenses, amount Class of Stock [Axis] us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Unrealized Loss Unrealized Gain Amortized Cost Total, amortized cost State taxes (net of deferred benefit), amount Foreign tax rate differential, amount us-gaap_IncomeTaxReconciliationTaxCreditsResearch Research & Development, amount EX-101.PRE 12 asxc-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2022
Feb. 24, 2023
Jun. 30, 2022
Document Information [Line Items]      
Entity Central Index Key 0000876378    
Entity Registrant Name ASENSUS SURGICAL, INC.    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Document Transition Report false    
Entity File Number 0-19437    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 11-2962080    
Entity Address, Address Line One 1 TW Alexander Drive, Suite 160    
Entity Address, City or Town Durham    
Entity Address, State or Province NC    
Entity Address, Postal Zip Code 27703    
City Area Code 919    
Local Phone Number 765-8400    
Title of 12(b) Security Common Stock $0.001 par value per share    
Trading Symbol ASXC    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 93,100,000
Entity Common Stock, Shares Outstanding   239,279,746  
Auditor Name BDO USA, LLP    
Auditor Location Raleigh, NC    
Auditor Firm ID 243    
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current Assets:    
Cash and cash equivalents $ 6,329 $ 18,129
Short-term investments, available-for-sale 64,195 80,262
Accounts receivable, net 2,256 749
Inventories 8,284 8,634
Prepaid expenses 3,584 3,255
Employee retention tax credit receivable 554 1,311
Other current assets 1,671 957
Total Current Assets 86,873 113,297
Restricted cash 1,141 1,154
Long-term investments, available-for-sale 3,865 37,435
Inventories, net of current portion 5,469 7,074
Property and equipment, net 9,542 10,971
Intellectual property, net 1,576 9,892
Net deferred tax assets 174 288
Operating lease right-of-use assets, net 4,950 5,348
Other long-term assets 2,463 1,014
Total Assets 116,053 186,473
Current Liabilities:    
Accounts payable 3,348 3,448
Accrued employee compensation and benefits 4,508 3,559
Accrued expenses and other current liabilities 1,293 1,617
Operating lease liabilities - current portion 800 683
Deferred revenue 465 543
Total Current Liabilities 10,414 9,850
Long-Term Liabilities:    
Contingent consideration 1,256 2,371
Noncurrent operating lease liabilities 4,738 5,006
Total Liabilities 16,408 17,227
Commitments and Contingencies (Note 16)
Stockholders' Equity:    
Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2022 and December 31, 2021; 236,895,440 and 235,218,552 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively 237 235
Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and December 31, 2021 0 0
Additional paid-in capital 962,731 954,649
Accumulated deficit (860,935) (785,374)
Accumulated other comprehensive loss (2,388) (264)
Total Stockholders' Equity 99,645 169,246
Total Liabilities and Stockholders' Equity 116,053 186,473
Intellectual Property [Member]    
Current Assets:    
Intellectual property, net $ 1,576 $ 9,892
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 750,000,000 750,000,000
Common stock, shares issued (in shares) 236,895,440 235,218,552
Common stock, shares outstanding (in shares) 236,895,440 235,218,552
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 25,000,000 25,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue:    
Revenue $ 7,087 $ 8,232
Cost of revenue:    
Cost of revenue 10,872 11,096
Gross loss (3,785) (2,864)
Operating Expenses:    
Research and development 28,942 19,348
Sales and marketing 14,756 13,395
General and administrative 20,172 19,323
Amortization of intangible assets 7,708 11,254
Change in fair value of contingent consideration (1,115) (1,565)
Property and equipment impairment 1,431 0
Total Operating Expenses 71,894 61,755
Operating Loss (75,679) (64,619)
Other Income (Expense), net    
Gain on extinguishment of debt 0 2,847
Change in fair value of warrant liabilities 0 (1,981)
Interest income 1,141 590
Interest expense (410) (370)
Employee retention tax credit 0 1,311
Other expense, net (295) (15)
Total Other Income (Expense), net 436 2,382
Loss before income taxes (75,243) (62,237)
Income tax expense (318) (225)
Net loss (75,561) (62,462)
Comprehensive loss:    
Net loss (75,561) (62,462)
Foreign currency translation loss (1,867) (2,985)
Unrealized loss on available-for-sale investments (257) (247)
Comprehensive loss $ (77,685) $ (65,694)
Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share) $ (0.32) $ (0.28)
Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares) 236,492 226,960
Product [Member]    
Revenue:    
Revenue $ 4,327 $ 5,399
Cost of revenue:    
Cost of revenue 5,303 5,741
Service [Member]    
Revenue:    
Revenue 1,373 1,520
Cost of revenue:    
Cost of revenue 2,174 1,799
Lease [Member]    
Revenue:    
Revenue 1,387 1,313
Cost of revenue:    
Cost of revenue $ 3,395 $ 3,556
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balance (in shares) at Dec. 31, 2020 116,231,000 0        
Balance at Dec. 31, 2020 $ 116 $ 0 $ 781,397 $ (722,912) $ 2,968 $ 61,569
Stock-based compensation $ 0   9,429 0 0 9,429
Issuance of common stock, net of issuance costs (in shares) 71,787,000 0        
Issuance of common stock, net of issuance costs $ 72 $ 0 131,857 0 0 131,929
Exercise of stock options and warrants (in shares) 45,630,000 0        
Exercise of stock options and warrants $ 46 $ 0 33,029 0 0 33,075
Award of restricted stock units (in shares) 1,571,000          
Award of restricted stock units $ 1          
Return of common stock to pay withholding taxes on restricted stock (in shares) 0 320,000        
Return of common stock to pay withholding taxes on restricted stock $ 0 $ 0 (1,063) 0 0 (1,063)
Cancellation of treasury stock (in shares) 0 (320,000)        
Cancellation of treasury stock $ 0 $ 0 0 0 0 0
Other comprehensive loss 0 0 0 0 (3,232) (3,232)
Net loss $ 0 $ 0   (62,462) 0 (62,462)
Balance (in shares) at Dec. 31, 2021 235,219,000 0        
Balance at Dec. 31, 2021 $ 235 $ 0 954,649 (785,374) (264) 169,246
Stock-based compensation $ 0   8,416 0 0 8,416
Award of restricted stock units (in shares) 1,633,000 0        
Award of restricted stock units $ 2 $ 0 0 0 0 2
Return of common stock to pay withholding taxes on restricted stock (in shares) 0 443,000        
Return of common stock to pay withholding taxes on restricted stock $ 0 $ 0 (352) 0 0 (352)
Cancellation of treasury stock (in shares) 0 (443,000)        
Cancellation of treasury stock $ 0 $ 0 0 0 0 0
Other comprehensive loss 0     0 (2,124) (2,124)
Net loss $ 0     (75,561) 0 $ (75,561)
Exercise of stock options (in shares) 43,000 0       43,453
Exercise of stock options $ 0 $ 0 18 0 0 $ 18
Balance (in shares) at Dec. 31, 2022 236,895,000 0        
Balance at Dec. 31, 2022 $ 237 $ 0 $ 962,731 $ (860,935) $ (2,388) $ 99,645
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating Activities:    
Net loss $ (75,561) $ (62,462)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:    
Depreciation 3,368 2,857
Amortization of intangible assets 7,708 11,254
Amortization of discounts and premiums on investments, net 565 409
Stock-based compensation 8,416 9,429
Gain on extinguishment of debt 0 (2,847)
Deferred tax expense 318 225
Change in inventory reserves 620 (492)
Bad debt expense 9 144
Property and equipment impairment 1,431 0
Loss on disposal of property and equipment 122 0
Change in fair value of warrant liabilities (0) 1,981
Change in fair value of contingent consideration (1,115) (1,565)
Changes in operating assets and liabilities:    
Accounts receivable (1,528) 174
Inventories (2,302) (611)
Operating lease right-of-use assets 232 (4,254)
Prepaid expenses (450) 146
Employee retention tax credit receivable 757 (1,311)
Other current and long-term assets (2,101) 902
Accounts payable 35 1,614
Accrued employee compensation and benefits 4,523 (859)
Accrued expenses (3,955) 384
Deferred revenue (55) (229)
Operating lease liabilities 26 4,452
Net cash and cash equivalents used in operating activities (58,937) (40,659)
Investing Activities:    
Purchase of available-for-sale investments (33,886) (122,330)
Proceeds from maturities of available-for-sale investments 82,702 4,030
Purchase of property and equipment (1,279) (1,368)
Net cash and cash equivalents provided by (used in) investing activities 47,537 (119,668)
Financing Activities:    
Proceeds from issuance of common stock, net of issuance costs 0 131,929
Taxes paid related to net share settlement of vesting of restricted stock units (350) (1,063)
Proceeds from exercise of stock options and warrants 18 30,839
Net cash and cash equivalents (used in) provided by financing activities (332) 161,705
Effect of exchange rate changes on cash and cash equivalents (81) 376
Net (decrease) increase in cash, cash equivalents and restricted cash (11,813) 1,754
Cash, cash equivalents and restricted cash, beginning of period 19,283 17,529
Cash, cash equivalents and restricted cash, end of period 7,470 19,283
Supplemental Disclosure for Cash Flow Information    
Cash paid for leases 984 1,490
Cash paid for taxes 165 170
Supplemental Schedule of Non-cash Investing and Financing Activities:    
Transfer of inventories to property and equipment 2,693 3,244
Reclass of warrant liability to common stock and additional paid-in-capital 0 2,236
Lease liabilities arising from obtaining right-of-use assets $ 577 $ 5,119
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Note 1 - Description of the Business
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]

1.

Description of the Business

 

Asensus Surgical, Inc. (formerly known as TransEnterix, Inc.) (the "Company") is a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The Company is focused on the market development for and commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance System is the first and only digital, multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including 3mm microlaparoscopic instruments, 5mm articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

2.

Summary of Significant Accounting Policies

 

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its direct and indirect wholly owned subsidiaries.

 

Going Concern

The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $860.9 million and working capital of $76.5 million as of December 31, 2022. The Company has not established sufficient sales revenues to cover its operating costs and requires additional capital to proceed with its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.

 

The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to meet its existing obligations, and to continue as a going concern within one year from the date that these financial statements are issued. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

Principles of Consolidation and Foreign Currency Considerations

The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.

 

The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive loss as a separate component of stockholders’ equity.

 

The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 were not material.

 

Reclassifications

Certain amounts reported previously have been reclassified to conform to the current year presentation, with no effect on stockholders’ equity or net loss as previously reported. Revenue and cost of revenue for leases were historically included in product and service revenue and corresponding cost of revenue on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. Accrued employee compensation and benefits were historically included in accrued expenses and other current liabilities on the consolidated balance sheets for the year ended December 31, 2021.

 

Revision of Previously Disclosed Amounts

During the course of preparing the Company’s unaudited consolidated financial statements as of and for the six months ended June 30, 2022, the Company determined that its December 31, 2021 inventory footnote presentation overstated raw materials and understated finished goods by $2.5 million.  For comparative purposes, Note 7 – Inventories, has been revised to reflect the adjustment to raw materials and finished goods as of December 31, 2021.  The revision had no effect on the previously reported total gross and net carrying value of inventory.  The revision also had no effect on the previously reported consolidated balance sheets, statements of operations and comprehensive loss, cash flows and stockholders’ equity. 

 

Risk and Uncertainties

The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: negative impacts on the Company's operations caused by the COVID-19 pandemic and other geopolitical factors; the historical lack of profitability; the Company’s ability to raise additional capital; the success of its market development efforts; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan, and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic surgical devices; and its ability to identify and pursue development of additional products.

 

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, short-term and long-term investments, excess and obsolete inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use (“ROU”) assets, and deferred tax asset valuation allowances.

 

Cash and Cash Equivalents, Restricted Cash, and Investments

The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents.

 

Restricted cash as of December 31, 2022 and 2021 includes $1.1 million in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, and automobile leases.

 

The Company’s investments as of December 31, 2022 consisted of commercial paper, corporate bonds, and United States government agencies and were classified as available-for-sale. Investments classified as available-for-sale are measured at fair value, and net unrealized gains and losses are recorded as a component of accumulated other comprehensive loss on the consolidated balance sheets until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization and accretion is included in interest expense, net. There were no gross realized gains or loss for the year ended December 31, 2022. The Company recognized an immaterial amount of gross realized losses for the year ended December 31, 2021. There were no gross realized gains for the year ended December 31, 2021.

 

Investments with remaining maturities at date of purchase greater than 90 days and remaining maturities as of the reporting period less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. 

 

There have been no credit losses for the years ended December 31, 2022 and 2021, and no allowance for credit losses as of December 31, 2022. Factors considered in determining whether a credit loss exists include credit ratings and other qualitative factors for each security type in the portfolio.

 

Fair Value Measurements

The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper and corporate notes and bonds without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy. The Company measures contingent consideration at fair value using a Monte-Carlo simulation utilizing Level 3 inputs. These inputs include the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones.

 

Concentrations and Credit Risk

The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents (including restricted cash), and investments, including amounts held in money market funds, commercial paper, and corporate bonds. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits may at times exceed the Federal Deposit Insurance Corporation’s insured limit. Balances in excess of federally insured limitations may not be insured. The Company has not experienced losses on these accounts, and management believes that the Company is not exposed to significant risks on such accounts. Investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investments consist of various major corporations, financial institutions, and government agencies of high credit standing.

 

The Company’s accounts receivable are derived from sales and leases to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no collateral from its customers. The Company had one customer that accounted for 69% of the Company’s net accounts receivable as of December 31, 2022. The Company had three customers that accounted for 26%, 20%, and 14%, respectively, of the Company’s net accounts receivable as of December 31, 2021. The Company had one customer who accounted for 47% of revenue in 2022, and two customers who accounted for 36% and 16% of revenue in 2021, respectively.

 

Accounts Receivable

Accounts receivable are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses is based on the Company’s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The allowance for expected credit losses was $1.6 million and $1.7 million as of December 31, 2022, and December 31, 2021, respectively. The Company recorded an immaterial amount for expected credit losses during the year ended December 31, 2022 and $0.1 million during the year ended December 31, 2021.          

 

Inventories

Inventories are stated at the lower of cost (determined on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers historical consumption and forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

 

Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming twelve months.

 

 

Definite-Lived Intangible Assets - Intellectual Property

Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified in-process research and development (“IPR&D”) assets related to (i) the Senhance System acquired in 2015 and reclassified in 2017 and (ii) a 2018 acquisition and reclassified in 2020. Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed technology is recorded using the straight-line method over the estimated useful life of 5 to 7 years.

 

The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To determine the recoverability, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the assets, then such assets are written down to their fair value. No impairment of intellectual property was identified during the years ended December 31, 2022 and 2021.

 

Property and Equipment

Property and equipment consists primarily of operating lease Senhance System assets, machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

 

  

Years

 

Operating lease assets – Senhance System leasing

   5  

Machinery, manufacturing, and demonstration equipment

  3-5 

Computer equipment

   3  

Furniture

   5  

Leasehold improvements

 

Lesser of lease term or 3 to 10

 

 

The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value.

 

During the year ended December 31, 2022, the Company recorded a non-cash asset impairment charge of $1.4 million to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are not expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the consolidated statements of operations and comprehensive loss. No such impairment charges were recorded during the year ended December 31, 2021.

 

Operating Leases

We have operating leases for our corporate office buildings, vehicles, and machinery and equipment. At inception, we determine whether an agreement represents a lease and, at commencement, we evaluate each lease agreement to determine whether the lease constitutes an operating or financing lease.

 

The Company accounts for lease components and non-lease components as a single component. Non-lease components consist of common area maintenance payments for most real estate leases, which are determined based on costs incurred by the lessor. Many of the Company’s leases include base rental periods coupled with options to renew or terminate the lease, generally at the Company’s discretion.  In evaluating the lease term, the Company considers whether renewal is reasonably certain.  To the extent a significant economic incentive exists to renew the lease, the option is included within the lease term.  Based on the Company’s leases, renewal options generally do not provide a significant economic incentive and are therefore excluded from the lease term. While our operating leases range from one year to ten years, some may include options to extend the lease generally between one year and six years, and some may include options to terminate the leases within one year.

 

The interest rate implicit in our lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.

 

Implementation Costs in a Cloud Computing Arrangement

The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract. These capitalized implementation costs are recorded within other current and long-term assets, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis and included within operating expenses.

 

Employee Retention Tax Credit Receivable

The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages. During the year ended December 31, 2021, we submitted an ERTC refund for $1.3 million and recorded the amount into Other Income (Expense) on the consolidated statements of operations and comprehensive loss. The Company received notification from the IRS that the relevant conditions of the employee retention credit provision were met and that it will receive the credit. The Company received $0.7 million of the ERTC refund during the year ended December 31, 2022. The remaining $0.6 million is recorded as a current asset on the consolidated balance sheets as of December 31, 2022.

 

Notes Payable 

The Company’s policy is to account for forgivable loans received through the U.S. Small Business Administration (the “SBA”) under the CARES Act Payroll Protection Program (“PPP”), as debt in accordance with ASC 470, Debt, and other related accounting pronouncements. The forgiveness of debt, in whole or part, is recognized once the debt is extinguished, which occurs when the Company is legally released from the liability by the SBA. Any portion of debt forgiven, adjusted for accrued interest forgiven and unamortized debt issuance costs, is recorded as a gain on extinguishment of debt, and presented in the consolidated statements of operations and comprehensive loss. On June 10, 2021, the Company received notification from the SBA that the principal amount of its PPP loan of $2.8 million and related interest had been forgiven.

 

As of December 31, 2022, the Company has $0.6 million available under a letter of credit. No amounts have been utilized by the Company as of December 31, 2022.

 

Contingent Consideration

Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, revenue volatility and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

 

On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar S.p.A., an Italian company (“Sofar”), an Italian company, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System. Under the terms of the Purchase Agreement, as amended in 2016, as of December 31, 2022, the Company has accrued $1.3 million of estimated fair value of remaining contingent consideration related to a milestone of €15.0 million which shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least €25.0 million over a calendar quarter or in the event that (i) the Company or Asensus International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. In 2022, Sofar assigned its right to receive the contingent payment to Three Heads Investment S.r.l.

 

Warrant Liabilities

The Company’s Series B Warrants were measured at fair value using a simulation model which considered, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant. The warrant liability was revalued at each reporting period and changes in fair value were recognized in the consolidated statements of operations and comprehensive loss. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. All remaining outstanding Series B Warrants were exercised in the first quarter 2021.

 

Revenue Recognition

The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements generally include a five-year service period; the first year of service is generally free and included in the Senhance System sale arrangement and the remaining four years are generally included at a stated service price.

 

The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements may include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.

 

For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services; however due to limited sales to date, standalone selling prices generally are not directly observable. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer, and market conditions. The Company regularly reviews estimated standalone selling prices and updates these estimates if necessary.

 

The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows:

 

•  System sales. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from Senhance System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when the Company receives an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do not provide a right of return. The Senhance Systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.

 

•  Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.

 

•  Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.

 

The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements, and are included in accounts receivable.

 

In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do not meet the requirements to be capitalized as the Company does not expect to generate future economic benefits from the related revenue from the initial sales transaction and such costs are expensed as incurred.

 

Senhance System Leasing

The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. For the years ended December 31, 2022 and 2021, variable lease revenue related to usage-based arrangements was not material.  

 

In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, the Company considers the following terms at lease commencement: (1) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (3) whether the lease term is for the major part of the remaining economic life of the leased System, (4) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (5) whether the underlying Senhance System is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. All such arrangements through December 31, 2022 are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage. As of December 31, 2022 future minimum lease payments due from customers was $2.2 million, which is expected to be received over the next one to three years.

 

Cost of Revenue

Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Depreciation expense related to leased systems is included in the cost of revenue. Shipping and handling costs incurred by the Company are included in the cost of revenue.  We expense all inventory obsolescence provisions as cost of revenue.

 

Research and Development Costs

Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.

 

Stock-Based Compensation

The Company recognizes expenses for share-based awards exchanged for services rendered equal to the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of stock options. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimates forfeitures based on its historical experience and adjust the estimated forfeiture rate based upon actual experience. For performance-based restricted stock awards with performance conditions, we begin recognizing compensation expense when it becomes probable that the performance condition will be attained.

 

The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. See “Note 13 – Stock-Based Compensation,” for a detailed discussion of the Company’s stock plans and stock-based compensation expense.

 

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred.

 

The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than not sustain the position following audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.

 

Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company may be subject to examination by authorities for all previously filed income tax returns.

 

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

 

Segments

The Company operates in one business segment—the research, development and sale of medical device robotics to improve minimally invasive surgery. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

 

Impact of Recently Issued Accounting Standards

 

The Company has evaluated issued ASUs not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Revenue Recognition
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

3.

Revenue Recognition

 

The following table presents revenue disaggregated by type and geography:

 

     

Years Ended December 31,

 
     

2022

    

2021

  
     

(in thousands)

  

U.S.

                  

Systems

   $ -     $ -  

Instruments and accessories

     211       273  

Services

     300       383  

Leases

     256       377  

Total U.S. revenue

     767       1,033  
                   

Outside of U.S. ("OUS")

                

Systems

     2,551       3,286  

Instruments and accessories

     1,565       1,840  

Services

     1,073       1,137  

Leases

     1,131       936  

Total OUS revenue

     6,320       7,199  
                   

Total

                  

Systems

     2,551       3,286  

Instruments and accessories

     1,776       2,113  

Services

     1,373       1,520  

Leases

     1,387       1,313  
Total revenue   $ 7,087     $ 8,232  

 

Remaining Performance Obligations

The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to service obligations performed under the Company's system sales contracts that will be invoiced and recognized as revenue in future periods. Transaction price allocated to remaining performance obligations as of December 31, 2022 was $1.1 million, which is expected to be recognized over one to four years. 

 

Contract Assets and Liabilities

Deferred revenue for the periods presented was primarily related to service obligations, for which the service fees are billed up-front, generally annually. The associated deferred revenue is generally recognized ratably over the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2022 and 2021 that was included in the deferred revenue balance at the beginning of each reporting period was $0.5 million and $0.6 million, respectively.

 

The following information summarizes the Company’s contract assets and liabilities:

 

   

December 31, 2022

    

December 31, 2021

  
   

(in thousands)

  

Contract Assets

   $ 116     $ 91  

Deferred Revenue

   $ 465     $ 543  

 
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Cash, Cash Equivalents, and Restricted Cash
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Cash, Cash Equivalents, and Restricted Cash Disclosure [Text Block]

4.

Cash, Cash Equivalents, and Restricted Cash

 

Cash, cash equivalents and restricted cash consist of the following:

 

   

December 31,

    

December 31,

  
   

2022

    

2021

  
   

(in thousands)

  

Cash

   $ 3,473     $ 8,343  

Money Market

     2,856       5,287  

Commerical Paper

     -       4,499  

Total cash and cash equivalents

   $ 6,329     $ 18,129  

Restricted Cash

     1,141       1,154  

Total

   $ 7,470     $ 19,283  

 

 

Restricted cash at December 31, 2022 and 2021 includes $1.1 million and $1.2 million, respectively, in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, automobile leases, and a performance guarantee required by the government of a country in which a Senhance System was sold in 2018.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Investments, Available-for-sale
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

5.

Investments, available-for-sale

 

The aggregate fair values of investment securities along with cumulative unrealized gains and losses determined on an individual investment security basis and included in other comprehensive loss are as follows:

 

  

December 31, 2022

 
  

(in thousands)

 
                         
  

Amortized

Cost

  

Unrealized

Gain

  

Unrealized

Loss

  

Fair Value

  

Short-term

investments

  

Long-term

investments

 

Commercial Paper

 $12,364  $-  $(49) $12,315  $12,315  $- 

Corporate Bonds

  55,201   -   (447)  54,754   50,889   3,865 

U.S. Government Agencies

  999   -   (8)  991   991   - 

Total Investments

 $68,564  $-  $(504) $68,060  $64,195  $3,865 

 

 

  

December 31, 2021

 
  

(in thousands)

 
                         
  

Amortized

Cost

  

Unrealized

Gain

  

Unrealized

Loss

  

Fair Value

  

Short-term

investments

  

Long-term

investments

 

Commercial Paper

 $50,705  $-  $(46) $50,659  $50,660  $- 

Corporate Bonds

  67,239   1   (202)  67,038   29,602   37,435 

Total Investments

 $117,944  $1  $(248) $117,697  $80,262  $37,435 

 

 

The following table summarizes the contractual maturities of the Company’s available-for-sale investments:

 

  

December 31, 2022

 
  

(in thousands)

 
  

Amortized

Cost

  

Fair Value

 

Mature in less than one year

 $64,662  $64,195 

Mature in one to two years

  3,902   3,865 

Total

 $68,564  $68,060 

 

Actual maturities may differ from contractual maturities because certain borrowers have the right to call or prepay certain obligations. There were no sales of investments for the years ended December 31, 2022 or 2021, respectively. There were no realized gains or losses for the years ended December 31, 2022. The company recorded an immaterial amount of gross realized losses for the year ended December 31, 2021 related to the maturity of investments.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Fair Value
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

6.

Fair Value

 

The following are categories of assets and liabilities measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):

 

   

December 31, 2022

  
   

(in thousands)

  
                                 

Description

  

Quoted Prices in

Active Markets for

Identical Assets

(Level 1)

    

Significant Other

Observable Inputs

(Level 2)

    

Significant

Unobservable

Inputs (Level 3)

    

Total

  

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 6,329     $ -     $ -     $ 6,329  

Restricted cash

     1,141       -       -       1,141  

Short-term investments

     -       64,195       -       64,195  

Long-term investments

     -       3,865       -       3,865  

Total assets measured at fair value

   $ 7,470     $ 68,060     $ -     $ 75,530  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 1,256     $ 1,256  

Total liabilities measured at fair value

   $ -     $ -     $ 1,256     $ 1,256  

 

 (1) Includes investments that are readily convertible to cash with original maturities of 90 days or less.

 

   

December 31, 2021

  
   

(in thousands)

  
                                 

Description

  

Quoted Prices in

Active Markets for

Identical Assets

(Level 1)

    

Significant Other

Observable Inputs

(Level 2)

    

Significant

Unobservable

Inputs (Level 3)

    

Total

  

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 18,129     $ -     $ -     $ 18,129  

Restricted cash

     1,154       -       -       1,154  

Short-term investments

     -       80,262       -       80,262  

Long-term investments

     -       37,435       -       37,435  

Total assets measured at fair value

   $ 19,283     $ 117,697     $ -     $ 136,980  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 2,371     $ 2,371  

Total liabilities measured at fair value

   $ -     $ -     $ 2,371     $ 2,371  

 

 (1) Includes investments that are readily convertible to cash with original maturities of 90 days or less.

 

The carrying values of accounts receivable, prepaid expenses, employee retention tax credit receivables, other current assets, accounts payable, accrued employee compensation and benefits, accrued expenses, deferred revenue, and other current liabilities as of December 31, 2022, and December 31, 2021, approximate their fair values due to the short-term nature of these items.

 

The Company’s financial liabilities consisted of contingent consideration payable to Three Heads Investment S.r.l., related to the Company’s 2015 acquisition of the Senhance Surgical System from an assignor to Three Heads Investment S.r.l. (the “Senhance Acquisition”). Adjustments associated with the change in fair value of contingent consideration are included in the Company’s consolidated statements of operations and comprehensive loss.

 

The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements for contingent consideration utilizing a Monte-Carlo simulation as of December 31, 2022 and December 31, 2021:

 

 

Valuation

Methodology

  

Significant Unobservable

Input

  

December 31, 2022

    

December 31, 2021

  
                   

Contingent consideration

Probability weighted

income approach

  

Milestone dates

  

2032

    

2031

  
     

Discount rate

   16.5%     9.5%  
     

Revenue volatility

   45.0%     39.0%  
     

EUR-to-USD exchange rate

   1.07     1.14  

 

The following table presents the current and long-term portion of the contingent consideration for the year ended December 31, 2022 and summarizes the change in fair value, as determined by Level 3 inputs for the contingent consideration for the year ended December 31, 2022 and 2021:

 

  

Fair Value

Measurement at

Reporting Date

(Level 3)

 
  

(in thousands)

 
  

Contingent

consideration

 

Balance at December 31, 2020

 $3,936 

Change in fair value

  (1,565)

Balance at December 31, 2021

 $2,371 

Change in fair value

  (1,115)

Balance at December 31, 2022

 $1,256 
     

Current portion

 $- 

Long-term portion

  1,256 

Balance at December 31, 2022

 $1,256 

 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Inventories
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Inventory Disclosure [Text Block]

7.

Inventories

 

The components of inventories are as follows:

 

   

December 31, 2022

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Reserve Balance

    

Net

Carrying

Amount

  

Finished goods

   $ 15,337     $ (4,129 )   $ 11,208  

Raw materials

     4,718       (2,173 )     2,545  

Total inventories

   $ 20,055     $ (6,302 )   $ 13,753  
                         

Current Portion

   $ 9,399     $ (1,115 )   $ 8,284  

Long-term portion

     10,656       (5,187 )     5,469  

Total inventories

   $ 20,055     $ (6,302 )   $ 13,753  

 

   

December 31, 2021

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Reserve Balance

    

Net

Carrying

Amount

  

Finished goods

   $ 13,066     $ (2,987 )   $ 10,079  

Raw materials

     8,324       (2,695 )     5,629  

Total inventories

   $ 21,390     $ (5,682 )   $ 15,708  
                         

Current Portion

   $ 9,931     $ (1,297 )   $ 8,634  

Long-term portion

     11,459       (4,385 )     7,074  

Total inventories

   $ 21,390     $ (5,682 )   $ 15,708  

 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Property and Equipment
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

8.

Property and Equipment

 

Property and equipment consisted of the following:

 

   

December 31,
2022

    

December 31,
2021

  
   

(In thousands)

  

Machinery, manufacturing, and demonstration equipment

   $ 8,450     $ 8,289  

Operating lease assets - Senhance System leasing

     10,251       10,143  

Computer equipment

     600       325  

Furniture

     831       644  

Leasehold improvements

     1,654       1,259  

Construction in process

     436    

‑

  

Total property and equipment

     22,222       20,660  

Accumulated depreciation and amortization

     (12,680

)

     (9,689

)

Property and equipment, net

   $ 9,542     $ 10,971  

 

Depreciation expense was approximately $3.4 million and $2.9 million for the years ended December 31, 2022 and 2021, respectively. 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Intellectual Property
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Intangible Assets Disclosure [Text Block]

9.

Intellectual Property

 

The components of gross intellectual property, accumulated amortization, and net intellectual property are as follows:

 

   

December 31, 2022

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Accumulated Amortization

    

Foreign

Currency

Translation

Impact

    

Net

Carrying

Amount

  

Developed technology

   $ 68,838     $ (66,562 )   $ (874 )   $ 1,402  

Technology and patents purchased

     400       (239 )     13       174  

Total intellectual property

   $ 69,238     $ (66,801 )   $ (861 )   $ 1,576  

 

   

December 31, 2021

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Accumulated

Amortization

    

Foreign

Currency

Translation

Impact

    

Net

Carrying

Amount

  

Developed technology

   $ 68,838     $ (58,912 )   $ (262 )   $ 9,664  

Technology and patents purchased

     400       (199 )     27       228  

Total intellectual property

   $ 69,238     $ (59,111 )   $ (235 )   $ 9,892  

 

The weighted average remaining useful life of the developed technology and technology and patents purchased was 4.2 years and 4.3 years, respectively, as of December 31, 2022. The weighted average remaining useful life of the developed technology and technology and patents purchased was 1.6 years and 5.3 years, respectively as of December 31, 2021.

 

The estimated future amortization expense of intellectual property as of December 31, 2022 is as follows (in thousands):

 

  

Year Ending
December 31, 2022

 

2023

 $377 

2024

  377 

2025

  377 

2026

  377 

2027

  68 

Total

 $1,576 

 

 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Leases
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

10.

Leases

 

Lessee Information

Components of operating lease expense are primarily recorded in general and administrative on the consolidated statements of operations and comprehensive loss were as follows:

 

   

Years Ended December 31,

  
   

2022

    

2021

  
   

(in thousands)

  

Long-term Operating

   $ 1,557     $ 1,826  

Short-term Operating

     -       -  

Total Operating lease expense

   $ 1,557     $ 1,826  

 

Supplemental balance sheet information related to operating leases was as follows:

 

   

December 31, 2022

    

December 31, 2021

  

Weighted-average remaining lease term (in years)

  

6.8

    

7.8

  

Weighted-average discount rate

   8.4%     7.8%  

Incremental borrowing rate

   6.1% - 14.5%     6.1% - 8.5%  

 

Maturities of operating lease obligations as of December 31, 2022 were as follows (in thousands):

 

Fiscal Year

        

2023

   $ 1,222  

2024

     1,136  

2025

     1,058  

2026

     837  

2027

     775  

Thereafter

     2,195  

Total minimum lease payments

   $ 7,223  

Less: Amount of lease payments representing interest

     (1,685 )

Present value of future minimum lease payments

   $ 5,538  

 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Accrued Expenses
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Accrued Liabilities [Text Block]

11.

Accrued Expenses

 

The following table presents the components of accrued expenses:

 

   

December 31,
2022

    

December 31,
2021

  
   

(In thousands)

  

Consulting and other vendors

   $ 155     $ 128  

Other

     —       124  

Royalties

     24       247  

Legal and professional fees

     275       503  

Taxes and other assessments

     839       615  

Total

   $ 1,293     $ 1,617  

 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

12.

Income Taxes

 

The components for the income tax expense are as follows for the years ended December 31 (in thousands):

 

  

2022

  

2021

 

Current income taxes

        

Federal

 $-  $- 

State

  -   - 

Foreign

  239   232 

Deferred income taxes

        

Federal

  -   - 

State

  -   - 

Foreign

  79   (7)

Total income tax expense

 $318  $225 

 

The United States and foreign components of loss from operations before taxes are as follows for the years ended December 31 (in thousands):

 

  

2022

  

2021

 
         

United States

 $(44,802) $(32,094)

Foreign

  (30,441)  (30,143)

Total loss from operations before taxes

 $(75,243) $(62,237)

 

 

 

Significant components of the Company’s deferred tax assets consist of the following at December 31 (in thousands):

 

  

2022

  

2021

 
         

Deferred Tax assets:

        

Stock-based compensation

 $2,840  $2,440 

Accrued expenses and other

  2,538   2,423 

Research credit carryforward

  1,341   564 

Fixed Assets

  162   101 

Capitalized start-up costs and other intangibles

  921   1,109 

Capitalized research costs

  4,382   - 

Net operating loss carryforwards

  83,908   75,237 
   96,092   81,874 

Valuation Allowance

  (94,704)  (78,294)

Net deferred tax asset

  1,388   3,580 

Deferred tax liabilities

        

Fixed assets and other

  (1,214)  (1,176)

Purchase accounting intangibles

  -   (2,116)

Net deferred tax liability

  (1,214)  (3,292)

Net deferred tax asset (liability)

 $174  $288 

 

During 2021, the Company completed an assessment of the available net operating loss and tax credit carryforwards under Section 382 and Section 383 of the Internal Revenue Code, respectively. The Company determined that it underwent multiple ownership changes throughout its history as defined under Section 382, including most recently in 2020. As a result of the identified ownership changes, the portion of net operating loss and tax credits carryforwards attributable to the pre-ownership change periods are subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code. The Company has adjusted its net operating loss and tax credit carryforwards to address the impact of the 382 ownership changes. This resulted in a reduction of available Federal and State NOLs of $253 million and $204 million, respectively.

 

At December 31, 2022 and 2021, the Company has provided a full valuation allowance against its net deferred assets in the U.S., Canada, Italy, Luxembourg, Switzerland, and Taiwan tax jurisdictions, since realization of these benefits is not more likely than not. The valuation allowance increased approximately $16.4 million from the prior year. At December 31, 2022, the Company had U.S. federal net operating loss carryforwards of $419.4 million, of which $253 million are expected to expire unused under the limitations imposed by Internal Revenue Code Section 382 (as discussed above). Of the total amount of Federal NOLs (notwithstanding the 382 limitation), $254.5 million begin to expire in 2027, while the remaining $164.9 million carry forward indefinitely. At December 31, 2022, the Company had U.S. state net operating loss carryforwards of $328.9 million, of which $204 million are expected to expire unused under the state tax law equivalents of Internal Revenue Code Section 382. Of this amount (notwithstanding the 382 limitations), $317.4 million of state NOLs begin to expire in 2022, while the remaining $11.5 million carry forward indefinitely. At December 31, 2022, the Company had federal research credit carryforwards in the amount of $10.2 million. These carryforwards begin to expire in 2027. However, under the limitations of Internal Revenue Code Section 383, it is expected that $8.8 million of this carryforward will expire unused. The utilization of the federal net operating loss carryforwards and credit carryforwards will depend on the Company’s ability to generate sufficient taxable income prior to the expiration of the carryforwards.

 

At December 31, 2022, the Company had foreign operating loss carryforwards in Italy of approximately $24.6 million, which can be carried forward indefinitely; foreign operating loss carryforwards in Luxembourg of approximately $95.9 million, which will begin to expire in 2034; foreign operating loss carryforwards in Switzerland of approximately $116.5 million, which begin to expire in 2023, and foreign operating loss carryforwards in Canada of approximately $0.9 million, which begin to expire in 2040.

 

The Company has evaluated its tax positions to consider whether it has any unrecognized tax benefits. As of December 31, 2022, the Company had gross unrecognized tax benefits of approximately $0.3 million. Of the total, none would reduce the Company’s effective tax rate if recognized. The Company does not anticipate a significant change in total unrecognized tax benefits or the Company’s effective tax rate due to the settlement of audits or the expiration of statutes of limitations within the next twelve months. Furthermore, the Company does not expect any cash settlement with the taxing authorities as a result of these unrecognized tax benefits as the Company has sufficient unutilized carryforward attributes to offset the tax impact of these adjustments.

 

The following is a tabular reconciliation of the Company’s change in gross unrecognized tax positions at December 31 (in thousands):

 

  

2022

  

2021

 
         

Beginning balance

 $141  $- 

Gross increases for tax positions related to current periods

  194   141 

Gross decreases related to 382 limitations

  -   - 

Ending balance

 $335  $141 

 

 

The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes. As of December 31, 2022 and 2021, the Company had no accrued interest or penalties related to uncertain tax positions.

 

The Company has analyzed its filing positions in all significant federal, state, and foreign jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, the Company is no longer subject to United States Federal, state, and local tax examinations by tax authorities for years before 2019, although carryforward attributes that were generated prior to 2019 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.

 

Taxes computed at the then-current statutory federal income tax rate of 21% are reconciled to the provision for income taxes as follows for the years ended December 31:

 

  

2022

  

2021

 
  

Amount

  

Percent

of

Pretax

Earnings

  

Amount

  

Percent

of

Pretax

Earnings

 

United States federal tax at statutory rate

 $(15,801)  21.0% $(13,070)  21.0%

State taxes (net of deferred benefit)

  (2,912)  3.9%  (2,205)  3.5%

Nondeductible expenses

  1,077   (1.4%)  (440)  0.7%

Change in fair market value of contingent consideration

  (283)  0.4%  (397)  0.6%

Warrant remeasurment and financing costs

  -   -   502   (0.8%)

Research & Development

  (970)  1.3%  (705)  1.1%

Change in unrecognized tax benefits

  194   (0.3%)  141   (0.2%)

Foreign tax rate differential

  2,676   (3.6%)  1,911   (3.1%)

True-up to Stock Compensation - Cancellations

  49   (0.1%)  2,832   (4.6%)

Change in enacted tax rates and other, net

  (96)  0.2%  731   (1.0%)

Change in valuation allowance

  16,384   (21.8%)  10,925   (17.6%)

Income tax expense (benefit)

 $318   (0.4%) $225   (0.4%)
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Stock-based Compensation
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

13.

Stock-Based Compensation

 

Overview

 

On July 22, 2021, at the 2021 Annual Meeting of Stockholders, stockholders voted to approve the Company’s Amended and Restated Incentive Compensation Plan (the “Plan”) to increase the number of shares reserved for issuance under the Plan by 22,000,000 shares. As of December 31, 2022, there were 32,072,308 shares authorized for issuance, and 11,038,824 shares available for future issuance under the Plan. To date all equity awards under the Plan have consisted of nonqualified stock options, incentive stock options, and restricted stock units.

 

Under the Plan, which is administered by the Compensation Committee, the Company may grant stock options, stock appreciation rights, restricted stock and/or deferred stock to employees, officers, directors, consultants, and vendors. The exercise price of stock options or stock appreciation rights may not be less than the fair market value of the Company’s shares at the date of grant. Additionally, no stock options or stock appreciation rights granted under the Plan may have a term exceeding ten years.

 

Stock Options

The following table summarizes the Company’s stock option activity, including grants to non-employees, for the year ended December 31, 2022:

 

   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average

Remaining

Contractual Term

(Years)

  

Balance at December 31, 2021

     4,640,660     $ 6.64       5.66  

Granted

     3,153,881       0.70          

Forfeited

     (129,134 )     1.60          

Cancelled

     (36,987 )     21.11          

Exercised

     (43,453 )     0.41          

Balance at December 31, 2022

     7,584,967     $ 4.22       5.31  

 

 

The aggregate intrinsic value of stock options exercised under the Company’s stock plans was not material during the year ended December 31, 2022.

 

The following table summarizes information about stock options outstanding at December 31, 2022:

 

   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average

Remaining

Contractual Term

(Years)

    

Aggregate

Intrinsic Value

(Millions)

  

Exercisable at December 31, 2022

     3,524,473     $ 7.40       4.75     $ -  

Vested or expected to vest at December 31, 2022

     7,350,141     $ 4.32       5.28     $ -  

 

 

The fair value of options granted were estimated using the Black-Scholes-Merton option pricing model based on the assumptions in the table below:

 

  Years Ended December 31,
  2022  2021

Expected dividend yield

 0%  0%

Expected volatility

 126%-133%  118%-139%

Risk-free interest rate

 1.25%-4.40%  0.33%-1.11%

Expected life (in years)

 3.8-4.5  3.8-4.5 

 

Restricted Stock Units

The following is a summary of the restricted stock units activity, including performance restricted stock units, for the year ended December 31, 2022:

 

   

Number of

Restricted

Stock Units

Outstanding

    

Weighted-

Average Grant

Date Fair

Value

  

Unvested December 31, 2021

     3,839,030     $ 2.36  

Granted

     6,996,822       0.71  

Vested

     (2,076,663 )     2.34  

Forfeited

     (275,698 )     1.19  

Unvested December 31, 2022

     8,483,491     $ 1.04  

 

Performance Restricted Stock Units

In 2022 and 2021, the Company granted performance-based restricted stock units with vesting terms based on our attainment of certain operational targets by October 1, 2023 and October 1, 2022, respectively. The number of shares earnable under the 2022 and 2021 awards are based on achieving designated corporate goals. These operational targets were achieved for 2022 and 2021, therefore the performance-based restricted stock units are fully earned and remain subject to three-year time-based vesting requirements.

 

Stock-based Compensation Expense

The following table summarizes non-cash stock-based compensation expense by award type for the years ended December 31, 2022, and 2021:

 

   

Years Ended December 31,

 
   

2022

    

2021

  
   

(in thousands)

  

Stock options

   $ 3,654     $ 4,535  

Restricted stock units

     3,319       3,954  

Performance restricted stock units

     1,443       940  
    $ 8,416     $ 9,429  

 

As of December 31, 2022, the Company had future employee stock-based compensation expense of approximately $2.1 million related to unvested stock options, which is expected to be recognized over an estimated weighted-average period of 1.5 years. As of December 31, 2022, the unrecognized stock-based compensation expense related to unvested restricted stock units and performance restricted stock units was approximately $4.2 million, which is expected to be recognized over a weighted average period of approximately 1.4 years.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Offerings
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

14.

Equity Offerings

 

Equity financing transactions for the years ended December 31, 2022 and 2021, include:

 

2020 ATM Offering. On October 9, 2020, the Company filed a prospectus supplement relating to an at-the-market offering with Cantor pursuant to which the Company could sell from time to time, at its option, up to an aggregate of $40.0 million of shares of the Company’s common stock (the “2020 ATM Offering”). The Company terminated this agreement in January 2021. 

 

January 2021 Public Offering. On January 29, 2021, the Company completed an underwritten public offering of 26,545,832 shares of its common stock, including the underwriter’s full exercise of an over-allotment option on February 1, 2021, at the public offering price of $3.00 per share, generating net proceeds of approximately $73.4 million.

 

January 2021 Registered Direct Purchase Agreement. On January 12, 2021, the Company sold in a registered direct offering 25,000,000 shares of common stock at a purchase price per share of $1.25 for aggregate net proceeds of $28.6 million.

 

2021 ATM Offering. On May 19, 2021, we entered into a Controlled Equity OfferingSM Sales Agreement with Cantor, Robert W. Baird & Co. Incorporated and Oppenheimer & Co. Inc., as our sales agents, relating to an at-the-market offering of up to an aggregate of $100,000,000 of shares of our common stock, referred to as the “2021 ATM Offering”.

 

Sales during the year ended December 31, 2021, under the 2021 and 2020 ATM Offering are as follows (in thousands, except for share and per share amounts):

 

  

Year Ended

December 31, 2021

 
     

Total shares of common stock sold

  20,237,045 

Average price per share

 $1.53 

Gross proceeds

 $30,943 

Commisssion earned by Sales Agents

 $928 

Net proceeds

 $30,015 

 

 

2021 Exercise of Warrants. During the year ended December 31, 2021, certain holders of our Series B, C and D warrants to purchase shares of our common stock exercised such warrants for aggregate proceeds to the Company of $30.6 million.

 

2022 ATM Offering. On March 18, 2022, the Company entered a Controlled Equity Offering Sales Agreement (the “2022 Sales Agreement”), with Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc. The Company commenced an at-the-market offering (the “2022 ATM Offering”) pursuant to which the Company could sell from time to time, at its option, up to an aggregate of $100.0 million shares of the Company’s common stock. No sales of common stock were made under the 2022 ATM Offering during the year ended December 31, 2022.

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Note 15 - Basic and Diluted Net Loss Per Share
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Earnings Per Share [Text Block]

15.

Basic and Diluted Net Loss per Share

 

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all potential dilutive common shares that were outstanding during the period when the effect is dilutive. Potential dilutive common shares consist of incremental shares issuable upon exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding common shares figures for the years ended December 31, 2022 or 2021 as the assumed exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.

 

Potential common shares not included in calculating diluted net loss per share are as follows:

 

 

   

December 31,

 
   

2022

    

2021

  

Stock options

     7,584,967       4,640,660  

Stock warrants

     1,021,076       1,120,300  

Nonvested restricted stock units

     8,483,491       3,839,030  

Total

     17,089,534       9,599,990  

 

 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Note 16 - Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

16.

Commitments and Contingencies

 

License and Supply Agreements

As part of the Company’s acquisition of the Senhance System in 2015, the Company assumed certain license and supply agreements. The Company has purchase orders with various suppliers for certain tooling, supplies, contract engineering and research services. Commitments related to license agreements and purchase orders are as follows (in thousands):

 

Fiscal Year

        

2023

   $ 5,976  

2024

     407  

2025

     313  

2026

     303  

Total commitments

   $ 6,999  

 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Note 17 - Segments and Geographic Areas
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

17.

Segments and Geographic Areas

 

The following table presents consolidated assets and long-lived assets by geographic area, which includes property and equipment, intellectual property, and operating lease assets:

 

   

December 31, 2022

  
   

Long-Lived Assets

    

Total Assets

  

U.S.

     35 %     72 %
                 

EMEA

                

Switzerland

     46 %     24 %

Italy

     8 %     2 %

Other

     8 %     1 %

Total EMEA

     62 %     27 %
                 

Asia

     3 %     1 %

Total

     100 %     100 %

 

 

   

December 31, 2021

  
   

Long-Lived Assets

    

Total Assets

  

U.S.

     26 %     77 %
                 

EMEA

                

Switzerland

     34 %     16 %

Italy

     36 %     5 %

Other

     4 %     1 %

Total EMEA

     74 %     22 %
                 

Asia

     0 %     1 %

Total

     100 %     100 %

 

 

The following table presents sales by geographic area based on the country in which the customer is based.

 

 

   

Years Ended December 31,

 
   

2022

    

2021

  
                 
                 

US

     11 %     13 %

EMEA

     77 %     62 %

Asia

     12 %     25 %

Total

     100 %     100 %
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Note 18 - Related Party Transactions
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

18.

Related Party Transactions

 

In March 2018, Asensus Surgical Europe S.à r.l. entered into a Service Supply Agreement with 1 Med S.A. for certain regulatory consulting services. Andrea Biffi, a current member of the Company’s Board of Directors, owns a non-controlling interest in 1 Med S.A. Expenses under the Service Supply Agreement were approximately $290,000 and $186,000 for the years ended December 31, 2022 and 2021, respectively.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its direct and indirect wholly owned subsidiaries.

 
Substantial Doubt about Going Concern [Policy Text Block]

Going Concern

The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $860.9 million and working capital of $76.5 million as of December 31, 2022. The Company has not established sufficient sales revenues to cover its operating costs and requires additional capital to proceed with its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.

 

The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to meet its existing obligations, and to continue as a going concern within one year from the date that these financial statements are issued. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 
Consolidation, Policy [Policy Text Block]

Principles of Consolidation and Foreign Currency Considerations

The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.

 

The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive loss as a separate component of stockholders’ equity.

 

The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2022 and 2021 were not material.

 
Reclassification, Comparability Adjustment [Policy Text Block]

Reclassifications

Certain amounts reported previously have been reclassified to conform to the current year presentation, with no effect on stockholders’ equity or net loss as previously reported. Revenue and cost of revenue for leases were historically included in product and service revenue and corresponding cost of revenue on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2021. Accrued employee compensation and benefits were historically included in accrued expenses and other current liabilities on the consolidated balance sheets for the year ended December 31, 2021.

 
Error Correction and Revisions [Policy Text Block]

Revision of Previously Disclosed Amounts

During the course of preparing the Company’s unaudited consolidated financial statements as of and for the six months ended June 30, 2022, the Company determined that its December 31, 2021 inventory footnote presentation overstated raw materials and understated finished goods by $2.5 million.  For comparative purposes, Note 7 – Inventories, has been revised to reflect the adjustment to raw materials and finished goods as of December 31, 2021.  The revision had no effect on the previously reported total gross and net carrying value of inventory.  The revision also had no effect on the previously reported consolidated balance sheets, statements of operations and comprehensive loss, cash flows and stockholders’ equity. 

 
Risk And Uncertainties, Policy [Policy Text Block]

Risk and Uncertainties

The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: negative impacts on the Company's operations caused by the COVID-19 pandemic and other geopolitical factors; the historical lack of profitability; the Company’s ability to raise additional capital; the success of its market development efforts; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan, and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic surgical devices; and its ability to identify and pursue development of additional products.

 
Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, short-term and long-term investments, excess and obsolete inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use (“ROU”) assets, and deferred tax asset valuation allowances.

 
Cash and Cash Equivalents, Restricted Cash, and Investments, Policy [Policy Text Block]

Cash and Cash Equivalents, Restricted Cash, and Investments

The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents.

 

Restricted cash as of December 31, 2022 and 2021 includes $1.1 million in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, and automobile leases.

 

The Company’s investments as of December 31, 2022 consisted of commercial paper, corporate bonds, and United States government agencies and were classified as available-for-sale. Investments classified as available-for-sale are measured at fair value, and net unrealized gains and losses are recorded as a component of accumulated other comprehensive loss on the consolidated balance sheets until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization and accretion is included in interest expense, net. There were no gross realized gains or loss for the year ended December 31, 2022. The Company recognized an immaterial amount of gross realized losses for the year ended December 31, 2021. There were no gross realized gains for the year ended December 31, 2021.

 

Investments with remaining maturities at date of purchase greater than 90 days and remaining maturities as of the reporting period less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. 

 

There have been no credit losses for the years ended December 31, 2022 and 2021, and no allowance for credit losses as of December 31, 2022. Factors considered in determining whether a credit loss exists include credit ratings and other qualitative factors for each security type in the portfolio.

 
Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper and corporate notes and bonds without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy. The Company measures contingent consideration at fair value using a Monte-Carlo simulation utilizing Level 3 inputs. These inputs include the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones.

 
Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations and Credit Risk

The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents (including restricted cash), and investments, including amounts held in money market funds, commercial paper, and corporate bonds. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits may at times exceed the Federal Deposit Insurance Corporation’s insured limit. Balances in excess of federally insured limitations may not be insured. The Company has not experienced losses on these accounts, and management believes that the Company is not exposed to significant risks on such accounts. Investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investments consist of various major corporations, financial institutions, and government agencies of high credit standing.

 

The Company’s accounts receivable are derived from sales and leases to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no collateral from its customers. The Company had one customer that accounted for 69% of the Company’s net accounts receivable as of December 31, 2022. The Company had three customers that accounted for 26%, 20%, and 14%, respectively, of the Company’s net accounts receivable as of December 31, 2021. The Company had one customer who accounted for 47% of revenue in 2022, and two customers who accounted for 36% and 16% of revenue in 2021, respectively.

 
Receivable [Policy Text Block]

Accounts Receivable

Accounts receivable are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses is based on the Company’s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The allowance for expected credit losses was $1.6 million and $1.7 million as of December 31, 2022, and December 31, 2021, respectively. The Company recorded an immaterial amount for expected credit losses during the year ended December 31, 2022 and $0.1 million during the year ended December 31, 2021.          

 
Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the lower of cost (determined on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers historical consumption and forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

 

Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming twelve months.

 
Goodwill and Intangible Assets, Policy [Policy Text Block]

Definite-Lived Intangible Assets - Intellectual Property

Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified in-process research and development (“IPR&D”) assets related to (i) the Senhance System acquired in 2015 and reclassified in 2017 and (ii) a 2018 acquisition and reclassified in 2020. Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed technology is recorded using the straight-line method over the estimated useful life of 5 to 7 years.

 

The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To determine the recoverability, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the assets, then such assets are written down to their fair value. No impairment of intellectual property was identified during the years ended December 31, 2022 and 2021.

 
Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment consists primarily of operating lease Senhance System assets, machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

 

  

Years

 

Operating lease assets – Senhance System leasing

   5  

Machinery, manufacturing, and demonstration equipment

  3-5 

Computer equipment

   3  

Furniture

   5  

Leasehold improvements

 

Lesser of lease term or 3 to 10

 

 

The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value.

 

During the year ended December 31, 2022, the Company recorded a non-cash asset impairment charge of $1.4 million to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are not expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the consolidated statements of operations and comprehensive loss. No such impairment charges were recorded during the year ended December 31, 2021.

 
Lessee, Leases [Policy Text Block]

Operating Leases

We have operating leases for our corporate office buildings, vehicles, and machinery and equipment. At inception, we determine whether an agreement represents a lease and, at commencement, we evaluate each lease agreement to determine whether the lease constitutes an operating or financing lease.

 

The Company accounts for lease components and non-lease components as a single component. Non-lease components consist of common area maintenance payments for most real estate leases, which are determined based on costs incurred by the lessor. Many of the Company’s leases include base rental periods coupled with options to renew or terminate the lease, generally at the Company’s discretion.  In evaluating the lease term, the Company considers whether renewal is reasonably certain.  To the extent a significant economic incentive exists to renew the lease, the option is included within the lease term.  Based on the Company’s leases, renewal options generally do not provide a significant economic incentive and are therefore excluded from the lease term. While our operating leases range from one year to ten years, some may include options to extend the lease generally between one year and six years, and some may include options to terminate the leases within one year.

 

The interest rate implicit in our lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.

 
Capitalization of Internal Costs, Policy [Policy Text Block]

Implementation Costs in a Cloud Computing Arrangement

The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract. These capitalized implementation costs are recorded within other current and long-term assets, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis and included within operating expenses.

 
Employer Retention Tax Credit, Policy [Policy Text Block]

Employee Retention Tax Credit Receivable

The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages. During the year ended December 31, 2021, we submitted an ERTC refund for $1.3 million and recorded the amount into Other Income (Expense) on the consolidated statements of operations and comprehensive loss. The Company received notification from the IRS that the relevant conditions of the employee retention credit provision were met and that it will receive the credit. The Company received $0.7 million of the ERTC refund during the year ended December 31, 2022. The remaining $0.6 million is recorded as a current asset on the consolidated balance sheets as of December 31, 2022.

 
Debt, Policy [Policy Text Block]

Notes Payable 

The Company’s policy is to account for forgivable loans received through the U.S. Small Business Administration (the “SBA”) under the CARES Act Payroll Protection Program (“PPP”), as debt in accordance with ASC 470, Debt, and other related accounting pronouncements. The forgiveness of debt, in whole or part, is recognized once the debt is extinguished, which occurs when the Company is legally released from the liability by the SBA. Any portion of debt forgiven, adjusted for accrued interest forgiven and unamortized debt issuance costs, is recorded as a gain on extinguishment of debt, and presented in the consolidated statements of operations and comprehensive loss. On June 10, 2021, the Company received notification from the SBA that the principal amount of its PPP loan of $2.8 million and related interest had been forgiven.

 

As of December 31, 2022, the Company has $0.6 million available under a letter of credit. No amounts have been utilized by the Company as of December 31, 2022.

 
Contingent Consideration [Policy Text Block]

Contingent Consideration

Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, revenue volatility and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

 

On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar S.p.A., an Italian company (“Sofar”), an Italian company, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System. Under the terms of the Purchase Agreement, as amended in 2016, as of December 31, 2022, the Company has accrued $1.3 million of estimated fair value of remaining contingent consideration related to a milestone of €15.0 million which shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least €25.0 million over a calendar quarter or in the event that (i) the Company or Asensus International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. In 2022, Sofar assigned its right to receive the contingent payment to Three Heads Investment S.r.l.

 
Warrant Liabilities [Policy Text Block]

Warrant Liabilities

The Company’s Series B Warrants were measured at fair value using a simulation model which considered, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant. The warrant liability was revalued at each reporting period and changes in fair value were recognized in the consolidated statements of operations and comprehensive loss. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. All remaining outstanding Series B Warrants were exercised in the first quarter 2021.

 
Revenue [Policy Text Block]

Revenue Recognition

The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements generally include a five-year service period; the first year of service is generally free and included in the Senhance System sale arrangement and the remaining four years are generally included at a stated service price.

 

The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements may include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.

 

For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services; however due to limited sales to date, standalone selling prices generally are not directly observable. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer, and market conditions. The Company regularly reviews estimated standalone selling prices and updates these estimates if necessary.

 

The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows:

 

•  System sales. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from Senhance System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when the Company receives an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do not provide a right of return. The Senhance Systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.

 

•  Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.

 

•  Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.

 

The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements, and are included in accounts receivable.

 

In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do not meet the requirements to be capitalized as the Company does not expect to generate future economic benefits from the related revenue from the initial sales transaction and such costs are expensed as incurred.

 
Lessor, Leases [Policy Text Block]

Senhance System Leasing

The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. For the years ended December 31, 2022 and 2021, variable lease revenue related to usage-based arrangements was not material.  

 

In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, the Company considers the following terms at lease commencement: (1) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (3) whether the lease term is for the major part of the remaining economic life of the leased System, (4) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (5) whether the underlying Senhance System is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. All such arrangements through December 31, 2022 are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage. As of December 31, 2022 future minimum lease payments due from customers was $2.2 million, which is expected to be received over the next one to three years.

 
Cost of Goods and Service [Policy Text Block]

Cost of Revenue

Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Depreciation expense related to leased systems is included in the cost of revenue. Shipping and handling costs incurred by the Company are included in the cost of revenue.  We expense all inventory obsolescence provisions as cost of revenue.

 
Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.

 
Share-Based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

The Company recognizes expenses for share-based awards exchanged for services rendered equal to the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of stock options. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimates forfeitures based on its historical experience and adjust the estimated forfeiture rate based upon actual experience. For performance-based restricted stock awards with performance conditions, we begin recognizing compensation expense when it becomes probable that the performance condition will be attained.

 

The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. See “Note 13 – Stock-Based Compensation,” for a detailed discussion of the Company’s stock plans and stock-based compensation expense.

 
Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred.

 

The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than not sustain the position following audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.

 

Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company may be subject to examination by authorities for all previously filed income tax returns.

 
Comprehensive Income, Policy [Policy Text Block]

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

 
Segment Reporting, Policy [Policy Text Block]

Segments

The Company operates in one business segment—the research, development and sale of medical device robotics to improve minimally invasive surgery. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

 
New Accounting Pronouncements, Policy [Policy Text Block]

Impact of Recently Issued Accounting Standards

 

The Company has evaluated issued ASUs not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Property Plant and Equipment Useful Life [Table Text Block]
  

Years

 

Operating lease assets – Senhance System leasing

   5  

Machinery, manufacturing, and demonstration equipment

  3-5 

Computer equipment

   3  

Furniture

   5  

Leasehold improvements

 

Lesser of lease term or 3 to 10

 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Disaggregation of Revenue [Table Text Block]
     

Years Ended December 31,

 
     

2022

    

2021

  
     

(in thousands)

  

U.S.

                  

Systems

   $ -     $ -  

Instruments and accessories

     211       273  

Services

     300       383  

Leases

     256       377  

Total U.S. revenue

     767       1,033  
                   

Outside of U.S. ("OUS")

                

Systems

     2,551       3,286  

Instruments and accessories

     1,565       1,840  

Services

     1,073       1,137  

Leases

     1,131       936  

Total OUS revenue

     6,320       7,199  
                   

Total

                  

Systems

     2,551       3,286  

Instruments and accessories

     1,776       2,113  

Services

     1,373       1,520  

Leases

     1,387       1,313  
Total revenue   $ 7,087     $ 8,232  
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
   

December 31, 2022

    

December 31, 2021

  
   

(in thousands)

  

Contract Assets

   $ 116     $ 91  

Deferred Revenue

   $ 465     $ 543  
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Cash, Cash Equivalents, and Restricted Cash [Table Text Block]
   

December 31,

    

December 31,

  
   

2022

    

2021

  
   

(in thousands)

  

Cash

   $ 3,473     $ 8,343  

Money Market

     2,856       5,287  

Commerical Paper

     -       4,499  

Total cash and cash equivalents

   $ 6,329     $ 18,129  

Restricted Cash

     1,141       1,154  

Total

   $ 7,470     $ 19,283  
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Investments, Available-for-sale (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Debt Securities, Available-for-Sale [Table Text Block]
  

December 31, 2022

 
  

(in thousands)

 
                         
  

Amortized

Cost

  

Unrealized

Gain

  

Unrealized

Loss

  

Fair Value

  

Short-term

investments

  

Long-term

investments

 

Commercial Paper

 $12,364  $-  $(49) $12,315  $12,315  $- 

Corporate Bonds

  55,201   -   (447)  54,754   50,889   3,865 

U.S. Government Agencies

  999   -   (8)  991   991   - 

Total Investments

 $68,564  $-  $(504) $68,060  $64,195  $3,865 
  

December 31, 2021

 
  

(in thousands)

 
                         
  

Amortized

Cost

  

Unrealized

Gain

  

Unrealized

Loss

  

Fair Value

  

Short-term

investments

  

Long-term

investments

 

Commercial Paper

 $50,705  $-  $(46) $50,659  $50,660  $- 

Corporate Bonds

  67,239   1   (202)  67,038   29,602   37,435 

Total Investments

 $117,944  $1  $(248) $117,697  $80,262  $37,435 
Investments Classified by Contractual Maturity Date [Table Text Block]
  

December 31, 2022

 
  

(in thousands)

 
  

Amortized

Cost

  

Fair Value

 

Mature in less than one year

 $64,662  $64,195 

Mature in one to two years

  3,902   3,865 

Total

 $68,564  $68,060 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Fair Value (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
   

December 31, 2022

  
   

(in thousands)

  
                                 

Description

  

Quoted Prices in

Active Markets for

Identical Assets

(Level 1)

    

Significant Other

Observable Inputs

(Level 2)

    

Significant

Unobservable

Inputs (Level 3)

    

Total

  

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 6,329     $ -     $ -     $ 6,329  

Restricted cash

     1,141       -       -       1,141  

Short-term investments

     -       64,195       -       64,195  

Long-term investments

     -       3,865       -       3,865  

Total assets measured at fair value

   $ 7,470     $ 68,060     $ -     $ 75,530  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 1,256     $ 1,256  

Total liabilities measured at fair value

   $ -     $ -     $ 1,256     $ 1,256  
   

December 31, 2021

  
   

(in thousands)

  
                                 

Description

  

Quoted Prices in

Active Markets for

Identical Assets

(Level 1)

    

Significant Other

Observable Inputs

(Level 2)

    

Significant

Unobservable

Inputs (Level 3)

    

Total

  

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 18,129     $ -     $ -     $ 18,129  

Restricted cash

     1,154       -       -       1,154  

Short-term investments

     -       80,262       -       80,262  

Long-term investments

     -       37,435       -       37,435  

Total assets measured at fair value

   $ 19,283     $ 117,697     $ -     $ 136,980  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 2,371     $ 2,371  

Total liabilities measured at fair value

   $ -     $ -     $ 2,371     $ 2,371  
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
 

Valuation

Methodology

  

Significant Unobservable

Input

  

December 31, 2022

    

December 31, 2021

  
                   

Contingent consideration

Probability weighted

income approach

  

Milestone dates

  

2032

    

2031

  
     

Discount rate

   16.5%     9.5%  
     

Revenue volatility

   45.0%     39.0%  
     

EUR-to-USD exchange rate

   1.07     1.14  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
  

Fair Value

Measurement at

Reporting Date

(Level 3)

 
  

(in thousands)

 
  

Contingent

consideration

 

Balance at December 31, 2020

 $3,936 

Change in fair value

  (1,565)

Balance at December 31, 2021

 $2,371 

Change in fair value

  (1,115)

Balance at December 31, 2022

 $1,256 
     

Current portion

 $- 

Long-term portion

  1,256 

Balance at December 31, 2022

 $1,256 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Inventories (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
   

December 31, 2022

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Reserve Balance

    

Net

Carrying

Amount

  

Finished goods

   $ 15,337     $ (4,129 )   $ 11,208  

Raw materials

     4,718       (2,173 )     2,545  

Total inventories

   $ 20,055     $ (6,302 )   $ 13,753  
                         

Current Portion

   $ 9,399     $ (1,115 )   $ 8,284  

Long-term portion

     10,656       (5,187 )     5,469  

Total inventories

   $ 20,055     $ (6,302 )   $ 13,753  
   

December 31, 2021

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Reserve Balance

    

Net

Carrying

Amount

  

Finished goods

   $ 13,066     $ (2,987 )   $ 10,079  

Raw materials

     8,324       (2,695 )     5,629  

Total inventories

   $ 21,390     $ (5,682 )   $ 15,708  
                         

Current Portion

   $ 9,931     $ (1,297 )   $ 8,634  

Long-term portion

     11,459       (4,385 )     7,074  

Total inventories

   $ 21,390     $ (5,682 )   $ 15,708  
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Property, Plant and Equipment [Table Text Block]
   

December 31,
2022

    

December 31,
2021

  
   

(In thousands)

  

Machinery, manufacturing, and demonstration equipment

   $ 8,450     $ 8,289  

Operating lease assets - Senhance System leasing

     10,251       10,143  

Computer equipment

     600       325  

Furniture

     831       644  

Leasehold improvements

     1,654       1,259  

Construction in process

     436    

‑

  

Total property and equipment

     22,222       20,660  

Accumulated depreciation and amortization

     (12,680

)

     (9,689

)

Property and equipment, net

   $ 9,542     $ 10,971  
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Intellectual Property (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Finite-Lived Intangible Assets [Table Text Block]
   

December 31, 2022

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Accumulated Amortization

    

Foreign

Currency

Translation

Impact

    

Net

Carrying

Amount

  

Developed technology

   $ 68,838     $ (66,562 )   $ (874 )   $ 1,402  

Technology and patents purchased

     400       (239 )     13       174  

Total intellectual property

   $ 69,238     $ (66,801 )   $ (861 )   $ 1,576  
   

December 31, 2021

  
   

(in thousands)

  
   

Gross

Carrying

Amount

    

Accumulated

Amortization

    

Foreign

Currency

Translation

Impact

    

Net

Carrying

Amount

  

Developed technology

   $ 68,838     $ (58,912 )   $ (262 )   $ 9,664  

Technology and patents purchased

     400       (199 )     27       228  

Total intellectual property

   $ 69,238     $ (59,111 )   $ (235 )   $ 9,892  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
  

Year Ending
December 31, 2022

 

2023

 $377 

2024

  377 

2025

  377 

2026

  377 

2027

  68 

Total

 $1,576 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Leases (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Lease, Cost [Table Text Block]
   

Years Ended December 31,

  
   

2022

    

2021

  
   

(in thousands)

  

Long-term Operating

   $ 1,557     $ 1,826  

Short-term Operating

     -       -  

Total Operating lease expense

   $ 1,557     $ 1,826  
Lessee, Operating Lease, Disclosure [Table Text Block]
   

December 31, 2022

    

December 31, 2021

  

Weighted-average remaining lease term (in years)

  

6.8

    

7.8

  

Weighted-average discount rate

   8.4%     7.8%  

Incremental borrowing rate

   6.1% - 14.5%     6.1% - 8.5%  
Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Fiscal Year

        

2023

   $ 1,222  

2024

     1,136  

2025

     1,058  

2026

     837  

2027

     775  

Thereafter

     2,195  

Total minimum lease payments

   $ 7,223  

Less: Amount of lease payments representing interest

     (1,685 )

Present value of future minimum lease payments

   $ 5,538  
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
   

December 31,
2022

    

December 31,
2021

  
   

(In thousands)

  

Consulting and other vendors

   $ 155     $ 128  

Other

     —       124  

Royalties

     24       247  

Legal and professional fees

     275       503  

Taxes and other assessments

     839       615  

Total

   $ 1,293     $ 1,617  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

2022

  

2021

 

Current income taxes

        

Federal

 $-  $- 

State

  -   - 

Foreign

  239   232 

Deferred income taxes

        

Federal

  -   - 

State

  -   - 

Foreign

  79   (7)

Total income tax expense

 $318  $225 
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
  

2022

  

2021

 
         

United States

 $(44,802) $(32,094)

Foreign

  (30,441)  (30,143)

Total loss from operations before taxes

 $(75,243) $(62,237)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

2022

  

2021

 
         

Deferred Tax assets:

        

Stock-based compensation

 $2,840  $2,440 

Accrued expenses and other

  2,538   2,423 

Research credit carryforward

  1,341   564 

Fixed Assets

  162   101 

Capitalized start-up costs and other intangibles

  921   1,109 

Capitalized research costs

  4,382   - 

Net operating loss carryforwards

  83,908   75,237 
   96,092   81,874 

Valuation Allowance

  (94,704)  (78,294)

Net deferred tax asset

  1,388   3,580 

Deferred tax liabilities

        

Fixed assets and other

  (1,214)  (1,176)

Purchase accounting intangibles

  -   (2,116)

Net deferred tax liability

  (1,214)  (3,292)

Net deferred tax asset (liability)

 $174  $288 
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
  

2022

  

2021

 
         

Beginning balance

 $141  $- 

Gross increases for tax positions related to current periods

  194   141 

Gross decreases related to 382 limitations

  -   - 

Ending balance

 $335  $141 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

2022

  

2021

 
  

Amount

  

Percent

of

Pretax

Earnings

  

Amount

  

Percent

of

Pretax

Earnings

 

United States federal tax at statutory rate

 $(15,801)  21.0% $(13,070)  21.0%

State taxes (net of deferred benefit)

  (2,912)  3.9%  (2,205)  3.5%

Nondeductible expenses

  1,077   (1.4%)  (440)  0.7%

Change in fair market value of contingent consideration

  (283)  0.4%  (397)  0.6%

Warrant remeasurment and financing costs

  -   -   502   (0.8%)

Research & Development

  (970)  1.3%  (705)  1.1%

Change in unrecognized tax benefits

  194   (0.3%)  141   (0.2%)

Foreign tax rate differential

  2,676   (3.6%)  1,911   (3.1%)

True-up to Stock Compensation - Cancellations

  49   (0.1%)  2,832   (4.6%)

Change in enacted tax rates and other, net

  (96)  0.2%  731   (1.0%)

Change in valuation allowance

  16,384   (21.8%)  10,925   (17.6%)

Income tax expense (benefit)

 $318   (0.4%) $225   (0.4%)
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Stock-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average

Remaining

Contractual Term

(Years)

  

Balance at December 31, 2021

     4,640,660     $ 6.64       5.66  

Granted

     3,153,881       0.70          

Forfeited

     (129,134 )     1.60          

Cancelled

     (36,987 )     21.11          

Exercised

     (43,453 )     0.41          

Balance at December 31, 2022

     7,584,967     $ 4.22       5.31  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]
   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average

Remaining

Contractual Term

(Years)

    

Aggregate

Intrinsic Value

(Millions)

  

Exercisable at December 31, 2022

     3,524,473     $ 7.40       4.75     $ -  

Vested or expected to vest at December 31, 2022

     7,350,141     $ 4.32       5.28     $ -  
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
  Years Ended December 31,
  2022  2021

Expected dividend yield

 0%  0%

Expected volatility

 126%-133%  118%-139%

Risk-free interest rate

 1.25%-4.40%  0.33%-1.11%

Expected life (in years)

 3.8-4.5  3.8-4.5 
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
   

Number of

Restricted

Stock Units

Outstanding

    

Weighted-

Average Grant

Date Fair

Value

  

Unvested December 31, 2021

     3,839,030     $ 2.36  

Granted

     6,996,822       0.71  

Vested

     (2,076,663 )     2.34  

Forfeited

     (275,698 )     1.19  

Unvested December 31, 2022

     8,483,491     $ 1.04  
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
   

Years Ended December 31,

 
   

2022

    

2021

  
   

(in thousands)

  

Stock options

   $ 3,654     $ 4,535  

Restricted stock units

     3,319       3,954  

Performance restricted stock units

     1,443       940  
    $ 8,416     $ 9,429  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Offerings (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Sales Under Sales Agency Agreement [Table Text Block]
  

Year Ended

December 31, 2021

 
     

Total shares of common stock sold

  20,237,045 

Average price per share

 $1.53 

Gross proceeds

 $30,943 

Commisssion earned by Sales Agents

 $928 

Net proceeds

 $30,015 
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Note 15 - Basic and Diluted Net Loss Per Share (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   

December 31,

 
   

2022

    

2021

  

Stock options

     7,584,967       4,640,660  

Stock warrants

     1,021,076       1,120,300  

Nonvested restricted stock units

     8,483,491       3,839,030  

Total

     17,089,534       9,599,990  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Note 16 - Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Contractual Obligation, Fiscal Year Maturity [Table Text Block]

Fiscal Year

        

2023

   $ 5,976  

2024

     407  

2025

     313  

2026

     303  

Total commitments

   $ 6,999  
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Note 17 - Segments and Geographic Areas (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Long-Lived Assets by Geographic Areas [Table Text Block]
   

December 31, 2022

  
   

Long-Lived Assets

    

Total Assets

  

U.S.

     35 %     72 %
                 

EMEA

                

Switzerland

     46 %     24 %

Italy

     8 %     2 %

Other

     8 %     1 %

Total EMEA

     62 %     27 %
                 

Asia

     3 %     1 %

Total

     100 %     100 %
   

December 31, 2021

  
   

Long-Lived Assets

    

Total Assets

  

U.S.

     26 %     77 %
                 

EMEA

                

Switzerland

     34 %     16 %

Italy

     36 %     5 %

Other

     4 %     1 %

Total EMEA

     74 %     22 %
                 

Asia

     0 %     1 %

Total

     100 %     100 %
Revenue from External Customers by Geographic Areas [Table Text Block]
   

Years Ended December 31,

 
   

2022

    

2021

  
                 
                 

US

     11 %     13 %

EMEA

     77 %     62 %

Asia

     12 %     25 %

Total

     100 %     100 %
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies (Details Textual)
$ in Thousands, € in Millions
 12 Months Ended
Jun. 10, 2021
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
USD ($)
Retained Earnings (Accumulated Deficit), Total   $ (860,935)   $ (785,374)
Working Capital   76,500    
Overstated Raw Materials, Amount       2,500
Restricted Cash, Total   1,100   1,100
Debt Securities, Available-for-Sale, Realized Gain (Loss), Total   0   0
Accounts Receivable, Allowance for Credit Loss, Ending Balance   1,600   1,700
Accounts Receivable, Credit Loss Expense (Reversal)   9   144
Property, Plant and Equipment, Including Purchased Software, Impairment Charges   1,400   0
Other Income, Employer Retention Tax Credit   0   1,311
Proceeds From Employee Retention Tax Credit   700    
Employer Retention Tax Credit Receivable   554   1,311
Letters of Credit Outstanding, Amount   0    
Business Combination, Contingent Consideration, Liability, Total   $ 1,256   $ 2,371
Period Of Service Sale Arrangement (Year)   5 years 5 years  
Period of Service Sale Arrangement at Stated Service Price (Year)   4 years 4 years  
Lessor, Operating Lease, Payments to be Received, Total   $ 2,200    
Number of Operating Segments   1 1  
Senhance Surgical Robotic System Acquisition[Member]        
Business Combination, Contingent Consideration, Liability, Total   $ 1,300    
Business Combination, Contingent Consideration, Liability, Related Milestone | €     € 15  
Letter of Credit [Member]        
Line of Credit Facility, Remaining Borrowing Capacity   $ 600    
Paycheck Protection Program CARES Act [Member]        
Debt Instrument, Decrease, Forgiveness $ 2,800      
Minimum [Member]        
Lessee, Operating Lease, Term of Contract (Year)   1 year    
Lessee, Operating Lease, Renewal Term (Year)   1 year    
Minimum [Member] | Senhance Surgical Robotic System Acquisition[Member]        
Business Combination Contingent Consideration Arrangements Target Revenue | €     € 25  
Maximum [Member]        
Lessee, Operating Lease, Term of Contract (Year)   10 years    
Lessee, Operating Lease, Renewal Term (Year)   6 years    
Patents [Member]        
Finite-Lived Intangible Asset, Useful Life (Year)   10 years 10 years  
Developed Technology Rights [Member] | Minimum [Member]        
Finite-Lived Intangible Asset, Useful Life (Year)   5 years 5 years  
Developed Technology Rights [Member] | Maximum [Member]        
Finite-Lived Intangible Asset, Useful Life (Year)   7 years 7 years  
Intellectual Property [Member]        
Impairment of Intangible Assets, Finite-lived   $ 0    
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]        
Number of Major Customers   1 1  
Concentration Risk, Percentage   69.00% 69.00%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customers [Member]        
Number of Major Customers       3
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]        
Concentration Risk, Percentage       26.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]        
Concentration Risk, Percentage       20.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member]        
Concentration Risk, Percentage       14.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]        
Number of Major Customers   1 1  
Concentration Risk, Percentage   47.00% 47.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]        
Concentration Risk, Percentage       36.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]        
Concentration Risk, Percentage       16.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]        
Number of Major Customers       2
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)
 12 Months Ended
Dec. 31, 2022
Operating Lease Assets [Member]  
Property and equipment, estimated useful lives (Year) 5 years
Machinery, Manufacturing and Demonstration Equipment [Member] | Minimum [Member]  
Property and equipment, estimated useful lives (Year) 3 years
Machinery, Manufacturing and Demonstration Equipment [Member] | Maximum [Member]  
Property and equipment, estimated useful lives (Year) 5 years
Computer Equipment [Member]  
Property and equipment, estimated useful lives (Year) 3 years
Furniture and Fixtures [Member]  
Property and equipment, estimated useful lives (Year) 5 years
Leasehold Improvements [Member] | Minimum [Member]  
Property and equipment, estimated useful lives (Year) 3 years
Leasehold Improvements [Member] | Maximum [Member]  
Property and equipment, estimated useful lives (Year) 10 years
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Revenue Recognition 1 (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Contract with Customer, Liability, Revenue Recognized $ 0.5 $ 0.6
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Revenue Recognition 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
$ in Millions
Dec. 31, 2022
USD ($)
Revenue, Remaining Performance Obligation, Amount $ 1.1
Minimum [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) 1 year
Maximum [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) 4 years
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue $ 7,087 $ 8,232
UNITED STATES    
Revenue 767 1,033
Non-US [Member]    
Revenue 6,320 7,199
Systems [Member]    
Revenue 2,551 3,286
Systems [Member] | UNITED STATES    
Revenue 0 0
Systems [Member] | Non-US [Member]    
Revenue 2,551 3,286
Instruments and Accessories [Member]    
Revenue 1,776 2,113
Instruments and Accessories [Member] | UNITED STATES    
Revenue 211 273
Instruments and Accessories [Member] | Non-US [Member]    
Revenue 1,565 1,840
Service [Member]    
Revenue 1,373 1,520
Service [Member] | UNITED STATES    
Revenue 300 383
Service [Member] | Non-US [Member]    
Revenue 1,073 1,137
Lease [Member]    
Revenue 1,387 1,313
Lease [Member] | UNITED STATES    
Revenue 256 377
Lease [Member] | Non-US [Member]    
Revenue $ 1,131 $ 936
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Contract Assets $ 116 $ 91
Deferred Revenue $ 465 $ 543
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Restricted Cash and Cash Equivalents, Noncurrent, Total $ 1,141 $ 1,154
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Cash $ 3,473 $ 8,343
Money Market 2,856 5,287
Commerical Paper 0 4,499
Total cash and cash equivalents 6,329 18,129
Restricted Cash and Cash Equivalents, Noncurrent, Total 1,141 1,154
Total $ 7,470 $ 19,283
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Investments, Available-for-sale (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Proceeds from Sale of Debt Securities, Available-for-Sale $ 0 $ 0
Debt Securities, Available-for-Sale, Realized Gain (Loss), Total $ 0 $ 0
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Amortized Cost $ 68,564 $ 117,944
Unrealized Gain 0 1
Unrealized Loss (504) (248)
Fair Value 68,060 117,697
Short-term investments 64,195 80,262
Long-term investments 3,865 37,435
Commercial Paper [Member]    
Amortized Cost 12,364 50,705
Unrealized Gain 0 0
Unrealized Loss (49) (46)
Fair Value 12,315 50,659
Short-term investments 12,315 50,660
Long-term investments 0 0
Corporate Debt Securities [Member]    
Amortized Cost 55,201 67,239
Unrealized Gain 0 1
Unrealized Loss (447) (202)
Fair Value 54,754 67,038
Short-term investments 50,889 29,602
Long-term investments 3,865 $ 37,435
US Government Agencies Debt Securities [Member]    
Amortized Cost 999  
Unrealized Gain 0  
Unrealized Loss (8)  
Fair Value 991  
Short-term investments 991  
Long-term investments $ 0  
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Investments, Available-for-sale - Contractual Maturities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Mature in less than one year, amortized cost $ 64,662  
Mature in less than one year, fair value 64,195  
Mature in one to two years, amortized cost 3,902  
Mature in one to two years, fair value 3,865  
Total, amortized cost 68,564 $ 117,944
Total, fair value $ 68,060 $ 117,697
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Cash and cash equivalents [1] $ 6,329 $ 18,129
Restricted cash 1,141 1,154
Short-term investments 64,195 80,262
Long-term investments 3,865 37,435
Total assets measured at fair value 75,530 136,980
Contingent consideration 1,256 2,371
Total liabilities measured at fair value 1,256 2,371
Fair Value, Inputs, Level 1 [Member]    
Cash and cash equivalents [1] 6,329 18,129
Restricted cash 1,141 1,154
Short-term investments 0 0
Long-term investments 0 0
Total assets measured at fair value 7,470 19,283
Contingent consideration 0 0
Total liabilities measured at fair value 0 0
Fair Value, Inputs, Level 2 [Member]    
Cash and cash equivalents [1] 0 0
Restricted cash 0 0
Short-term investments 64,195 80,262
Long-term investments 3,865 37,435
Total assets measured at fair value 68,060 117,697
Contingent consideration 0 0
Total liabilities measured at fair value 0 0
Fair Value, Inputs, Level 3 [Member]    
Cash and cash equivalents [1] 0 0
Restricted cash 0 0
Short-term investments 0 0
Long-term investments 0 0
Total assets measured at fair value 0 0
Contingent consideration 1,256 2,371
Total liabilities measured at fair value $ 1,256 $ 2,371
[1] Includes investments that are readily convertible to cash with original maturities of 90 days or less.
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details) - Senhance Surgical Robotic System Acquisition[Member] - Fair Value, Inputs, Level 3 [Member]
Dec. 31, 2022
Dec. 31, 2021
Measurement Input, Discount Rate [Member]    
Contingent consideration, measurement input 0.165 0.095
Measurement Input, Price Volatility [Member]    
Contingent consideration, measurement input 0.450 0.390
Measurement Input, Currency Exchange Rate [Member]    
Contingent consideration, measurement input 1.07 1.14
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) - Warrant [Member] - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Balance $ 2,371 $ 3,936
Change in fair value (1,115) (1,565)
Balance 1,256 $ 2,371
Current portion 0  
Long-term portion $ 1,256  
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Inventories - Components of Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Finished goods, gross $ 15,337 $ 13,066
Finished goods, reserve (4,129) (2,987)
Finished goods, net 11,208 10,079
Raw materials, gross 4,718 8,324
Raw materials, reserve (2,173) (2,695)
Raw materials, net 2,545 5,629
Total inventories, gross 20,055 21,390
Total inventories, reserve (6,302) (5,682)
Total inventories, net 13,753 15,708
Current Portion, gross 9,399 9,931
Current Portion, reserve (1,115) (1,297)
Inventories 8,284 8,634
Long-term portion, gross 10,656 11,459
Long-term portion, reserve (5,187) (4,385)
Inventories, net of current portion $ 5,469 $ 7,074
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Property and Equipment (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Depreciation, Total $ 3,368 $ 2,857
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Property, plant and equipment, gross $ 22,222 $ 20,660
Accumulated depreciation and amortization (12,680) (9,689)
Property and equipment, net 9,542 10,971
Machinery, Manufacturing and Demonstration Equipment [Member]    
Property, plant and equipment, gross 8,450 8,289
Operating Lease Assets [Member]    
Property, plant and equipment, gross 10,251 10,143
Computer Equipment [Member]    
Property, plant and equipment, gross 600 325
Furniture and Fixtures [Member]    
Property, plant and equipment, gross 831 644
Leasehold Improvements [Member]    
Property, plant and equipment, gross 1,654 1,259
Construction in Progress [Member]    
Property, plant and equipment, gross $ 436
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Intellectual Property (Details Textual) - Weighted Average [Member]
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Developed Technology Rights [Member]    
Finite-Lived Intangible Assets, Remaining Amortization Period (Year) 4 years 2 months 12 days 1 year 7 months 6 days
Technology-Based Intangible Assets [Member]    
Finite-Lived Intangible Assets, Remaining Amortization Period (Year) 4 years 3 months 18 days 5 years 3 months 18 days
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Intellectual Property - Intellectual Property (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets, Gross $ 69,238 $ 69,238
Finite-Lived Intangible Assets, Accumulated Amortization (66,801) (59,111)
Finite-Lived Intangible Assets, Foreign Currency Translation Impact (861) (235)
Intellectual property, net 1,576 9,892
Developed Technology Rights [Member]    
Finite-Lived Intangible Assets, Gross 68,838 68,838
Finite-Lived Intangible Assets, Accumulated Amortization (66,562) (58,912)
Finite-Lived Intangible Assets, Foreign Currency Translation Impact (874) (262)
Intellectual property, net 1,402 9,664
Technology-Based Intangible Assets [Member]    
Finite-Lived Intangible Assets, Gross 400 400
Finite-Lived Intangible Assets, Accumulated Amortization (239) (199)
Finite-Lived Intangible Assets, Foreign Currency Translation Impact 13 27
Intellectual property, net $ 174 $ 228
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Total $ 1,576 $ 9,892
Intellectual Property [Member]    
2023 377  
2024 377  
2025 377  
2026 377  
2027 68  
Total $ 1,576 $ 9,892
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Leases - Components of Operating Lease Expense (Details) - General and Administrative Expense [Member] - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Long-term Operating $ 1,557 $ 1,826
Short-term Operating 0 0
Total Operating lease expense $ 1,557 $ 1,826
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Leases -Supplemental Balance Sheet Information (Details)
Dec. 31, 2022
Dec. 31, 2021
Weighted-average remaining lease term (in years) (Year) 6 years 9 months 18 days 7 years 9 months 18 days
Weighted-average discount rate 8.40% 7.80%
Minimum [Member]    
Incremental borrowing rate 6.10% 6.10%
Maximum [Member]    
Incremental borrowing rate 14.50% 8.50%
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Leases - Minimum Lease Payments (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
2023 $ 1,222
2024 1,136
2025 1,058
2026 837
2027 775
Thereafter 2,195
Total minimum lease payments 7,223
Less: Amount of lease payments representing interest (1,685)
Present value of future minimum lease payments $ 5,538
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Accrued Expenses - Components of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Consulting and other vendors $ 155 $ 128
Other 0 124
Royalties 24 247
Legal and professional fees 275 503
Taxes and other assessments 839 615
Total $ 1,293 $ 1,617
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ 16,400    
Unrecognized Tax Benefits, Ending Balance 335 $ 141 $ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total $ 0 $ 0  
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00% 21.00%  
Domestic Tax Authority [Member]      
Increase (Decrease) in Operating Loss Carryforwards $ (253,000)    
Operating Loss Carryforwards 419,400    
Operating Loss Carryforwards, Subject to Expiration 254,500    
Operating Loss Carryforwards, Not Subject to Expiration 164,900    
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]      
Tax Credit Carryforward, Amount 10,200    
Increase (Decrease) in Tax Credit Carryforward (8,800)    
Domestic Tax Authority [Member] | Impact of 382 Ownership Changes [Member]      
Increase (Decrease) in Operating Loss Carryforwards (253,000)    
State and Local Jurisdiction [Member]      
Operating Loss Carryforwards 328,900    
Operating Loss Carryforwards, Subject to Expiration 317,400    
Operating Loss Carryforwards, Not Subject to Expiration 11,500    
State and Local Jurisdiction [Member] | Impact of 382 Ownership Changes [Member]      
Increase (Decrease) in Operating Loss Carryforwards (204,000)    
Foreign Tax Authority [Member] | Ministry of Economic Affairs and Finance, Italy [Member]      
Operating Loss Carryforwards 24,600    
Foreign Tax Authority [Member] | Luxembourg Inland Revenue [Member]      
Operating Loss Carryforwards, Subject to Expiration 95,900    
Foreign Tax Authority [Member] | Swiss Federal Tax Administration (FTA) [Member]      
Operating Loss Carryforwards, Subject to Expiration 116,500    
Foreign Tax Authority [Member] | Canada Revenue Agency [Member]      
Operating Loss Carryforwards, Subject to Expiration $ 900    
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Federal $ 0 $ 0
State 0 0
Foreign 239 232
Federal 0 0
State 0 0
Foreign 79 (7)
Total income tax expense $ 318 $ 225
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
United States $ (44,802) $ (32,094)
Foreign (30,441) (30,143)
Loss before income taxes $ (75,243) $ (62,237)
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes - Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Stock-based compensation $ 2,840 $ 2,440
Accrued expenses and other 2,538 2,423
Research credit carryforward 1,341 564
Fixed Assets 162 101
Net operating loss carryforwards 83,908 75,237
Deferred Tax Assets, Gross, Total 96,092 81,874
Valuation Allowance (94,704) (78,294)
Net deferred tax asset 1,388 3,580
Fixed assets and other (1,214) (1,176)
Purchase accounting intangibles 0 (2,116)
Net deferred tax liability (1,214) (3,292)
Net deferred tax asset (liability) 174 288
Start-up Costs and Other Intangibles [Member]    
Capitalized costs 921 1,109
Research Tax Credit Carryforward [Member]    
Capitalized costs $ 4,382 $ 0
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes - Unrecognized Tax Positions (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Beginning balance $ 141 $ 0
Gross increases for tax positions related to current periods 194 141
Gross decreases related to 382 limitations 0 0
Ending balance $ 335 $ 141
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
United States federal tax at statutory rate, amount $ (15,801) $ (13,070)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00% 21.00%
State taxes (net of deferred benefit), amount $ (2,912) $ (2,205)
State taxes (net of deferred benefit), percent 3.90% 3.50%
Nondeductible expenses, amount $ 1,077 $ (440)
Nondeductible expenses, percent (1.40%) 0.70%
Change in fair market value of contingent consideration, amount $ (283) $ (397)
Change in fair market value of contingent consideration, percent 0.40% 0.60%
Warrant remeasurment and financing costs, amount $ 0 $ 502
Warrant remeasurment and financing costs, percent 0.00% (0.80%)
Research & Development, amount $ (970) $ (705)
Research & Development, percent 1.30% 1.10%
Change in unrecognized tax benefits, amount $ 194 $ 141
Change in unrecognized tax benefits, percent (0.30%) (0.20%)
Foreign tax rate differential, amount $ 2,676 $ 1,911
Foreign tax rate differential, percent (3.60%) (3.10%)
True-up to Stock Compensation - Cancellations, amount $ 49 $ 2,832
True-up to Stock Compensation - Cancellations, percent (0.10%) (4.60%)
Change in enacted tax rates and other, net, amount $ (96) $ 731
Change in enacted tax rates and other, net, percent 0.20% (1.00%)
Change in valuation allowance, amount $ 16,384 $ 10,925
Change in valuation allowance, percent (21.80%) (17.60%)
Total income tax expense $ 318 $ 225
Income tax expense (benefit), percent (0.40%) (0.40%)
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Stock-based Compensation (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Jul. 22, 2021
Dec. 31, 2022
Share-Based Payment Arrangement, Option [Member]    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total   $ 2.1
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)   1 year 6 months
Restricted Stock Units (RSUs) [Member]    
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total   $ 4.2
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)   1 year 4 months 24 days
Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 22,000,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)   32,072,308
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)   11,038,824
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)   10 years
XML 85 R73.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Stock-based Compensation - Stock Option Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Options, Outstanding, Number of Shares (in shares) 4,640,660  
Options, Outstanding, Weighted Average Exercise Price (in dollars per share) $ 6.64  
Options, Outstanding, Weighted Average Remaining Contractual Term (Year) 5 years 3 months 21 days 5 years 7 months 28 days
Options, Granted, Number of Shares (in shares) 3,153,881  
Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) $ 0.70  
Options, Forfeited, Number of Shares (in shares) (129,134)  
Options, Forfeitures in Period, Weighted Average Exercise Price (in dollars per share) $ 1.60  
Options, Cancelled, Number of Shares (in shares) (36,987)  
Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share) $ 21.11  
Options, Exercised, Number of Shares (in shares) (43,453)  
Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share) $ 0.41  
Options, Outstanding, Number of Shares (in shares) 7,584,967 4,640,660
Options, Outstanding, Weighted Average Exercise Price (in dollars per share) $ 4.22 $ 6.64
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Stock-based Compensation - Stock Options Outstanding (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
$ / shares
shares
Options, Exercisable, Number of Shares (in shares) | shares 3,524,473
Options, Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares (in dollars per share) | $ / shares $ 7.40
Options, Exercisable, Weighted Average Remaining Contractual Term (Year) 4 years 9 months
Options, Exercisable, Aggregate Intrinsic Value | $ $ 0
Options, Vested and Expected to Vest, Exercisable, Number of Shares (in shares) | shares 7,350,141
Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 4.32
Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term (Year) 5 years 3 months 10 days
Options, Vested or Expected to Vest, Aggregate Intrinsic Value | $ $ 0
XML 87 R75.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Expected dividend yield 0.00% 0.00%
Minimum [Member]    
Expected volatility 126.00% 118.00%
Risk-free interest rate 1.25% 0.33%
Expected life (in years) (Year) 3 years 9 months 18 days 3 years 9 months 18 days
Maximum [Member]    
Expected volatility 133.00% 139.00%
Risk-free interest rate 4.40% 1.11%
Expected life (in years) (Year) 4 years 6 months 4 years 6 months
XML 88 R76.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Stock-based Compensation - RSU Activity (Details) - Restricted Stock Units (RSUs) [Member]
 12 Months Ended
Dec. 31, 2022
$ / shares
shares
Beginning of period, Restricted stock units, Unvested (in shares) | shares 3,839,030
Beginning of period, Restricted stock units, Unvested, weighted average grant date fair value (in dollars per share) | $ / shares $ 2.36
Restricted stock units, Granted (in shares) | shares 6,996,822
Restricted stock units, Granted, weighted average grant date fair value (in dollars per share) | $ / shares $ 0.71
Restricted stock units, Vested (in shares) | shares (2,076,663)
Restricted stock units, Vested, weighted average grant date fair value (in dollars per share) | $ / shares $ 2.34
Restricted stock units, Forfeited (in shares) | shares (275,698)
Restricted stock units, Forfeited, weighted average grant date fair value (in dollars per share) | $ / shares $ 1.19
Unvested (in shares) | shares 8,483,491
Unvested December 31, 2022 (in dollars per share) | $ / shares $ 1.04
XML 89 R77.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Share-based compensation $ 8,416 $ 9,429
Share-Based Payment Arrangement, Option [Member]    
Share-based compensation 3,654 4,535
Restricted Stock Units (RSUs) [Member]    
Share-based compensation 3,319 3,954
Performance Restricted Stock Unit [Member]    
Share-based compensation $ 1,443 $ 940
XML 90 R78.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Offerings (Details Textual) - USD ($)
 12 Months Ended
Jan. 29, 2021
Jan. 12, 2021
Dec. 31, 2022
Dec. 31, 2021
Mar. 18, 2022
May 19, 2021
Oct. 09, 2020
Proceeds from Issuance of Common Stock, Net     $ 0 $ 131,929,000      
Proceeds from Warrant Exercises       $ 30,600,000      
The 2020 ATM Offering [Member]              
Stock Offering Agreement, Maximum Share Value             $ 40,000,000.0
Public Offering [Member]              
Stock Issued During Period, Shares, New Issues (in shares) 26,545,832            
Shares Issued, Price Per Share (in dollars per share) $ 3.00            
Proceeds from Issuance of Common Stock, Net $ 73,400,000            
Registered Direct Offering [Member]              
Stock Issued During Period, Shares, New Issues (in shares)   25,000,000          
Shares Issued, Price Per Share (in dollars per share)   $ 1.25          
Proceeds from Issuance of Common Stock, Net   $ 28,600,000          
The 2021 ATM Offering [Member]              
Stock Offering Agreement, Maximum Share Value           $ 100,000,000  
The 2022 ATM Offering [Member]              
Stock Offering Agreement, Maximum Share Value         $ 100,000,000.0    
Stock Issued During Period, Shares, New Issues (in shares)     0        
XML 91 R79.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Offerings - Summary of Sales Under Offering (Details) - The 2021 and 2020 ATM Offering [Member]
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Total shares of common stock sold (in shares) | shares 20,237,045
Average price per share (in dollars per share) | $ / shares $ 1.53
Gross proceeds $ 30,943
Commisssion earned by Sales Agents 928
Net proceeds $ 30,015
XML 92 R80.htm IDEA: XBRL DOCUMENT v3.22.4
Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 17,089,534 9,599,990
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 7,584,967 4,640,660
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 1,021,076 1,120,300
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 8,483,491 3,839,030
XML 93 R81.htm IDEA: XBRL DOCUMENT v3.22.4
Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details) - License and Supply Agreement [Member] - Senhance Surgical Robotic System Acquisition[Member]
$ in Thousands
Dec. 31, 2022
USD ($)
2023 $ 5,976
2024 407
2025 313
2026 303
Total commitments $ 6,999
XML 94 R82.htm IDEA: XBRL DOCUMENT v3.22.4
Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details) - Geographic Concentration Risk [Member]
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Long-lived Assets [Member] | UNITED STATES    
Percentage 35.00% 26.00%
Long-lived Assets [Member] | SWITZERLAND    
Percentage 46.00% 34.00%
Long-lived Assets [Member] | ITALY    
Percentage 8.00% 36.00%
Long-lived Assets [Member] | Other Countries in EMEA [Member]    
Percentage 8.00% 4.00%
Long-lived Assets [Member] | Europe, Middle East, and Africa [Member]    
Percentage 62.00% 74.00%
Long-lived Assets [Member] | Asia [Member]    
Percentage 3.00% 0.00%
Long-lived Assets [Member] | All Countries [Member]    
Percentage 100.00% 100.00%
Assets, Total [Member] | UNITED STATES    
Percentage 72.00% 77.00%
Assets, Total [Member] | SWITZERLAND    
Percentage 24.00% 16.00%
Assets, Total [Member] | ITALY    
Percentage 2.00% 5.00%
Assets, Total [Member] | Other Countries in EMEA [Member]    
Percentage 1.00% 1.00%
Assets, Total [Member] | Europe, Middle East, and Africa [Member]    
Percentage 27.00% 22.00%
Assets, Total [Member] | Asia [Member]    
Percentage 1.00% 1.00%
Assets, Total [Member] | All Countries [Member]    
Percentage 100.00% 100.00%
XML 95 R83.htm IDEA: XBRL DOCUMENT v3.22.4
Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details) - Revenue Benchmark [Member] - Geographic Concentration Risk [Member]
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
UNITED STATES    
Concentration risk, percent 11.00% 13.00%
EMEA [Member]    
Concentration risk, percent 77.00% 62.00%
Asia [Member]    
Concentration risk, percent 12.00% 25.00%
All Countries [Member]    
Concentration risk, percent 100.00% 100.00%
XML 96 R84.htm IDEA: XBRL DOCUMENT v3.22.4
Note 18 - Related Party Transactions (Details Textual) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Asensus Surgical Europe S.à.R.L [Member] | 1 Med S.A. [Member] | Service Supply Agreement [Member]    
Related Party Transaction, Expenses from Transactions with Related Party $ 290,000 $ 186,000
XML 97 asxc20221231_10k_htm.xml IDEA: XBRL DOCUMENT 0000876378 2022-01-01 2022-12-31 0000876378 2022-06-30 0000876378 2023-02-24 0000876378 2022-12-31 0000876378 2021-12-31 0000876378 us-gaap:IntellectualPropertyMember 2022-12-31 0000876378 us-gaap:IntellectualPropertyMember 2021-12-31 0000876378 us-gaap:ProductMember 2022-01-01 2022-12-31 0000876378 us-gaap:ProductMember 2021-01-01 2021-12-31 0000876378 us-gaap:ServiceMember 2022-01-01 2022-12-31 0000876378 us-gaap:ServiceMember 2021-01-01 2021-12-31 0000876378 asxc:LeaseMember 2022-01-01 2022-12-31 0000876378 asxc:LeaseMember 2021-01-01 2021-12-31 0000876378 2021-01-01 2021-12-31 0000876378 us-gaap:CommonStockMember 2020-12-31 0000876378 us-gaap:TreasuryStockMember 2020-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000876378 us-gaap:RetainedEarningsMember 2020-12-31 0000876378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000876378 2020-12-31 0000876378 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000876378 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000876378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000876378 us-gaap:TreasuryStockMember 2021-01-01 2021-12-31 0000876378 us-gaap:CommonStockMember 2021-12-31 0000876378 us-gaap:TreasuryStockMember 2021-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000876378 us-gaap:RetainedEarningsMember 2021-12-31 0000876378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000876378 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000876378 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000876378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000876378 us-gaap:TreasuryStockMember 2022-01-01 2022-12-31 0000876378 us-gaap:CommonStockMember 2022-12-31 0000876378 us-gaap:TreasuryStockMember 2022-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000876378 us-gaap:RetainedEarningsMember 2022-12-31 0000876378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000876378 asxc:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:TwoCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 us-gaap:PatentsMember 2022-01-01 2022-12-31 0000876378 srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-12-31 0000876378 srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-12-31 0000876378 us-gaap:IntellectualPropertyMember 2022-01-01 2022-12-31 0000876378 asxc:OperatingLeaseAssetsMember 2022-01-01 2022-12-31 0000876378 srt:MinimumMember asxc:MachineryManufacturingAndDemonstrationEquipmentMember 2022-01-01 2022-12-31 0000876378 srt:MaximumMember asxc:MachineryManufacturingAndDemonstrationEquipmentMember 2022-01-01 2022-12-31 0000876378 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0000876378 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0000876378 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0000876378 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0000876378 srt:MinimumMember 2022-12-31 0000876378 srt:MaximumMember 2022-12-31 0000876378 asxc:PaycheckProtectionProgramCaresActMember 2021-06-10 2021-06-10 0000876378 us-gaap:LetterOfCreditMember 2022-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember 2022-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember 2022-01-01 2022-12-31 0000876378 srt:MinimumMember asxc:SenhanceSurgicalRoboticSystemAcquisitionMember 2022-01-01 2022-12-31 0000876378 asxc:SystemsMember country:US 2022-01-01 2022-12-31 0000876378 asxc:SystemsMember country:US 2021-01-01 2021-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember country:US 2022-01-01 2022-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember country:US 2021-01-01 2021-12-31 0000876378 us-gaap:ServiceMember country:US 2022-01-01 2022-12-31 0000876378 us-gaap:ServiceMember country:US 2021-01-01 2021-12-31 0000876378 asxc:LeaseMember country:US 2022-01-01 2022-12-31 0000876378 asxc:LeaseMember country:US 2021-01-01 2021-12-31 0000876378 country:US 2022-01-01 2022-12-31 0000876378 country:US 2021-01-01 2021-12-31 0000876378 asxc:SystemsMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000876378 asxc:SystemsMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000876378 us-gaap:ServiceMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000876378 us-gaap:ServiceMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000876378 asxc:LeaseMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000876378 asxc:LeaseMember us-gaap:NonUsMember 2021-01-01 2021-12-31 0000876378 us-gaap:NonUsMember 2022-01-01 2022-12-31 0000876378 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000876378 asxc:SystemsMember 2022-01-01 2022-12-31 0000876378 asxc:SystemsMember 2021-01-01 2021-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember 2022-01-01 2022-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember 2021-01-01 2021-12-31 0000876378 2023-01-01 2022-12-31 0000876378 srt:MinimumMember 2023-01-01 2022-12-31 0000876378 srt:MaximumMember 2023-01-01 2022-12-31 0000876378 us-gaap:CommercialPaperMember 2022-12-31 0000876378 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000876378 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000876378 us-gaap:CommercialPaperMember 2021-12-31 0000876378 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000876378 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000876378 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000876378 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000876378 us-gaap:FairValueInputsLevel1Member 2021-12-31 0000876378 us-gaap:FairValueInputsLevel2Member 2021-12-31 0000876378 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2022-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member asxc:MeasurementInputCurrencyExchangeRateMember 2022-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member asxc:MeasurementInputCurrencyExchangeRateMember 2021-12-31 0000876378 us-gaap:WarrantMember 2020-12-31 0000876378 us-gaap:WarrantMember 2021-01-01 2021-12-31 0000876378 us-gaap:WarrantMember 2021-12-31 0000876378 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000876378 us-gaap:WarrantMember 2022-12-31 0000876378 asxc:MachineryManufacturingAndDemonstrationEquipmentMember 2022-12-31 0000876378 asxc:MachineryManufacturingAndDemonstrationEquipmentMember 2021-12-31 0000876378 asxc:OperatingLeaseAssetsMember 2022-12-31 0000876378 asxc:OperatingLeaseAssetsMember 2021-12-31 0000876378 us-gaap:ComputerEquipmentMember 2022-12-31 0000876378 us-gaap:ComputerEquipmentMember 2021-12-31 0000876378 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000876378 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000876378 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000876378 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000876378 us-gaap:ConstructionInProgressMember 2022-12-31 0000876378 us-gaap:ConstructionInProgressMember 2021-12-31 0000876378 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000876378 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000876378 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000876378 us-gaap:TechnologyBasedIntangibleAssetsMember 2021-12-31 0000876378 srt:WeightedAverageMember us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-12-31 0000876378 srt:WeightedAverageMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-01-01 2022-12-31 0000876378 srt:WeightedAverageMember us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-12-31 0000876378 srt:WeightedAverageMember us-gaap:TechnologyBasedIntangibleAssetsMember 2021-01-01 2021-12-31 0000876378 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0000876378 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0000876378 srt:MinimumMember 2021-12-31 0000876378 srt:MaximumMember 2021-12-31 0000876378 asxc:StartupCostsAndOtherIntangiblesMember 2022-12-31 0000876378 asxc:StartupCostsAndOtherIntangiblesMember 2021-12-31 0000876378 us-gaap:ResearchMember 2022-12-31 0000876378 us-gaap:ResearchMember 2021-12-31 0000876378 us-gaap:DomesticCountryMember asxc:ImpactOf382OwnershipChangesMember 2022-01-01 2022-12-31 0000876378 us-gaap:StateAndLocalJurisdictionMember asxc:ImpactOf382OwnershipChangesMember 2022-01-01 2022-12-31 0000876378 us-gaap:DomesticCountryMember 2022-12-31 0000876378 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0000876378 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0000876378 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2022-12-31 0000876378 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2022-01-01 2022-12-31 0000876378 us-gaap:ForeignCountryMember us-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember 2022-12-31 0000876378 us-gaap:ForeignCountryMember us-gaap:LuxembourgInlandRevenueMember 2022-12-31 0000876378 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember 2022-12-31 0000876378 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember 2022-12-31 0000876378 asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember 2021-07-22 2021-07-22 0000876378 asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember 2022-12-31 0000876378 asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember 2022-01-01 2022-12-31 0000876378 srt:MinimumMember 2022-01-01 2022-12-31 0000876378 srt:MaximumMember 2022-01-01 2022-12-31 0000876378 srt:MinimumMember 2021-01-01 2021-12-31 0000876378 srt:MaximumMember 2021-01-01 2021-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000876378 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000876378 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0000876378 asxc:PerformanceRestrictedStockUnitMember 2022-01-01 2022-12-31 0000876378 asxc:PerformanceRestrictedStockUnitMember 2021-01-01 2021-12-31 0000876378 us-gaap:EmployeeStockOptionMember 2022-12-31 0000876378 asxc:The2020ATMOfferingMember 2020-10-09 0000876378 asxc:PublicOfferingMember 2021-01-29 2021-01-29 0000876378 asxc:PublicOfferingMember 2021-01-29 0000876378 asxc:RegisteredDirectOfferingMember 2021-01-12 2021-01-12 0000876378 asxc:RegisteredDirectOfferingMember 2021-01-12 0000876378 asxc:The2021ATMOfferingMember 2021-05-19 0000876378 asxc:The2021And2020ATMOfferingMember 2021-01-01 2021-12-31 0000876378 asxc:The2021And2020ATMOfferingMember 2021-12-31 0000876378 asxc:The2022AtmOfferingMember 2022-03-18 0000876378 asxc:The2022AtmOfferingMember 2022-01-01 2022-12-31 0000876378 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000876378 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000876378 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000876378 us-gaap:WarrantMember 2021-01-01 2021-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember asxc:LicenseAndSupplyAgreementMember 2022-12-31 0000876378 country:US asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 country:US us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 country:CH asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 country:CH us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 country:IT asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 country:IT us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:OtherCountriesInEmeaMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:OtherCountriesInEmeaMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:EuropeMiddleEastAndAfricaMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:EuropeMiddleEastAndAfricaMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 srt:AsiaMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 srt:AsiaMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:AllCountriesMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:AllCountriesMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 country:US asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 country:US us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 country:CH asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 country:CH us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 country:IT asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 country:IT us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:OtherCountriesInEmeaMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:OtherCountriesInEmeaMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:EuropeMiddleEastAndAfricaMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:EuropeMiddleEastAndAfricaMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 srt:AsiaMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 srt:AsiaMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:AllCountriesMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:AllCountriesMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 srt:AsiaMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 srt:AsiaMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:AllCountriesMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:AllCountriesMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0000876378 asxc:ServiceSupplyAgreementMember asxc:OneMedSaMember asxc:AsensusSurgicalEuropeSrlMember 2022-01-01 2022-12-31 0000876378 asxc:ServiceSupplyAgreementMember asxc:OneMedSaMember asxc:AsensusSurgicalEuropeSrlMember 2021-01-01 2021-12-31 iso4217:USD shares thunderdome:item iso4217:USD shares pure utr:Y iso4217:EUR 0000876378 ASENSUS SURGICAL, INC. false --12-31 FY 2022 0.001 0.001 750000000 750000000 236895440 236895440 235218552 235218552 0.01 0.01 25000000 25000000 0 0 0 0 1100000 1 3 2 P3Y P10Y P1Y P10Y P1Y P6Y 15000000.0 25000000.0 P5Y P4Y 1 P1Y P4Y 0 0 436000 0 P10Y P4Y6M 10-K true 2022-12-31 false 0-19437 DE 11-2962080 1 TW Alexander Drive, Suite 160 Durham NC 27703 919 765-8400 Common Stock $0.001 par value per share ASXC NYSE No No Yes Yes Non-accelerated Filer true false false false 93100000 239279746 BDO USA, LLP Raleigh, NC 243 6329000 18129000 64195000 80262000 2256000 749000 8284000 8634000 3584000 3255000 554000 1311000 1671000 957000 86873000 113297000 1141000 1154000 3865000 37435000 5469000 7074000 9542000 10971000 1576000 9892000 174000 288000 4950000 5348000 2463000 1014000 116053000 186473000 3348000 3448000 4508000 3559000 1293000 1617000 800000 683000 465000 543000 10414000 9850000 1256000 2371000 4738000 5006000 16408000 17227000 237000 235000 0 0 962731000 954649000 -860935000 -785374000 -2388000 -264000 99645000 169246000 116053000 186473000 4327000 5399000 1373000 1520000 1387000 1313000 7087000 8232000 5303000 5741000 2174000 1799000 3395000 3556000 10872000 11096000 -3785000 -2864000 28942000 19348000 14756000 13395000 20172000 19323000 7708000 11254000 -1115000 -1565000 1431000 0 71894000 61755000 -75679000 -64619000 0 2847000 -0 1981000 1141000 590000 410000 370000 0 1311000 -295000 -15000 436000 2382000 -75243000 -62237000 318000 225000 -75561000 -62462000 -75561000 -62462000 -1867000 -2985000 -257000 -247000 -77685000 -65694000 -0.32 -0.28 236492000 226960000 116231000 116000 0 0 781397000 -722912000 2968000 61569000 0 9429000 0 0 9429000 71787000 72000 0 0 131857000 0 0 131929000 45630000 46000 0 0 33029000 0 0 33075000 1571000 1000 0 -0 320000 -0 1063000 -0 -0 1063000 -0 -0 320000 -0 -0 -0 -0 -0 0 0 0 0 -3232000 -3232000 0 0 -62462000 0 -62462000 235219000 235000 0 0 954649000 -785374000 -264000 169246000 0 8416000 0 0 8416000 43000 0 0 0 18000 0 0 18000 1633000 2000 0 0 0 0 0 2000 0 -0 443000 -0 352000 -0 -0 352000 -0 -0 443000 -0 -0 -0 -0 -0 0 0 -2124000 -2124000 0 -75561000 0 -75561000 236895000 237000 0 0 962731000 -860935000 -2388000 99645000 -75561000 -62462000 3368000 2857000 7708000 11254000 -565000 -409000 8416000 9429000 -0 2847000 318000 225000 -620000 492000 9000 144000 1431000 0 -122000 -0 0 1981000 -1115000 -1565000 1528000 -174000 2302000 611000 -232000 4254000 450000 -146000 -757000 1311000 2101000 -902000 35000 1614000 4523000 -859000 -3955000 384000 -55000 -229000 26000 4452000 -58937000 -40659000 33886000 122330000 82702000 4030000 1279000 1368000 47537000 -119668000 0 131929000 350000 1063000 18000 30839000 -332000 161705000 -81000 376000 -11813000 1754000 19283000 17529000 7470000 19283000 984000 1490000 165000 170000 2693000 3244000 0 2236000 577000 5119000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">1.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Description of the Business </b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Asensus Surgical, Inc. (formerly known as TransEnterix, Inc.) (the "Company") is a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The Company is focused on the market development for and commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance System is the <em style="font: inherit;">first</em> and only digital, multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including <em style="font: inherit;">3mm</em> microlaparoscopic instruments, <em style="font: inherit;">5mm</em> articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.</p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Summary of Significant Accounting Policies</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Basis of Presentation</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its direct and indirect wholly owned subsidiaries.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Going Concern</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $860.9 million and working capital of $76.5 million as of <em style="font: inherit;"> December 31, 2022. </em>The Company has <em style="font: inherit;">not</em> established sufficient sales revenues to cover its operating costs and requires additional capital to proceed with its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company <em style="font: inherit;"> may </em>include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to meet its existing obligations, and to continue as a going concern within <em style="font: inherit;">one</em> year from the date that these financial statements are issued. The consolidated financial statements of the Company do <em style="font: inherit;">not</em> include any adjustments that <em style="font: inherit;"> may </em>result from the outcome of these aforementioned uncertainties.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Principles of Consolidation and Foreign Currency Considerations</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive loss as a separate component of stockholders’ equity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> were <em style="font: inherit;">not</em> material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Reclassifications</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Certain amounts reported previously have been reclassified to conform to the current year presentation, with <em style="font: inherit;">no</em> effect on stockholders’ equity or net loss as previously reported. Revenue and cost of revenue for leases were historically included in product and service revenue and corresponding cost of revenue on the consolidated statements of operations and comprehensive loss for the year ended <em style="font: inherit;"> December 31, 2021. </em>Accrued employee compensation and benefits were historically included in accrued expenses and other current liabilities on the consolidated balance sheets for the year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Revision of Previously Disclosed Amounts</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the course of preparing the Company’s unaudited consolidated financial statements as of and for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022, </em>the Company determined that its <em style="font: inherit;"> December 31, 2021 </em>inventory footnote presentation overstated raw materials and understated finished goods by $2.5 million.  For comparative purposes, Note <em style="font: inherit;">7</em> – Inventories, has been revised to reflect the adjustment to raw materials and finished goods as of <em style="font: inherit;"> December 31, 2021.  </em>The revision had <em style="font: inherit;">no</em> effect on the previously reported total gross and net carrying value of inventory.  The revision also had <em style="font: inherit;">no</em> effect on the previously reported consolidated balance sheets, statements of operations and comprehensive loss, cash flows and stockholders’ equity. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Risk and Uncertainties</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: negative impacts on the Company's operations caused by the COVID-<em style="font: inherit;">19</em> pandemic and other geopolitical factors; the historical lack of profitability; the Company’s ability to raise additional capital; the success of its market development efforts; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan, and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic surgical devices; and its ability to identify and pursue development of additional products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Use of Estimates</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, short-term and long-term investments, excess and obsolete inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use (“ROU”) assets, and deferred tax asset valuation allowances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cash and Cash Equivalents, Restricted Cash, and Investments</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company considers all highly liquid investments with original maturities of <em style="font: inherit;">90</em> days or less at the time of purchase to be cash equivalents.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Restricted cash as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> includes $1.1 million in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, and automobile leases.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s investments as of <em style="font: inherit;"> December 31, 2022 </em>consisted of commercial paper, corporate bonds, and United States government agencies and were classified as available-for-sale. Investments classified as available-for-sale are measured at fair value, and net unrealized gains and losses are recorded as a component of accumulated other comprehensive loss on the consolidated balance sheets until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization and accretion is included in interest expense, net. There were no gross realized gains or loss for the year ended <em style="font: inherit;"> December 31, 2022. </em>The Company recognized an immaterial amount of gross realized losses for the year ended <em style="font: inherit;"> December 31, 2021. </em>There were no gross realized gains for the year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Investments with remaining maturities at date of purchase greater than <em style="font: inherit;">90</em> days and remaining maturities as of the reporting period less than <em style="font: inherit;">one</em> year are classified as short-term investments. Investments with remaining maturities greater than <em style="font: inherit;">one</em> year are classified as long-term investments. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">There have been <em style="font: inherit;">no</em> credit losses for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> and <em style="font: inherit;">no</em> allowance for credit losses as of <em style="font: inherit;"> December 31, 2022. </em>Factors considered in determining whether a credit loss exists include credit ratings and other qualitative factors for each security type in the portfolio.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Fair Value Measurements </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level <em style="font: inherit;">1</em> securities. Marketable securities measured at fair value using Level <em style="font: inherit;">2</em> inputs are primarily comprised of commercial paper and corporate notes and bonds without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is <em style="font: inherit;">not</em> available, the Company uses market pricing and other observable market inputs for similar securities obtained from various <em style="font: inherit;">third</em>-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level <em style="font: inherit;">2</em> classification of these securities within the fair value hierarchy. The Company measures contingent consideration at fair value using a Monte-Carlo simulation utilizing Level <em style="font: inherit;">3</em> inputs. These inputs include the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Concentrations and Credit Risk</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents (including restricted cash), and investments, including amounts held in money market funds, commercial paper, and corporate bonds. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits <em style="font: inherit;"> may </em>at times exceed the Federal Deposit Insurance Corporation’s insured limit. Balances in excess of federally insured limitations <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be insured. The Company has <em style="font: inherit;">not</em> experienced losses on these accounts, and management believes that the Company is <em style="font: inherit;">not</em> exposed to significant risks on such accounts. Investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investments consist of various major corporations, financial institutions, and government agencies of high credit standing.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s accounts receivable are derived from sales and leases to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires <em style="font: inherit;">no</em> collateral from its customers. The Company had <span style="-sec-ix-hidden:c94008136">one</span> customer that accounted for 69% of the Company’s net accounts receivable as of <em style="font: inherit;"> December 31, 2022. </em>The Company had <span style="-sec-ix-hidden:c94008138">three</span> customers that accounted for 26%, 20%, and 14%, respectively, of the Company’s net accounts receivable as of <em style="font: inherit;"> December 31, 2021. </em>The Company had one customer who accounted for 47% of revenue in <em style="font: inherit;">2022,</em> and <span style="-sec-ix-hidden:c94008145">two</span> customers who accounted for 36% and 16% of revenue in <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Accounts Receivable</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Accounts receivable are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses is based on the Company’s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that <em style="font: inherit;"> may </em>affect a customer’s ability to pay. The allowance for expected credit losses was $1.6 million and $1.7 million as of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively. The Company recorded an immaterial amount for expected credit losses during the year ended <em style="font: inherit;"> December 31, 2022 </em>and $0.1 million during the year ended <em style="font: inherit;"> December 31, 2021.          </em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Inventories</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Inventories are stated at the lower of cost (determined on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers historical consumption and forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do <em style="font: inherit;">not</em> result in the restoration or increase in that newly established cost basis.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming <em style="font: inherit;">twelve</em> months.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Definite-Lived Intangible Assets - Intellectual Property</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified in-process research and development (“IPR&amp;D”) assets related to (i) the Senhance System acquired in <em style="font: inherit;">2015</em> and reclassified in <em style="font: inherit;">2017</em> and (ii) a <em style="font: inherit;">2018</em> acquisition and reclassified in <em style="font: inherit;">2020.</em> Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed technology is recorded using the straight-line method over the estimated useful life of 5 to 7 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. To determine the recoverability, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the assets, then such assets are written down to their fair value. No impairment of intellectual property was identified during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Property and Equipment</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Property and equipment consists primarily of operating lease Senhance System assets, machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets – Senhance System leasing</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;">5</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery, manufacturing, and demonstration equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt;">3</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt;">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;">3</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;">5</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; width: 17%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt; text-align: center;"><span style="-sec-ix-hidden:c94008271"><em style="font: inherit;"><span style="-sec-ix-hidden:c94008273">Lesser of lease term or 3 to 10</span></em></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the year ended <em style="font: inherit;"> December 31, 2022, </em>the Company recorded a non-cash asset impairment charge of $1.4 million to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are <em style="font: inherit;">not</em> expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the consolidated statements of operations and comprehensive loss. No such impairment charges were recorded during the year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i/></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Operating Leases</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We have operating leases for our corporate office buildings, vehicles, and machinery and equipment. At inception, we determine whether an agreement represents a lease and, at commencement, we evaluate each lease agreement to determine whether the lease constitutes an operating or financing lease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company accounts for lease components and non-lease components as a single component. Non-lease components consist of common area maintenance payments for most real estate leases, which are determined based on costs incurred by the lessor. Many of the Company’s leases include base rental periods coupled with options to renew or terminate the lease, generally at the Company’s discretion.  In evaluating the lease term, the Company considers whether renewal is reasonably certain.  To the extent a significant economic incentive exists to renew the lease, the option is included within the lease term.  Based on the Company’s leases, renewal options generally do <em style="font: inherit;">not</em> provide a significant economic incentive and are therefore excluded from the lease term. While our operating leases range from <span style="-sec-ix-hidden:c94008172">one</span> year to <span style="-sec-ix-hidden:c94008173">ten</span> years, some <em style="font: inherit;"> may </em>include options to extend the lease generally between <span style="-sec-ix-hidden:c94008174">one</span> year and <span style="-sec-ix-hidden:c94008175">six</span> years, and some <em style="font: inherit;"> may </em>include options to terminate the leases within <em style="font: inherit;">one</em> year.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The interest rate implicit in our lease contracts is typically <em style="font: inherit;">not</em> readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Implementation Costs in a Cloud Computing Arrangement</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract. These capitalized implementation costs are recorded within other current and long-term assets, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis and included within operating expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Employee Retention Tax Credit Receivable </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages. During the year ended <em style="font: inherit;"> December 31, 2021, </em>we submitted an ERTC refund for $1.3 million and recorded the amount into Other Income (Expense) on the consolidated statements of operations and comprehensive loss. The Company received notification from the IRS that the relevant conditions of the employee retention credit provision were met and that it will receive the credit. The Company received $0.7 million of the ERTC refund during the year ended <em style="font: inherit;"> December 31, 2022. </em>The remaining $0.6 million is recorded as a current asset on the consolidated balance sheets as of <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Notes Payable </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s policy is to account for forgivable loans received through the U.S. Small Business Administration (the “SBA”) under the CARES Act Payroll Protection Program (“PPP”), as debt in accordance with ASC <em style="font: inherit;">470,</em> Debt, and other related accounting pronouncements. The forgiveness of debt, in whole or part, is recognized once the debt is extinguished, which occurs when the Company is legally released from the liability by the SBA. Any portion of debt forgiven, adjusted for accrued interest forgiven and unamortized debt issuance costs, is recorded as a gain on extinguishment of debt, and presented in the consolidated statements of operations and comprehensive loss. On <em style="font: inherit;"> June 10, 2021, </em>the Company received notification from the SBA that the principal amount of its PPP loan of $2.8 million and related interest had been forgiven.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company has $0.6 million available under a letter of credit. No amounts have been utilized by the Company as of <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Contingent Consideration</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, revenue volatility and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> September 21, 2015, </em>the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar S.p.A., an Italian company (“Sofar”), an Italian company, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System. Under the terms of the Purchase Agreement, as amended in <em style="font: inherit;">2016,</em> as of <em style="font: inherit;"> December 31, 2022, </em>the Company has accrued $1.3 million of estimated fair value of remaining contingent consideration related to a milestone of <span style="-sec-ix-hidden:c94008186">€15.0</span> million which shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least <span style="-sec-ix-hidden:c94008187">€25.0</span> million over a calendar quarter or in the event that (i) the Company or Asensus International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. In <em style="font: inherit;">2022,</em> Sofar assigned its right to receive the contingent payment to Three Heads Investment S.r.l.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Warrant Liabilities</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s Series B Warrants were measured at fair value using a simulation model which considered, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant. The warrant liability was revalued at each reporting period and changes in fair value were recognized in the consolidated statements of operations and comprehensive loss. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. All remaining outstanding Series B Warrants were exercised in the <em style="font: inherit;">first</em> quarter <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Revenue Recognition</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements generally include a <span style="-sec-ix-hidden:c94008192">five</span>-year service period; the <em style="font: inherit;">first</em> year of service is generally free and included in the Senhance System sale arrangement and the remaining <span style="-sec-ix-hidden:c94008194">four</span> years are generally included at a stated service price.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements <em style="font: inherit;"> may </em>include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services; however due to limited sales to date, standalone selling prices generally are <em style="font: inherit;">not</em> directly observable. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but <em style="font: inherit;">not</em> limited to, features and functionality of the products and services, geographies, type of customer, and market conditions. The Company regularly reviews estimated standalone selling prices and updates these estimates if necessary.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 27pt;"><i>•  System sales</i>. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from Senhance System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when the Company receives an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do <em style="font: inherit;">not</em> provide a right of return. The Senhance Systems are generally covered by a <em style="font: inherit;">one</em>-year warranty. Warranty costs were <em style="font: inherit;">not</em> material for the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 27pt;"><i>•  Instruments and accessories</i>. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 27pt;"><i>•  Service</i>. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due <em style="font: inherit;">30</em> to <em style="font: inherit;">60</em> days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements, and are included in accounts receivable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do <em style="font: inherit;">not</em> meet the requirements to be capitalized as the Company does <em style="font: inherit;">not</em> expect to generate future economic benefits from the related revenue from the initial sales transaction and such costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Senhance System Leasing</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> variable lease revenue related to usage-based arrangements was <em style="font: inherit;">not</em> material.  </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, the Company considers the following terms at lease commencement: (<em style="font: inherit;">1</em>) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (<em style="font: inherit;">2</em>) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (<em style="font: inherit;">3</em>) whether the lease term is for the major part of the remaining economic life of the leased System, (<em style="font: inherit;">4</em>) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (<em style="font: inherit;">5</em>) whether the underlying Senhance System is of such a specialized nature that it is expected to have <em style="font: inherit;">no</em> alternative use to the Company at the end of the lease term. All such arrangements through <em style="font: inherit;"> December 31, 2022 </em>are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage. As of <em style="font: inherit;"> December 31, 2022 </em>future minimum lease payments due from customers was $2.2 million, which is expected to be received over the next <em style="font: inherit;">one</em> to <em style="font: inherit;">three</em> years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cost of Revenue</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Depreciation expense related to leased systems is included in the cost of revenue. Shipping and handling costs incurred by the Company are included in the cost of revenue.  We expense all inventory obsolescence provisions as cost of revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Research and Development Costs</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Stock-Based Compensation</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes expenses for share-based awards exchanged for services rendered equal to the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of stock options. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted has been determined based upon the simplified method, because the Company does <em style="font: inherit;">not</em> have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has <em style="font: inherit;">not</em> paid and does <em style="font: inherit;">not</em> anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimates forfeitures based on its historical experience and adjust the estimated forfeiture rate based upon actual experience. For performance-based restricted stock awards with performance conditions, we begin recognizing compensation expense when it becomes probable that the performance condition will be attained.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. See “Note <em style="font: inherit;">13</em> – Stock-Based Compensation,” for a detailed discussion of the Company’s stock plans and stock-based compensation expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Income Taxes</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than <em style="font: inherit;">not</em> sustain the position following audit. For tax positions meeting the more likely than <em style="font: inherit;">not</em> threshold, the amount recognized in the financial statements is the largest benefit that has a greater than <em style="font: inherit;">50%</em> likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company <em style="font: inherit;"> may </em>be subject to examination by authorities for all previously filed income tax returns.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Comprehensive Loss</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Segments</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company operates in <span style="-sec-ix-hidden:c94008221">one</span> business segment—the research, development and sale of medical device robotics to improve minimally invasive surgery. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does <em style="font: inherit;">not</em> manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i/></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Impact of Recently Issued Accounting Standards</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has evaluated issued ASUs <em style="font: inherit;">not</em> yet adopted and believes the adoption of these standards will <em style="font: inherit;">not</em> have a material impact on its consolidated financial statements.</p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Basis of Presentation</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its direct and indirect wholly owned subsidiaries.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Going Concern</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $860.9 million and working capital of $76.5 million as of <em style="font: inherit;"> December 31, 2022. </em>The Company has <em style="font: inherit;">not</em> established sufficient sales revenues to cover its operating costs and requires additional capital to proceed with its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company <em style="font: inherit;"> may </em>include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to meet its existing obligations, and to continue as a going concern within <em style="font: inherit;">one</em> year from the date that these financial statements are issued. The consolidated financial statements of the Company do <em style="font: inherit;">not</em> include any adjustments that <em style="font: inherit;"> may </em>result from the outcome of these aforementioned uncertainties.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> -860900000 76500000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Principles of Consolidation and Foreign Currency Considerations</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive loss as a separate component of stockholders’ equity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> were <em style="font: inherit;">not</em> material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Reclassifications</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Certain amounts reported previously have been reclassified to conform to the current year presentation, with <em style="font: inherit;">no</em> effect on stockholders’ equity or net loss as previously reported. Revenue and cost of revenue for leases were historically included in product and service revenue and corresponding cost of revenue on the consolidated statements of operations and comprehensive loss for the year ended <em style="font: inherit;"> December 31, 2021. </em>Accrued employee compensation and benefits were historically included in accrued expenses and other current liabilities on the consolidated balance sheets for the year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Revision of Previously Disclosed Amounts</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the course of preparing the Company’s unaudited consolidated financial statements as of and for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022, </em>the Company determined that its <em style="font: inherit;"> December 31, 2021 </em>inventory footnote presentation overstated raw materials and understated finished goods by $2.5 million.  For comparative purposes, Note <em style="font: inherit;">7</em> – Inventories, has been revised to reflect the adjustment to raw materials and finished goods as of <em style="font: inherit;"> December 31, 2021.  </em>The revision had <em style="font: inherit;">no</em> effect on the previously reported total gross and net carrying value of inventory.  The revision also had <em style="font: inherit;">no</em> effect on the previously reported consolidated balance sheets, statements of operations and comprehensive loss, cash flows and stockholders’ equity. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2500000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Risk and Uncertainties</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: negative impacts on the Company's operations caused by the COVID-<em style="font: inherit;">19</em> pandemic and other geopolitical factors; the historical lack of profitability; the Company’s ability to raise additional capital; the success of its market development efforts; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan, and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic surgical devices; and its ability to identify and pursue development of additional products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Use of Estimates</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, short-term and long-term investments, excess and obsolete inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use (“ROU”) assets, and deferred tax asset valuation allowances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cash and Cash Equivalents, Restricted Cash, and Investments</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company considers all highly liquid investments with original maturities of <em style="font: inherit;">90</em> days or less at the time of purchase to be cash equivalents.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Restricted cash as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> includes $1.1 million in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, and automobile leases.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s investments as of <em style="font: inherit;"> December 31, 2022 </em>consisted of commercial paper, corporate bonds, and United States government agencies and were classified as available-for-sale. Investments classified as available-for-sale are measured at fair value, and net unrealized gains and losses are recorded as a component of accumulated other comprehensive loss on the consolidated balance sheets until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization and accretion is included in interest expense, net. There were no gross realized gains or loss for the year ended <em style="font: inherit;"> December 31, 2022. </em>The Company recognized an immaterial amount of gross realized losses for the year ended <em style="font: inherit;"> December 31, 2021. </em>There were no gross realized gains for the year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Investments with remaining maturities at date of purchase greater than <em style="font: inherit;">90</em> days and remaining maturities as of the reporting period less than <em style="font: inherit;">one</em> year are classified as short-term investments. Investments with remaining maturities greater than <em style="font: inherit;">one</em> year are classified as long-term investments. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">There have been <em style="font: inherit;">no</em> credit losses for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> and <em style="font: inherit;">no</em> allowance for credit losses as of <em style="font: inherit;"> December 31, 2022. </em>Factors considered in determining whether a credit loss exists include credit ratings and other qualitative factors for each security type in the portfolio.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1100000 0 0 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Fair Value Measurements </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level <em style="font: inherit;">1</em> securities. Marketable securities measured at fair value using Level <em style="font: inherit;">2</em> inputs are primarily comprised of commercial paper and corporate notes and bonds without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is <em style="font: inherit;">not</em> available, the Company uses market pricing and other observable market inputs for similar securities obtained from various <em style="font: inherit;">third</em>-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level <em style="font: inherit;">2</em> classification of these securities within the fair value hierarchy. The Company measures contingent consideration at fair value using a Monte-Carlo simulation utilizing Level <em style="font: inherit;">3</em> inputs. These inputs include the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Concentrations and Credit Risk</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents (including restricted cash), and investments, including amounts held in money market funds, commercial paper, and corporate bonds. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits <em style="font: inherit;"> may </em>at times exceed the Federal Deposit Insurance Corporation’s insured limit. Balances in excess of federally insured limitations <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be insured. The Company has <em style="font: inherit;">not</em> experienced losses on these accounts, and management believes that the Company is <em style="font: inherit;">not</em> exposed to significant risks on such accounts. Investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investments consist of various major corporations, financial institutions, and government agencies of high credit standing.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s accounts receivable are derived from sales and leases to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires <em style="font: inherit;">no</em> collateral from its customers. The Company had <span style="-sec-ix-hidden:c94008136">one</span> customer that accounted for 69% of the Company’s net accounts receivable as of <em style="font: inherit;"> December 31, 2022. </em>The Company had <span style="-sec-ix-hidden:c94008138">three</span> customers that accounted for 26%, 20%, and 14%, respectively, of the Company’s net accounts receivable as of <em style="font: inherit;"> December 31, 2021. </em>The Company had one customer who accounted for 47% of revenue in <em style="font: inherit;">2022,</em> and <span style="-sec-ix-hidden:c94008145">two</span> customers who accounted for 36% and 16% of revenue in <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.69 0.26 0.20 0.14 1 0.47 0.36 0.16 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Accounts Receivable</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Accounts receivable are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses is based on the Company’s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that <em style="font: inherit;"> may </em>affect a customer’s ability to pay. The allowance for expected credit losses was $1.6 million and $1.7 million as of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively. The Company recorded an immaterial amount for expected credit losses during the year ended <em style="font: inherit;"> December 31, 2022 </em>and $0.1 million during the year ended <em style="font: inherit;"> December 31, 2021.          </em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1600000 1700000 100000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Inventories</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Inventories are stated at the lower of cost (determined on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers historical consumption and forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do <em style="font: inherit;">not</em> result in the restoration or increase in that newly established cost basis.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming <em style="font: inherit;">twelve</em> months.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Definite-Lived Intangible Assets - Intellectual Property</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified in-process research and development (“IPR&amp;D”) assets related to (i) the Senhance System acquired in <em style="font: inherit;">2015</em> and reclassified in <em style="font: inherit;">2017</em> and (ii) a <em style="font: inherit;">2018</em> acquisition and reclassified in <em style="font: inherit;">2020.</em> Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed technology is recorded using the straight-line method over the estimated useful life of 5 to 7 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. To determine the recoverability, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the assets, then such assets are written down to their fair value. No impairment of intellectual property was identified during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> P10Y P5Y P7Y 0 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Property and Equipment</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Property and equipment consists primarily of operating lease Senhance System assets, machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets – Senhance System leasing</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;">5</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery, manufacturing, and demonstration equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt;">3</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt;">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;">3</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;">5</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; width: 17%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt; text-align: center;"><span style="-sec-ix-hidden:c94008271"><em style="font: inherit;"><span style="-sec-ix-hidden:c94008273">Lesser of lease term or 3 to 10</span></em></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the year ended <em style="font: inherit;"> December 31, 2022, </em>the Company recorded a non-cash asset impairment charge of $1.4 million to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are <em style="font: inherit;">not</em> expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the consolidated statements of operations and comprehensive loss. No such impairment charges were recorded during the year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets – Senhance System leasing</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;">5</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery, manufacturing, and demonstration equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt;">3</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 7%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt;">5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;">3</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; text-align: center;">5</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 7%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 74%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="4" style="font-family: Times New Roman; font-size: 10pt; margin-left: 5pt; width: 17%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt; text-align: center;"><span style="-sec-ix-hidden:c94008271"><em style="font: inherit;"><span style="-sec-ix-hidden:c94008273">Lesser of lease term or 3 to 10</span></em></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> </tbody></table> P5Y P3Y P5Y P3Y P5Y 1400000 0 <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Operating Leases</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We have operating leases for our corporate office buildings, vehicles, and machinery and equipment. At inception, we determine whether an agreement represents a lease and, at commencement, we evaluate each lease agreement to determine whether the lease constitutes an operating or financing lease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company accounts for lease components and non-lease components as a single component. Non-lease components consist of common area maintenance payments for most real estate leases, which are determined based on costs incurred by the lessor. Many of the Company’s leases include base rental periods coupled with options to renew or terminate the lease, generally at the Company’s discretion.  In evaluating the lease term, the Company considers whether renewal is reasonably certain.  To the extent a significant economic incentive exists to renew the lease, the option is included within the lease term.  Based on the Company’s leases, renewal options generally do <em style="font: inherit;">not</em> provide a significant economic incentive and are therefore excluded from the lease term. While our operating leases range from <span style="-sec-ix-hidden:c94008172">one</span> year to <span style="-sec-ix-hidden:c94008173">ten</span> years, some <em style="font: inherit;"> may </em>include options to extend the lease generally between <span style="-sec-ix-hidden:c94008174">one</span> year and <span style="-sec-ix-hidden:c94008175">six</span> years, and some <em style="font: inherit;"> may </em>include options to terminate the leases within <em style="font: inherit;">one</em> year.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The interest rate implicit in our lease contracts is typically <em style="font: inherit;">not</em> readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Implementation Costs in a Cloud Computing Arrangement</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract. These capitalized implementation costs are recorded within other current and long-term assets, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis and included within operating expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Employee Retention Tax Credit Receivable </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages. During the year ended <em style="font: inherit;"> December 31, 2021, </em>we submitted an ERTC refund for $1.3 million and recorded the amount into Other Income (Expense) on the consolidated statements of operations and comprehensive loss. The Company received notification from the IRS that the relevant conditions of the employee retention credit provision were met and that it will receive the credit. The Company received $0.7 million of the ERTC refund during the year ended <em style="font: inherit;"> December 31, 2022. </em>The remaining $0.6 million is recorded as a current asset on the consolidated balance sheets as of <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1300000 700000 600000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Notes Payable </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s policy is to account for forgivable loans received through the U.S. Small Business Administration (the “SBA”) under the CARES Act Payroll Protection Program (“PPP”), as debt in accordance with ASC <em style="font: inherit;">470,</em> Debt, and other related accounting pronouncements. The forgiveness of debt, in whole or part, is recognized once the debt is extinguished, which occurs when the Company is legally released from the liability by the SBA. Any portion of debt forgiven, adjusted for accrued interest forgiven and unamortized debt issuance costs, is recorded as a gain on extinguishment of debt, and presented in the consolidated statements of operations and comprehensive loss. On <em style="font: inherit;"> June 10, 2021, </em>the Company received notification from the SBA that the principal amount of its PPP loan of $2.8 million and related interest had been forgiven.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company has $0.6 million available under a letter of credit. No amounts have been utilized by the Company as of <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2800000 600000 0 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Contingent Consideration</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, revenue volatility and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> September 21, 2015, </em>the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar S.p.A., an Italian company (“Sofar”), an Italian company, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System. Under the terms of the Purchase Agreement, as amended in <em style="font: inherit;">2016,</em> as of <em style="font: inherit;"> December 31, 2022, </em>the Company has accrued $1.3 million of estimated fair value of remaining contingent consideration related to a milestone of <span style="-sec-ix-hidden:c94008186">€15.0</span> million which shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least <span style="-sec-ix-hidden:c94008187">€25.0</span> million over a calendar quarter or in the event that (i) the Company or Asensus International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. In <em style="font: inherit;">2022,</em> Sofar assigned its right to receive the contingent payment to Three Heads Investment S.r.l.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1300000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Warrant Liabilities</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s Series B Warrants were measured at fair value using a simulation model which considered, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant. The warrant liability was revalued at each reporting period and changes in fair value were recognized in the consolidated statements of operations and comprehensive loss. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. All remaining outstanding Series B Warrants were exercised in the <em style="font: inherit;">first</em> quarter <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Revenue Recognition</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements generally include a <span style="-sec-ix-hidden:c94008192">five</span>-year service period; the <em style="font: inherit;">first</em> year of service is generally free and included in the Senhance System sale arrangement and the remaining <span style="-sec-ix-hidden:c94008194">four</span> years are generally included at a stated service price.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements <em style="font: inherit;"> may </em>include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services; however due to limited sales to date, standalone selling prices generally are <em style="font: inherit;">not</em> directly observable. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but <em style="font: inherit;">not</em> limited to, features and functionality of the products and services, geographies, type of customer, and market conditions. The Company regularly reviews estimated standalone selling prices and updates these estimates if necessary.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 27pt;"><i>•  System sales</i>. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from Senhance System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when the Company receives an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do <em style="font: inherit;">not</em> provide a right of return. The Senhance Systems are generally covered by a <em style="font: inherit;">one</em>-year warranty. Warranty costs were <em style="font: inherit;">not</em> material for the periods presented.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 27pt;"><i>•  Instruments and accessories</i>. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 27pt;"><i>•  Service</i>. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due <em style="font: inherit;">30</em> to <em style="font: inherit;">60</em> days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements, and are included in accounts receivable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do <em style="font: inherit;">not</em> meet the requirements to be capitalized as the Company does <em style="font: inherit;">not</em> expect to generate future economic benefits from the related revenue from the initial sales transaction and such costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Senhance System Leasing</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. For the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> variable lease revenue related to usage-based arrangements was <em style="font: inherit;">not</em> material.  </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 5pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, the Company considers the following terms at lease commencement: (<em style="font: inherit;">1</em>) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (<em style="font: inherit;">2</em>) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (<em style="font: inherit;">3</em>) whether the lease term is for the major part of the remaining economic life of the leased System, (<em style="font: inherit;">4</em>) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (<em style="font: inherit;">5</em>) whether the underlying Senhance System is of such a specialized nature that it is expected to have <em style="font: inherit;">no</em> alternative use to the Company at the end of the lease term. All such arrangements through <em style="font: inherit;"> December 31, 2022 </em>are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage. As of <em style="font: inherit;"> December 31, 2022 </em>future minimum lease payments due from customers was $2.2 million, which is expected to be received over the next <em style="font: inherit;">one</em> to <em style="font: inherit;">three</em> years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2200000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cost of Revenue</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Depreciation expense related to leased systems is included in the cost of revenue. Shipping and handling costs incurred by the Company are included in the cost of revenue.  We expense all inventory obsolescence provisions as cost of revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Research and Development Costs</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Stock-Based Compensation</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes expenses for share-based awards exchanged for services rendered equal to the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of stock options. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted has been determined based upon the simplified method, because the Company does <em style="font: inherit;">not</em> have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has <em style="font: inherit;">not</em> paid and does <em style="font: inherit;">not</em> anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimates forfeitures based on its historical experience and adjust the estimated forfeiture rate based upon actual experience. For performance-based restricted stock awards with performance conditions, we begin recognizing compensation expense when it becomes probable that the performance condition will be attained.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. See “Note <em style="font: inherit;">13</em> – Stock-Based Compensation,” for a detailed discussion of the Company’s stock plans and stock-based compensation expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Income Taxes</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than <em style="font: inherit;">not</em> sustain the position following audit. For tax positions meeting the more likely than <em style="font: inherit;">not</em> threshold, the amount recognized in the financial statements is the largest benefit that has a greater than <em style="font: inherit;">50%</em> likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company <em style="font: inherit;"> may </em>be subject to examination by authorities for all previously filed income tax returns.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Comprehensive Loss</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Segments</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company operates in <span style="-sec-ix-hidden:c94008221">one</span> business segment—the research, development and sale of medical device robotics to improve minimally invasive surgery. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does <em style="font: inherit;">not</em> manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Impact of Recently Issued Accounting Standards</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has evaluated issued ASUs <em style="font: inherit;">not</em> yet adopted and believes the adoption of these standards will <em style="font: inherit;">not</em> have a material impact on its consolidated financial statements.</p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em></b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Revenue Recognition</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">The following table presents revenue disaggregated by type and geography:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Years Ended December 31,</b> </b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 31%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>U.S.</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Systems</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">211</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">273</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">300</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">383</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">377</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total U.S. revenue</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">767</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,033</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Outside of U.S. ("OUS")</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Systems</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,551</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,286</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,565</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,840</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,073</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,137</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,131</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">936</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total OUS revenue</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,320</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,199</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Systems</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,551</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,286</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,776</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,113</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,373</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,520</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,387</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,313</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; padding: 0pt 0pt 0pt 36pt;">Total revenue</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7,087</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8,232</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Remaining Performance Obligations</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has <em style="font: inherit;">not</em> yet been recognized. A significant portion of this amount relates to service obligations performed under the Company's system sales contracts that will be invoiced and recognized as revenue in future periods. Transaction price allocated to remaining performance obligations as of <em style="font: inherit;"> December 31, 2022 </em>was $1.1 million, which is expected to be recognized over <span style="-sec-ix-hidden:c94008277">one</span> to <span style="-sec-ix-hidden:c94008278">four</span> years. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Contract Assets and Liabilities</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Deferred revenue for the periods presented was primarily related to service obligations, for which the service fees are billed up-front, generally annually. The associated deferred revenue is generally recognized ratably over the service period. The Company did <em style="font: inherit;">not</em> have any significant impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> that was included in the deferred revenue balance at the beginning of each reporting period was $0.5 million and $0.6 million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following information summarizes the Company’s contract assets and liabilities:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract Assets</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">116</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">91</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred Revenue</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">465</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">543</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Years Ended December 31,</b> </b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 31%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>U.S.</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Systems</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">211</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">273</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">300</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">383</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">377</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total U.S. revenue</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">767</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,033</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Outside of U.S. ("OUS")</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Systems</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,551</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,286</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,565</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,840</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,073</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,137</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,131</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">936</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" rowspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total OUS revenue</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,320</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,199</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Systems</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,551</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,286</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,776</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,113</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,373</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,520</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,387</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,313</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; padding: 0pt 0pt 0pt 36pt;">Total revenue</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7,087</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8,232</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 0 0 211000 273000 300000 383000 256000 377000 767000 1033000 2551000 3286000 1565000 1840000 1073000 1137000 1131000 936000 6320000 7199000 2551000 3286000 1776000 2113000 1373000 1520000 1387000 1313000 7087000 8232000 1100000 500000 600000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract Assets</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">116</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">91</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred Revenue</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">465</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">543</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 116000 91000 465000 543000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">4.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cash, Cash Equivalents, and Restricted Cash</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash, cash equivalents and restricted cash consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b>December 31,</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b>December 31,</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,473</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,343</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Money Market</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,856</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,287</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Commerical Paper</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">4,499</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,329</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted Cash</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,141</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,154</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">7,470</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">19,283</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Restricted cash at <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> includes $1.1 million and $1.2 million, respectively, in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, automobile leases, and a performance guarantee required by the government of a country in which a Senhance System was sold in <em style="font: inherit;">2018.</em></p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b>December 31,</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black;"> </td> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-top: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b>December 31,</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,473</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,343</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Money Market</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,856</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,287</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Commerical Paper</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">4,499</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,329</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted Cash</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,141</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,154</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">7,470</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">19,283</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 3473000 8343000 2856000 5287000 0 4499000 6329000 18129000 1141000 1154000 7470000 19283000 1100000 1200000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">5.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Investments, available-for-sale</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The aggregate fair values of investment securities along with cumulative unrealized gains and losses determined on an individual investment security basis and included in other comprehensive loss are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 66%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 66%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 22%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Cost</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Unrealized</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gain</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Unrealized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Loss</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Short-term</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>investments</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Long-term</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>investments</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial Paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">12,364</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(49</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">12,315</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">12,315</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Bonds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">55,201</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(447</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">54,754</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">50,889</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. Government Agencies</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">991</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">991</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">68,564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(504</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">68,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">64,195</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">3,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 66%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 66%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 22%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Cost</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Unrealized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gain</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Unrealized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Loss</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Short-term </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>investments</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Long-term </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>investments</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial Paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">50,705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">50,659</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">50,660</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Bonds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">67,239</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(202</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">67,038</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">29,602</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">37,435</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">117,944</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(248</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">117,697</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">80,262</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">37,435</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table summarizes the contractual maturities of the Company’s available-for-sale investments:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Cost</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Mature in less than one year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">64,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">64,195</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Mature in one to two years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,902</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">68,564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">68,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Actual maturities <em style="font: inherit;"> may </em>differ from contractual maturities because certain borrowers have the right to call or prepay certain obligations. There were <span style="-sec-ix-hidden:c94008341"><span style="-sec-ix-hidden:c94008342">no</span></span> sales of investments for the years ended <em style="font: inherit;"> December 31, 2022 </em>or <em style="font: inherit;">2021,</em> respectively. There were no realized gains or losses for the years ended <em style="font: inherit;"> December 31, 2022. </em>The company recorded an immaterial amount of gross realized losses for the year ended <em style="font: inherit;"> December 31, 2021 </em>related to the maturity of investments.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 66%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 66%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 22%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Cost</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Unrealized</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gain</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Unrealized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Loss</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Short-term</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>investments</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-top: 1px solid black; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-top: 1px solid black; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Long-term</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>investments</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial Paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">12,364</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(49</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">12,315</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">12,315</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Bonds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">55,201</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(447</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">54,754</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">50,889</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. Government Agencies</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">991</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">991</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">68,564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(504</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">68,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">64,195</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">3,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 66%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="22" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 66%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="width: 22%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Cost</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Unrealized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gain</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Unrealized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Loss</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Short-term </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>investments</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Long-term </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>investments</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial Paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">50,705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(46</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">50,659</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">50,660</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Bonds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">67,239</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(202</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">67,038</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">29,602</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">37,435</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 22%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">117,944</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(248</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">117,697</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">80,262</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">37,435</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 12364000 0 49000 12315000 12315000 0 55201000 0 447000 54754000 50889000 3865000 999000 0 8000 991000 991000 0 68564000 0 504000 68060000 64195000 3865000 50705000 0 46000 50659000 50660000 0 67239000 1000 202000 67038000 29602000 37435000 117944000 1000 248000 117697000 80262000 37435000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Cost</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Mature in less than one year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">64,662</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">64,195</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Mature in one to two years</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,902</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">68,564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">68,060</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 64662000 64195000 3902000 3865000 68564000 68060000 0 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">6.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Fair Value</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following are categories of assets and liabilities measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level <em style="font: inherit;">1</em>); significant other observable inputs (Level <em style="font: inherit;">2</em>); and significant unobservable inputs (Level <em style="font: inherit;">3</em>):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31, 2022</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Quoted Prices in </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Active Markets for </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Identical Assets </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 1)</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant Other </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Observable Inputs </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 2)</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Unobservable </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Inputs (Level 3)</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets measured at fair value</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup><span style="font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,329</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,329</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,141</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,141</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Short-term investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64,195</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64,195</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,865</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,865</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,470</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,060</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,530</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities measured at fair value</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities measured at fair value</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> <span style="font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">1</em>)</sup></span><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>Includes investments that are readily convertible to cash with original maturities of <em style="font: inherit;">90</em> days or less.</p> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted Prices in</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Active Markets for </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Identical Assets </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 1)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant Other</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Observable Inputs </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 2)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Unobservable </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Inputs (Level 3)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets measured at fair value</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup><span style="font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,154</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,154</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Short-term investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">80,262</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">80,262</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">37,435</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">37,435</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">19,283</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">117,697</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">136,980</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities measured at fair value</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,371</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,371</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities measured at fair value</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,371</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,371</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;;"> </p> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> (<em style="font: inherit;">1</em>)</sup><span style="font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>Includes investments that are readily convertible to cash with original maturities of <em style="font: inherit;">90</em> days or less.</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The carrying values of accounts receivable, prepaid expenses, employee retention tax credit receivables, other current assets, accounts payable, accrued employee compensation and benefits, accrued expenses, deferred revenue, and other current liabilities as of <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;"> December 31, 2021, </em>approximate their fair values due to the short-term nature of these items.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s financial liabilities consisted of contingent consideration payable to Three Heads Investment S.r.l., related to the Company’s <em style="font: inherit;">2015</em> acquisition of the Senhance Surgical System from an assignor to Three Heads Investment S.r.l. (the “Senhance Acquisition”). Adjustments associated with the change in fair value of contingent consideration are included in the Company’s consolidated statements of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements for contingent consideration utilizing a Monte-Carlo simulation as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 20%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Valuation </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Methodology</b></p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Significant Unobservable </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Input</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 20%;"> </td> <td style="width: 18%;"> </td> <td style="width: 1%;"> </td> <td style="width: 20%;"> </td> <td style="width: 1%;"> </td> <td style="width: 18%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 18%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 20%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Probability weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">income approach</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Milestone dates</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2032</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2031</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 20%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 18%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Discount rate</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">16.5%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">9.5%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 20%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 18%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Revenue volatility</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">45.0%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">39.0%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 20%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 18%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">EUR-to-USD exchange rate</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">1.07</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">1.14</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The following table presents the current and long-term portion of the contingent consideration for the year ended <em style="font: inherit;"> December 31, 2022 </em>and summarizes the change in fair value, as determined by Level <em style="font: inherit;">3</em> inputs for the contingent consideration for the year ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair Value </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Measurement at </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Reporting Date </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 3)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contingent </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>consideration</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,936</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,115</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,256</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,256</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,256</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31, 2022</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Quoted Prices in </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Active Markets for </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Identical Assets </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 1)</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant Other </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Observable Inputs </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>(Level 2)</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Significant </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Unobservable </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Inputs (Level 3)</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets measured at fair value</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup><span style="font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,329</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,329</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,141</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,141</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Short-term investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64,195</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64,195</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,865</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,865</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,470</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,060</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,530</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities measured at fair value</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities measured at fair value</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 32%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 14%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%; border-bottom: 1px solid black;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted Prices in</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Active Markets for </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Identical Assets </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 1)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant Other</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Observable Inputs </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 2)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Unobservable </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Inputs (Level 3)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets measured at fair value</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup><span style="font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">18,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,154</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,154</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Short-term investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">80,262</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">80,262</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term investments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">37,435</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">37,435</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">19,283</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">117,697</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">136,980</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities measured at fair value</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 14%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,371</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,371</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 32%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities measured at fair value</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,371</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,371</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 6329000 0 0 6329000 1141000 0 0 1141000 0 64195000 0 64195000 0 3865000 0 3865000 7470000 68060000 0 75530000 0 0 1256000 1256000 0 0 1256000 1256000 18129000 0 0 18129000 1154000 0 0 1154000 0 80262000 0 80262000 0 37435000 0 37435000 19283000 117697000 0 136980000 0 0 2371000 2371000 0 0 2371000 2371000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 20%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Valuation </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Methodology</b></p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Significant Unobservable </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Input</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 20%;"> </td> <td style="width: 18%;"> </td> <td style="width: 1%;"> </td> <td style="width: 20%;"> </td> <td style="width: 1%;"> </td> <td style="width: 18%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 18%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 20%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Probability weighted</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">income approach</p> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Milestone dates</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2032</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2031</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 20%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 18%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Discount rate</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">16.5%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">9.5%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 20%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 18%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Revenue volatility</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">45.0%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">39.0%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 20%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 18%;"><em style="font: inherit;"> </em></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 20%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">EUR-to-USD exchange rate</em></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">1.07</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 18%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">1.14</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 0.165 0.095 0.450 0.390 1.07 1.14 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair Value </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Measurement at </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Reporting Date </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level 3)</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contingent </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>consideration</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,936</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,565</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,115</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,256</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term portion</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,256</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,256</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 3936000 1565000 2371000 1115000 1256000 0 1256000 1256000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b><em style="font: inherit;">7.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Inventories</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The components of inventories are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Reserve Balance</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,337</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(4,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">11,208</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">4,718</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(2,173</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,545</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">20,055</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(6,302</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">13,753</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current Portion</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,399</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,115</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,284</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term portion</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">10,656</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(5,187</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,469</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">20,055</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(6,302</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">13,753</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Reserve Balance</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">13,066</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,987</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">10,079</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,324</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(2,695</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,629</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">21,390</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(5,682</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">15,708</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current Portion</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,931</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,297</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,634</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term portion</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">11,459</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(4,385</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">7,074</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">21,390</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(5,682</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">15,708</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Reserve Balance</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,337</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(4,129</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">11,208</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">4,718</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(2,173</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,545</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">20,055</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(6,302</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">13,753</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current Portion</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,399</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,115</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,284</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term portion</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">10,656</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(5,187</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,469</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">20,055</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(6,302</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">13,753</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Reserve Balance</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">13,066</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,987</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">10,079</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,324</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(2,695</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,629</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">21,390</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(5,682</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">15,708</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Current Portion</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,931</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,297</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,634</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term portion</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">11,459</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(4,385</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">7,074</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">21,390</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(5,682</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">15,708</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 15337000 4129000 11208000 4718000 2173000 2545000 20055000 6302000 13753000 9399000 1115000 8284000 10656000 5187000 5469000 20055000 6302000 13753000 13066000 2987000 10079000 8324000 2695000 5629000 21390000 5682000 15708000 9931000 1297000 8634000 11459000 4385000 7074000 21390000 5682000 15708000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">8.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Property and Equipment</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment consisted of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b><br/> <b>2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b><br/> <b>2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery, manufacturing, and demonstration equipment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,450</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,289</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets - Senhance System leasing</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,251</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,143</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">600</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">325</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">831</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">644</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,654</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,259</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Construction in process</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c94008545">436</span></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c94008546"> </span><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">‑</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total property and equipment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,222</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,660</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation and amortization</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,680</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,689</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,542</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,971</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Depreciation expense was approximately $3.4 million and $2.9 million for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively. </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b><br/> <b>2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b><br/> <b>2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery, manufacturing, and demonstration equipment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,450</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,289</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets - Senhance System leasing</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,251</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,143</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">600</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">325</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">831</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">644</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,654</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,259</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Construction in process</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c94008545">436</span></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="-sec-ix-hidden:c94008546"> </span><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">‑</p> </td> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total property and equipment</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22,222</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20,660</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation and amortization</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,680</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,689</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,542</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,971</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 8450000 8289000 10251000 10143000 600000 325000 831000 644000 1654000 1259000 22222000 20660000 12680000 9689000 9542000 10971000 3400000 2900000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">9.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Intellectual Property</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The components of gross intellectual property, accumulated amortization, and net intellectual property are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated Amortization</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Foreign </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Currency </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Translation </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Impact</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Developed technology</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">68,838</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,562</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(874</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,402</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Technology and patents purchased</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">400</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(239</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">13</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">174</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intellectual property</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">69,238</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(66,801</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(861</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,576</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortization</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Foreign </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Currency </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Translation </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Impact</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Developed technology</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">68,838</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(58,912</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(262</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,664</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Technology and patents purchased</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">400</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(199</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">27</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intellectual property</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">69,238</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(59,111</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(235</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">9,892</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The weighted average remaining useful life of the developed technology and technology and patents purchased was 4.2 years and 4.3 years, respectively, as of <em style="font: inherit;"> December 31, 2022. </em>The weighted average remaining useful life of the developed technology and technology and patents purchased was 1.6 years and 5.3 years, respectively as of <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The estimated future amortization expense of intellectual property as of <em style="font: inherit;"> December 31, 2022 </em>is as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ending</b><br/> <b>December 31, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">68</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,576</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated Amortization</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Foreign </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Currency </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Translation </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Impact</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Developed technology</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">68,838</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,562</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(874</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,402</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Technology and patents purchased</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">400</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(239</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">13</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">174</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intellectual property</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">69,238</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(66,801</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(861</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,576</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortization</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Foreign </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Currency </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Translation </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Impact</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Net </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Carrying </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 36%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Developed technology</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">68,838</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(58,912</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(262</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,664</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Technology and patents purchased</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">400</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(199</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">27</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">228</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intellectual property</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">69,238</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(59,111</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(235</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">9,892</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 68838000 66562000 -874000 1402000 400000 239000 13000 174000 69238000 66801000 -861000 1576000 68838000 58912000 -262000 9664000 400000 199000 27000 228000 69238000 59111000 -235000 9892000 P4Y2M12D P4Y3M18D P1Y7M6D P5Y3M18D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ending</b><br/> <b>December 31, 2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">377</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">68</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,576</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 377000 377000 377000 377000 68000 1576000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">10.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Leases</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Lessee Information</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Components of operating lease expense are primarily recorded in general and administrative on the consolidated statements of operations and comprehensive loss were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years Ended December 31,</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term Operating</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,557</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,826</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Short-term Operating</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Operating lease expense</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,557</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,826</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Supplemental balance sheet information related to operating leases was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 58%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 58%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (in years)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">6.8</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">7.8</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 58%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="3" rowspan="1" style="width: 11%; font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">8.4%</em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="3" rowspan="1" style="width: 11%; font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">7.8%</em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 58%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Incremental borrowing rate</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">6.1%</td> <td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14.5%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">6.1%</td> <td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.5%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Maturities of operating lease obligations as of <em style="font: inherit;"> December 31, 2022 </em>were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Fiscal Year</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,222</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,136</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,058</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">837</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">775</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,195</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total minimum lease payments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,223</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Amount of lease payments representing interest</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,685</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of future minimum lease payments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,538</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years Ended December 31,</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term Operating</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,557</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,826</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Short-term Operating</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Operating lease expense</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,557</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,826</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody> </table> 1557000 1826000 0 0 1557000 1826000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 58%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 58%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (in years)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">6.8</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 11%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><em style="font: inherit;">7.8</em></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 58%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="3" rowspan="1" style="width: 11%; font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">8.4%</em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="3" rowspan="1" style="width: 11%; font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">7.8%</em></td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 58%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Incremental borrowing rate</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">6.1%</td> <td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14.5%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">6.1%</td> <td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td> <td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.5%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> P6Y9M18D P7Y9M18D 0.084 0.078 0.061 0.145 0.061 0.085 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Fiscal Year</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,222</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,136</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,058</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">837</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">775</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,195</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total minimum lease payments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,223</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Amount of lease payments representing interest</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,685</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of future minimum lease payments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,538</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 1222000 1136000 1058000 837000 775000 2195000 7223000 1685000 5538000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">11.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Accrued Expenses </b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents the components of accrued expenses:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b><br/> <b>2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b><br/> <b>2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Consulting and other vendors</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">155</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">128</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">124</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Royalties</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">247</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal and professional fees</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">275</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">503</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Taxes and other assessments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">839</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">615</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,293</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,617</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b><br/> <b>2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b><br/> <b>2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Consulting and other vendors</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">155</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">128</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">124</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Royalties</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">247</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal and professional fees</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">275</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">503</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Taxes and other assessments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">839</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">615</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,293</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,617</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 155000 128000 0 124000 24000 247000 275000 503000 839000 615000 1293000 1617000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">12.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Income Taxes </b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The components for the income tax expense are as follows for the years ended <em style="font: inherit;"> December </em><em style="font: inherit;">31</em> (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current income taxes</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 58.8%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">239</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">232</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred income taxes</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total income tax expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">318</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The United States and foreign components of loss from operations before taxes are as follows for the years ended <em style="font: inherit;"> December </em><em style="font: inherit;">31</em> (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(44,802</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(32,094</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(30,441</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(30,143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total loss from operations before taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(75,243</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(62,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Significant components of the Company’s deferred tax assets consist of the following at <em style="font: inherit;"> December </em><em style="font: inherit;">31</em> (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred Tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 58.1%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,840</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,440</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,538</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research credit carryforward</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,341</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Fixed Assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">162</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Capitalized start-up costs and other intangibles</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">921</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Capitalized research costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,382</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">83,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">75,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">96,092</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">81,874</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Valuation Allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(94,704</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(78,294</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,388</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,580</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Fixed assets and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,214</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Purchase accounting intangibles</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,214</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(3,292</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset (liability)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">288</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During <em style="font: inherit;">2021,</em> the Company completed an assessment of the available net operating loss and tax credit carryforwards under Section <em style="font: inherit;">382</em> and Section <em style="font: inherit;">383</em> of the Internal Revenue Code, respectively. The Company determined that it underwent multiple ownership changes throughout its history as defined under Section <em style="font: inherit;">382,</em> including most recently in <em style="font: inherit;">2020.</em> As a result of the identified ownership changes, the portion of net operating loss and tax credits carryforwards attributable to the pre-ownership change periods are subject to a substantial annual limitation under Sections <em style="font: inherit;">382</em> and <em style="font: inherit;">383</em> of the Internal Revenue Code. The Company has adjusted its net operating loss and tax credit carryforwards to address the impact of the <em style="font: inherit;">382</em> ownership changes. This resulted in a reduction of available Federal and State NOLs of $253 million and $204 million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">At <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> the Company has provided a full valuation allowance against its net deferred assets in the U.S., Canada, Italy, Luxembourg, Switzerland, and Taiwan tax jurisdictions, since realization of these benefits is <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not.</em> The valuation allowance increased approximately $16.4 million from the prior year. At <em style="font: inherit;"> December 31, 2022, </em>the Company had U.S. federal net operating loss carryforwards of $419.4 million, of which $253 million are expected to expire unused under the limitations imposed by Internal Revenue Code Section <em style="font: inherit;">382</em> (as discussed above). Of the total amount of Federal NOLs (notwithstanding the <em style="font: inherit;">382</em> limitation), $254.5 million begin to expire in <em style="font: inherit;">2027,</em> while the remaining $164.9 million carry forward indefinitely. At <em style="font: inherit;"> December 31, 2022, </em>the Company had U.S. state net operating loss carryforwards of $328.9 million, of which $204 million are expected to expire unused under the state tax law equivalents of Internal Revenue Code Section <em style="font: inherit;">382.</em> Of this amount (notwithstanding the <em style="font: inherit;">382</em> limitations), $317.4 million of state NOLs begin to expire in <em style="font: inherit;">2022,</em> while the remaining $11.5 million carry forward indefinitely. At <em style="font: inherit;"> December 31, 2022, </em>the Company had federal research credit carryforwards in the amount of $10.2 million. These carryforwards begin to expire in <em style="font: inherit;">2027.</em> However, under the limitations of Internal Revenue Code Section <em style="font: inherit;">383,</em> it is expected that $8.8 million of this carryforward will expire unused. The utilization of the federal net operating loss carryforwards and credit carryforwards will depend on the Company’s ability to generate sufficient taxable income prior to the expiration of the carryforwards.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">At <em style="font: inherit;"> December 31, 2022, </em>the Company had foreign operating loss carryforwards in Italy of approximately $24.6 million, which can be carried forward indefinitely; foreign operating loss carryforwards in Luxembourg of approximately $95.9 million, which will begin to expire in <em style="font: inherit;">2034;</em> foreign operating loss carryforwards in Switzerland of approximately $116.5 million, which begin to expire in <em style="font: inherit;">2023,</em> and foreign operating loss carryforwards in Canada of approximately $0.9 million, which begin to expire in <em style="font: inherit;">2040.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has evaluated its tax positions to consider whether it has any unrecognized tax benefits. As of <em style="font: inherit;"> December 31, 2022, </em>the Company had gross unrecognized tax benefits of approximately $0.3 million. Of the total, <em style="font: inherit;">none</em> would reduce the Company’s effective tax rate if recognized. The Company does <em style="font: inherit;">not</em> anticipate a significant change in total unrecognized tax benefits or the Company’s effective tax rate due to the settlement of audits or the expiration of statutes of limitations within the next <em style="font: inherit;">twelve</em> months. Furthermore, the Company does <em style="font: inherit;">not</em> expect any cash settlement with the taxing authorities as a result of these unrecognized tax benefits as the Company has sufficient unutilized carryforward attributes to offset the tax impact of these adjustments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following is a tabular reconciliation of the Company’s change in gross unrecognized tax positions at <em style="font: inherit;"> December </em><em style="font: inherit;">31</em> (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross increases for tax positions related to current periods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross decreases related to 382 limitations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">335</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes. As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the Company had no accrued interest or penalties related to uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has analyzed its filing positions in all significant federal, state, and foreign jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, the Company is <em style="font: inherit;">no</em> longer subject to United States Federal, state, and local tax examinations by tax authorities for years before <em style="font: inherit;">2019,</em> although carryforward attributes that were generated prior to <em style="font: inherit;">2019</em> <em style="font: inherit;"> may </em>still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. <em style="font: inherit;">No</em> income tax returns are currently under examination by taxing authorities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Taxes computed at the then-current statutory federal income tax rate of 21% are reconciled to the provision for income taxes as follows for the years ended <em style="font: inherit;"> December </em><em style="font: inherit;">31:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percent</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Pretax </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Earnings</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percent </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Pretax </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Earnings</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">United States federal tax at statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(15,801</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(13,070</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes (net of deferred benefit)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,912</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,205</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Nondeductible expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,077</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1.4%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(440</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair market value of contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(283</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(397</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrant remeasurment and financing costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">502</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.8%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; Development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(970</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in unrecognized tax benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.3%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.2%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign tax rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,676</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(3.6%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,911</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(3.1%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">True-up to Stock Compensation - Cancellations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">49</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.1%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(4.6%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in enacted tax rates and other, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">731</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1.0%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">16,384</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(21.8%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">10,925</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(17.6%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense (benefit)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">318</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(0.4%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(0.4%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current income taxes</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 58.8%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">239</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">232</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred income taxes</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total income tax expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">318</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 0 0 0 0 239000 232000 0 0 0 0 79000 -7000 318000 225000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">United States</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(44,802</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(32,094</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(30,441</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(30,143</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total loss from operations before taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(75,243</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(62,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> -44802000 -32094000 -30441000 -30143000 -75243000 -62237000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred Tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 58.1%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,840</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,440</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,538</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,423</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Research credit carryforward</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,341</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">564</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Fixed Assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">162</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Capitalized start-up costs and other intangibles</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">921</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Capitalized research costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,382</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">83,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">75,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">96,092</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">81,874</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Valuation Allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(94,704</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(78,294</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,388</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,580</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax liabilities</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Fixed assets and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,214</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Purchase accounting intangibles</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,214</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(3,292</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset (liability)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">288</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 2840000 2440000 2538000 2423000 1341000 564000 162000 101000 921000 1109000 4382000 0 83908000 75237000 96092000 81874000 94704000 78294000 1388000 3580000 1214000 1176000 -0 2116000 1214000 3292000 174000 288000 -253000000 -204000000 16400000 419400000 -253000000 254500000 164900000 328900000 -204000000 317400000 11500000 10200000 -8800000 24600000 95900000 116500000 900000 300000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross increases for tax positions related to current periods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross decreases related to 382 limitations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">335</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 141000 0 194000 141000 -0 -0 335000 141000 0 0.21 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percent</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Pretax </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Earnings</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Percent </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Pretax </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Earnings</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">United States federal tax at statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(15,801</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(13,070</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes (net of deferred benefit)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,912</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,205</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Nondeductible expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,077</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1.4%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(440</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair market value of contingent consideration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(283</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(397</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrant remeasurment and financing costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">502</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.8%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; Development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(970</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in unrecognized tax benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.3%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.2%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign tax rate differential</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,676</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(3.6%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,911</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(3.1%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">True-up to Stock Compensation - Cancellations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">49</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.1%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,832</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(4.6%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in enacted tax rates and other, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(96</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">731</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1.0%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">16,384</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(21.8%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">10,925</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(17.6%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense (benefit)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">318</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(0.4%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">225</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(0.4%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> -15801000 0.210 -13070000 0.210 -2912000 0.039 -2205000 0.035 1077000 -0.014 -440000 0.007 -283000 0.004 -397000 0.006 0 0 502000 -0.008 970000 0.013 705000 0.011 194000 -0.003 141000 -0.002 2676000 -0.036 1911000 -0.031 49000 -0.001 2832000 -0.046 -96000 0.002 731000 -0.010 16384000 -0.218 10925000 -0.176 318000 -0.004 225000 -0.004 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">13.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Stock-Based Compensation</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Overview</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On <em style="font: inherit;"> July 22, 2021, </em>at the <em style="font: inherit;">2021</em> Annual Meeting of Stockholders, stockholders voted to approve the Company’s Amended and Restated Incentive Compensation Plan (the “Plan”) to increase the number of shares reserved for issuance under the Plan by 22,000,000 shares. As of <em style="font: inherit;"> December 31, 2022, </em>there were 32,072,308 shares authorized for issuance, and 11,038,824 shares available for future issuance under the Plan. To date all equity awards under the Plan have consisted of nonqualified stock options, incentive stock options, and restricted stock units.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Under the Plan, which is administered by the Compensation Committee, the Company <em style="font: inherit;"> may </em>grant stock options, stock appreciation rights, restricted stock and/or deferred stock to employees, officers, directors, consultants, and vendors. The exercise price of stock options or stock appreciation rights <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be less than the fair market value of the Company’s shares at the date of grant. Additionally, <em style="font: inherit;">no</em> stock options or stock appreciation rights granted under the Plan <em style="font: inherit;"> may </em>have a term exceeding <span style="-sec-ix-hidden:c94008816">ten</span> years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Stock Options </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table summarizes the Company’s stock option activity, including grants to non-employees, for the year ended <em style="font: inherit;"> December 31, 2022:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted-</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Average Exercise </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted-Average </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Remaining </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Contractual Term </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Years)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,640,660</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.64</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.66</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,153,881</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(129,134</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1.60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cancelled</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(36,987</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.11</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(43,453</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">0.41</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,584,967</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.22</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The aggregate intrinsic value of stock options exercised under the Company’s stock plans was <em style="font: inherit;">not</em> material during the year ended <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table summarizes information about stock options outstanding at <em style="font: inherit;"> December 31, 2022:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted-</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average Exercise </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Price</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted-Average </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Remaining </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contractual Term </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Years)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Intrinsic Value </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Millions)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2022</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,524,473</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.40</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.75</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested or expected to vest at December 31, 2022</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,350,141</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.32</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.28</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The fair value of options granted were estimated using the Black-Scholes-Merton option pricing model based on the assumptions in the table below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="8" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 29%; vertical-align: bottom;"><b>Years Ended December 31,</b></td></tr> <tr><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"><b>2022</b></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"><b>2021</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="3" rowspan="1" style="width: 11%; font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">0%</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="3" rowspan="1" style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">0%</em></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">126%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">133%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">118%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">139%</td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">1.25%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.40%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">0.33%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.11%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">3.8</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">3.8</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c94008880">4.5 </span></td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><i>Restricted Stock Units </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following is a summary of the restricted stock units activity, including performance restricted stock units, for the year ended <em style="font: inherit;"> December 31, 2022:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Restricted </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stock Units </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Outstanding</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted-</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average Grant </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Date Fair </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested December 31, 2021</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,839,030</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.36</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,996,822</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.71</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,076,663</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.34</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(275,698</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1.19</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested December 31, 2022</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,483,491</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.04</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Performance Restricted Stock Units</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the Company granted performance-based restricted stock units with vesting terms based on our attainment of certain operational targets by <em style="font: inherit;"> October 1, 2023 </em>and <em style="font: inherit;"> October 1, 2022, </em>respectively. The number of shares earnable under the <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> awards are based on achieving designated corporate goals. These operational targets were achieved for <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> therefore the performance-based restricted stock units are fully earned and remain subject to <em style="font: inherit;">three</em>-year time-based vesting requirements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Stock-based Compensation Expense</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table summarizes non-cash stock-based compensation expense by award type for the years ended <em style="font: inherit;"> December 31, 2022, </em>and <em style="font: inherit;">2021:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Years Ended December 31,</b> </b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,654</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,535</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,319</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,954</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Performance restricted stock units</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,443</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">940</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,416</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,429</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company had future employee stock-based compensation expense of approximately $2.1 million related to unvested stock options, which is expected to be recognized over an estimated weighted-average period of 1.5 years. As of <em style="font: inherit;"> December 31, 2022, </em>the unrecognized stock-based compensation expense related to unvested restricted stock units and performance restricted stock units was approximately $4.2 million, which is expected to be recognized over a weighted average period of approximately 1.4 years.</p> 22000000 32072308 11038824 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Number of </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Shares</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted-</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Average Exercise </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Price</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted-Average </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Remaining </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Contractual Term </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Years)</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,640,660</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.64</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.66</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,153,881</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(129,134</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1.60</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cancelled</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(36,987</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.11</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(43,453</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">0.41</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"><em style="font: inherit;"> </em></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,584,967</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.22</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 4640660 6.64 P5Y7M28D 3153881 0.70 129134 1.60 36987 21.11 43453 0.41 7584967 4.22 P5Y3M21D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 9pt;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted-</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average Exercise </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Price</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted-Average </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Remaining </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Contractual Term </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Years)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Intrinsic Value </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Millions)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2022</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,524,473</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.40</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.75</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested or expected to vest at December 31, 2022</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,350,141</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.32</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.28</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 3524473 7.40 P4Y9M 0 7350141 4.32 P5Y3M10D 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="8" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 29%; vertical-align: bottom;"><b>Years Ended December 31,</b></td></tr> <tr><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"><b>2022</b></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"><b>2021</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="3" rowspan="1" style="width: 11%; font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">0%</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="3" rowspan="1" style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;">0%</em></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">126%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">133%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">118%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">139%</td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">1.25%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.40%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">0.33%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.11%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 59%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">3.8</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; text-align: right;">3.8</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c94008880">4.5 </span></td></tr> </tbody></table> 0 0 1.26 1.33 1.18 1.39 0.0125 0.0440 0.0033 0.0111 P3Y9M18D P4Y6M P3Y9M18D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Restricted </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stock Units </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Outstanding</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted-</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Average Grant </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Date Fair </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested December 31, 2021</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,839,030</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.36</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,996,822</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.71</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,076,663</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.34</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(275,698</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1.19</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested December 31, 2022</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,483,491</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1.04</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 3839030 2.36 6996822 0.71 2076663 2.34 275698 1.19 8483491 1.04 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Years Ended December 31,</b> </b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in thousands)</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,654</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,535</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,319</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,954</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Performance restricted stock units</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,443</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">940</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,416</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,429</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 3654000 4535000 3319000 3954000 1443000 940000 8416000 9429000 2100000 P1Y6M 4200000 P1Y4M24D <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">14.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Equity Offerings</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Equity financing transactions for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> include:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i><em style="font: inherit;">2020</em> ATM Offering</i>. On <em style="font: inherit;"> October 9, 2020, </em>the Company filed a prospectus supplement relating to an at-the-market offering with Cantor pursuant to which the Company could sell from time to time, at its option, up to an aggregate of $40.0 million of shares of the Company’s common stock (the <em style="font: inherit;">“2020</em> ATM Offering”). The Company terminated this agreement in <em style="font: inherit;"> January 2021. </em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i><em style="font: inherit;"> January 2021 </em>Public Offering. </i>On <em style="font: inherit;"> January 29, 2021, </em>the Company completed an underwritten public offering of 26,545,832 shares of its common stock, including the underwriter’s full exercise of an over-allotment option on <em style="font: inherit;"> February 1, 2021, </em>at the public offering price of $3.00 per share, generating net proceeds of approximately $73.4 million.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i><em style="font: inherit;"> January 2021 </em>Registered Direct Purchase Agreement. </i>On <em style="font: inherit;"> January 12, 2021, </em>the Company sold in a registered direct offering 25,000,000 shares of common stock at a purchase price per share of $1.25 for aggregate net proceeds of $28.6 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i><em style="font: inherit;">2021</em> ATM Offering</i>. On <em style="font: inherit;"> May 19, 2021, </em>we entered into a Controlled Equity Offering<sup style="vertical-align:top;line-height:120%;font-size:pt">SM</sup> Sales Agreement with Cantor, Robert W. Baird &amp; Co. Incorporated and Oppenheimer &amp; Co. Inc., as our sales agents, relating to an at-the-market offering of up to an aggregate of $100,000,000 of shares of our common stock, referred to as the <em style="font: inherit;">“2021</em> ATM Offering”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Sales during the year ended <em style="font: inherit;"> December 31, 2021, </em>under the <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> ATM Offering are as follows (in thousands, except for share and per share amounts):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total shares of common stock sold</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">20,237,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Average price per share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross proceeds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">30,943</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Commisssion earned by Sales Agents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">928</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net proceeds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">30,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i><em style="font: inherit;">2021</em> Exercise of Warrants.</i> During the year ended <em style="font: inherit;"> December 31, 2021, </em>certain holders of our Series B, C and D warrants to purchase shares of our common stock exercised such warrants for aggregate proceeds to the Company of $30.6 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i><em style="font: inherit;">2022</em> ATM Offering. </i>On <em style="font: inherit;"> March 18, 2022, </em>the Company entered a Controlled Equity Offering Sales Agreement (the <em style="font: inherit;">“2022</em> Sales Agreement”), with Cantor Fitzgerald &amp; Co., and Oppenheimer &amp; Co. Inc. The Company commenced an at-the-market offering (the <em style="font: inherit;">“2022</em> ATM Offering”) pursuant to which the Company could sell from time to time, at its option, up to an aggregate of $100.0 million shares of the Company’s common stock. No sales of common stock were made under the <em style="font: inherit;">2022</em> ATM Offering during the year ended <em style="font: inherit;"> December 31, 2022.</em><i> </i></p> 40000000.0 26545832 3.00 73400000 25000000 1.25 28600000 100000000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total shares of common stock sold</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">20,237,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Average price per share</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.53</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross proceeds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">30,943</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Commisssion earned by Sales Agents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">928</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net proceeds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">30,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 20237045 1.53 30943000 928000 30015000 30600000 100000000.0 0 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">15.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Basic and Diluted Net Loss per Share</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all potential dilutive common shares that were outstanding during the period when the effect is dilutive. Potential dilutive common shares consist of incremental shares issuable upon exercise of stock options, restricted stock units, and warrants. <em style="font: inherit;">No</em> adjustments have been made to the weighted average outstanding common shares figures for the years ended <em style="font: inherit;"> December 31, 2022 </em>or <em style="font: inherit;">2021</em> as the assumed exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Potential common shares <em style="font: inherit;">not</em> included in calculating diluted net loss per share are as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b> </b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 13px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,584,967</td> <td style="width: 13px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 11px; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,640,660</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock warrants</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,021,076</td> <td style="width: 13px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 11px; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,120,300</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Nonvested restricted stock units</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,483,491</td> <td style="width: 13px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 11px; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,839,030</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">17,089,534</td> <td style="width: 13px; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 11px; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">9,599,990</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b> </b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0); width: 13px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 11px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,584,967</td> <td style="width: 13px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 11px; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,640,660</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock warrants</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,021,076</td> <td style="width: 13px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 11px; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,120,300</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Nonvested restricted stock units</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,483,491</td> <td style="width: 13px; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 11px; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,839,030</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">17,089,534</td> <td style="width: 13px; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 11px; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">9,599,990</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table> 7584967 4640660 1021076 1120300 8483491 3839030 17089534 9599990 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">16.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Commitments and Contingencies</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>License and Supply Agreements</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As part of the Company’s acquisition of the Senhance System in <em style="font: inherit;">2015,</em> the Company assumed certain license and supply agreements. The Company has purchase orders with various suppliers for certain tooling, supplies, contract engineering and research services. Commitments related to license agreements and purchase orders are as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Fiscal Year</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,976</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">407</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">313</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total commitments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,999</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Fiscal Year</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,976</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">407</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">313</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">303</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total commitments</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,999</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> 5976000 407000 313000 303000 6999000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">17.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Segments and Geographic Areas</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents consolidated assets and long-lived assets by geographic area, which includes property and equipment, intellectual property, and operating lease assets:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Long-Lived Assets</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total Assets</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>U.S.</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>EMEA</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Switzerland</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Italy</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total EMEA</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asia</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </tbody> </table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Long-Lived Assets</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total Assets</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>U.S.</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>EMEA</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Switzerland</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Italy</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total EMEA</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asia</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents sales by geographic area based on the country in which the customer is based.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Years Ended December 31,</b> </b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">US</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">EMEA</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Asia</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Long-Lived Assets</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total Assets</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>U.S.</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>EMEA</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Switzerland</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">46</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Italy</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total EMEA</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asia</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </tbody> </table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Long-Lived Assets</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total Assets</b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>U.S.</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>EMEA</b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> <td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Switzerland</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Italy</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total EMEA</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">22</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Asia</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </tbody> </table> 0.35 0.72 0.46 0.24 0.08 0.02 0.08 0.01 0.62 0.27 0.03 0.01 1 1 0.26 0.77 0.34 0.16 0.36 0.05 0.04 0.01 0.74 0.22 0 0.01 1 1 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Years Ended December 31,</b> </b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">US</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">EMEA</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Asia</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </tbody> </table> 0.11 0.13 0.77 0.62 0.12 0.25 1 1 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em style="font: inherit;">18.</em></b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Related Party Transactions</b></p> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> March 2018, </em>Asensus Surgical Europe S.à r.l. entered into a Service Supply Agreement with <em style="font: inherit;">1</em> Med S.A. for certain regulatory consulting services. Andrea Biffi, a current member of the Company’s Board of Directors, owns a non-controlling interest in <em style="font: inherit;">1</em> Med S.A. Expenses under the Service Supply Agreement were approximately $290,000 and $186,000 for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> 290000 186000 Includes investments that are readily convertible to cash with original maturities of 90 days or less. EXCEL 98 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /.!8E8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #S@6)6@X.&)NT K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OITG10^CFLN))07!!\1:2V=U@DX9DI-VW-ZV[740?0,@E,W^^ M^0;2F2C-D/ Y#1$3."1M-6F8@55&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M\X%B5C2/K(!U!P O3 !@ !X;"]W;W)KQ(_M9USC.?L15$4=JAE]3H1"^+6\"Q_[T8.ST2JPB#F-Y(D M:10Q^7;!0_%RWK);ZS=N@_E"96]TAF=+-NQ,\@*\C.^!_PEV7I-LJ8\"O$S.YCZYRTKNR,>.FT1GS^Q-%2WXN4/7C3H M)-/S1)CD/\G+ZMQNMT6\-%$B*HKA#J(@7OUFKP6([0*KIH 6!?1=@5UW!:;5T/P@SO[N,R7ATP#JU' L MO!3^C(J,8I]$6I1J;LC%RR?\\9C0;E[N M:,K'>/F?:0Q7MW17K[3&V:!W)3 MLF0>/V_!+)!P^&LP@NE*@MSR(WT-%ZMU M$GA=8V2'WMO;S]) @YN4ZC1RZUJ';8^K8]Z#I]+2RCIMZ46A56:>OM MO7S]-/:$A%Z59\HC,E,P.(F0Q!4I)"0(2L+7#U9 MR/=!/3E:OR#YHL:W6-_G<$F;W/T@HY"_,@CUDHQE\,RA1ZV MF0%OI'@.8D_?$W'-:U>+S6A4,*5675XMLP+%O?Y[;#"&_PZ6M8^,'8JT MW[=T:ZTN7M>4FRFU*K>#$"PSL@1:2T=1@2JT*J4P-%+?Z M5R)?VEB(&#-R.T3ZO9/V:=?2SOMX:6-:AT@*M$P*%#?W=X$"PRN>B$T_/OY& M9MQ+)?0R+3)>TW SN$KA]FVKB ES6F=8BX0,NX0/>*"S]X&+9_QF#)8*"R!&8X MGTR3)*V9XG#-:Z'%9C0GF%*K8BMS MTK)WP7(>11)E?I7FK7;WNH&0T IM2J.Q+* .#L%0#RX4A8X?.M8C; MS/,XR("(OQ+4;D$P&@-,J57IE3' P5U\06\6L3 D%VD"'R?:\;E#I^Y+!+RL M,:Q#Q &GC ,.[N0+6)<1E_-L-OL,"FH! 2I:LEC?YW#!VN5PO*XQMD/D F=K MTQ#NYJ?NY):,4C]00I*14AP2>KX^6;<;88=>/36SNX,.X?V=TOL[>WV),%N M44.[&"Y3#\MH!#"E5H551@!GKR\1;M+',/"@7PFF?5SB*HWWHAF-!87:2:Z6 M[7U]'@X<.]O<99UUGG5T2LOO[&7YMU/U$70L2- )^98J&(YQ%C.UQ$QZ>+=0 MZVVUD3H#VA_TN[U-(PLKNB2YH_QB_(W7>S M-W^4[TCOE*>O-O9_99G[2DC(GZ#4.N[#E"E7>^57!THL\]WCCT(I$>4O%YSY M7&8GP.=/0JCU07:!S?]8&/X/4$L#!!0 ( /.!8E;F 5(#B < "PB 8 M >&PO=V]R:W-H965T&ULK5I=<]NV$OTK&-W,O>V,%!$ MOY3:FDGL=IJ9-/7$:?O0N0\P!5NJYTLX)M[5>9"PVWYL*QV MI12;9E">+9GGAR2PSG@#'7T>GL_:99F#_^MG[ M3TWP$,R=J.25ROY(-WI[.8MG9"/O19WI3^KQ9WD,*##^$I55S?_D\6CKS4A2 M5UKEQ\& ($^+PU_Q]9B(W@#J3PQ@QP'LU '\.( W@1Z0-6%="RW6%Z5Z)*6Q M!F_FHLE-,QJB20LSC;>ZA&]3&*?75ZJH5)9NA)8;\DYDHD@DN37N*K(@O]U> MD^]>?4]>D;0@G[>JKD2QJ2Z6&IYLQB^3XU/>'9[")IYR+9/7A-,Y81YCR/"K MTX?3X? EQ-L&S=J@6>./3P5=EZ4L-'E;51#G&RR>@P,?=V#VUIMJ)Q)Y.8/- M4\ER+V?K?_^+AMX/6'1GQUEI7.#<4[$ M7J29N,OD DK6H@+H&.Z#[["/VZ>K8 3- "#YS WR:)J@$JU+1$ M0FX!ZIP44F,P PL 8T$X0FD;1?Y$EW(ET0^178*4*!Q=9S^6!!0XQ8D& @XM;<+$3W(_Y+E-/ M4L+$:LB>X1PMOI*DE)M4]V8; QU;>()@C-FVH9Q2'/.JQ;QR8OY5;V4)M'$H M;Z(I;QB^E?WL,*(C@+;1*HAP?-3KZ,9S(ORLM,C(L "C?.(AZRV.^ @C8D8I ME*PIG#U:I$Z;$H1SJ9\:)C4DNC,)GRSTU*::5>"S,5;;BGJK:*(&T(Z1 MJ)N2WA<:9#'HY!JVVNZ(?!JK33@TB,:LA%BMXM4$=]*.F*B;F3["](/HEC#[ MFZ:\3MR=LP[(Y4F9M4KU1AEKZ9 MGD055;II]L+$.D<(TV[Y$2O&IW0@ZVB5N6GUHRJ>MZ*:WK H;)M(@46MVFA; M!9X7XK!Y1[;\E!;QA97/D<8O]*WRC9E%C$T40-YQ(W=SXY7*\_30=#6ENUT3 MB2F!WWU46A(:?H\B=WK&5R_!ML$9' VC[XB7N\]/;[5*OFQ5!BN_^@_Y$=HA M_83N>W[68]1S>1M&W3M(?>$D%>8<=$5E@B>OO->>1T$:E60OLEK.211X<\]K M_I%J*TI#ZK7>0I_[/R ;HK)SQI_0'PG@XCU?!W/>]QH3Q M8,YH/ \"]NPYK2HC'QK54.M*PX79W*<_90[T5^UD\Q(E>T+GSI8.4)3&^PLS MFC@AX)V\X"]UV\\F$"W_A MI'FS20W/F*9>I)M%6I!$[%(HEBA(I&$/6<3'YU.87>"'4T?.O!,RW"UD0.+6 M>9TU+Y:@Q4^3%.V/N:U-%G'HK?A8;F&&41SPJ<,=WND8[F[O^TB/&AP:B5)N MS=O*/9"EJG .LIOV!>.QQ4&863B%NI,AW"U##C2)E6(4JRTQ5JO0MY*,Z)5P MQ?PI4N^T"#^EQ>^1>K/=3D9_X@$ 9N*[-1N&W\D=G_[3%Z;^WU CCGC/Y&T8;R=P?/?)PK>=H!Z=#=Z(VB>H MB!5R@KKLOKPQ/QAH?R"R_C]02P,$% @ \X%B5H:$!I"H @ 3@D M !@ !X;"]W;W)KCR$&QSSO$YQA64M54(-=M?%UJ8!F-:G@?A@$$[^@ M3'C)O!Y;J60N*\.9@)4BNBH*JO[< 9>[A3?T7@8>V"8W=L!/YB7=P".8[^5* M8<]O53)6@-!,"J)@O? ^#6^7,XNO 3\8[/1>F]@D3U(^V\[7;.$%UA!P2(U5 MH'C9PA(XMT)HXU>CZ;536N)^^T7]9<@SR5(*+3G+J(&,W%%. M10KDTD# (PQ[Z\GSZL$OW,72;/&R3A[7>^,WD18'["%;=$R&T,KE4 M["\^21O"C?8Z=^*3/4_3*'"_ _?G(#L)QFV"\>4)F-;5:??C5Y["T22>1>/Q MH?L^9!0.XR@*^]U'K?OHQ$B-L(\;LBG%<$ M\2M7A[Z/(3J&9ZWAV;L,7[#O9R=='T,XU_[>:6>_-+Y1M6%"$PYKY 2#*9:, MWZQA9U@?@DS1XG-;-'#]X0%D WE]+:5XZ]DQM/Z&2?U!+ P04 " #S M@6)6O!77$=D' !V)P & 'AL+W=OUE_53LA-'HHBTI=S79:[R\6"[7=B9*K MUW(O*OCF5M8EU_"VOENH?2UXU@PJBP59+N-%R?-JMKYL/OM4KR_E01=Y)3[5 M2!W*DM??WHI"WE_-\.SQ@\_YW4Z;#Q;KRSV_$S="?]E_JN'=XN0ERTM1J5Q6 MJ!:W5[,W^.*:I69 8_&?7-RKL]?(4-E(^=6\^9!=S98&D2C$5AL7'/X=Q;4H M"N,)Y[IW=5L-4.9N.6'0G^6]_\4 M':'(^-O*0C5_T7UGNYRA[4%I67:# 4&95^U__M!-Q-D ''L&D&X &0Y@G@&T M&T ;HBVRAM8[KOGZLI;WJ#;6X,V\:.:F&0UL\LHLXXVNX=L9>A:EA H.[."1X%^E4JA.?IR\PZ]^.DE M4CM>"X7R"OVVDP<%]NH5^JGW_G*A :_YU<6VP_:VQ48\V#!!'V6E=PJ]KS*1 M]1TL@.B)+7ED^Y8$/;X3V]>(XE>(+ EQ +K^_N$X (>>)I\V_JC'WV=Q%-5! M7+BFIAW)W"/-YKY0>[X55S-8%"7JHYBM__XW'"__X:(UD;,>278BR4+>'TFZ M.+8#HV:@R3?'=;)<)9>+XSGVL=&*4'(RZF&*3IBBX,1?2Z5-B->!!8BF7(") MG/7(QB>R<7 !!F1=7%L'\=D<8U@(,E@)AQ5>IK%[*9(3NB2([I?:9)("_KB M):.?G--D%0V .:S(*F9N8*L3L%4P1KKT5]VA]P\@FDHH9YBLI@R3B9SU^*8G MOND3^U0)7F]W3;+/(%8*N3=:X"*=CB:Q%4XI6[F7!2^M8BV#0&]X M(5I)@L+CJS!+Y-26Y?CG61+% Y N,TK3R(/R3%=Q.*Y%!?%3-#AY!LJ=*VWB MZ>C<@)VSWHPN\6@'.LQ@2@GU@"46+ F"?5/*6N=_-FIO4D5>:5[=Y9M"(*Z4 MT&[Q)B,P">3O(>2Q%<8D\FQ.;*43!T5K?;T#A,)4&+<\K]&1%P=AH&^A8H"( M@, U+U6>=46,DP$=)PZ,\3"].,VBV![#>4 MEWM@Y-MZG<]^6%,\A#RV6GK@6LW$095:_R8UQ/,X+3I11N/8P) BAC#'9C%. M(M_,6L7#8B]D3L+RHG>B1A^JK2P% M>M'-YY667%0R-:_0'N)(-.(![-&AUSMFL"'W9N) MC9O^*A#/':>Q"5FQQ+-.5A5Q6!9]>>:>US4'T$7.-WF1Z]RS$<8B. (^-IGC M=(7=R(G521+6R0^5%K!ZD%":('.A(P[QPVR83!Q64>I))\0*) D+Y F>:&/? MB6^L=W.&AQ/HLJ*)#Z 511(6Q??EOI#?A(#"64-X&FG4_ %M:Y'ESB E8ZD; M076H(<6^I;9B2,)BV":3;B*].80X=(RD0[5S66%/1B96ZTA8ZSKQ>%[2(V,5 M8W18P#F,"%UY&D1BU8Z$U:XYX-B(6UF+;@.9U7=OD?">O?A!#"XFQQ:1O&P8'-9$>(+ *MW)-SG_4MH;Y='' T<5 'Q*!$Y M[&+"8M]B6T$BX5ZO?[9E8#I[/3)ILS>5MSYG*VPD+&S!!7%(DG-!'':!!:%6 MNVA8NWZ&;9??56A[J&M1;;\AZ)TJ5;0-B@\U'>O4'*_BX8&2RXRD*T^$4RMH M-"QH7ZI:\"+_4V0-0E/@\"//"PYMU!SRR%Q!XPJYY BBUQRR.CDXM(Q$(PHN M*U^M0ZWBT;#BC;>!$R(9GGD%S:+WA*M^VQQQY<3 'WR^@O,MD M4?"Z==IX>^DDWT);G9-:OJ;#1MUM1CQG']3** W+Z._-8PE S(_0X4!=6AW* M#0"&@K0[@C\H^!;H /7]H6F!*N]T^::B=>7F[U+;F*6C"7#8D3B-/549M;I, MP[H,37-VV&KTWX_",/^?$^2D9[=3>>L3MMI.XQ]_2! L"YY-=")O?:*V0J#A M"B'PH* ;>9Y*&"6CK#BVBFCJZ=2I+0[H4\7!TP\+Z*25P53>^H1M94"?:'F? M?F! Q\(?T>6PWG59)%;HZYV08<2ZKB'A$A]F*@X4?U'Y/"F"3/K&= MREN?\-DSVW"=\1TI@#D4'B?#$UZ'%4Y\.9G9*H ]T9T+KIY( )/6 %-YZ].U M-0#[\1J 35H#3.6M3]36 .R':P V;OXQ'=\6<%EASP,R9FL ]M=K #9I#3"5 MMSYA6P.POUP#=![.RZW>@]..A\,JBH:7!A9G-YA*4=\U%[L4="N'2K?7>TZ? MGBZ/O6FN3 T^?XLOKMLK8-9->R/M(Z_O\DJA0MR"R^7K!"#5[26O]HV6^^:> MU$9J+&PO=V]R:W-H965T&ULM5M=Y?0M6>.*_W)'ZE7. M^&%]/Z'K&N>+UFA53I#C!)-57E2CB[/VNZOZXHQL6%E4^*H&=+-:Y?73>UR2 M[?D(CIZ_N"[NEZSY8G)QML[O\0UF7]97-3^:[%D6Q0I7M" 5J/'=^>@2OLO< MUJ!%_%W@+3WX#)I3N27D:W/P87$^7SK2$?[ M,1O#P\_/[&E[\OQD;G.*8U+^4RS8\GPT'8$%OLLW);LFVS]Q=T)^PSW^YX^=(PX,$#IB@#H#)!IX1PS;4.3Y"R_.*O)%M0-FK,U M']KXMM8\(D75I.(-J_FO!;=C%S&I*"F+1<[P MPP_H_G&:. W(%XF5?WF(*B MXC^0^=XIK^!V;=-P9[ &'RY2<#OKUZ#5PWF\Y)L:%XMZ-F$\8DU])-Y M-XGWNTF@HY-8K4@W"OCW(U[=XOH_!4VLI_G,:Y%NZB]!HSOC)P+\_RNBJJ>ZKC2@T3_!1_ )>,U<7MAN6W M)0:,\*G6/'0ZULS@/\+/<&@VX>FTSRFTSRG4\GA'>-[G95[-,?B=^XTN^:SH M:Y SD.#Y6^#"-P YR%$ER8XU:%F;)?3A L( N=!Q./SA, ]DI(!(M#-LUO=W M=)W/\?F(+^ 4UP]X=/'K+S!P_E %UB99:I,LLT0V"+.[#[/[HC"_)+0[)G\8 M6B&H,D8,JHP(I]"-PB%L)L/&(4(11$-<*N-0%$R'H$P&!= /HCUJX#IO[SI/ MZ[IV@1HW6^@"S,F*7U?0O%EP5*[S3&Z)M6.=F%&))Y56Y*%(\+ ,$N:4&A&9 M8:"!7_V]7WVM7S]0NFESDF]?\]VF0AM7OP$5OZKC7Q;/@#FA?)<[6*%4KO>E M*88PG(;R>B0#Q=35SOO4]<@F66J3++-$-@A^L ]^8#/XJH '\@(C+!JQ#!%# M'T=63K04#6S>I$ ;^\ M ]N\KO/*7#RA-#?/#UQ'+AX9*'I4.]U3B\"KE@.LZTK8CH\22,2(RY4BAKZZ8:.^]2.N]2^Z@1>,Z'AA^ M43YOFJF=%S=582Z52"YC/U1<]FHG<>I&;Y-L9I,LM4F662(;I 5T^N[:^9'$ M4+;*CGRM+.2!?M!3$\$JV\PJ6VJ5+;/%-DR& ZD%:I/A&K--78F7)TWKOLZ? MP+9@RT9B*:I[P/)'3$$K]@EI8UA)NAEH%L!8 7&1O"TG^I,Y.2ULLJ56V3); M;,.TZ-42J)=++*2%,A60L7$T0Q(H2RUCZ 2NL#,K8.+6;(9DQL&&'NZ%"JA7 M*N+FJK\LVQ:[\3-[%@I?5E.NN:9DR%A=5-J)GEQ4-ME2JVR9+;9AR'N!!>H5 M%GW(E6$V"RUF2 *-PL?,#$G-D$P+&3JM5T^@7C[YQ):X;@6I&B^;VTT/&)2$ MJB]3C)I';(8D9LC,#$D5$%Y^+A)=9H(-W=;K#E O//R%V7$W&?6"V Q)]!,X M>=F098-Q@+Q U$<5."D+C51#G_82!-1K$"^XAP"5_I;5!.3Z"$9R-Z6 2GZW MJCQ894NMLF6VV(;A[M4'J)\%GJ@Z*'#C M<.J[H2?6BP*( D\L&1D%@P@=B"9#'_8:!-2+$*?<5.BHM,N25;4!RAK'U!-O M )Y<;XG^9$XN)KL/"]A]6N!G/"Z ^C8:,6D!JAF2FL8;^[7M>]",]K[&BC#UGK(",U25E\Y&$F56VU"I;9HMM M&/*^8T?ZCOUTF:,CU%:+$9(@<]]NAJ1F2*:%#)W6]^M(WZ^?(G,@8P\))YVI-E=M=L&)5;89D@6&<>C[ M 10C8!0B,H4G!*JA^_O&&WWO?7_3=B&WL8J=(%; I+5$.\.3G6Z3+;7*EBE] MYOE'[F^@OO-'^L[_:!"5@3.W_F9(@A3/+$S%'<#WE7 MW\N_0%Y$RN=8Y=XU;?Q1^1% M=8@5_;L;BL$U=_ *2!2@T!56_YD"-YX&3B1*FJD*B-RI],"R8MPH\,0GG"8' M[XPT+QU]S.O[@B_[);[C=L[;D!/4N_=X=@>,K-O72&X)8V35?ESB?('K!L!_ MOR.$/1\T;Z;LWZ:Z^!]02P,$% @ \X%B5HF"YP(S"0 I"D !@ !X M;"]W;W)K78G MVN]RSYA*[NNJD>>SO5*'MXN%+/:LIO*-.+ &?MF)MJ8*/K8W"WEH&2W-H+I: MX#1=+FK*F]GVS'SWI=V>B4Y5O&%?VD1V=4W;AW>L$G?G,S1[_.(KO]DK_<5B M>W:@-^R*J3\.7UKXM#C.4O*:-9*+)FG9[GQV@=Y>YF: L?@79W=R=)UH5ZZ% M^*X_?"K/9ZE&Q"I6*#T%A7^W[))5E9X)(2IJ_R=U@F\Z2HI-*U,-@0%#S MIO]/[X= C :@96 '@;@Z8 L,( , XAQM$=FW'I/%=V>M>(N:;4US*8O3&S, M:/"&-WH9KU0+OW(8I[:7HI&BXB55K$RN%/R#-5(R$;ODDLI]\A'662;SY(^K M]\FKGWY.?DIXDWS;BT[2II1G"P48]$R+8KC?N_Y^.' _A)/?1*/V,OG0E*P\ MG6 !X(\>X$G?IK,/XW>O6_E@1;L? ;;4[+VELVV?_\;6J;_\/GX0I.= M>)P=/\R6.%OBH]D)L/P( M+(\NQ47Y']A ?3XK 46G$$W!*Y8T V+]K;XN=*9#/O<7[,^.W]+*#.LD; O( M>'%<51I?U?PE5_6%)CL)WO(8O&5T5=\SF+3@5!=;GZ/]Z.5HR0A9KB?KZAKA M=;[RK^KJ"&P5!791BU;Q_QI@NDSQ1M'FAE_#NE(IF?+FXXZQ^"6W)9B$[GEDXXB''-NQKJ;0..W+(A75_KM/3YL78@YLM\XH9K MDZ4;OQ.;HQ.;J!-72A3?YYHN88^(&C2$#";&QKG].D/+"4;7:)/A $B46BY+ MHS!_H7JK-@F[UUNUXW*OHVFBSJZ]\1PF' -))U ])G.\S@)9C$;$BY[88#O6 MMA!01>\!L8XI\T)$[DY#T]3U&&&;0*E'EG91E..V[VAI5CD:2N*FW12=:X*R0 E EB%1G"*_ MM)I U(/9\YI?#B8Q>7V@O-677K29!PJ94J?'*@W M;R)HLRR_55S(^PCJ%4' M(6FE=]#!ZX(7=^[BQG@*VS4*P;:,A>*49=-U!V%-@,,[IJ'?T;:E$.Z*TVM> M&>[VXG;9RLE=UP1MUB@ W#(:BE-:"#CH%5W(=*K I>2E$2'^LHM<]IHCA*;D MX#4;<\BI"Y;ET#JJM7H7Y$0K&3XV&3.*O5JG93H-AV1+%Z?*B M&"@>%!0#+0G:Q.NSRX*P%MBI[:X96@5*$K9-<^6FHZ('-@'VL1]+I-O:9 M+5%@0V#+C3C.C;:)JAB(CJ35S?A<[.:@QR,J#WM8D#B07:-Y%I1YV)(ECI/E MEY9!-2\?^<*Q0M@S@LP2)XP3YH3Y4XH%!,)F"E==R5"N/ B0( M5T]D*G99<372\0-LUVB.2# 9+'GB.'G^KO:L38H.Q!(40E-,1',S5ZRM8[G@ M\N(FR7>3B. M;'(GN*X968=B:XD0Q_N]HZQO&138SK_T;HLV=^%YC'"H1\*6FW"D.F5/^=@,,J-/WPR^$*SG7IM69$\P8I=6^QUGH&45[HBG4-? MP<9G'MY0>/B2D/5ZFH$^.^@Y" GT%&1TFAMG3>C<"L9*F>Q:42AH+9[?SA$/D2*\FC;.7K/QB> I:$NE)$ZE M\2H ;MQ"6P2$]9"\&DK"S\,J/*,FN/2:K7*W)+AFT%IMED'G+!&39;0F?.0- M;8KGU(0HH?]P37BAV4Z]MAQ.XAQ^NJ>XE!T$86AXZQH4B-3'C>8,U!SP/AH4 M0@:VE,ZWSN&;\RCQ&&YXJR#UM60+Z5%7L M\1SR,2_A$B*K6E[H <;?I&L"@HMXE !QN@:?%4J7)."@%0PD+AA.5XO=L[;@ M?0WI88N#5HU]ES^,^E5H$/-K%;(XEI!K]*KDD%'"B2EJWA_I56>1O[:73GMU&@? MZ=^]/OGD 5JC:<_BL4.KT,E 9C5$%M<0E\\&_QH:KQO>-$.) (;FHO1ZY#FF MWN"UXY#';)6'BEXV>N(;5Q(_XA&#+^.^N,IAE:VFYKQJ2M67V3QA\17 MW>'0UV=:)>^Y+"HA.ZC;(.GL&Q#)IZ9_8R9P^)J]Z&/?EYKM-")6E&1/'*-K MKPVAZ1B8+M%?*=P.?S/JGP=?/"?FV28@93,K(;(G3LQ/,"K-P5Z('M9WGI?Z MC%8AA%879/$#\9.\NBKVK.PJPYJ?13,W.\K0%#CW:RZVTR./2XBLK*BJE M[SG3@W9C+&F-*[0LN:XCD!8Z@>=OT>"BA+9*7S6\,"_83;Y_A]Y>]B\,VFGZ]Q=_HRT0L83RMX,ITST9+UFH#^'TGA'K\H&]P?#%S^S]02P,$% M @ \X%B5OY#ET5^ P 6 < !@ !X;"]W;W)KE8B"SY)#EN M]NN/E)VL [K@7A)))C]^'TE1L]:ZG2\1 SQ5VOAY4H907Z6IER56P@]MC8:^ M%-95(M#6;5-?.Q1Y=*ITFHU&[]-**),L9O%LY18SVP2M#*X<^*:JA#LL4=MV MGHR3X\%GM2T#'Z2+62VVN,;P3[URM$M/*+FJT'AE#3@LYLG-^&HY9?MH\$5A MZY^M@95LK-WQYCZ?)R,FA!IE8 1!?WN\1:T9B&C\VV,FIY#L^'Q]1/\4M9.6 MC?!X:_57E8=RGEPFD&,A&AT^V_9/[/5<,)ZTVL=?:'O;40*R\<%6O3,QJ)3I M_L53GX?_XY#U#EGDW06*+.]$$(N9LRTXMB8T7D2IT9O(*<-%60='7Q7YA<5? M-B",X1WS]) D=@^E3WJLD/-?H,ZSN#!FE!Z^&AR MS'\%2(GBB6=VY+G,SB+>H1S"9#R ;)1E9_ F)]V3B#TP6KU^-WX^NSY"=GLA.SZ$O_G9; M8=0/P<49P*TUWFJ5]]NE\,ISR58UHW;*BGT .X-%?,-3Q1T^@ [8UOB MYN'1">,_FH!./756;^$-8R6WMJJ%.21O@;0*J#!G)+I^>R419/>5PHK !KG: MJJ!^L$3V5HQ84'%@@Z%%-/'4$QWL<\+[FA)'Z>.>J$D&HJ- AL8*.A'32Q@\ M!XS$=W\TBMHZ*D)W>/WJB7V?(%9?6)H; MQ,YV.FG6[FBX4ZIH M?TTP$M:B%LU[:6DF>4JH2FI0HLZ?FW..1Z@ H\,/]NJ-\#-*C,G6. M72CG TRJ"BZJZJ7+DSZ;=D1_&V>ZA]C5W> [G9Z>C9MN6OXT[]Z?&@ &%$ !@ !X;"]W;W)K MM7U7FT9?VL+UJY6R]V]UW6Y>'YPB-RSX7=))9V][0EXOJ]<$Q :1K77:T M@L+_;O6YKFM:"&#\YM<\B%O2Q/QS6/U[/CO.,E-.G[?U+Z;JEJ\/OCTH*CU7 M?=U=M9N_:W^>I[1>V=:._Q8;&?OT]* H>]>U*S\9$*Q,(_]7=QX/V81OC_=, M./433AENV8BA?*:5;3>%I=%8C3[P47DV@#,-$>6ZL_C58%[WYL>VT\5I M<5A<"U6*=EYN+4J]>L#B(K3 M]E8?O/GJ;R?/CE\^ .R3".R3AU9_\P?T*?[WD[[KBK=U6][\WQCL#Z]^.OT7 M>*%XJYQQ-/"2SMD 9R1KGY8:\E:VJ[5J[FE\V38.4RJ@M"KF$<?]9J65 FTM358?%T# MN$=?_>W;T]/CESSKA[.S2_Y^\O*;0C6T?%GWE2XZ#VQ/8. D]/U<0)=Q>%P9 M"S7BI_DOFV5+,+2;!@"X?N9,990%4K!72Y"F(M$ _S6U(^=58LK=.TY@9@:0=CID=#/0#%9A@_:JO M^7!0CF"2CN;\U[?/CJ??08'5->MB[$S:FD%7:]-A QKU_-GT:1K$U("DZ]5, MVRCM4T#4#;;>8$+1:.P(C+2S3A'C5)6A0V%ACV-LA9_7MBUI)',343:B1_0 -L" MR]$4Y[VUNBGO>8BIP. TQ/T[HO27,?:D.(.,N]Y!0]@%N+ N/E]/BHNFG*:? M+L!ZME&"J.T?X[P+D-RHXGIJI_78[^]["\<#OW_UM]/3)R^+/<,^*;,!C3YT MU=BO_U X:_'/Z3]'(7!6Z7K?U!\UL&5!_PHZ;OHSAA"*=H:=@UTJ):0I%VE ]][]:S&B40LA V4*-(,"T0'+Z7!S$6M*;.(@ZQ>DO<+2.H6"@KZ M$%N362"U3@.@9QI6KW 3RQM(+=2&\^0I-!1[=S]0TI%RS*6[3 I,5KII,W;L M'N:_'0[ ?C] 57H6 M3 .70E7&1"T]RV*V^/5EJYWK+"HL4& $$):7-+)LX1 M]KJ!XBJ]>F1O;<8&26&G9G&(%598Z%:[CI?%(; #GPHKPHT@[B <[B&QJG[M M_=2_E"1LI&&^%W\JHGB*&J$(\ZRX!4,#T,$XKUDJ(/1=K<*9#01\!Q&Y:- QO6?L&4TUO>:-)&F8&37P: _ M)VR_KW190R6R_ROKGFLKKL!*1 9>6FL)$E(LINU=?9^I=AOGBV\"V"F,IH]\ M%):FCJ$IUIG_/!'WI&EW@#N9CCVZPM[.>W"7"9!WQI4X-O8^\^"^2SHO^7/B M:H;GVZJB;U0/MT=77^*X,AD(]P'1SMP5_^CA#CT^%N1.=N$OGH^="8?'?U?& MW?""G\F_)=2S0 "32FJ6?#>67?\ 2''F=RV\H9K, MRUWIB@UZ!>S!\L 7@BZPHCZ!)EG6\Z60I^W!F%A62/8"C+H0G6*P=$D0( M_=KE_%FJGN@R$P-\_M//%^\.BY/OBL]"DO>N,RL633JI$"CZZ'M\OL!=T#!9 MK,0Q@R7% _Z"0QJ\6T+-2MW 0,:M",W@UGZU%AA9]2JQ>Z*+/*\'YM^.))+# MP.X.IE3"@:0^,)BB$K 9[;YOGNQ$+!9-S"BC^?7'0 +_ZZ;W0'A7P>767B9Q MJ.CM_EG9]>+40_]2A-;7B%X,CFZ#*H88)51-!V&QN"$9#[H>NG8_7H-[3GQB M+!.C'/K\)#ULTFKP4^61-2GF&%[,+T5$=52'NZPG1]"PF(& MX.JGSRGV]^BDJ0A1M:4PNU-W\@,CV#L$==UNR!$%P<^56_(,_O >\H1Q@H4K M(,2:DHA /\K"%PE/ VV5W!>L7BP!*W22!.$Y;D6"6YS%D-^U(E=[ ME@S9>*PL^G7< TQ[[9L\$GI_F3VZV#X(* C53=3)3J*Z*.AKQ-)+(NW":CSR M3C/.29$T_<,1H$.291TQC7+8R>A/T^)[DIV?678^)IX:TL8SFQ.]DX0- *X M!,7V]@8< H>X MV]01(]VUF>#/NB2W] 803Q^79I2QET ]I7FN0*5"972_:C M+'-%YN.WOA7?PI1BJ22'[>$0/0%F(D\.3!)TJBL^0*3KXJ0X92^F6QI;X?-C M24@U7>XDG8/Y32=V=HQ/?#8MI5$4Q;A@OE[.DJF]-8 %*)PKRO9AS2^[6+;F M(&09I(D_Z"1-Q2/1CBS(0Q[_9N*S%)D"2H.# 5CJFMW&48*UJQ6<9X)PK:#[ M)T%[P!X0(\Z@0;:R6NM:$>H9S IVPYE /[C:NO)I2""DMP.GB%!DNCX%\2D] M!!>&_5U:2?#0@>+-C=!C= D:/!;XD/H(N/T-%@R,]K)8MAN0'X<;\^80^9/I M*+=.1(DJ^D?L$OZ-<4,,%5/DX:-&RY:*C:53M5?,K*X97JED$/!U6XJ]6MJV M7[ 718!N6EM70U1IT<3:HRJL$(*IA*F2-'](J$U2>GB2'!\H!5(C(XH!<.C= M'Z#$Q%OM-JW7*V?A[%?I[&=[\)'BS8X#&)]_C2(>\K3>%7"<.0W6AL6:S+.P MOI!7(B.?I?F"D>061STRQ@FD+9P+AK5L:ZJ3B5WE\#[@.])\2!RK%[TXU!1O MZ(THS039+)DZ#FBAN5KKQ#6"AEH:K&Y9;1'\UFA,FFSQLK P97&\+SC&?CY7 MY+5M<"2 ?\ICE(DWO#]+7+[#!2-!R>ZC77OH+1UY-F3/\L_$!.ROQH04$(.9 MC&K7%8^"VA<"09D8B\?REZ3OK+G/W"8,6;(;V?E@)7E%;$(I@R:^V#!51^4& MCQ$O"J*U(V>D+ !)*ZP&KR 2# [*PE?E,B]P)[09Q(:#]-V0;[YVVRX@>74# M[S(XCUYR#=N6X.]*NH[<=YD:$),F,I7AEY.*%+&CD]YJB4?[=4GI+00"&UW? MDMQ#C<"!/_S ^NL"NKE9&!9ML::'G,]FX: 0X9*RTA82,GBZ#D^9Y9W$(<&G M@?U6'5. '%/GW4Z@&G.@!G6Y;-JZ75 >CH_,J$:\UTEJ*]8G^&=GQ*2\&UL@ M:I-!WL$TAUST<)Q@TLJ6RQP&9J+@)E]<7GVE5NN7[[:&2^851>ZV;) M9+Z^=XB $OA@QM/CDZ?TYSG]^99DY7C+KG+D1?)?#Q3]*%;9S4G!TF8)!4\$ MI<"%<&T+R?%*%&QLV:\@>XWX3+0)\XV7G5)9>Y\\AFCVQMW)::(XX8S\?L'8 MX+&.CR,#P&^"\T$.7DI,85,)8'90YR.2E2J7(+:]IX]-3TI3PM:XP01D@VOC M@F^5_4#174^^<_9LWEMP-U3%)-ECRDD2.BV$PKM18HRV#1ZO! MOW5P :(0#=$V+N6F#-.GL\+7X<&^L5FC@NJQ6Y#+"J$L;HAF5LK>Z%SPF* M%2D-LKLDV800H6.N8S+7)_HAI&LX,]9S-L;G14GYM):+\GM+GIY/0E*-5BS( MX2$#PD:&\WGK.M3\VY#=;&F8WA"2?03NW0M><9)WF73CL91Q\%=%#UXT@06" M7"11'T1B61@7&('!H("/U*=R+:4"[D-V 0278H&^8R>"")=2C]'--1QP4VY MW[']BVR*H M(! ^$RMS/4L3S[ ?NZ+F%L-E*)+Z*!]0R912!]C=_=J[#;3\!2:PC(G&/O=L M!#2=UVU?>95--#FSEI0@R^,@(2?M)W 3G<0=XC0-U]UB3]Y@B6>L*+.%68T: M*0I:+B0$V$,A(6VW9Y.!%?:D\?7'+$F:7.8\FTES,[9=D9\\<'_GYDY7$TFQ MDNS6M302L4&*FKXE@XYI8R?D8&5HTF?< I9U5"6XHR8+>?AI\1Z';N\1O9A2()+_/[JTWF<3D9=*FUPLR&'XA'#$H!9N=M EI0< MS8W6Z_!$AW*0L:0O+;P94>6TO'",U92F$GH #!\**RZ.=C'9Z"?3$&IG4(:5 M9=J7,P*UD1AF YB \B^SUF,A[VYV]Y3L!!FJ2W6?D6DK:4C=@5R9HQ8U,5(, M&?XM/'GK5C4AD$_IH-0H<;VB!/G;$/V<5=#0)KIF.96OWYY% @&#GM4C[0E2 M1AE<]L[W N/CPJI5)/+E96P-G)!YK/0L- $,V@_/KL^+)\^/)U+3/#D.B#L; MSZ"/8O0\56D&K5[Y#X/RS<"O9ML="B"^C#?MK,L347.'EQF4C'D>?FSCYR6ZF?2R$#M3H==>_CY^MU6 M>U JAMVV!&9$,;1%"E3([C-'L\G*]"6S"%<8N5KL84GY.4JYSBF* :8Z:V9] M%]HX:=PMPL46>BY!O%5F;$HKO@X$J=+A"W%I\HX2=GRMR/6EY(4&44"$2= 7 MZVMI)9BJ!$BQX8JHU$?%^F5$HY8'6 .*<*Q/7GR='H)K MS?G(MV$":$F5M#^0V4Q.5VVEZ]16S#@F'T)%!D\%4\+,).9ZAW(;,[-W5()Q M6JI:DZ&(P/N*^FLC $\&LWE2&,'*ON9HE0O<$XZ:XV))AB<%!>72/.NZU#T M,3V<4_I_Z(6&YI7<+?+0"-OY+YD>WJC_C.&8*'\VQQ&HZ?Y+\._6E%:P)$X9 MY83* 3%>\8XWA#"@/M4W"&R'O! 3N+EZ_[6O%JO@P_XE72GAF,&D#4WE6+\( MXUF,P( F_WI;R&2;P*+XLK,,?'L0J[AIVDTCG<.I1MX"^9V2;H8]\AND*#5I M1JA$C+J^'SI#VD/'.[!VV5EQ2C@%X MGF().2^J'MX&%3"GO,E_NC*AB*+-%05>8M#2ATS.U-#T3727O(OU]8Q9YK2M%TA^CCV$Y1 MDN$NMM#0T8HLC<]*TFE"P,G9RAA5L<53-><(=5W[FWPE9/\7TFX1#Y.](T4= MQ'VR0#+\W(WTP6<,0*NY$$8))R9F<;&SIJAZI@8W_WINYUA%W-_]X&6I.:O' M^FR2!YCI.%;N1# /VAX1X(X#?':LZBB!3E<;J+O17QKK;%MG8>*V+/!EPE'F MRN#>A2\ZRWOARFIWG&-Y]C)G3A>SQ/3_,.!BOZ%-BWC ,31L MA)D9(0K=;Z]Z4?$\WOI]-J%9+Q]&];0WSPI=%! MYQ6%0T[N;GD/)=<6#&I(2*:<><1W\D S?VVP0@H-97E=9U=?!RHEUMVR4E8< MG=/5V*15]HI@< GC"F/&=,?MD^LZ(_OOSLX\Q,D^]S 83D?WV7;1.QFH^7 ; MN(6-'*:8X)MQUV5HG8WUFVJWOZ"3S=:MH8XA20<#H"-2*\)-FGJXYSM%(+ W MSQQ03P:L<]$82%COLIZM+5BBS_ %=W"D?'S11/8GL&.I-K]/2?WJ%)S-]%;+ MDA(I..SNUU#-T>^>< Y-;KMN55CW5>LXR&)%QN$!X&&#$@NFL1[\HGC$K;>/ MBR?%T_%&Y=TG7";C3D0J81'N@@B%[V-13%0>6ZT,9%$1X=?@)=A,(C+7Q?.. M$G))E_ Q\J(6W]LE;I9[TK 0>F -M]H]PC7,3,@]_SD)"+=O.08-F!T'8=_2 MK->>'[F7JPYYFMUZ<'0@*03YHX5_T1%"Q1=S8S,=7U5PI>;B=:CHL*7:6>0J M[YAZEW5,2:7Q:E]#5;QWDOJ LDJZ;A;0Y5J(%6QQ/EUR%=1AR1"'U2:#$B2= M6LI0DWPR&%C[NAWU/XCTA00O!0>)G'O!3Z5(OS4+4]@<1*-TVZ%4B,_S6R5[ MG)F(#K)-;HF%#T5CJ(VRE8MI>+DX%EU_2]J!3JO)R@0/./F,8VEFOV(L>7*6 MR<%1BYY.?MMW!%;ETMT86F!!:9=#;K,<[B>7:D+EFR_!L&;BY_Y\@RLWQKG> M.\JQ*A@L6WCBM1+E3__P"(.NBE07YSR<9P$_<'C8WOD[#F]K!#"'U^62Y.'P M(RQZ3 5N]UP^<'19/*^8Q'1=T6WU[F?9%O(0GI:QTKH?PRGY/'X:[\)\Y5[$TH&1DE M&8W4KR>WH/*;>?<1*\)N,7$KS)F2C !J]T(5!U'YE:V47E]12Q?TF^14-;>D MA?14:N]/:72?@/$=!WM0-GZU<)*NI5)QG;K<\$5T!>7K&U6&''LO#ZZ51;F1("%,2G8J2T<3L!Z2041!(8N0;^S[D_B)CT.AE7Z#J.RYL(%G4[X_LQL5<;8!\2^JJ E%#7_^'BPZ>+ MK)>9TD""I/@.B2;U13!3XA@F-W5[K(3DW'>NIL:<#^<0,Q$K^*8-"TE#"8 Y M]9'F?FV,Z^!.Z5LJEF 6,[U/&=[[*NRJM70%\D:SJE=-U$9/C_^;&UB\X\!* MT#?B<&+F5W"*JXQ_&QJE"]+=K2ZT8L&_ZU1>+XK>'5:NU<;EODDT?%XCA)<3 MA?ECI9\A1H>7M[GQPU^KXG5#39SQ.^&[0W409'[-07XF[G2)>;)MM<")W91W MI[3J,/>GAY$KD0]+X>BBHYDTAV8;%[Q5$P((HM)%TN^+ZZ MQ!R43 !?78BGDKWPZYI#:M*6.U+J6U^KX-^<77^.9G+L;6='V=OJ$.$N^)U\ M7%YK.GEQ77P:7_MW)F^[2\/EG8$?E5W07;I:SS'U>/K\Z8%$QN%+UZ[YW7>S MMD,XS1\IZM&6!N#W>0N3Z;_0!O%EB&_^'U!+ P04 " #S@6)6@>$YHE\$ M #2"0 & 'AL+W=O_<2$XW4CWJ'-' R-@47>*M UV7)U/8*"[F9^:&_6[CCZ]S8 MA<%\6K$U+M \5+>*9H,.)>,E"LVE (6KF7\97EP-K;P3^)WC1A^,P7JRE/+1 M3KYE,S^PA+# U%@$1G]/>(U%88&(QC\MIM^9M(J'XQWZ5^<[^;)D&J]E\0?/ M3#[S)SYDN&)U8>[DYE=L_1E9O%06VGUAT\@.SWU(:VUDV2H3@Y*+YI\]MW$X M4)@$;RA$K4+D>#>&',LOS+#Y5,D-*"M-:';@7'7:1(X+FY2%4;3+2<_,?Y,& M(89/<(=/*&JD_U2N!;W/D;.[SXA+\:C(2O7#"1A[,M2H/QN%C&NV7BM<4TPS6&[!;"L$)C)8HUPK5N7;"^]/9*HM$: $8[DD M1RC)GDVRS73H?> "3"YK3:KZH_?07_2]Q593HC2<4;G2S_LFM%&URYRSP-(4 MM9:*4X:C,(0HB;T%N<1I&>(@@'@2>]^1>ICV1V.(D\2[EX9*P,)W+B3C!,)> M$,?>36TTSQ#DJI'XX-\\+/R/'9&H-QJ%$/>BR?@DF; W&H_H.QD&>T)D(HGI M&\;)CI2=A' >CUM:9*UC->[%40!)+SP_;W;_!XLD&9-T&,:'+&+'8A0%>Q;Q MQ$8@)KF&QX[#&=D/:.\,)KTHCJ@Z[+%OJ^$6E;L@1(IPLRPXI9]*1KN:H:H5 MFC6'<*7(*C JHM05"#6BZD"J Q!Y **P8&W7LE+6SK=#A$K)K$Y;C_7.,X*" M3<[3G.H(.Q=RID%(\Z+LW-D"4MCRKM6^T2ZUQA;U.V=+7E ?$/ 77*%29'J' M:2U9&\2?RTSOFH(D-LS..%UWO-BV?CC*+L#-=5T][]VG]F&WH)\0O7" M?.-4 WPMRXJ)+35Y]D80;>^^.BBX:)X.-OW-U4\&M;/1XKU_-XG"Y+.&=!=Y MMH]\L8_\A?>SP=TA]>@:C80S'CN_!P3U+ M9^_:O28L;:K)YLKM5KL'RV5S3^_%F]?.#Z;6G&J[P!6I!OUDY(-J7A#-Q,C* MW=I+:>B@=\.<'EVHK #MKR3=9.W$&NB>>+DQFU$0Z#3'DNFVW*"@FZ54)3.T5:M ;Q2R MS!F511!U.KV@9%QXT[$[FZOI6&Y-P07.%>AM63+U-,-"[B9>Z#T?W/!5;NQ! M,!UOV IOT?S8S!7M@H8EXR4*S:4 AQPK" E-C&1A-#WB.16&)2,9]S>DU+JWA_OJ9_RQSL.>P:#S MAD%4&T1.=^7(J;Q@ADW'2NY 632QV84+U5F3."YL46Z-HEM.=F;Z71J$!$[A MG.G<=R-(%I&^+0AZ@314?XXB8/L>.+C^1!@Y%PQ043 M*6<%W!IFL+19.!1P19<GX<#6D.!WX8#5O_QA_Z81+:L9O49"?0)U$=:S(DY_%^ MRBI'YE6,T,1(0SAH'_IP@KV73X&L7'_3E-&M,%43:$Z;%GI6=8X7>-5_*3LK M+C04N"333KO?]4!5/:W:&+EQ?60A#74EM\SI-X#* NA^*>D-U1OKH/FQ3/\" M4$L#!!0 ( /.!8E;^?SNP7 0 !\* 9 >&PO=V]R:W-H965TV"D MLT1$(EV2LI/]]3M2LN,N7K"][4$V?]P=O^_C'5L0.C^<6&E;A"\VUSJZ@W.D0I>(-"Z;Q4M:_\<)4,V_J08%KUM;FJ]Q]QIY/8N/ELM;N M%W:];>!!WFHCF]Z9$#1<=/_LL=?AWSA$O4/D<'<+.917S+#YA9([4-::HMF& MH^J\"1P7=E-61M$L)S\S_U4:A 0&\$5L41N2VV@?%EO&:W9?XX"V?:!9C11UYVD:-_B!Q&<".%J31\% 46/P<8$B3<^.-7N&LP$JZY8"+GK(:580:="*<(=^'BT^%L^9SK#*O M0CM-/!G^G%+L14K!787 RE)A2:+#FG$%6U:WA%NNB>/>&?0S(59+8K#CIJ+B M:-J:V9J&5M!Y5/,_L8"2F&HG#%'3Y%&@046%0W/V$! 4N.!;7K2TVR_7>+(E MSKL 7.1U2YEKY9:F0@6Y;(A@98\D6M4N (S48QK6LJ;C39_3ON38W)/M/D_A MC-Q-)5M-,4GU12.5<5 OI3;P[1GZ)[M)1_U?;/QKJ\IWJPJL*O(<6#9'P#69 MB?+EZ*5L&E0NIV_9AO"\A3#RQVE,C0%]9W$&[_O!,#EN#,A7;:2R>[*4A!F2 MQ(^"D";.XGA"7DGL3Y(8DL"?3C,8^],T@6_#U1 ^R2TJX?1$L0.'XT&:6 ;L1]F%E^WWM]U#O\_.I,N MDR YZ)PZ'C28)EG?<(1>ZIQ._&B< 5$A0N1%_6 \A2CS4^J/)WX\3DY*%X83 M/XNM=J%=,HJGW=[2<)I-J#4-_"B-K'A]$*J\+F7M@="='MVU3(K0D4C3.9W= MBNY,6R=T^>T+D"K3SA+M#1-/[]Y,HW#R09^J[B.5_GM9'&W'C5W5%ZJCU"?)L;HWH<#<[Z6PU94YF=73YT\EXE'5]HBU>,&[8$PAY M@H'-.O_E^/!$;IXZ_T='ES:E4.F>)IIT;X7I[N_#Z.'UL^@N_6?S[NE$=T!I MC[T:U^0:#">)!ZI[CG0=(S?N"7 O#3TH7+.B%QPJ:T#S:TE78=^Q"QS>A/._ M %!+ P04 " #S@6)6OKE.IM$% :$ &0 'AL+W=OO&+@'$D"Q=?A,$P,Y6K1 LLWFZ#XL]H&6 MQS81251(*HGWU^\,)&5!E.DJ="+4TS4TW$S:"XGKN5L;GFB/3K*Q0QOT-[E5YK>VC7*1*:8 M&:DRT#@];IX$AZ<=EG<"/R0^F;4QL"=CI>[YY=ODN.FS09A@;!E!T,\CGF&2 M,!"9\5!A-FN5O'%]O$3_XGPG7\;"X)E*_I 3.S]N#IHPP:DH$GNMGKYBY4^7 M\6*5&/>$IU(VZC4A+HQ5:;69+$AE5OZ*YRH.:QL&_I8-8;4A=':7BIR5Y\** MT9%63Z!9FM!XX%QUN\DXF7%2;JRF54G[[.@W91%Z< !?A-3P0R0%'K4M ?-R M.ZY 3DN0< M($,*ERNSX!5'@0>B'X0Z\ MJ'8SK5,"Y-'&B3$%*X,];?+9PFJCX_J]-)N\$W6QR MK[66=[B=(TQ50N=49C,0&B&F$,V4EJ1=34$8@]: R":02#&6B;2\DJ)@ R<@ M+$P9[=&A\9&C8QL76C,<'1UIH# \?B@H'1/(M8QIOUR>3>*UOF<-5&M 3B@U M,J9$56KW+O 1$P@@A*A!_,!TC+KF2&./8.Q<%8;,,_LD8&(MV39>^AY43BDWX/JS[TWKM%8 M2=@= UKN=;Q@V*T'C0N5S3;)1=Z@ MUUW^-IPCRS1M8<-[Z'N=OL\F#CR_YU?V]KM>-_(;%[^D4^.,"@QQAPR 6-$W M88):N.RNG ^\L-M;_E96O8&H6P!@C[@V]%]1+?B?4BT8>,$+KI43F\C6[2S) MUNUL)]O ]\)>6 ^VDXV8$W7KP1OI%@R]U5#,A9P /E.;9M!X M@&F>J 4BB5DF&AELQ3/$9(:T:WM)5#F*<85F)\N(>BL]N5B42FA&%^1%#1VK ME-65X6#.C#'#J:QVE[*U0=0CH>8@:*)C5C >[7BI>SUHPGG[JL)[KZ;HR:$Z M(V-$MOCX;A &_4]TQNI/_#JJ2Z%AEA)XO"VUE2ED?.)(+12-)N,"+T@^Y/'U3KD-W'EZ/[4-"YE=2$<'V06=E?NWB.J7EV MH+(\QQPNID&YG"+5GHE*U(S=*@S9P%5EDQ%KE*N86)XIEM\:@L)2R/YV'8#K MZO#@3.A$@9%ID506;L[0ZP0=-G[4=E_6=B]^4;G>@KS]=%YI-2[3OH GUY13 MA&1&E$40>:Z5B.=P*>D 6)4A3 1WAJ$?A?P(&MQQ,?V!X!""7JO[ 8;TH#KG MV N/BJ/@X#O=EO\!HB$]&Y_OK@^L.KB[.2?JQW-!IE40+;]/CZ"SFPZESJ-_5T0J_JY M#2((?@$1UA_]LRH%RZ!SF;YXE8I2]DV F^X#[;7[6HIZYFZE7**(=^75K9ZM M+[XGY7UO)5[>FJFQF,G,0()3VNJW^MTFZ/(F6KY8E;O;WUA9NDNZX9QJ&FH6 MH/6IHHZE>F$%];\#1O\ 4$L#!!0 ( /.!8E:=09/:3 , *D' 9 M>&PO=V]R:W-H965T9Y(1J]FP4T>%FXD:NU\POA?+KA*W$K MW)^;:X.S<&2I92N4E5J!$_2X&/ZGGJW1CNU_8]=@X":#:6J?;(1@5M%+U__QIR,->0!&]$<"& M -;I[@_J5%YQQ^=3HW=@/!K9_*"SVD6C.*E\46Z=P5V)<6[^53L!.;R'S^I1 M**>-%'8:.F3V^V$UL"QZ%O8&"V7P12NWMO!!U:+^+T&(DD9=[$77@AUEO!+5 M&<24 (L8.\(7CS[CCB\^XM."T_!1*JXJR1NX==P)_+[<0<,]77*8SE^5<[OA ME9@%>!>L,(\BF/_Z"\VBWXZ(34:QR3'V^4LMGN%*VJK1=FL$?+L33PX6C:X> MOA\2?)3RL.#\;+_L<+<64.EVHY5/"N@ER+U=CAJXA:5N\"+;\PE62+3WPHQ5 MFIQ*!6ZMMY:KVKZ;?#+:6KCDQCQ+M8*+5F^5@YO^<%CP!NL@X"LVGE>8"=9( MXB==PTKKVL()T)3$<8Z#TX105L([OT8)BXK)#=_A?7#"8$DM)"2G!9PR0O,8 M48RD23JYTP[+O>_E! 63*$T]8T;BB/6,,'*Y-0:1<*U-USA.H"1Q67HL M)92F';8@K$@F?VBU>H]GM[ 9P#0B69K!:4IHD2,R)4E6_JR"UZFE_V=J8Q)E MF9?!2-E)/O$FHKQ\E=J"Q"SQJ*Q,.V,9>\,8Q71%GA$QQ6 L)3D6ZU!JRYCV MJ65E/J0VBP^FEI(D+?TG$!=>08XBDY]4 (=N9[C7/EMA5MTC8?$J8,+Z3CJN MCN_01=]^_X7WC]@7;E9266C$$D.CLSP-P/0/0S]Q>M,UXWOML+5WPS6^I<)X M .XO-3:J8>(/&%_G^3]02P,$% @ \X%B5DO5<:1T P /@< !D !X M;"]W;W)K&UL?57;;N,V$'WW5PRTP2(!5$NB9:^= MM0WDLD$7:%ICO6T?BCXPTM@B0I%:DHKM?GV'DJTXK>,7D1S-G#ESX7"ZT>;9 M%H@.MJ54=A84SE77462S DMN^[I"17]6VI3P/7_-9$'M"*#%S'H'3 M\H)W**4'(AH_]IA!Y](;'N\/Z ]-[!3+$[=XI^6?(G?%+!@'D..*U])]TYN? M<1_/T.-E6MKF"YM6=Y@&D-76Z7)O3 Q*H=J5;_=Y.#(8Q^\8L+T!:WBWCAJ6 M]]SQ^=3H#1BO36A^TX3:6!,YH7Q1EL[07T%V;OZK=@AC^ D6A@IMW ZXRN'+ MCUI4E'HWC1PY\:I1M@>\;0'9.X )@T>M7&'AB\HQ?PL0$;N.(CM0O&5G$>\Q MZ\,@"8'%C)W!&W0A#QJ\P9F0+3@-#T)QE0DN8>FX0Q^O/15P"Y>>AO.WYMI6 M/,-90-?"HGG!8/[Q0S**/Y\AFW9DTW/H\T-90EA(KMS;ZL"]L)G4MC8(?WW' MK8-;J;/GOT\%<=[-N/]. [P58R?.--U+ZS 'O0)7(*RTI LNU/JZ1P7#\@E- M5S3XKR3I77Y59*9K2[#VJO?(LX(H&8JSY*I>T66M#8&%C=L<2W+G#&\N\BN) M"QB'Z3!N5C:>]'XCIJ2CUB"1;BIP:]%9:NXEJH)*C;#<$>>R^>W5DCADP\0O M23KHW>FRJAVQ?/4PBF,8L&'OH39*.)_G\2"!49KV?O$>"BUS$&5E]$O;/I"$ MHV%*7S:<$)XG7;?C1R@@M0RMA70P@H\?QBR>?.Y]UX[ZKSJ=9,9"1MEC<3@: MQ;V;+*O+6G*?]!RIUZAUV\E&1KS4QHE_6L%EPL+1.(8KN)S09@)7O=-E#$&A M3^,D'*:,5DK$Y%-"Y3I"QRT] )3,#;? *V*Z%30,4>[@8M!/:29)>2!QP?J3 M3D /1M,8.^3& OIA\+\^8$TSA*?N270TTTHTZV9R6^J[6KEVO'72[G&X:6?B MJWK[LCQRLQ;*4M579!KW/PT#,.VT;@].5\V$?-*.YFVS+>B!0^,5Z/]*T\C8 M'[R#[LF<_PM02P,$% @ \X%B5H6\D)S' P 0 D !D !X;"]W;W)K M&ULS591;^,V#'[OKR"\8>@!66S+CI-T28"TW6U] MN$-Q[38,PQX4FXF-RI)/DIMFOWZ4[.2R-26#QO%3+565!+O-9BVKKG>7:-0VWD0!_N-3]6FM&XC7,P:OL$'M+\T]YI6X0&E MJ&J4IE(2-*[GP3*^NDZ=OE?XM<*M.9+!1;)2ZLDM[HIY$#E"*#"W#H'3WS/> MH! .B&A\[C&#@TMG>"SOT=_[V"F6%3=XH\1O56'+>3 )H, U;X7]I+8_8Q_/ MR.'E2AC_"]M.-V4!Y*VQJNZ-B4%=R>Z?O_1Y.#*81&\8L-Z >=Z=(\_REEN^ MF&FU!>VT"0JZ2[EP6HZK[[K#8V_@Q0P^*&E+ S_* HM_ H1$[L"0[1E>L[.(MY@/(8D' MP"+&SN EAX@3CY>FG6G JX@TM/P[FBN3(-SW$> M4%48U,\8++[[)LZB'\Z030]DTW/H"[H5+C?52B LC4%KX+8RN5"FU0A_/.*+ MA6NA\J<_3Q$_"WV:^'1X^B' 8XF0J[I1TJ4)U!HV6AD#U;%VTVL/J-CRMFX% MI;4 7BMMJ[^XJT(ZD05(:C8G#8%36-S 6@GJ%N;J@BX?ZQ7JPP.XN*PDV%*U MAH#,NXN?/(L;KO6NDAM8UJJ5%I9'[I='[H$JF>I4PDVK-T.D7 :;5N\C2:#:=SGC?4)G ZR+/W*O,53ES6#+JG4ZFS#_SK>_D[N$^HZ;!1+/'33<756MPW0H0U1I="5C2+DY%Z C; M_^*_I8>>#AGLD&OC==)ATJT&Y-,TZ">6<.7D*^Y5,0Q?;<5#'P(:6]7^%M>M M=:WBN 8!7VBD&Q_!&U5XVAW\3MQ<7W>I>'U*/PDE,AF/G9CNA=%>R/;"F.X? MNKOJWRN<:I7AT52K46_\[#;4A>AA=0/NL'OX/%AV4_&+>O=M\8'K324-"%R3 M:30O.&C-T ".9128OL6)F MJ&J4M+)6NF*6AGH3F5HC*WQ0):)D-)I&%>,R7,[]W+U>SE5C!9=XK\$T5<7T MZR4*M5V$<;B;^,(WI743T7)>LPT^H/VSOM#4[)2ZLD-;HI%.'*$4&!N'0*CSS->H1 .B&A\ZS##/J4+W+=W MZ-=>.VE9,8-72GSEA2T7819"@6O6"/M%;7_'3D_J\'(EC/^%;>L[)N>\,595 M73 QJ+ALO^REJ\->0#9Z)R#I A+/NTWD67YBEBWG6FU!.V]"HM>U!P"S.R;FI68Z+D,Z!0?V,X?+GG^+IZ-YAT/!KNT-NT<"/;<^X.S)6J:B5= MC4"M0?5\A(L ?*%[@;Y,(]2:TXGFXI6.::XT=0%P"1N4%"* R0)80;W+C740 MSPB$;DN$7$FC!"]H+PHP_9;LI2,''Y\3%XVENPPH7"AC8(N4F1E8*T$WBSD/ M_D:FNR8$:B&L5JA=&P6NC5POQ<%'[A*KQA"F.0UNE=R<6=357K4_0#Q(TYG_ M9LDT>"B5MF^=SN L>%26Q'U^IRQO8."AJ6OAY5'0B@GJ0X3VVN5[-=[ O=-T&)]0J>+),#W9#3)G MWS';:&XY'NPLM1)\L]M[[_&#TN":V%!"M^5N>\>^S@DMT&!"9CR>.C,E!.R7G M<%'Y0A"Q-VX:_=F27@R7!([&PL=X,,U2. WNVT5X9J)!%[YNJ [X?M)TD(XS M.'2I1'LW?H5ZX]\U WZ'VLN_G^V?SHOVQ?CNWKZ[=TQO.)5:X)I"1\-9&H)N MW[)V8%7MWX^5LO0:>;.DYQ^U?CG.Q@( .X% 9 >&PO=V]R:W-H965T[T4KI)[- M+ NA33C8&%M=1:&)EM@R4Q;52CII%"Z9)9$ M/0]-I9'EWJD48=SI],.2<1FD(Z^[U^E(+:W@$N\UF&59,OTR0:%6XR *MHH' M/E]8IPC34<7F^(CV6W6O20H;E)R7* U7$C06X^ B.IMTG;TW^,YQ97;VX#*9 M*?7DA)M\''0<(12868? :'G&2Q3" 1&-WQO,H GI''?W6_1KGSOE,F,&+Y7X MP7.[& ?# '(LV%+8![7ZC)M\>@XO4\+X/ZQJVR0)(%L:J\J-,S$HN:Q7MM[< MPX[#L/.&0[QQB#WO.I!G^8E9EHZT6H%VUH3F-CY5[TWDN'1%>;2:3CGYV?2+ ML@A1!!_A(LOT$G.X6E/!#9I1: G?6879!FM28\5O8$4QW"EI%P:N9([YWP A M$6O8Q5MVD_@@XB?,VI!$)Q!WXO@ 7M)DFWB\Y$"V!JR":RZ9S#@3\&B917IE M=F_"-5QW/YQKF#-3L0S' 76$0?V,07I\%/4[YP?(=ANRW4/HZ;8@MYS-N."6 M$_6?4UQ;F B5/?W:Q_<@XGZ^4=3^K_8P72 42E#+5 7U5NV/&_^S%E4.RQGJIGKPKR9JO;^1A*66ALG4>9*&W@'4:_G_O&P]=6?'!\-XR@^)TVW]:!>F/ 7%'?I&[1N<4ZU=3"5 M5@4:-T-(4: S&?2@UTE:4[8FZ344,\3<^*< P^04^E&O-566W"CL27R:^+4? M#6!?<<.='BQ1S_VD,71/2VGK=FRTS3"[J'OXU;R>A'=,S[DT(+ @UTY[T M MU].E%JRJ?$?/E*7YX+<+&LBHG0&=%XK>^49P 9H1G_X!4$L#!!0 ( /.! M8E9?J9?V< < *\1 9 >&PO=V]R:W-H965TR&, *W&HK(UT597?96SFW.A\,J7ZFUK 9FHTJ\61B[ ME@Y;NQQ6&ZODW".MBZ&(X_%P+779N[KP9W?VZL+4KM"ENK.LJM=K:9]N5&&V MESW>VQU\U,N5HX/AU<5&+M4GY7[=W%GLABV5N5ZKLM*F9%8M+GO7_/PF)7@/ M\)M6VZJS9J3)S)@OM'D_O^S%)) J5.Z(@L3C0=VJHB!"$.-K0[/7LB3$[GI' M_9W7';K,9*5N3?%9S]WJLI?UV%PM9%VXCV;[LVKT&1&]W!25_V?; )N,>BRO M*V?6#3(D6.LR/.5C8X<.0A:?0! -@O!R!T9>RK?2R:L+:[;,$C2HT<*KZK$A MG"[)*9^!CCA!!R1^ M,:5;5>S',1$+,0S]))6T\332Y[1M&+. ML'>ZE&6N9<$^.>D4(LP=53B02X^3HV0YKS8R5Y<]9$.E[(/J7;WZ@8_C-\\( MF[;"IL]1O]H[@[W555Z8JK:*_7ZO'AV[*4S^Y8]C$C]/DXO!@9/9_4HQ;#>F M)!,P9#AS.-(!QH&W>D3R5XI),)<$42")]Y!/2MJ**7(X@[O4>J8L7.8]1G^< MW=;6@GB')OB^4W-E8?X7B#KZ>3?@><:0:$BCDHEDBI\ T84"@?EQ_+.CN),I MZT_8:W9O'&".*/,"(F;X%V+D3?!KJ1U8>$H5D^6<]/.D.L8Q"P8G0'5KU@PE MT4HJ*A6;*0)N!/O?9CH4X07KIVF4Q0):8)V(*)ZF6.\T["=QE*8<)[3B:=)J M^\\B@MYD% F/@_581"(A:WT"8;W0N82S#M4F#6YQ(LNG5S]D@D_>5%3V@E_( MKK*J%$!S\-*5VZ$$(^ARR:0[H77KW?N6RCEL@.@^HT([]X+ 95X/Y[FM =2X-7C.@+4%P"C)"$PD["-R4]I\Q7)PTE!.6OL$@VREG3,>);#C M:)RB*#R"UG50A8\%XS&B5VXTS*J_X57EI'5G]09"5:[+3)=.EDL]*R#"%%KQ MB,?3 U3;BN!1TRC)J.!^0,MMW 0K>==UA:M8ED33.&/D+_AH.D88");Q*)ND M[#=9U,$NUV1G%#3%^M,TFL04*?U)%@D?,\3D>V^1XEG&DFB4Q7LWT.M"RYDN MM-.49]XFC7OW"O=Y)+CG E4G8RSN:F@GJ4[DN:E+KT_7+&>L+R+.Q\?DV3%\ MZM!-(+PX+7R_Q:$8YK &8@+JO*TM<:;8BAC9.,D2>OH6$@^Z1^SZ("BC?51& MK#2.?H/O 794/>0D.@$PV$&(HQ"$2B!)=%0(^D_2-[1.:)U"\/M]"C+8F:D' M[WVJB_ ,&69C*AVR'0W.9R)*)-NN5 A1Y]$(O2ZMR@UR_5MCTIDJU0)D!@A^ MRMTC I4H!MXJ;JN*A["\/TAQ#>*@-JL+:1DQ0'^%DWQ\GB@A")AR2"[54Z64!NU%*7)0DPDX5/ 80#$IJ:RD^>*LH_1E6J#KX8'Y"UJO V)(LU M;0K9J TRCR-WB% @,E<[(AT4\G&AUTCR0(U:$$:?0V&29-2(U'5AJRC)YQ3* M@_/IA3HF"Y]Y'3XU*%F'Z?IOTM,!:&ZL>=!^0B8%NVWRI$.;,/][4$DP?_K6 MQ-0"[H,F!^QD4;"JTR86H0U'5!J=B@XZYY](Q6JN\X",.$0#0A1J4NUKK6W0 M#5P.Q@VK7&W+*J(FBE KZ$G7#_\R=-&@-DK- 8P'&3Y45K*ANI?0!Q.'#N] M?(WM*NRUPYS 1YA':.(0?!"SE_XHB>))O#\*DUC0JU\JS[4MWDV5>4V-8,JI MMB>#*9"P%?'(;T?8?C"D=PVGHF_L.SL'IPDX#M*7U!ZH^[]F\6 "C-NVC"RD MMG"J_0+65!^]5^ +ZD;*3S6A*H:JU!=9XHFD)$4RG?C-&)O/Z,$4WA8W XFQ MF^X'(;;#O0%I$?HX9?P(0UH_'F0D5SMIO)+KS1LX[P%7WHU'[T^]I?@@(6X3 MKS$?\ /Y3U9F7XW )"$F5$NP%B\[\V ;AG.]@+W!D"XW(AJC.?>3P=CCP>R< M=IQV]YB<:)9!A/IYRV=).VF=87I!U2F*IK2E4V+I$3&"82SOIX'H7GA4KMPU MSIV%M80.<)BCB<&1^2>&@G&ME.-'R,.07*(\2\B7D<33&U M]_DD"/#^^^F^WX9:F/,AN8^:,.\WNV,WM&'G$KU6=ND_%5!E0":%^W1[VGZ- MN Z7\#UX^)3QB[1H3!4KU *H"%1<_FWX/! VSFS\E7QF'"[X?KE2$L%) 'B_ M,+BL-AMBT'ZCN?H+4$L#!!0 ( /.!8E;%;[,+Y04 #8. 9 >&PO M=V]R:W-H965T;""5Z)!W'^_4[4K;L-':*?1F0%XKD'>_N>>Z1>+I4 M^L',$"T\E;(R9^V9M?.3;M<4,RRY"=4<*UJ9*%UR2X]ZVC5SC7SLC4K9C:,H M[Y9<5.WS4S]WH\]/U<)*4>&-!K,H2ZY70Y1J>=9F[*OE=C.WLK-UO MPQ@G?"'MK5K^ANM\,N>O4-+XO["L]Z99&XJ%L:I<&U,$I:CJ__QI78<=@WYT MP"!>&\0^[OH@'^4';OGYJ59+T&XW>7,#GZJWIN!$Y4"YLYI6!=G9\R_*(K $ M.G!G5?'0<1F.X5*5A+KAKG"G74OGN-W=8NUS6/N,#_AD,5RIRLX,?*S&.'[N MH$L!-E'&FRB'\:L>/V 10L("B*,X?L5?TF2=>'_)*UD;L H^B8I7A>"2TN<6 MB6W6[$NX=I?N=^<:Y\3,>8%G;>H,@_H1V^>_O&%Y]/Z58-,FV/0U[^=W,ZZQ M,_3 W/"5BQ$NM.;5U,<+?W[%)PM#2?#]M2_V5[WOCYTEX9H/PQ=\@.M'VN3Z M[;J"WQ=R!7'L@:GA84!@83E"W0 6P#WQ0(.=(=Q(7@6PG(EB!L( 'Q.GA;&H MZ931RF]Y=A@]E,):Q*!9X]6*.J#^K92E7S^T6-4QP_7%0-?/>R@>,.7%!920;AXQ/J0A@J ME18%;C=LUF_1::V+Y9*:3%.0"Z+O5]0E'/]!AYMWK2&G*I,MMR]B8) &>1H% M>1[!6\C#/(4LS//6KRXOBCD)6)8$_3Z#*.Q%+5*^"0JW<,SB0<"2%-X!"_.H M=>E.D-*M)'DPZ/=H(68A8ZU- K22)D&:);02A2E[+:P8>D'63X-!WJ.PTI F MLC!A'D(^G6J<4G<2#%8+>A\4\,CE ET9=P$S@,W1BX9Q^R&>4R@&EMQX"KT( M)_P9>415OQ ]3T;TMOLA$IHQEE>>,_OR_9^H !=-\3XWQ?OFBW=\):1TL;[; M(.9SW M.$F1Q&J2]A,#IA6E$"/4R&G=:W] X=A#Y\6E.;UH:4V\\TNPAF),L M"EC*/,R)@SGN.T]UP;G06VPWM9RNN;DDE0#R+*CN#F+CD2&SH>0D57?%3$DT MG2O4EE!9-_&<2N?VE6J,$NK7&TT[,VX(T/49HIZJ<1ZY;Y43\"6LWV%[,O'- M]'&3])B48DQM#RN!<@S1D?MI5A^5)*I(TA)@<7Y$V;(D.0+&^O5X< 2WPCQT M)AH]RRE1*J!VL+$PSMRFE,I.3D-G1R;4:#O^I9@0H)3#JD8]"?O>)-L9W9)+ MJH7;7LOD?27LCR+I)'GS@>8@<#716\.:XPMON$\=YZA]6[@NWV_VWX7R0-S7 M.PWVLG.\G,$'5\!/CE.>\JW[ZK&FZTM5),U+!D&4.%6,PV0KB*1M@SSH$^ D MB&S#]^,XB'HYJ:@3-]J?[BIEW,N"?-#W2LD&AT^-H1^D?9+(@>L&%D8IW.P4 M\$#BGZLM_P*X+JQR+FN/R0_/\2Y7=ZSLS!'MT!>?YU5%LO,3#71OP(*;68WO MVE&QZPC7CNC-SI=80!6I<3EJ'FK#5I-,Z]LVK%H;H0&IV]TR( MWQ*T>98ZN0FR)&O=[F=S$B1L0'\'6=JZ^2F+J;QIFL @C5IO'8@L)_^#((T' M<&$<:?>DLV=JW\=A=^=;OD0]]3<60V5=5+;^K&]FFTO117T7V&ZO;U177$]) M\4'BA$R)OG0'T?4MI7ZP:NYO!B-EZ9[AAS.ZV*%V&VA]HN@[>?W@#FBNBN?_ M E!+ P04 " #S@6)6;Q3YJ!L# C!P &0 'AL+W=O72.*5&CE51/.D,T\%KD0H^]S)CEJ>_K.,." MZ:Y,"V\R92@,)T[)V'I].^ MC72V[6<)>FJ+A8Z)%O"-]&^7&--:VPH@^PP@AN MI#"9ABN18+(+X!.QAEVT83>-]B)>8MR%7MB!*(BB/7B]1FW/X?7VJ-5@)%QS MP43,60XSPPS2*3.M@BNX?CNLEB''MT(S2J%_0FAP?A47"VAVR_(=O? MASZ9&1D_93)/4.G/F_*X>EUR'>=2EPKA[R.^&ICF%/JO3<#>+=H%A/WNN\.P M<:35?Q,+,(H)S=S5TD#- 4R&L$:F-*"M/E#ML)BC:NIGAVH:P%ULI%T[J>P. M'!X,HR@X-<^5"$O%8QH)QR7")PB[@QY\55)K6I0Q8J+)VPLZ)_T> M7! FU]IU3.(BB,A\7>LY7]A#3K$GT1!NJ=WOI@?AH.+9KI"N-E-Q!N&P,K];T:TIAJA[6>)L7X+QJ?&_AU?-!]!:.!!ZIJR95AY-*UP;DTU%3=-*-7#)4-H/54TM6J#;M!\RY._@-02P,$ M% @ \X%B5B "[T!G P Q < !D !X;"]W;W)K&ULC57;CMLV$'WW5PQ4H$^J=?5M:QN(LPD:H%D8<9(^%'V@I;%%+$6J M)&5O_KY#2E:\A>/V1>)ESIDS0\YP>5;ZV52(%EYJ(!4EP6?C$CY5U"]%ZV; C[M!^:;::9M' 4O(:I>%*@L;#*GB3/&QR9^\- MOG(\FZLQN$CV2CV[R8=R%<1.$ HLK&-@]#OA6Q3"$9&,OWO.8'#I@-?C"_M[ M'SO%LF<&WRKQ!R]MM0KF 91X8*VPG]3Y-^SCF3B^0@GCOW#N;/-9 $5KK*I[ M,"FHN>S^[*7/PQ5@'O\ D/: U.ON''F5C\RR]5*K,VAG36QNX$/U:!+'I3N4 MG=6TRPEGUT_*(B03^ 4VS/ "F"SAD8O68@E/="=^5\; %C7L*J9Q&5GRZ9!1 MT?-O.O[T!_Q)"A^5M)6!=[+$\C5!1&('Q>E%\2:]R_B(Q1BR)(0T3M,[?-F0 M@,\EDP5G G:66:2;9\VM@#NZ_#:=*Z('T[ "5P%5B4%]PF#] M\T_)-/[UCMA\$)O?8U^_8UIR>;PZ$OCS,[Y8V A5//]U2^Y=PMMRD\GXWG5H M!M^=D:0-<=DH5%U3M1F_SXV;-QZ^_P8E/_&2Y']',&LUW[>6[06Z,[B@+453 M*5&B-@YH*X2S+S B8B?4U"] MO6>'*K#*Y\&J/482\*=H[+5[N?P)(ZK#A0&W$*61"0$-71EIW4TI'1FWE7Q)LQ2P))JZ[8N!C)R5/))UDWXX MYF$^S\)\D4 6SK-%&&?QZ+-R*4IF83Q?A),L!_HN%N%B$<.M\HRN.FN-^NC? M#Y?Y5MJNR0ZKPQ/UINO,W\V[]^TCTT=.T0H\$#0>SR8!Z.[-Z"96-;Y/[Y6E MKN^'%3VSJ)T![1\4);J?. ?#P[W^!U!+ P04 " #S@6)6;#N8DYH" "V M!0 &0 'AL+W=O]7$&[1 MIRR^Y=*TB8&D7;$!ZU TW89AV(-J,[%06_(DN6G^?I3L>AF0^L4F)9XC'E'D M?"?5L\X1#;R6A= ++S>FNO1]G>98,CV4%0K:V4A5,D.NVOJZ4L@R!RH+/PJ" MB5\R+KQD[M;N53*7M2FXP'L%NBY+IO8K+.1NX87>V\(#W^;&+OC)O&);7*/Y M5MTK\OR.)>,E"LVE (6;A;<,+U(%-" M, MC65@]'O!:RP*2T1I_&DYO>Y("SRTW]AOG7;2\L0T7LOB!\],OO N/,APP^K" M/,C=)VSUC"U?*@OMOK!K8LXEF7)#=VW MTNSXXA[I&HR$6RX8J60%K TSZ*[@F."&;G2< MSG;/I:Y8B@N/VD.C>D$O.3\-)\%53[*C+ME1'WO26QVXX3HMI*X5PJ]'?#6P M*F3Z_/N8B-YCCHL()\/^UP%?>$I]BFYG75=5L8?E5F%SE;#44#%E0&[ Y&BI M*B;VYZ<743B](KKT3\TU=TW:AJQ1Y%02,O::"@)<4-'#\>#DEH12G7XB4R?T M#&(X@_%@-IU89P2C8&J-,;V2V!H3B(/XY%$:@J0' LY@,IC-9G"L+OY!+Y6H MMFYB:(+7PC1MU:UV0VG9].*_\&:BW3&UY4)#@1N"!L/IV /53(G&,;)RG?DD M#?6Y,W,:K*AL .UO)#W1UK$'=*,Z^0M02P,$% @ \X%B5D5>E'E4 P MM < !D !X;"]W;W)K&ULC57?;]LX#'[/7T'X ML'OJXA]QDJ*7!$C6[C9@W8JFO6$XW(-B,[906?(D>6GVUX^2'2_#TN!>;)$B M/WXD)6JV4_K)E(@6GBLAS3PHK:VOPM!D)5;,#%6-DG:V2E?,DJB+T-0:6>Z= M*A$F430)*\9EL)AYW9U>S%1C!9=XI\$T5<7T?H5"[>9!'!P4][PHK5.$BUG- M"ERC?:SO-$EACY+S"J7A2H+&[3Q8QE>KU-E[@W\X[LS1&EPF&Z6>G/ ^GP>1 M(X0",^L0&/V^X1L4P@$1C:\=9M"'=(['ZP/Z6Y\[Y;)A!M\H\9GGMIP'EP'D MN&6-L/=J]PZ[?,8.+U/"^"_L6MLT"2!KC%55YTP,*B[;/WONZG#DN*6NK:9>3GUU\5!8AGL)K6&-! MQ;8&F,SA;U2%9G7),UA2K\TLM!3,N819![QJ@9,7@.,$;I6TI8$;F6/^*T!( M+'NJR8'J*CF+>(W9$$;Q!211DIS!&_6ICSS>Z$SJ!JR"MUPRF7$F8&V915^% M4PFW<.EI.'=[KDS-,IP'=#T,ZF\8+/[\(YY$?YTAF_9DTW/HBZX[<(^UTI;+ M JZYR80RC4;X]P&?+:R$RI[^.T7\/'0\'9YO/CR4"%LEZ *[P)9M!(+/T7ED M2AHE>$Z5RX$9@QV*4+)X+>C*]=K-'HJ?T(R@+V!'RQ*XS$234S=J3>-&V[U' MP*\-KQVM"S*P=''I)C?4I8/1A;=R:^8K(H@K=L&N!G1+ ?K';??40L7*)W05I+2UGORVL.E M$TGZ9$N*XJ28I!;2.<,D<1934BX-9S#ZQ2*.(B>[[V]4X_]%-7%\IM-35$>I MPY[T5$?.=-QS37_G.G6Z)#EPC5[B>OXL&";P5)_]X*162:#X=&(::?6>FMJU MWRO]K"-RW+36P\$79+H;'W!,VZLK@"^(KWR82^QZ,3Z5R MZE:&1Y.4R!3^O3 MXW:H]MK^25JVD_BG>?N>W3)=<&GH5&[)-1I.QP'H]HUH M!:MJ/Y&PO=V]R:W-H965T3',3"L3/[*/3?[^RD&9-H%,GQ MV7???9]]Y]G!V)TK$0F.E=)N'I5$]74-!HN;>7237"\FWC\X_)!X<"=S\$K6QNR\\5#, MHY$GA IS\@B"?R]XBTIY(*;QI\6,NI0^\'3^AGX?M+.6M7!X:]1/65 YCZ81 M%+@1>T4K<_B*K9X+CY<;Y<((A\;W@C/F>T>F:H/9KJ1N_N+8GL-)P-7DG8"T M#4@#[R918'DG2&0S:PY@O3>C^4F0&J*9G-3^4I[(\J[D.,J^&4)(IO )5J@$ M80%+8>D5GJW03H23<[.8.)/WC_,6==&@IN^@)BD\&DVE@R^ZP.)_@)@I=CS3 M-YZ+M!?Q#O,AC),!I*,T[<$;=[K' 6_F,_(B.5NSS=A.VN=[DS9C)>V\N?,^0"0DH>&B J05]]>_LV"E*'II.],F M$@4"!V??@+S:-OJ+64O99E^KLC:O#]9MNWEQ?&SRM:R$.6HVLH9?EHVN1 M? M]>K8;+04!;U4E<>SDY.GQY50]<&;5_3LHW[SJNG:4M7RH\Y,5U5"WYS+LMF^ M/I@>N =7:K5N\<'QFU<;L9)SV7[>?-3P[=C/4JA*UD8U=:;E\O7!V?3%^>D, M7Z 1ORJY-='G#+>R:)HO^.6R>'UP@A#)4N8M3B'@KVMY(W8DX,L[TS;5/9E@*!2-?\MOEI$W.6%F7V!$'',"Q&4;T4KWKS2S3;3.!IF MPP^T57H;@%,U4F7>:OA5P7OMF[E:U6JI-UW=JGJ5?6Q*E2MILD?N MT_>OCEM8#]\ZSNWU84LT@F. 5 /[SX;G?&M MS(^RT^DDFYW,9B/SG?K=G])\IWOF&]KQ?\X6IM7 +?\WM&.>[_'P?"A"+\Q& MY/+U =GD7P;!'UU@&'R_ZD=\5+>"I.G36H)$Y4VU$?4-XB]O:@,@%**51;94 MM:AS)>C^5&VDK74 MHBQO\&>YP2E%(-5&*YA\4R)[?OO-\]GLY"6]]=/9V4?Z/GWY?29JG#XONT)F MK06V0S!@)_C]@D'GSGQK8;%/"E$01,"JE M^I/9"X@DC)&X#A"D5']T"(O]I51BH4K5HK0"!^&[-6KH$J;LM)$X9H$@20.4 MBC8&+ B,1#S755U)FP,-#G+?XCO_]?SIR=$/H&7+D@P&K(PFA4 7&]7" CCJ MV=.C)V$0,13H)5DMI/:ZZ0@@:I.EM_!"5DM8$3#2+%J!O%\4"C<%$UL)7"I$MG\2!^50[^_ZS1X=/#[M]_,9H]?9GN&?1)J"VSUOBV&?OV7@+UF M_S[Z]R $1@M9[GOU9PG8TL"RA\5*++@O+:L]K@"JAO::>EW1*(/"G< M IA*:!C09O)KOA;U"E0IC"'=*)=+8L.6%EJ(D@PM^_O(Z4>(X::2!)K\"KX^ MJ$\%#+^SH)T"T*M!]_27@LU?"]@6R%'1:5)C,!BPIIJ"46 U+KC@?E8450L@ M*B@1-GQC+8H8)A*R$"P@6/='6$ Z6"EUSH57]/P63()MJB]2>R*IQQQZ2Z3 B8+63<1.[;C M_+?# ;#>3Z#=+0L!U(!S4(40>B":EKJIK FMI#"=)H6%DR4 @1*2ZAJMLD'L MM8GBRJUZ-&A+%F1#!:Q4KPYAA@HFNI:FI6EA$[ "[0IF!.<-N0-QN(?$HOB] MLZ_^HR0AOP(\CM7?BBAZ10Q0A'B6/9G4 +3@3VQ(*D#HVU*ZG3O"&BG),UIV MNWBTPQ);%%D@ -2K(M[B+O*8,VL0\!U$Q**! PC7?\.2WK^XD:B))$9[NSX1 M_C$EEV/$W7CFW8UGH^[&E1B=+^?78+@0:89\&/1!+2"BUA-=M$T=>$ M/<.ZV4'R]&CHT0B^GWM\/Q_%]SNM@<87C=8NG0*<< 5[,K3O.^)X=(U]..8U M; 3JD/A6F1Q8#_!V9E']-MB=$ 9PA.*>]]5U5XL.O&59W"7>(5' 73MF-^IK M]J\.O.C3$V;PR2[NLV=#] #"P7\C5/G!4^6'<2E0YDMV!C!]QL@*.:\E=_)^ MWO?H&GNH@@N+_L))P .F&)3E[VC=@9\UO /P"5#,XWA"NE^^P (:M2?DG6+ MJ*/ KI(%.80%4!X\%_"E0:PUFU\@,4]K]1J+!8;0Z/JQJ+P 1;=BFZ1@ZAPU M6ATSPWKB4F1PI8D8>1KLHLHB7ZX$02@LLB;9 M$H9GUZ+L8JIIRO),V8F#E_DU,"F[ MK0!&[DNR0 M[#J6 !!$%9CEP!'- A2R;"4-@&!'HUM&3 WCPK/4 (-9;;=H69WIQ)GJICZT MWR=9S^TKX:O/7+YY!JM.C$5PL)-,:4 M6"N^\@^$8.L)EV6SQ0AL/($XC9+WT_&DBS!K6I8^O .AA,48E5> 5:URI"3^ MR-!=QLB^I_(9A618^?P%\!)3$F(3P&"V!GJ P>"D8,P_K*4:H)?"H*K".,4' MVC^!1V>C//HC*IE?2T%M6V;3;$815KM6NH#/IZ,T#&6RZ6A=ZPT5">K6N@SH M_$&\!5I.M?;+/8GY@"I: @*KZ0B"07&U=:*071>81P0=T#%-(@N[ :1S)29/ MMHI.!J^BR>,%>A!%JNU"HC14#<#-IYP"SL1X:(%SZR],C\$I(_#(C2NL#D&= M\'(5'H$'AF;7:*V;;D61!@*Z;719I*B2;/2E196;P26L J9R=#)<0#T)A<]) M\+%!-Z,V']#/ (?<_0%L"4>C[;:QZGU,"83J\W2\_'P5\'97.7] N?G,D2E: M[FP/Z4+ZL:5\EJT@>JWJ*HW60394^W,^&&E2=%I92ID3.5%FD_9W&(E1KE?= M0TR+"MH8YV[F38GM*"Y)A4\L:WCV3/E(RU7'\3&F/N26[52 ;!&<(\IO@K%H MM.& 8S"6L'LFBP%PJ^5A) ?T]IY8&,; MY:% [C#L0'YD]]&N!S6>P)J&YNK!Q37W6+HL\6?D6TI[O05 M%2 E[)68P[39(^<;,$N!IE8:'O.?J-K.ZILH_($A:PH'6YLM"=$-N8E8 N*8 M*JTU88G?TM#J&3:)GI=#&AM5(;@6- .K1^#Y*&\I3!3-[>16DL1:4G]*.?T[ MTP_E,#I+HD07!%JUJ,APN[B5ZTT8AO.K#C'A1>)+B*_1_K"BP)U>2T[F=9L< MZS,0T&]E">[6&,>%DOATO";^4],45/?GX*85]4J1/K,!XSW9\ %5\K<23(UJ MY>%[LG$[,&2'5%4=(WAM(@+/\!7%2TQ$L;)QD;! MP#'P#IA*F:_KIFQ66 \CRA'';(1NN<3D6QOH9Z/8[7@[-(%7XTG>7-6'U"]A MJ- CA<[7,0PD"RYJO_QX]:VH-B_?]F+W..GQ2'U/'#&7]9JX=7YC6ED%\$&F M9B?3)_C',_SC.2JIDY[O18D@5+QEX@P,8I5<^I"[V:[!"4"^Q#P*XEIG7&OE MI)S2>5=AXQ#'![@(L;]5 ;G0^B9XE=XU&H[\QE5K*,9,QZLQCFV I4MATRX8 M[F\>%.H]H!+C^399.4L>2__8LS%$".!F8T@6RER .LX*[3" E=I*Y&N ">U( M)>H.;2[G F78<2'!B3L1LD"%' S0Z9 49'L&\H)*87K2<\O8&5/$0X,\ M9O>*L@V!BB&=^X\)>4H(+_(A14TEQ#UUVC\+E9+K&\M.A4B2$Y2-NU!'$KGP(.8.^AV9#&IJ;+>_]4-+!SV08, MXQ/JNS]0RP;,64:/C[*?A\9:_&><79$TJ82-N6"P1B@IU'/IL MJ(@0(4S'6"5&;K/W85$U4G6DHXR\+>JAKFPT-5'N[?>R?.(**SACALXR6FVR M[%33V92N1[-Q%:X&A\DM(MFF^*QK2C-.XL;F=CC)H0Q$9ZRV+VO' DZ,@V9* M4B11?L4Q H&!F1C4]L(TF&N\<>E+(#AW&( 0DJX"PH7RDP_J%&7",/DHOY*Y M]-N+=H0?>?M)\Q6BQ99P ]!'V?E8K.RHZF!W6 U(*QK259@. RP=U^5,XT]YLK*]V2WO*-%3FI^.E^0ON&(X: MFFT#9PG[-@_P_A]0I;^$G9.R8!@NK#P O2_*IBNLJ43F.M,:C0\IEJ3RXG8! MTD#I G:YTWE[1Q/NQ/&:[R*** M7X@;X](R*RJ,F=Q;Z#&;C?0;O '/-#6SJ2E)6&X]KB*\V77Y?OAM? M:YCO+ !R$( XL<>LID$[72O=F>Q,%5@:+)5<,LW>.5TTYQ++#9;6LT=("AO2 M79Q=O9OC4Q_2>3R#V1N'Q(6%[ZX^7?C7T27DCB,(-4$MN C!L'DY0HU[KBTOV91R"K;5" MD>T*ZU(ZLE0.5O%JK3L_'J]%NYN#^[/:#,_'.# M3LY'<1/Q5*\2Q&LKHIEU< B-\/_*\F+9B-JE/$../W08SRLL/I^[=,59 =9= M^2@D9LGY^9GG)B"WU2Z>41%2HB]$IZWMIH./*RTJSY$?/_J33!-TK0I Y=!I MJ;/Y1?;XVB] JDARTN#/='U#?W;OF MQ9Z^E23V)8?5=7[8@QLFB79]QU!2%@ZEPDJ!+]FBT^&]U2B/-)38 D$=@\VF M;RFNCQ9UO?!XF%(>7@A=-M@XU]G^:K#@8#%Q2.S%=76S0#P1;ZL:[+R)2HZ4 M+=7-(JI$8(0#82V:(PPW[-X'=HN-0]RZC <<#MOF\//\;>] 0.@"NFX03(]B MT,DAF8#.+HDB^6F1;27>IM8JZN^SL(02#!8 EYAI $RU6BVZUITUPW'70F.7 M: 1QK[^JSC4[^* !"NF^H'B%D"!@QS:0F"[G1'H2J7N8&'V^L2C,!&Y- "3; M4BL8-X:QIQ01#9N#P7/ +(2V=8&4]_K3(9H- @ J"VN&MCT;3TUWW#IO(;68 MB5#L.=\>SQ@5&0* V))XH]_PQNL&I$1 .X<-]OCGW]7?_DL-[L"F93TV(STV M?4)_/AU0T SQ-!R0W9O+JGH=)[9%X#_L"7H%CT3Z9:J*609SFL27Z"/++Q0ANXVI.;$ MER!37>,+AE^QB<%([F^9I&(-T877N5L&>)*\32^Y$6192\J"43?BA+)Q?K*@ M=R89)OOXB)]I0ZLGJ);#)1;0TW#1M7?';K^%AD7%?HELQU;\-2$AHOS=4H*@ MAML/7/RRP72E1A4048ZI[!!CC<5P]RX!:@LA208JY05?I8M-TN]=L:I9>PC,;KH0F]^_AG?0)S,HZVDL2NP*QLB]ULZWY?&-H]FL M^:W@UM,]\NND*!PEH_+PK5G;6>CUF-W6Z\'6^ZXZ[ &-'FZ)J] F/*C#G".1 MU!YU4W1Y&[4:[YSPPE(U#NT5&8!,_;)#2$RZ+JW0(D;\1W:_X7/_,LCY3)Q_V35RQUE.IZ#N2HT<_":S98T^D*%:9&=%JFYB.D M2%?.?_*AD2'/ 13O%["P5KDM8Y'D=IA:+E7+#RABTIN.LD M(O[AAF:!A[_C$,RM\%#VP6P^DBUYR!T\.T0?QG:(0!4=&W"MFPW+TO!;03J5 M"^:I_.$C5K+,HJ2B@RQ+>QM-#K+_&VHWCX?)WI&L#OPZ49#N?FX'3A5'#("S M&1>B,B<&9C&^AS8K.J(&'86SW$YQ(+OI^\&+4N1:#G74!D\UTG&DW)%@%K0] M(D#M;_#9D*K#BAP>%,84 R7\D35L@[/IF9/3["2"+BM;2S AMDU/OFHP[M.7&J)KI39:]-3 MC1G58'VG0L\\(4TQT6FUJM]/*T7EJGNWE.!FH>%S-M[P^9ZH<=_6@_%)AWW9 MOD)[;SM9DI9PC#(-7]QA':I8N1%F704@E-H\>QQE5[ON93)#B+AY>EE&5S4E M&M#W'42E?#\Z9D.E@Q+"938QY%[+7[BM8: _;FPU8$A\F3"B=RE<=]3I,]G4K4.Q*>I>B&8"'[)]O M&/'],"^R1W2VZ31[G#T9/LBV^X3:!.B(Q)@Z"=V\L]MNN.*6%>SJ987OE/M= M-A<-%KZ5[/'+HN&@(=D )P3I ]J:,I;EU$WW\-SEQ=N M!;S+J+&F6"9N1Z^OT-T>%*DG*SF&(^_^Y3S.U$3;@?AZK38;*TG4P5VZQ-UN M)X_WU#'6NVWBWZ2'4-!]4KZ%G@X:FUQ2VY$K_I)+L#/)&!^%9MG9;5>71%W* M;Z,NY7?N!/4]2Z8/NKED#PS<(W*UKY':'W\/G;-1,Y>L5["X9*YSWEO\.F?A M\$@+H=[--DF:1Y!\7'J?Q"^##I&VXP);\%@!NG(+AI.!+_>"'YI([-*DS]SB MX_0-'8^S\8['^1H6..1.)^N9)?TU=R7K UH@YY@(MTM?Q(?S][COGISHC1F" MFXV.V I=&%_4XTM/?+"KT< @M20Z*B[F"U'24-'*SNB;;2C_:R T\;Y]?%O8 M *S"A"L&<((5)D0/Z91+NA[?3>":Q^@N 3)N]-SN+[FY0!G3V=#0=W(XY\@] ML88-*QNW;B%I3 RM990AMRQL!Z:;[8P]AWQ>0LA^.,_7J)@./X!3Z)/T_2,O M(UOGR>/ZJT^D9UV4/!Y9[;;3;='YLK .K^L+,:Z.XKOYD&[8/P4$I6/I.ZV; MW<8N9ZAUC]P.[DB?P!MT14L:=S0V0(N#U10QT7E'RL.7RDS"+5#8PX6M^/"%U1L6 M_VJ1NX)=QT?6>KEP?.0[V&,1;NDIJ4@2TU\>LT*&D]*_6H!8=RS(*+: M%@)K(4G"?LPK,/EV;FZT'9ONV!6'-+ [?[Z08AEWX^QD\*83MK8&&S246;O* M5RTQBD."44\Q^99#].[?Y^/Z&&P!;Q0QX=)?D\G2CXO;OU9ELZ#CZOY8'(!] MB.@K'%)<1]9/E^\_74;'QC!7RTCRUV;6H?V.F!*VH6+O8H]AXP+>SJ5$/C%+ MB?Y(Q#(Z^$Y"4F.6;HF'7>)HSB=?P!67UUAYA;>(Z6U>_\:VH52-QLMOODBR M3J+V"O3)R7]3GZ3UU4AOVZY5RI[^#IQB"F5O@L.<7KA*H74-V*!$6A$7GWUD M #.78FMB=]#;:JL1W!72[OVA.G**T?2^,6K9L[<XM]RN?AK;>T_&VWHNDR,^*^;XF8'R) M?2%HO.Y[W&[ZB*^1-'25=LTN=5I6M_>AI.<])?,(-H.XY(F3*,Y$QM?Z!B_. MGI>B0EUR2HI>0I<-[U?&1!#5*D9]^M/0RGHZWLHZE]RY<.4,R+T1_X"^5KMH M:G>9\=B>N(3TV!9#!^?I> ?GSW*;_ L0NJGA<^[R9_?<[OA:EW05'^2G? (@CDE'-&J[FAS>S"J<*[[V?RS]P"'D'$<_0,9E=0K^F= J*>C;OG? MRO!/_3\UA5W@%2BF7\.K)T;,G!YPW=%_:9D/_W,:B:=NF MHH^869$:!\#ORP:\0?L%%_#_ ,N;_P=02P,$% @ \X%B5LK_^ANV @ MQ@4 !D !X;"]W;W)K&UL?51K3]LP%/TK5T%" MF\3(HQ00M)$H#VT2;!6%3=.T#VYRTUCX$6R'TG^_:Z=D12K]DOAQS[GGVCYW MM-3FR=:(#EZE4'8Z044[E3:2.9J:16P;@ZP,("GB+$F. M8\FXBO)16)N:?*1;)[C"J0';2LG,:H)"+\=1&KTMW/-%[?Q"G(\:ML 9NL=F M:F@6]RPEEZ@LUPH,5N/H(CV;'/GX$/"3X])NC,%7,M?ZR4^^E>,H\8)08.$\ M Z/?"UZB$)Z(9#RO.:,^I0=NCM_8;T+M5,N<6;S4XA,&4@XNBT*UR7"U@J@4O.%KX],#F NWG4>Q(@>>)BW6V29VHUW:TBSV?D2/+5J"_HZDA7QJW M@JGPU\14"=?/+6_(+PX>+5:M@%M>(?P)M< #OCJ8"%T\_=U6UL[$V\OZC LD+$@11PZ[746I3 M96/T"_H82\NDSOCCZ\02A01M".PTI ELNZ-XPUL2S2)T$ O!%9W-^M6^25UT MWOP?WG6X.V867%E*7A$T.3P91F"ZKM%-G&Z"4^?:D>_#L*9&B\8'T'ZEZ76N M)SY!W[KS?U!+ P04 " #S@6)6]<>T6%4# #;!P &0 'AL+W=OHMHX+4J M:SWSM\;LKL-0YUNLN![*'=9TLI:JXH:6:A/JG4)>.*6J#),H2L.*B]J?3]W> MO9I/Y=Z4HL9[!7I?55R]+;"4AYD?^\>-!['9&KL1SJ<[OL$EFJ?=O:)5V*$4 MHL):"UF#PO7,OXFO%V,K[P1^$WC0)W.PGJRD?+:+#\7,CRPA+#$W%H'3[P5O ML2PM$-'XTF+ZG4FK>#H_HO_L?"=?5ESCK2Q_%X79SOR)#P6N^;XT#_+P"[;^ M.(*Y++4;X=#*1C[D>VUDU2H3@TK4S9^_MG'X%H6D54@<[\:08WG'#9]/E3R MLM*$9B?.5:=-Y$1M+V5I%)T*TC/S7Z5!8/ #/. +UGND?RXWM7 ANWCDJQ+U MY30T9,HJA'D+NVA@D_^ C1/X)&NSU?!376#Q-4!('#NBR9'H(NE%O,-\""P. M((F2I >/=8XSA\=Z'-?0.'C.OT9[=%[;ELJUWO$<9S[5@D;U@O[\^^_B-/JQ MA]NHXS;J0Y_?"CGN?^!7+67 M!11JK%:H;+@]&VX;\]B[$#68K=QK7A?ZTGL:+H?>\DT;K#0,*(/H\S[4VJ@] M%:W10&)4=#EJ+96@6"=Q#$G&O"59%+0-+(J 39CW$:FLZ'R< LLR[U$:7H*% MIZIOW,[2#.(@8LS[O#=:%&ACXB0N_,]/2_^R(Y($XW$,+$@F:2^9.!BG8QHG MH^B=$)G(&(TQRXZD["*&*Y:VM,A:QRH-6!)!%L175\WI_V"192E)QS$[9<$< MBW$2O;-@$QL!1G(-CR.' =F/Z&P DR!A"?1DW[C+OG%O]MU2X2KJEM2)S!9N M70]"%4"W?Z,UFI/U1\%7HA3F+7 .4@=!\>+R]-O2M9?.^70]35'7$>"?.__* MUZ_IVY2-XY3&J]B[PS4JA4579@,8478,8#QB9R,:GC1//L?>)J(VH-):Y)-1IF% W5/"7-PLB=:]\K:>@BW'1+KR\J M*T#G:TF=K%U8 ]U[/O\;4$L#!!0 ( /.!8E81*AA)I@( -4% 9 M>&PO=V]R:W-H965T7GJ>2G,LF;H06ZSH9B5DR329Z'O#[R2%963 M3.S90B8346M>5+B0H.JR9/)EAESLID[@O![<%>M MAY(5)5:J$!5(7$V=J^!R%AM_Z_"CP)W:VX-1LA1B8XROV=3Q#2'DF&J#P&AY MPCER;H"(QF.+Z70I3>#^_A7]L]5.6I9,X5SPGT6F\ZDS32++\III MEDRDV($TWH1F-E:JC29R164>Y5Y+NBTH3B??A$:(X1SF3.6N_<+-8UT\,8Z5 M5BZP*H,[5%H6J<:L<3A]8$N.ZFSB::)@@+RT33=KTH7OI M"N!65SA7<5!EF M?P-XQ+T3$+X*F(5'$:\QO8 H<"'TP_ (7M05)+)XT9&"*&@$'M+71,>'HTT+ M7:HM2W'J4(\HE$_H)!\_! /_TQ%N<<W%-+9C5'$*O_>J]?5@X\X+.& M&1?IYOW-1EDA2&(<%VQ+V.<1N/![W'H2F ML]2 &<5V@V]U(.2!&X5C6H.1&X3CWK\U"=P@#LRW'[=@)S D4KX)&5/R" Z] MF+?7:L1L;0>*@E34E6ZZKCOM9M95TZIO[LW ([GKHE+ <46A_H49$;(9(HVA MQ=8V[E)H&@-VF]/<16DR= MSZ,# #V" &0 'AL+W=OS^D;K6Z[-X^5'TP80!K$YO:!G;[ZSMVLEG:Y:(^ M]*$/ 8\S9^;,LJJR .PRRH&1?>9.3F[M5D)/>FX@+O%>A]73/U,L-*'L=>Y+U. M?.&;K;$3P62T8QM?@,0MX#8\6X2.9:WS+#)2,DC*.M-T>S E>K01(X+NR@+H^@M)YR9 M_"(-0@H]^"P.J W);;0/TP/C%5M6V*-E[VE6(5P]6%M?CP)#:2TX*-L4LR9% M_(T440QW4IBMAI_$"E=_#Q 0WXYT_$IZ%E^,>(ME'P:1#W$8QQ?B#3H1!B[> MX(((&IH"S]77H)/S:-LV-WK'2AQ[U!<:U0&]R0_?15GXXP5N2< M,['2US"MI3+\3US!7&H#CX(.ALK9'^E .+5_EEK#!\85?&75'F&Q)63/H*J! MOVT]H2LXJN&<[XO,]1+$_R!(:].BY2@JX;B>C]'30(ZS:2<5H MF\\D<88T]>,PHA=723(D5)KXPS2!-/3SO("!GVB*"PR)UQ11.[IP8,T1.RD@2AOEOOI&[TT3!P_F@VST X2/RHLOR;?/W6. M_C\ZDR[#,.UTSEP=-)FE13MP!;W7.1OZ\: *H4*(A39X2"'N/ SL@=#/QFD M9Z6+HJ%?)%:[R*:,D[Q96YK.BB&-\M"/L]B*UP2YT&5IUV7IQ2X[93"OF-9\ MS4G,Y0N5)8RBNV-//.^8L6WX K>VS'_7=1?S_C===[+:CB'2F@(=99HP3( 4 M""_(5+/M,J=W*V3D6".TOEJVIB%72:W/9M5.MG4[3X^)WQP&PO=V]R:W-H965T18%TNVN\1 G+18@6;-ACW0TK%%1")=DK+3?[]#W9RTMFH,>]N# MQ-OAQ^]<>$B>;Z5ZTBFB@><\$_JBGQJS?CL.B/SLO^V[5[%P6)N,";Q7H(L^9^CK'3&XO^EZ_Z;CC MJ]38CN'L?,U6>(_F<7VKJ#5L41*>H]!<"E"XO.A?>F_GD94O!3YSW.H7=;": M+*1\LHT/R47?M80PP]A8!$;%!J\PRRP0T?A28_;;)>W$E_4&_7VI.^FR8!JO M9/8G3TQZT9_T(<$E*S)S)[>_8:U/:/%BF>GR#]M:UNU#7&@C\WHR,5<+E2ROF6&SVR%"?G@\-K6#EAG&--J_0_ -HG@\W4IA4PSN18/(: M8$C46GY^PV_N=R)>8WP&@>> [_I^!U[0ZAN4>$&'OAHJ!??I5\T>[9]M=\A; MO68Q7O1I"VA4&^S/?OG)B]Q?.[B-6FZC+O39S@4.7&J-1L,-,ETH3( "^ [C M0BDN5C!GFFOXJ]0"'O#9P#R3\=/?^Q3J7'*_0F1SS!>H6KOW3K@ D\I",Y'H MT]XUZECQ=;FM_BC(H@G<*AZ384GNLMQG<,/4D]6 \@9\2% 8'K.L4>OD(VXP M ^\4[OE*\"6-"0.?3$J+?EI8&J5J'\2ZV$G[KZ4?A3PD&9S"@S0LZ]7+Y8T5 MF8&E-?+&&KEWQ70*I!'$MH)?"D[]Q)1PB-G/$#F!/Z5R4']ENW>'VI"R5NER MGN=X(X_&!U6M=Y]*908&54[6V)!P7D(.(!HYWC1L*[V/4JSVR07.) J;LE<D@TWY;T+M%0!T M9.:PS&R&[EQZ?X;>K7:#M&<2F6!K[ MKSID?RYBF2.P]5I)%J=PP^E4-5(@),P> ML[X;^/;G]:ZYCF5!J 2'X$5GX1N8TH_B?(."S+J1&2U4PH_",_<-!%/Z]]X] MW@V,'#S>7P,^QRDC:C7$F3NFGS?J?^3FK[W7\@')EEL*:\8%E>6ROM*X$S#2*X MJAQ!D"^VWXGGA'1NG79![#;E(0C/^P&$WQXE5^0/JT"I<9U =MFNZ:UDCP+< M%TG#%U?K'-6J?$!H*(.YNF6WO>T;Y;*ZFN_$JP<.G58K+C1DN*2I[MF8-KZJ M'@U5P\AU>5%?2$/7_K*:TCL+E16@\:6D8[!NV 7:E]OL'U!+ P04 " #S M@6)6M(7.PBT# !T!P &0 'AL+W=ODX^?4'88&4] W>_)[S!IO%$3L:W@3,8E_2!A^U7]D^= M=^=ER0W>J.9/4=O-+"@"J''%=XV]4_M?KY*-:;[PK['IE$ U#@**]P+8$, ZW?U"GVBG3@A_:;< M6^UFA8NS\Z_*(N3P 3[+)Y16:8$&SA_XLD%S,0VM6\(#PVJ@6_1T[!TZRN"+ MDG9CX&=98_U?@M!I&P6R5X$+=I+Q(U:7$%,"+&+L!%\\&HX[OOB$80.]P6/^ M^NCD>+2_(E=FRRNX.&-1/&,Q__(%FT4\GM"6CMN04^_S>7;EZUR"HU;@? M+P1N=EJ[-OS5J88'?+:P:%3U^/7.&[ Y1C;)>HQSY-S(<%NU,YP69N+ MR2]:&0,W7.L7(==PW:J=TW/7Q\."-UQ6"%]=#7F#F7P24KC36<-:J=K &="4 MQ''N&N<)H:R$"S]&"8N*R1W?NZ-M40O>&$A(3@LX9X3FL4,QDB;IY$%9WH X M.*MG3C")TM0S9B2.6,\8DSR-)Z^9NU6ZJP%G4)*X+#V6$DK3#EL05B23WY1< M?W!KM[ =P#0B69K!>4IHD3MD2I*L_%X%;U-+_\_4QB3*,B^#D;*3?.9-1'GY M)K4%B5GB45F9=L8R]HXQZM(5>4:'*09C*1.9/*="N#8A0L/*F&+>MW5>P.53UA?%,?1\4FY[BOIO_#^/?K" M]5I( PVN7&ATF: P B08 !D !X;"]W;W)K&UL?57?;]LV$'[W7W%0AR(!U$BB9=5.;0-QVF(%ELUHLNUA MV ,MG2TB(JF25)SLK]^1 M)HDM:Y3<7N@6%9ULM9'=A;VV6<]VY1BA< M&["=E-P\K;#1^T641<\;7\6N=GXC6[M@\%? O?VU1Q\)!NM[_WB2[6(4B\(&RR=9^ T/. U-HTG(AG?#IS1 MX-(#7\^?V3^'V"F6#;=XK9N_1>7J132-H,(M[QKW5>]_Q4,\$\]7ZL:&+^Q[ MVWP60=E9I^4!3 JD4/W('P]Y> 68IC\!L . !=V]HZ#R(W=\.3=Z#\9;$YN? MA% #FL0)Y2_EUADZ%81SR]^U0YC".U@;NFCCGH"K"CY]ZT1+J7=P=L>+(F\G1^'.VKY=*VO,1%1.5@T3Q@M'S[)BO2#R>T MY8.V_!3[\ODZ8E@WG.[A^UOY)XB&.WQTL&IT>?_O,?TG/1S73RE&N4$SI!E^ MW,E&9U\4N%IWEC39\]$-+VNB-B15N;C#(H\'_WF/=2ZJ4#(UN@']/86LKB8 MY/1EDQGQ>=%=WSF$ C(KT5K(QP6\?3-EZ>S#Z$X[WOB3E[IY\B3X@'<:F-$__U&V<9BXMI"N=P-J/)#,Y'ZZ,>8E#H MTSB+)SFCD1(Q>Y_!L:>7O&H/$LTN-$$+I>Z4ZSO%L#OTV:N^O;R8]TWZAIN= M4)9N84O0].+]) +3-[Y^X70;FLU&.VI=85K3OP*--Z#SK::B.RR\@^'OL_P? M4$L#!!0 ( /.!8E84IW<05P, ((( 9 >&PO=V]R:W-H965TM(YHH&7JA1Z[N3& MU->>I],<*ZZO9(V"5K925=S04.T\72OD6>M4E1[S_=BK>"&U"+F6Q, M60A\4*";JN+JL,)2[N=.X!PG/A6[W-@);S&K^0X?T?Q0-*5E0H="$% M*-S.G65PO8KL_G;#+P7N]2L;;"8;*9_LX#Z;.[XEA"6FQB)P>CWC#9:E!2(: M?_:8SA#2.KZVC^AW;>Z4RX9KO)'EKT5F\KF3.)#AEC>E^23W/V*?3TLPE:5N MG[#O]_H.I(TVLNJ=B4%5B.[-7WH=WN+ >@?6\NX"M2QON>&+F9)[4'8WH5FC M3;7U)G*%L(?R:!2M%N1G%A^E09C".[@7AJ0AK1I>PH.B4U?F !=KOBE17\X\ M0\&LBY?VP*L.F/T+<,#@@Q0FU_!>9)A]"> 1RX$J.U)=L;.(MYA>01BXP'S& MSN"%0^IABQ>>25U#E^"I_#KO\6EO6RS7NN8ISAVJ!HWJ&9W%=]\$L?_]&6[C M@=OX'/KBD8HO:TH$N86[0A0&W_U$7V]FCXF+74&<8:DU&@V_MQG &E\,K$J9 M/OUQ*IFSX4XG0WICM4$U:#ZZ* 287#::BTQ?CGY04FNXX4H="KΜ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end XML 99 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 100 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 101 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 226 435 1 true 86 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://transenterix.com/20221231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://transenterix.com/20221231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Description of the Business Sheet http://transenterix.com/20221231/role/statement-note-1-description-of-the-business Note 1 - Description of the Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Revenue Recognition Sheet http://transenterix.com/20221231/role/statement-note-3-revenue-recognition Note 3 - Revenue Recognition Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash Sheet http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash Note 4 - Cash, Cash Equivalents, and Restricted Cash Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Investments, Available-for-sale Sheet http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale Note 5 - Investments, Available-for-sale Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Fair Value Sheet http://transenterix.com/20221231/role/statement-note-6-fair-value Note 6 - Fair Value Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Inventories Sheet http://transenterix.com/20221231/role/statement-note-7-inventories Note 7 - Inventories Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Property and Equipment Sheet http://transenterix.com/20221231/role/statement-note-8-property-and-equipment Note 8 - Property and Equipment Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Intellectual Property Sheet http://transenterix.com/20221231/role/statement-note-9-intellectual-property Note 9 - Intellectual Property Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Leases Sheet http://transenterix.com/20221231/role/statement-note-10-leases- Note 10 - Leases Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Accrued Expenses Sheet http://transenterix.com/20221231/role/statement-note-11-accrued-expenses- Note 11 - Accrued Expenses Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Income Taxes Sheet http://transenterix.com/20221231/role/statement-note-12-income-taxes Note 12 - Income Taxes Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Stock-based Compensation Sheet http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation Note 13 - Stock-based Compensation Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Equity Offerings Sheet http://transenterix.com/20221231/role/statement-note-14-equity-offerings Note 14 - Equity Offerings Notes 20 false false R21.htm 020 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share Sheet http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share Note 15 - Basic and Diluted Net Loss Per Share Notes 21 false false R22.htm 021 - Disclosure - Note 16 - Commitments and Contingencies Sheet http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies Note 16 - Commitments and Contingencies Notes 22 false false R23.htm 022 - Disclosure - Note 17 - Segments and Geographic Areas Sheet http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas Note 17 - Segments and Geographic Areas Notes 23 false false R24.htm 023 - Disclosure - Note 18 - Related Party Transactions Sheet http://transenterix.com/20221231/role/statement-note-18-related-party-transactions Note 18 - Related Party Transactions Notes 24 false false R25.htm 024 - Disclosure - Significant Accounting Policies (Policies) Sheet http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies 25 false false R26.htm 025 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies 26 false false R27.htm 026 - Disclosure - Note 3 - Revenue Recognition (Tables) Sheet http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables Note 3 - Revenue Recognition (Tables) Tables http://transenterix.com/20221231/role/statement-note-3-revenue-recognition 27 false false R28.htm 027 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables) Sheet http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables) Tables http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash 28 false false R29.htm 028 - Disclosure - Note 5 - Investments, Available-for-sale (Tables) Sheet http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-tables Note 5 - Investments, Available-for-sale (Tables) Tables http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale 29 false false R30.htm 029 - Disclosure - Note 6 - Fair Value (Tables) Sheet http://transenterix.com/20221231/role/statement-note-6-fair-value-tables Note 6 - Fair Value (Tables) Tables http://transenterix.com/20221231/role/statement-note-6-fair-value 30 false false R31.htm 030 - Disclosure - Note 7 - Inventories (Tables) Sheet http://transenterix.com/20221231/role/statement-note-7-inventories-tables Note 7 - Inventories (Tables) Tables http://transenterix.com/20221231/role/statement-note-7-inventories 31 false false R32.htm 031 - Disclosure - Note 8 - Property and Equipment (Tables) Sheet http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-tables Note 8 - Property and Equipment (Tables) Tables http://transenterix.com/20221231/role/statement-note-8-property-and-equipment 32 false false R33.htm 032 - Disclosure - Note 9 - Intellectual Property (Tables) Sheet http://transenterix.com/20221231/role/statement-note-9-intellectual-property-tables Note 9 - Intellectual Property (Tables) Tables http://transenterix.com/20221231/role/statement-note-9-intellectual-property 33 false false R34.htm 033 - Disclosure - Note 10 - Leases (Tables) Sheet http://transenterix.com/20221231/role/statement-note-10-leases-tables Note 10 - Leases (Tables) Tables http://transenterix.com/20221231/role/statement-note-10-leases- 34 false false R35.htm 034 - Disclosure - Note 11 - Accrued Expenses (Tables) Sheet http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-tables Note 11 - Accrued Expenses (Tables) Tables http://transenterix.com/20221231/role/statement-note-11-accrued-expenses- 35 false false R36.htm 035 - Disclosure - Note 12 - Income Taxes (Tables) Sheet http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables Note 12 - Income Taxes (Tables) Tables http://transenterix.com/20221231/role/statement-note-12-income-taxes 36 false false R37.htm 036 - Disclosure - Note 13 - Stock-based Compensation (Tables) Sheet http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables Note 13 - Stock-based Compensation (Tables) Tables http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation 37 false false R38.htm 037 - Disclosure - Note 14 - Equity Offerings (Tables) Sheet http://transenterix.com/20221231/role/statement-note-14-equity-offerings-tables Note 14 - Equity Offerings (Tables) Tables http://transenterix.com/20221231/role/statement-note-14-equity-offerings 38 false false R39.htm 038 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share (Tables) Sheet http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables Note 15 - Basic and Diluted Net Loss Per Share (Tables) Tables http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share 39 false false R40.htm 039 - Disclosure - Note 16 - Commitments and Contingencies (Tables) Sheet http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-tables Note 16 - Commitments and Contingencies (Tables) Tables http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies 40 false false R41.htm 040 - Disclosure - Note 17 - Segments and Geographic Areas (Tables) Sheet http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-tables Note 17 - Segments and Geographic Areas (Tables) Tables http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas 41 false false R42.htm 041 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables 42 false false R43.htm 042 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) Sheet http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) Details 43 false false R44.htm 043 - Disclosure - Note 3 - Revenue Recognition 1 (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-1-details-textual Note 3 - Revenue Recognition 1 (Details Textual) Details http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables 44 false false R45.htm 044 - Disclosure - Note 3 - Revenue Recognition 2 (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual Note 3 - Revenue Recognition 2 (Details Textual) Details http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables 45 false false R46.htm 045 - Disclosure - Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) Details 46 false false R47.htm 046 - Disclosure - Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) Sheet http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) Details 47 false false R48.htm 047 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual) Details http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables 48 false false R49.htm 048 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details) Details 49 false false R50.htm 049 - Disclosure - Note 5 - Investments, Available-for-sale (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-details-textual Note 5 - Investments, Available-for-sale (Details Textual) Details http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-tables 50 false false R51.htm 050 - Disclosure - Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details) Sheet http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details) Details 51 false false R52.htm 051 - Disclosure - Note 5 - Investments, Available-for-sale - Contractual Maturities (Details) Sheet http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details Note 5 - Investments, Available-for-sale - Contractual Maturities (Details) Details 52 false false R53.htm 052 - Disclosure - Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 53 false false R54.htm 053 - Disclosure - Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details) Sheet http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details) Details 54 false false R55.htm 054 - Disclosure - Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) Sheet http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) Details 55 false false R56.htm 055 - Disclosure - Note 7 - Inventories - Components of Inventories (Details) Sheet http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details Note 7 - Inventories - Components of Inventories (Details) Details 56 false false R57.htm 056 - Disclosure - Note 8 - Property and Equipment (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-details-textual Note 8 - Property and Equipment (Details Textual) Details http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-tables 57 false false R58.htm 057 - Disclosure - Note 8 - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details Note 8 - Property and Equipment - Summary of Property and Equipment (Details) Details 58 false false R59.htm 058 - Disclosure - Note 9 - Intellectual Property (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual Note 9 - Intellectual Property (Details Textual) Details http://transenterix.com/20221231/role/statement-note-9-intellectual-property-tables 59 false false R60.htm 059 - Disclosure - Note 9 - Intellectual Property - Intellectual Property (Details) Sheet http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details Note 9 - Intellectual Property - Intellectual Property (Details) Details 60 false false R61.htm 060 - Disclosure - Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details) Sheet http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details) Details 61 false false R62.htm 061 - Disclosure - Note 10 - Leases - Components of Operating Lease Expense (Details) Sheet http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details Note 10 - Leases - Components of Operating Lease Expense (Details) Details 62 false false R63.htm 062 - Disclosure - Note 10 - Leases -Supplemental Balance Sheet Information (Details) Sheet http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details Note 10 - Leases -Supplemental Balance Sheet Information (Details) Details 63 false false R64.htm 063 - Disclosure - Note 10 - Leases - Minimum Lease Payments (Details) Sheet http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details Note 10 - Leases - Minimum Lease Payments (Details) Details 64 false false R65.htm 064 - Disclosure - Note 11 - Accrued Expenses - Components of Accrued Expenses (Details) Sheet http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details Note 11 - Accrued Expenses - Components of Accrued Expenses (Details) Details 65 false false R66.htm 065 - Disclosure - Note 12 - Income Taxes (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual Note 12 - Income Taxes (Details Textual) Details http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables 66 false false R67.htm 066 - Disclosure - Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) Sheet http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) Details 67 false false R68.htm 067 - Disclosure - Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details) Sheet http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details) Details 68 false false R69.htm 068 - Disclosure - Note 12 - Income Taxes - Deferred Tax Assets (Details) Sheet http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details Note 12 - Income Taxes - Deferred Tax Assets (Details) Details 69 false false R70.htm 069 - Disclosure - Note 12 - Income Taxes - Unrecognized Tax Positions (Details) Sheet http://transenterix.com/20221231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details Note 12 - Income Taxes - Unrecognized Tax Positions (Details) Details 70 false false R71.htm 070 - Disclosure - Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) Sheet http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) Details 71 false false R72.htm 071 - Disclosure - Note 13 - Stock-based Compensation (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual Note 13 - Stock-based Compensation (Details Textual) Details http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables 72 false false R73.htm 072 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Activity (Details) Sheet http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details Note 13 - Stock-based Compensation - Stock Option Activity (Details) Details 73 false false R74.htm 073 - Disclosure - Note 13 - Stock-based Compensation - Stock Options Outstanding (Details) Sheet http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details Note 13 - Stock-based Compensation - Stock Options Outstanding (Details) Details 74 false false R75.htm 074 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details) Sheet http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details) Details 75 false false R76.htm 075 - Disclosure - Note 13 - Stock-based Compensation - RSU Activity (Details) Sheet http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details Note 13 - Stock-based Compensation - RSU Activity (Details) Details 76 false false R77.htm 076 - Disclosure - Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details) Sheet http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details) Details 77 false false R78.htm 077 - Disclosure - Note 14 - Equity Offerings (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual Note 14 - Equity Offerings (Details Textual) Details http://transenterix.com/20221231/role/statement-note-14-equity-offerings-tables 78 false false R79.htm 078 - Disclosure - Note 14 - Equity Offerings - Summary of Sales Under Offering (Details) Sheet http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details Note 14 - Equity Offerings - Summary of Sales Under Offering (Details) Details 79 false false R80.htm 079 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 80 false false R81.htm 080 - Disclosure - Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details) Sheet http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details) Details 81 false false R82.htm 081 - Disclosure - Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details) Sheet http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details) Details 82 false false R83.htm 082 - Disclosure - Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details) Sheet http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details) Details 83 false false R84.htm 083 - Disclosure - Note 18 - Related Party Transactions (Details Textual) Sheet http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual Note 18 - Related Party Transactions (Details Textual) Details http://transenterix.com/20221231/role/statement-note-18-related-party-transactions 84 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 41 fact(s) appearing in ix:hidden were eligible for transformation: asxc:BusinessCombinationContingentConsiderationArrangementsTargetRevenue, asxc:BusinessCombinationContingentConsiderationLiabilityRelatedMilestone, asxc:NumberOfMajorCustomers, asxc:PeriodOfServiceSaleArrangement, asxc:PeriodOfServiceSaleArrangementAtStatedServicePrice, dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:NumberOfOperatingSegments, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt, us-gaap:PropertyPlantAndEquipmentGross, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:RestrictedCash, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued - asxc20221231_10k.htm 8, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 52, 53, 54 asxc20221231_10k.htm asxc-20221231.xsd asxc-20221231_cal.xml asxc-20221231_def.xml asxc-20221231_lab.xml asxc-20221231_pre.xml ex_480515.htm ex_480516.htm ex_480517.htm ex_480518.htm ex_480519.htm ex_481819.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 104 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "asxc20221231_10k.htm": { "axisCustom": 0, "axisStandard": 30, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 905, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 226, "dts": { "calculationLink": { "local": [ "asxc-20221231_cal.xml" ] }, "definitionLink": { "local": [ "asxc-20221231_def.xml" ] }, "inline": { "local": [ "asxc20221231_10k.htm" ] }, "labelLink": { "local": [ "asxc-20221231_lab.xml" ] }, "presentationLink": { "local": [ "asxc-20221231_pre.xml" ] }, "schema": { "local": [ "asxc-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 655, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 35, "http://transenterix.com/20221231": 7, "http://xbrl.sec.gov/dei/2022": 6, "total": 48 }, "keyCustom": 64, "keyStandard": 371, "memberCustom": 32, "memberStandard": 51, "nsprefix": "asxc", "nsuri": "http://transenterix.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://transenterix.com/20221231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash", "menuCat": "Notes", "order": "10", "role": "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "shortName": "Note 4 - Cash, Cash Equivalents, and Restricted Cash", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Investments, Available-for-sale", "menuCat": "Notes", "order": "11", "role": "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale", "shortName": "Note 5 - Investments, Available-for-sale", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Fair Value", "menuCat": "Notes", "order": "12", "role": "http://transenterix.com/20221231/role/statement-note-6-fair-value", "shortName": "Note 6 - Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Inventories", "menuCat": "Notes", "order": "13", "role": "http://transenterix.com/20221231/role/statement-note-7-inventories", "shortName": "Note 7 - Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Property and Equipment", "menuCat": "Notes", "order": "14", "role": "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment", "shortName": "Note 8 - Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Intellectual Property", "menuCat": "Notes", "order": "15", "role": "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "shortName": "Note 9 - Intellectual Property", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Leases", "menuCat": "Notes", "order": "16", "role": "http://transenterix.com/20221231/role/statement-note-10-leases-", "shortName": "Note 10 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "asxc:AccruedLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 11 - Accrued Expenses", "menuCat": "Notes", "order": "17", "role": "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-", "shortName": "Note 11 - Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "asxc:AccruedLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 12 - Income Taxes", "menuCat": "Notes", "order": "18", "role": "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "shortName": "Note 12 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 13 - Stock-based Compensation", "menuCat": "Notes", "order": "19", "role": "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "shortName": "Note 13 - Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 14 - Equity Offerings", "menuCat": "Notes", "order": "20", "role": "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "shortName": "Note 14 - Equity Offerings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share", "menuCat": "Notes", "order": "21", "role": "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "shortName": "Note 15 - Basic and Diluted Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 16 - Commitments and Contingencies", "menuCat": "Notes", "order": "22", "role": "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies", "shortName": "Note 16 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 17 - Segments and Geographic Areas", "menuCat": "Notes", "order": "23", "role": "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas", "shortName": "Note 17 - Segments and Geographic Areas", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 18 - Related Party Transactions", "menuCat": "Notes", "order": "24", "role": "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "shortName": "Note 18 - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "25", "role": "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "asxc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "26", "role": "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "asxc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 3 - Revenue Recognition (Tables)", "menuCat": "Tables", "order": "27", "role": "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables", "shortName": "Note 3 - Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "asxc:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables)", "menuCat": "Tables", "order": "28", "role": "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "shortName": "Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "asxc:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 5 - Investments, Available-for-sale (Tables)", "menuCat": "Tables", "order": "29", "role": "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-tables", "shortName": "Note 5 - Investments, Available-for-sale (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 6 - Fair Value (Tables)", "menuCat": "Tables", "order": "30", "role": "http://transenterix.com/20221231/role/statement-note-6-fair-value-tables", "shortName": "Note 6 - Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 7 - Inventories (Tables)", "menuCat": "Tables", "order": "31", "role": "http://transenterix.com/20221231/role/statement-note-7-inventories-tables", "shortName": "Note 7 - Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 8 - Property and Equipment (Tables)", "menuCat": "Tables", "order": "32", "role": "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-tables", "shortName": "Note 8 - Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 9 - Intellectual Property (Tables)", "menuCat": "Tables", "order": "33", "role": "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-tables", "shortName": "Note 9 - Intellectual Property (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 10 - Leases (Tables)", "menuCat": "Tables", "order": "34", "role": "http://transenterix.com/20221231/role/statement-note-10-leases-tables", "shortName": "Note 10 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "asxc:AccruedLiabilitiesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 11 - Accrued Expenses (Tables)", "menuCat": "Tables", "order": "35", "role": "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-tables", "shortName": "Note 11 - Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "asxc:AccruedLiabilitiesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 12 - Income Taxes (Tables)", "menuCat": "Tables", "order": "36", "role": "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables", "shortName": "Note 12 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 13 - Stock-based Compensation (Tables)", "menuCat": "Tables", "order": "37", "role": "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables", "shortName": "Note 13 - Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "asxc:ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 14 - Equity Offerings (Tables)", "menuCat": "Tables", "order": "38", "role": "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-tables", "shortName": "Note 14 - Equity Offerings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "asxc:ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share (Tables)", "menuCat": "Tables", "order": "39", "role": "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "shortName": "Note 15 - Basic and Diluted Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 16 - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "40", "role": "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-tables", "shortName": "Note 16 - Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 17 - Segments and Geographic Areas (Tables)", "menuCat": "Tables", "order": "41", "role": "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-tables", "shortName": "Note 17 - Segments and Geographic Areas (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "menuCat": "Details", "order": "42", "role": "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "asxc:SubstantialDoubtAboutGoingConcernPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-5", "lang": null, "name": "asxc:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OperatingLeaseAssetsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)", "menuCat": "Details", "order": "43", "role": "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-OperatingLeaseAssetsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 3 - Revenue Recognition 1 (Details Textual)", "menuCat": "Details", "order": "44", "role": "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-1-details-textual", "shortName": "Note 3 - Revenue Recognition 1 (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2023-01-01", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 3 - Revenue Recognition 2 (Details Textual)", "menuCat": "Details", "order": "45", "role": "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual", "shortName": "Note 3 - Revenue Recognition 2 (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2023-01-01", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 3 - Revenue Recognition - Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "46", "role": "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "shortName": "Note 3 - Revenue Recognition - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_StatementGeographicalAxis-US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details)", "menuCat": "Details", "order": "47", "role": "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "shortName": "Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual)", "menuCat": "Details", "order": "48", "role": "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual", "shortName": "Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details)", "menuCat": "Details", "order": "49", "role": "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "shortName": "Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "asxc:CashAndCashEquivalentsRestrictedCashAndInvestmentsPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 5 - Investments, Available-for-sale (Details Textual)", "menuCat": "Details", "order": "50", "role": "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-details-textual", "shortName": "Note 5 - Investments, Available-for-sale (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details)", "menuCat": "Details", "order": "51", "role": "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "shortName": "Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 5 - Investments, Available-for-sale - Contractual Maturities (Details)", "menuCat": "Details", "order": "52", "role": "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "shortName": "Note 5 - Investments, Available-for-sale - Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "menuCat": "Details", "order": "53", "role": "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "shortName": "Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31_BusinessAcquisitionAxis-SenhanceSurgicalRoboticSystemAcquisitionMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details)", "menuCat": "Details", "order": "54", "role": "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "shortName": "Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31_BusinessAcquisitionAxis-SenhanceSurgicalRoboticSystemAcquisitionMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_MeasurementInputTypeAxis-MeasurementInputDiscountRateMember", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2021-12-31_FairValueByLiabilityClassAxis-WarrantMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details)", "menuCat": "Details", "order": "55", "role": "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "shortName": "Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2020-12-31_FairValueByLiabilityClassAxis-WarrantMember", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 7 - Inventories - Components of Inventories (Details)", "menuCat": "Details", "order": "56", "role": "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details", "shortName": "Note 7 - Inventories - Components of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 8 - Property and Equipment (Details Textual)", "menuCat": "Details", "order": "57", "role": "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-details-textual", "shortName": "Note 8 - Property and Equipment (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 8 - Property and Equipment - Summary of Property and Equipment (Details)", "menuCat": "Details", "order": "58", "role": "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "shortName": "Note 8 - Property and Equipment - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember_RangeAxis-WeightedAverageMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 9 - Intellectual Property (Details Textual)", "menuCat": "Details", "order": "59", "role": "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual", "shortName": "Note 9 - Intellectual Property (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember_RangeAxis-WeightedAverageMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 9 - Intellectual Property - Intellectual Property (Details)", "menuCat": "Details", "order": "60", "role": "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details", "shortName": "Note 9 - Intellectual Property - Intellectual Property (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details)", "menuCat": "Details", "order": "61", "role": "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "shortName": "Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-IntellectualPropertyMember", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember", "decimals": "-3", "first": true, "lang": null, "name": "asxc:LongtermLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 10 - Leases - Components of Operating Lease Expense (Details)", "menuCat": "Details", "order": "62", "role": "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details", "shortName": "Note 10 - Leases - Components of Operating Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember", "decimals": "-3", "first": true, "lang": null, "name": "asxc:LongtermLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "em", "p", "td", "tr", "tbody", "table", "asxc:LesseeOperatingLeaseDisclosureTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 10 - Leases -Supplemental Balance Sheet Information (Details)", "menuCat": "Details", "order": "63", "role": "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "shortName": "Note 10 - Leases -Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "em", "p", "td", "tr", "tbody", "table", "asxc:LesseeOperatingLeaseDisclosureTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note 10 - Leases - Minimum Lease Payments (Details)", "menuCat": "Details", "order": "64", "role": "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details", "shortName": "Note 10 - Leases - Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "asxc:AccruedLiabilitiesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedMarketingCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note 11 - Accrued Expenses - Components of Accrued Expenses (Details)", "menuCat": "Details", "order": "65", "role": "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details", "shortName": "Note 11 - Accrued Expenses - Components of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "asxc:AccruedLiabilitiesTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedMarketingCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note 12 - Income Taxes (Details Textual)", "menuCat": "Details", "order": "66", "role": "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual", "shortName": "Note 12 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details)", "menuCat": "Details", "order": "67", "role": "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details", "shortName": "Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details)", "menuCat": "Details", "order": "68", "role": "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "shortName": "Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note 12 - Income Taxes - Deferred Tax Assets (Details)", "menuCat": "Details", "order": "69", "role": "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "shortName": "Note 12 - Income Taxes - Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Description of the Business", "menuCat": "Notes", "order": "7", "role": "http://transenterix.com/20221231/role/statement-note-1-description-of-the-business", "shortName": "Note 1 - Description of the Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note 12 - Income Taxes - Unrecognized Tax Positions (Details)", "menuCat": "Details", "order": "70", "role": "http://transenterix.com/20221231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details", "shortName": "Note 12 - Income Taxes - Unrecognized Tax Positions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details)", "menuCat": "Details", "order": "71", "role": "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "shortName": "Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note 13 - Stock-based Compensation (Details Textual)", "menuCat": "Details", "order": "72", "role": "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual", "shortName": "Note 13 - Stock-based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Activity (Details)", "menuCat": "Details", "order": "73", "role": "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details", "shortName": "Note 13 - Stock-based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Note 13 - Stock-based Compensation - Stock Options Outstanding (Details)", "menuCat": "Details", "order": "74", "role": "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details", "shortName": "Note 13 - Stock-based Compensation - Stock Options Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "em", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details)", "menuCat": "Details", "order": "75", "role": "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "shortName": "Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "em", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Note 13 - Stock-based Compensation - RSU Activity (Details)", "menuCat": "Details", "order": "76", "role": "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "shortName": "Note 13 - Stock-based Compensation - RSU Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details)", "menuCat": "Details", "order": "77", "role": "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "shortName": "Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "asxc:ProceedsFromIssuanceOfCommonStockNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Note 14 - Equity Offerings (Details Textual)", "menuCat": "Details", "order": "78", "role": "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual", "shortName": "Note 14 - Equity Offerings (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromWarrantExercises", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-The2021And2020ATMOfferingMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Note 14 - Equity Offerings - Summary of Sales Under Offering (Details)", "menuCat": "Details", "order": "79", "role": "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "shortName": "Note 14 - Equity Offerings - Summary of Sales Under Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-The2021And2020ATMOfferingMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "menuCat": "Details", "order": "80", "role": "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "shortName": "Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31_BusinessAcquisitionAxis-SenhanceSurgicalRoboticSystemAcquisitionMember_TypeOfArrangementAxis-LicenseAndSupplyAgreementMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualObligationDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080 - Disclosure - Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details)", "menuCat": "Details", "order": "81", "role": "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "shortName": "Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "i_2022-12-31_BusinessAcquisitionAxis-SenhanceSurgicalRoboticSystemAcquisitionMember_TypeOfArrangementAxis-LicenseAndSupplyAgreementMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractualObligationDueInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-LongLivedAssetsMember_ConcentrationRiskByTypeAxis-GeographicConcentrationRiskMember_StatementGeographicalAxis-US", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081 - Disclosure - Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details)", "menuCat": "Details", "order": "82", "role": "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "shortName": "Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-LongLivedAssetsMember_ConcentrationRiskByTypeAxis-GeographicConcentrationRiskMember_StatementGeographicalAxis-US", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-GeographicConcentrationRiskMember_StatementGeographicalAxis-US", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "082 - Disclosure - Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details)", "menuCat": "Details", "order": "83", "role": "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "shortName": "Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-GeographicConcentrationRiskMember_StatementGeographicalAxis-US", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_LegalEntityAxis-AsensusSurgicalEuropeSrlMember_RelatedPartyTransactionAxis-ServiceSupplyAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-OneMedSaMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "083 - Disclosure - Note 18 - Related Party Transactions (Details Textual)", "menuCat": "Details", "order": "84", "role": "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual", "shortName": "Note 18 - Related Party Transactions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_LegalEntityAxis-AsensusSurgicalEuropeSrlMember_RelatedPartyTransactionAxis-ServiceSupplyAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-OneMedSaMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Revenue Recognition", "menuCat": "Notes", "order": "9", "role": "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition", "shortName": "Note 3 - Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "asxc20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 86, "tag": { "asxc_AccruedLiabilitiesExcludingEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered, excluding employee related liabilities.", "label": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesExcludingEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "asxc_AccruedLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accrued liabilities at the end of the reporting period.", "label": "Accrued Liabilities [Text Block]" } } }, "localname": "AccruedLiabilitiesTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-" ], "xbrltype": "textBlockItemType" }, "asxc_AllCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents all countries.", "label": "All Countries [Member]" } } }, "localname": "AllCountriesMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "asxc_AsensusSurgicalEuropeSrlMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Asensus Surgical Europe S.\u00e0.R.L .", "label": "Asensus Surgical Europe S.\u00e0.R.L [Member]" } } }, "localname": "AsensusSurgicalEuropeSrlMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "asxc_AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the \"Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan\".", "label": "Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan [Member]" } } }, "localname": "AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "asxc_BusinessCombinationContingentConsiderationArrangementsTargetRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The target revenue to be achieved pursuant to the business combination agreement.", "label": "asxc_BusinessCombinationContingentConsiderationArrangementsTargetRevenue", "terseLabel": "Business Combination Contingent Consideration Arrangements Target Revenue" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsTargetRevenue", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_BusinessCombinationContingentConsiderationLiabilityRelatedMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the milestone amount associated with the specified liability arising from contingent consideration in a business combination.", "label": "asxc_BusinessCombinationContingentConsiderationLiabilityRelatedMilestone", "terseLabel": "Business Combination, Contingent Consideration, Liability, Related Milestone" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityRelatedMilestone", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_CashAndCashEquivalentsRestrictedCashAndInvestmentsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, restricted cash, and investments.", "label": "Cash and Cash Equivalents, Restricted Cash, and Investments, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndInvestmentsPolicyPolicyTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "asxc_CashCashEquivalentsAndRestrictedCashDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The complete disclosure for cash, cash equivalents, and restricted cash.", "label": "Cash, Cash Equivalents, and Restricted Cash Disclosure [Text Block]" } } }, "localname": "CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash" ], "xbrltype": "textBlockItemType" }, "asxc_ContingentConsiderationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure accounting policy for contingent consideration.", "label": "Contingent Consideration [Policy Text Block]" } } }, "localname": "ContingentConsiderationPolicyTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "asxc_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to customer one.", "label": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "asxc_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to customer three.", "label": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "asxc_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to customer two.", "label": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "asxc_DebtSecuritiesAvailableforsaleAmortizedCostMaturityNextOneToTwoYears": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year to second fiscal year following current fiscal year.", "label": "Mature in one to two years, amortized cost" } } }, "localname": "DebtSecuritiesAvailableforsaleAmortizedCostMaturityNextOneToTwoYears", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details" ], "xbrltype": "monetaryItemType" }, "asxc_DebtSecuritiesAvailableforsaleFairValueMaturityNextOneToTwoYears": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year to second fiscal year following current fiscal year.", "label": "Mature in one to two years, fair value" } } }, "localname": "DebtSecuritiesAvailableforsaleFairValueMaturityNextOneToTwoYears", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details" ], "xbrltype": "monetaryItemType" }, "asxc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities classified as noncurrent.", "label": "Accrued expenses and other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesNoncurrent", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "asxc_EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationAmount": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in fair market value of contingent consideration. .", "label": "Change in fair market value of contingent consideration, amount" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationAmount", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "asxc_EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationPercent": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in the fair market value of contingent consideration.", "label": "asxc_EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationPercent", "terseLabel": "Change in fair market value of contingent consideration, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationPercent", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "asxc_EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsAmount": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to true-up to stock compensation cancellations.", "label": "True-up to Stock Compensation - Cancellations, amount" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsAmount", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "asxc_EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsPercent": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to true-up to stock compensation cancellations.", "label": "asxc_EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsPercent", "terseLabel": "True-up to Stock Compensation - Cancellations, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsPercent", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "asxc_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsAmount": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefits.", "label": "Change in unrecognized tax benefits, amount" } } }, "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsAmount", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "asxc_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefits.", "label": "asxc_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent", "terseLabel": "Change in unrecognized tax benefits, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "asxc_EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsAmount": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant remeasurement and financing costs.", "label": "Warrant remeasurment and financing costs, amount" } } }, "localname": "EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsAmount", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "asxc_EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsPercent": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant remeasurement and financing costs.", "label": "asxc_EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsPercent", "terseLabel": "Warrant remeasurment and financing costs, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsPercent", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "asxc_EmployerRetentionTaxCreditPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to the Employer Retention Tax Credit under the CARES Act.", "label": "Employer Retention Tax Credit, Policy [Policy Text Block]" } } }, "localname": "EmployerRetentionTaxCreditPolicyPolicyTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "asxc_EmployerRetentionTaxCreditReceivable": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of employer retention tax credit receivable as of the specified date.", "label": "Employee retention tax credit receivable", "terseLabel": "Employer Retention Tax Credit Receivable" } } }, "localname": "EmployerRetentionTaxCreditReceivable", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_ErrorCorrectionAndRevisionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the accounting policies for error correction and revisions.", "label": "Error Correction and Revisions [Policy Text Block]" } } }, "localname": "ErrorCorrectionAndRevisionsPolicyTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "asxc_EuropeMiddleEastAndAfricaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Europe, Middle East, and Africa.", "label": "Europe, Middle East, and Africa [Member]" } } }, "localname": "EuropeMiddleEastAndAfricaMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "asxc_FairValueMeasurementWithUnobservableInputsRecurringBasisLiabilityValueCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current portion of liability measurement with unobservable inputs on recurring basis.", "label": "asxc_FairValueMeasurementWithUnobservableInputsRecurringBasisLiabilityValueCurrent", "verboseLabel": "Current portion" } } }, "localname": "FairValueMeasurementWithUnobservableInputsRecurringBasisLiabilityValueCurrent", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "asxc_FairValueMeasurementWithUnobservableInputsRecurringBasisLiabilityValueNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent portion of liability measurement with unobservable inputs on recurring basis.", "label": "asxc_FairValueMeasurementWithUnobservableInputsRecurringBasisLiabilityValueNonCurrent", "verboseLabel": "Long-term portion" } } }, "localname": "FairValueMeasurementWithUnobservableInputsRecurringBasisLiabilityValueNonCurrent", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "asxc_FiniteLivedIntangibleAssetsForeignCurrencyTranslationImpact": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The accumulated impact of foreign currency translation for finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Impact" } } }, "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationImpact", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "xbrltype": "monetaryItemType" }, "asxc_ImpactOf382OwnershipChangesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the impact of 382 ownership changes.", "label": "Impact of 382 Ownership Changes [Member]" } } }, "localname": "ImpactOf382OwnershipChangesMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "asxc_IncreaseDecreaseInAccruedLiabilitiesNotIncludingEmployeeRelatedLiabilities": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid, not including employee related liabilities.", "label": "asxc_IncreaseDecreaseInAccruedLiabilitiesNotIncludingEmployeeRelatedLiabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesNotIncludingEmployeeRelatedLiabilities", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "asxc_IncreaseDecreaseInInventoryReserve": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the changes in inventory reserve.", "label": "asxc_IncreaseDecreaseInInventoryReserve", "negatedLabel": "Change in inventory reserves" } } }, "localname": "IncreaseDecreaseInInventoryReserve", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "asxc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in right-of-use assets.", "label": "asxc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "negatedLabel": "Operating lease right-of-use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "asxc_IncreaseDecreaseInOperatingLossCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in operating loss carryforwards.", "label": "asxc_IncreaseDecreaseInOperatingLossCarryforwards", "terseLabel": "Increase (Decrease) in Operating Loss Carryforwards" } } }, "localname": "IncreaseDecreaseInOperatingLossCarryforwards", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_IncreaseDecreaseInTaxCreditCarryforward": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in tax credit carryforward.", "label": "asxc_IncreaseDecreaseInTaxCreditCarryforward", "terseLabel": "Increase (Decrease) in Tax Credit Carryforward" } } }, "localname": "IncreaseDecreaseInTaxCreditCarryforward", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_IncreaseDecreaseInTaxCreditReceivable": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) during the period in tax credit receivable.", "label": "asxc_IncreaseDecreaseInTaxCreditReceivable", "negatedLabel": "Employee retention tax credit receivable" } } }, "localname": "IncreaseDecreaseInTaxCreditReceivable", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "asxc_InstrumentsAndAccessoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents instruments and accessories, a type of products of the company.", "label": "Instruments and Accessories [Member]" } } }, "localname": "InstrumentsAndAccessoriesMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "asxc_InventoryCurrentAndNoncurrentGross": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of gross inventory before allowance, both current and noncurrent.", "label": "asxc_InventoryCurrentAndNoncurrentGross", "totalLabel": "Total inventories, gross" } } }, "localname": "InventoryCurrentAndNoncurrentGross", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "asxc_InventoryCurrentAndNoncurrentNet": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "asxc_InventoryCurrentAndNoncurrentNet", "totalLabel": "Total inventories, net" } } }, "localname": "InventoryCurrentAndNoncurrentNet", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "asxc_InventoryFinishedGoodsValuationAllowance": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 1.0, "parentTag": "asxc_InventoryValuationReservesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for finished goods.", "label": "asxc_InventoryFinishedGoodsValuationAllowance", "negatedLabel": "Finished goods, reserve" } } }, "localname": "InventoryFinishedGoodsValuationAllowance", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "asxc_InventoryNoncurrentGross": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 2.0, "parentTag": "asxc_InventoryCurrentAndNoncurrentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory before valuation allowance classified as noncurrent.", "label": "Long-term portion, gross" } } }, "localname": "InventoryNoncurrentGross", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "asxc_InventoryRawMaterialsValuationAllowance": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 0.0, "parentTag": "asxc_InventoryValuationReservesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for raw materials.", "label": "asxc_InventoryRawMaterialsValuationAllowance", "negatedLabel": "Raw materials, reserve" } } }, "localname": "InventoryRawMaterialsValuationAllowance", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "asxc_InventoryValuationReservesCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory classified as current and noncurrent.", "label": "asxc_InventoryValuationReservesCurrentAndNoncurrent", "negatedTotalLabel": "Total inventories, reserve" } } }, "localname": "InventoryValuationReservesCurrentAndNoncurrent", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "asxc_InventoryValuationReservesNoncurrent": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 3.0, "parentTag": "asxc_InventoryValuationReservesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory classified as noncurrent.", "label": "asxc_InventoryValuationReservesNoncurrent", "negatedLabel": "Long-term portion, reserve" } } }, "localname": "InventoryValuationReservesNoncurrent", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "asxc_LeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Lease.", "label": "Lease [Member]" } } }, "localname": "LeaseMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "asxc_LesseeOperatingLeaseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.", "label": "Lessee, Operating Lease, Disclosure [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseDisclosureTableTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "asxc_LicenseAndSupplyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents license and supply agreement.", "label": "License and Supply Agreement [Member]" } } }, "localname": "LicenseAndSupplyAgreementMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "xbrltype": "domainItemType" }, "asxc_LongLivedAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding long-lived assets.", "label": "Long-lived Assets [Member]" } } }, "localname": "LongLivedAssetsMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "asxc_LongtermLeaseCost": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term lease cost.", "label": "Long-term Operating" } } }, "localname": "LongtermLeaseCost", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "asxc_MachineryManufacturingAndDemonstrationEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents machinery, manufacturing and demonstration equipment.", "label": "Machinery, Manufacturing and Demonstration Equipment [Member]" } } }, "localname": "MachineryManufacturingAndDemonstrationEquipmentMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "asxc_MeasurementInputCurrencyExchangeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input using currency exchange rate.", "label": "Measurement Input, Currency Exchange Rate [Member]" } } }, "localname": "MeasurementInputCurrencyExchangeRateMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "xbrltype": "domainItemType" }, "asxc_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_NumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "asxc_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers" } } }, "localname": "NumberOfMajorCustomers", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "asxc_OneCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents one of the major customers.", "label": "One Customer [Member]" } } }, "localname": "OneCustomerMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "asxc_OneMedSaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents 1 Med S.A.", "label": "1 Med S.A. [Member]" } } }, "localname": "OneMedSaMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "asxc_OperatingLeaseAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to operating lease assets.", "label": "Operating Lease Assets [Member]" } } }, "localname": "OperatingLeaseAssetsMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "asxc_OperatingLeaseIncrementalBorrowingRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental borrowing rate for operating lease.", "label": "Incremental borrowing rate" } } }, "localname": "OperatingLeaseIncrementalBorrowingRate", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details" ], "xbrltype": "percentItemType" }, "asxc_OperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward that are not subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "asxc_OperatingLossCarryforwardsNotSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Not Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "asxc_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_OtherCountriesInEmeaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Countries in EMEA.", "label": "Other Countries in EMEA [Member]" } } }, "localname": "OtherCountriesInEmeaMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "asxc_OtherIncomeEmployerRetentionTaxCredit": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount recorded in other income in connection with the Employer Retention Tax Credit under the CARES Act.", "label": "Employee retention tax credit", "terseLabel": "Other Income, Employer Retention Tax Credit" } } }, "localname": "OtherIncomeEmployerRetentionTaxCredit", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_OverstatedRawMaterialsAndUnderstatedFinishedGoodsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount related to overtstsaed raw materials.", "label": "asxc_OverstatedRawMaterialsAndUnderstatedFinishedGoodsAmount", "terseLabel": "Overstated Raw Materials, Amount" } } }, "localname": "OverstatedRawMaterialsAndUnderstatedFinishedGoodsAmount", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_PaycheckProtectionProgramCaresActMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents loan designed to provide funds for small businesses to keep their employees on the payroll.", "label": "Paycheck Protection Program CARES Act [Member]" } } }, "localname": "PaycheckProtectionProgramCaresActMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "asxc_PerformanceRestrictedStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents performance restricted stock unit.", "label": "Performance Restricted Stock Unit [Member]" } } }, "localname": "PerformanceRestrictedStockUnitMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "asxc_PeriodOfServiceSaleArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the period of service sale arrangement.", "label": "asxc_PeriodOfServiceSaleArrangement", "terseLabel": "Period Of Service Sale Arrangement (Year)" } } }, "localname": "PeriodOfServiceSaleArrangement", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "asxc_PeriodOfServiceSaleArrangementAtStatedServicePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the period of service sale arrangement at stated service price.", "label": "asxc_PeriodOfServiceSaleArrangementAtStatedServicePrice", "terseLabel": "Period of Service Sale Arrangement at Stated Service Price (Year)" } } }, "localname": "PeriodOfServiceSaleArrangementAtStatedServicePrice", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "asxc_ProceedsFromEmployeeRetentionTaxCredit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash inflow from employee retention tax credit.", "label": "asxc_ProceedsFromEmployeeRetentionTaxCredit", "terseLabel": "Proceeds From Employee Retention Tax Credit" } } }, "localname": "ProceedsFromEmployeeRetentionTaxCredit", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_ProceedsFromIssuanceOfCommonStockNet": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of common stock, net of issuance cost.", "label": "Proceeds from issuance of common stock, net of issuance costs", "terseLabel": "Proceeds from Issuance of Common Stock, Net" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNet", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_ProceedsFromIssuanceOfEquityNet": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of equity, net of issuance cost.", "label": "asxc_ProceedsFromIssuanceOfEquityNet", "totalLabel": "Net proceeds" } } }, "localname": "ProceedsFromIssuanceOfEquityNet", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "xbrltype": "monetaryItemType" }, "asxc_ProceedsFromStockOptionsAndWarrantsExercised": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from stock options and warrants exercised.", "label": "Proceeds from exercise of stock options and warrants" } } }, "localname": "ProceedsFromStockOptionsAndWarrantsExercised", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "asxc_PropertyPlantAndEquipmentIncludingPurchasedSoftwareImpairmentCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of impairment charges associated with property, plant and equipment (including purchased software) during the period.", "label": "asxc_PropertyPlantAndEquipmentIncludingPurchasedSoftwareImpairmentCharges", "terseLabel": "Property, Plant and Equipment, Including Purchased Software, Impairment Charges" } } }, "localname": "PropertyPlantAndEquipmentIncludingPurchasedSoftwareImpairmentCharges", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the public offering of securities.", "label": "Public Offering [Member]" } } }, "localname": "PublicOfferingMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual" ], "xbrltype": "domainItemType" }, "asxc_ReclassificationOfWarrantLiabilityToCommonStockAndAdditionalPaidInCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of warrant liability reclassified to common stock and additional paid-in-capital.", "label": "Reclass of warrant liability to common stock and additional paid-in-capital" } } }, "localname": "ReclassificationOfWarrantLiabilityToCommonStockAndAdditionalPaidInCapital", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "asxc_RegisteredDirectOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding a registered direct offering.", "label": "Registered Direct Offering [Member]" } } }, "localname": "RegisteredDirectOfferingMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual" ], "xbrltype": "domainItemType" }, "asxc_RiskAndUncertaintiesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for risk and uncertainties for the reporting period.", "label": "Risk And Uncertainties, Policy [Policy Text Block]" } } }, "localname": "RiskAndUncertaintiesPolicyPolicyTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "asxc_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash, cash equivalents, and restricted cash.", "label": "Schedule of Cash, Cash Equivalents, and Restricted Cash [Table Text Block]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables" ], "xbrltype": "textBlockItemType" }, "asxc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the useful life of property, plant and equipment during the reporting period.", "label": "Schedule of Property Plant and Equipment Useful Life [Table Text Block]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "asxc_ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of sales under sales agency agreement.", "label": "Schedule of Sales Under Sales Agency Agreement [Table Text Block]" } } }, "localname": "ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-tables" ], "xbrltype": "textBlockItemType" }, "asxc_SenhanceSurgicalRoboticSystemAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Senhance Surgical Robotic System acquisition.", "label": "Senhance Surgical Robotic System Acquisition[Member]" } } }, "localname": "SenhanceSurgicalRoboticSystemAcquisitionMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "xbrltype": "domainItemType" }, "asxc_ServiceSupplyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the service supply agreement.", "label": "Service Supply Agreement [Member]" } } }, "localname": "ServiceSupplyAgreementMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "asxc_StartupCostsAndOtherIntangiblesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to start-up costs and other intangibles.", "label": "Start-up Costs and Other Intangibles [Member]" } } }, "localname": "StartupCostsAndOtherIntangiblesMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "domainItemType" }, "asxc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for the stock options and warrants exercised during period.", "label": "Exercise of stock options and warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "sharesItemType" }, "asxc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during period for stock options and warrants exercised.", "label": "Exercise of stock options and warrants" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "asxc_StockOfferingAgreementMaximumShareValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum share value issuable under a stock offering agreement.", "label": "asxc_StockOfferingAgreementMaximumShareValue", "terseLabel": "Stock Offering Agreement, Maximum Share Value" } } }, "localname": "StockOfferingAgreementMaximumShareValue", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_SubstantialDoubtAboutGoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for substantial doubt about going concern.", "label": "Substantial Doubt about Going Concern [Policy Text Block]" } } }, "localname": "SubstantialDoubtAboutGoingConcernPolicyTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "asxc_SystemsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the systems, a product of the company.", "label": "Systems [Member]" } } }, "localname": "SystemsMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "asxc_The2020ATMOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the 2020 ATM Offering.", "label": "The 2020 ATM Offering [Member]" } } }, "localname": "The2020ATMOfferingMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual" ], "xbrltype": "domainItemType" }, "asxc_The2021ATMOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2021 at the market offering.", "label": "The 2021 ATM Offering [Member]" } } }, "localname": "The2021ATMOfferingMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual" ], "xbrltype": "domainItemType" }, "asxc_The2021And2020ATMOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the 2021 and 2020 ATM offering.", "label": "The 2021 and 2020 ATM Offering [Member]" } } }, "localname": "The2021And2020ATMOfferingMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "xbrltype": "domainItemType" }, "asxc_The2022AtmOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2022 ATM offering.", "label": "The 2022 ATM Offering [Member]" } } }, "localname": "The2022AtmOfferingMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual" ], "xbrltype": "domainItemType" }, "asxc_ThreeCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to three customers.", "label": "Three Customers [Member]" } } }, "localname": "ThreeCustomersMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "asxc_TransferOfInventoryToPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory transferred to property and equipment.", "label": "Transfer of inventories to property and equipment" } } }, "localname": "TransferOfInventoryToPropertyAndEquipment", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "asxc_TwoCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the two major customers of the company.", "label": "Two Customers [Member]" } } }, "localname": "TwoCustomersMember", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "asxc_WarrantLiabilitiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy warrant liabilities.", "label": "Warrant Liabilities [Policy Text Block]" } } }, "localname": "WarrantLiabilitiesPolicyTextBlock", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "asxc_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities.", "label": "asxc_WorkingCapital", "terseLabel": "Working Capital" } } }, "localname": "WorkingCapital", "nsuri": "http://transenterix.com/20221231", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "asxc_statement-statement-note-10-leases-components-of-operating-lease-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Components of Operating Lease Expense (Details)" } } }, "localname": "statement-statement-note-10-leases-components-of-operating-lease-expense-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-10-leases-minimum-lease-payments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Minimum Lease Payments (Details)" } } }, "localname": "statement-statement-note-10-leases-minimum-lease-payments-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-10-leases-supplemental-balance-sheet-information-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases -Supplemental Balance Sheet Information (Details)" } } }, "localname": "statement-statement-note-10-leases-supplemental-balance-sheet-information-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-10-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Leases" } } }, "localname": "statement-statement-note-10-leases-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-11-accrued-expenses-components-of-accrued-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Accrued Expenses - Components of Accrued Expenses (Details)" } } }, "localname": "statement-statement-note-11-accrued-expenses-components-of-accrued-expenses-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-11-accrued-expenses-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Accrued Expenses" } } }, "localname": "statement-statement-note-11-accrued-expenses-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-12-income-taxes-deferred-tax-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Deferred Tax Assets (Details)" } } }, "localname": "statement-statement-note-12-income-taxes-deferred-tax-assets-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details)" } } }, "localname": "statement-statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details)" } } }, "localname": "statement-statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-12-income-taxes-income-tax-expense-benefit-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details)" } } }, "localname": "statement-statement-note-12-income-taxes-income-tax-expense-benefit-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-12-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes" } } }, "localname": "statement-statement-note-12-income-taxes-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-12-income-taxes-unrecognized-tax-positions-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Unrecognized Tax Positions (Details)" } } }, "localname": "statement-statement-note-12-income-taxes-unrecognized-tax-positions-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details)" } } }, "localname": "statement-statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-13-stockbased-compensation-rsu-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation - RSU Activity (Details)" } } }, "localname": "statement-statement-note-13-stockbased-compensation-rsu-activity-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-13-stockbased-compensation-stock-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-13-stockbased-compensation-stock-option-activity-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details)" } } }, "localname": "statement-statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-13-stockbased-compensation-stock-options-outstanding-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation - Stock Options Outstanding (Details)" } } }, "localname": "statement-statement-note-13-stockbased-compensation-stock-options-outstanding-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-13-stockbased-compensation-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation" } } }, "localname": "statement-statement-note-13-stockbased-compensation-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-14-equity-offerings-summary-of-sales-under-offering-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Equity Offerings - Summary of Sales Under Offering (Details)" } } }, "localname": "statement-statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-14-equity-offerings-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Equity Offerings" } } }, "localname": "statement-statement-note-14-equity-offerings-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)" } } }, "localname": "statement-statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-15-basic-and-diluted-net-loss-per-share-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 15 - Basic and Diluted Net Loss Per Share" } } }, "localname": "statement-statement-note-15-basic-and-diluted-net-loss-per-share-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details)" } } }, "localname": "statement-statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-16-commitments-and-contingencies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 16 - Commitments and Contingencies" } } }, "localname": "statement-statement-note-16-commitments-and-contingencies-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details)" } } }, "localname": "statement-statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details)" } } }, "localname": "statement-statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-17-segments-and-geographic-areas-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 17 - Segments and Geographic Areas" } } }, "localname": "statement-statement-note-17-segments-and-geographic-areas-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-3-revenue-recognition-contract-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-3-revenue-recognition-disaggregation-of-revenue-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Revenue Recognition - Disaggregation of Revenue (Details)" } } }, "localname": "statement-statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-3-revenue-recognition-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Revenue Recognition" } } }, "localname": "statement-statement-note-3-revenue-recognition-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details)" } } }, "localname": "statement-statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-4-cash-cash-equivalents-and-restricted-cash-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "statement-statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-5-investments-availableforsale-contractual-maturities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Investments, Available-for-sale - Contractual Maturities (Details)" } } }, "localname": "statement-statement-note-5-investments-availableforsale-contractual-maturities-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-5-investments-availableforsale-summary-of-investment-securities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details)" } } }, "localname": "statement-statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-5-investments-availableforsale-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Investments, Available-for-sale" } } }, "localname": "statement-statement-note-5-investments-availableforsale-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details)" } } }, "localname": "statement-statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)" } } }, "localname": "statement-statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details)" } } }, "localname": "statement-statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-6-fair-value-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value" } } }, "localname": "statement-statement-note-6-fair-value-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-7-inventories-components-of-inventories-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Inventories - Components of Inventories (Details)" } } }, "localname": "statement-statement-note-7-inventories-components-of-inventories-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-7-inventories-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Inventories" } } }, "localname": "statement-statement-note-7-inventories-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-8-property-and-equipment-summary-of-property-and-equipment-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Property and Equipment - Summary of Property and Equipment (Details)" } } }, "localname": "statement-statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-8-property-and-equipment-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Property and Equipment" } } }, "localname": "statement-statement-note-8-property-and-equipment-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details)" } } }, "localname": "statement-statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-9-intellectual-property-intellectual-property-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Intellectual Property - Intellectual Property (Details)" } } }, "localname": "statement-statement-note-9-intellectual-property-intellectual-property-details", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-note-9-intellectual-property-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Intellectual Property" } } }, "localname": "statement-statement-note-9-intellectual-property-tables", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "asxc_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://transenterix.com/20221231", "xbrltype": "stringItemType" }, "country_CH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SWITZERLAND" } } }, "localname": "CH", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_IT": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ITALY" } } }, "localname": "IT", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r662", "r663", "r664" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r662", "r663", "r664" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r662", "r663", "r664" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r662", "r663", "r664" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r665" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-document-and-entity-information", "http://transenterix.com/20221231/role/statement-note-1-description-of-the-business", "http://transenterix.com/20221231/role/statement-note-10-leases-", "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details", "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details", "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20221231/role/statement-note-10-leases-tables", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-tables", "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-tables", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-tables", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-tables", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-1-details-textual", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-details-textual", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-tables", "http://transenterix.com/20221231/role/statement-note-6-fair-value", "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-tables", "http://transenterix.com/20221231/role/statement-note-7-inventories", "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details", "http://transenterix.com/20221231/role/statement-note-7-inventories-tables", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-details-textual", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-tables", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-tables", "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r666" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r667" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r662", "r663", "r664" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-document-and-entity-information", "http://transenterix.com/20221231/role/statement-note-1-description-of-the-business", "http://transenterix.com/20221231/role/statement-note-10-leases-", "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details", "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details", "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20221231/role/statement-note-10-leases-tables", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-tables", "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-tables", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-tables", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-tables", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-1-details-textual", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-details-textual", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-tables", "http://transenterix.com/20221231/role/statement-note-6-fair-value", "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-tables", "http://transenterix.com/20221231/role/statement-note-7-inventories", "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details", "http://transenterix.com/20221231/role/statement-note-7-inventories-tables", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-details-textual", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-tables", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-tables", "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r661" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Asia.", "label": "Asia [Member]" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-tables" ], "xbrltype": "textBlockItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r283", "r643", "r709", "r768" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r322", "r323", "r324", "r325", "r394", "r551", "r581", "r607", "r608", "r640", "r649", "r658", "r707", "r757", "r758", "r759", "r760", "r761", "r762" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r322", "r323", "r324", "r325", "r394", "r551", "r581", "r607", "r608", "r640", "r649", "r658", "r707", "r757", "r758", "r759", "r760", "r761", "r762" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r283", "r643", "r709", "r768" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r279", "r554", "r641", "r656", "r702", "r703", "r709", "r767" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r279", "r554", "r641", "r656", "r702", "r703", "r709", "r767" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r322", "r323", "r324", "r325", "r386", "r394", "r422", "r423", "r424", "r527", "r551", "r581", "r607", "r608", "r640", "r649", "r658", "r701", "r707", "r758", "r759", "r760", "r761", "r762" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r322", "r323", "r324", "r325", "r386", "r394", "r422", "r423", "r424", "r527", "r551", "r581", "r607", "r608", "r640", "r649", "r658", "r701", "r707", "r758", "r759", "r760", "r761", "r762" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r280", "r281", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r610", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r642", "r657", "r709" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r280", "r281", "r591", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r610", "r611", "r642", "r657", "r709" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r607", "r608", "r757", "r759", "r762" ], "lang": { "en-us": { "role": { "documentation": "Average of a range of values, calculated with consideration of proportional relevance.", "label": "Weighted Average [Member]" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r655" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccountsPayableCurrent", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r593" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r285", "r286" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r50" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments", "negatedLabel": "Amortization of discounts and premiums on investments, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedLiabilitiesCurrent", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedMarketingCostsCurrent", "terseLabel": "Consulting and other vendors" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedProfessionalFeesCurrent", "terseLabel": "Legal and professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r19", "r623" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedRoyaltiesCurrent", "terseLabel": "Royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r89", "r183" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r28", "r29", "r187", "r576", "r586", "r587" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r26", "r29", "r132", "r514", "r582", "r583", "r675", "r676", "r677", "r685", "r686", "r687" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r8" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r431", "r432", "r433", "r685", "r686", "r687", "r746" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Return of common stock to pay withholding taxes on restricted stock" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r111", "r112", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r188", "r287", "r295", "r297", "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r49", "r79", "r84" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r150", "r163", "r186", "r216", "r260", "r270", "r275", "r293", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r472", "r474", "r486", "r655", "r705", "r706", "r755" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r177", "r193", "r216", "r293", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r472", "r474", "r486", "r655", "r705", "r706", "r755" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r134" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsFairValueDisclosure", "verboseLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total assets, when it serves as a benchmark in a concentration of risk calculation, representing the sum of all reported assets as of the balance sheet date.", "label": "Assets, Total [Member]" } } }, "localname": "AssetsTotalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "negatedLabel": "Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r289", "r304" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Amortized Cost", "totalLabel": "Total, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r74" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Mature in less than one year, amortized cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r73", "r290", "r574" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Mature in less than one year, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r70", "r288", "r304", "r569" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Fair Value", "totalLabel": "Total, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r69", "r304" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Short-term investments, available-for-sale", "verboseLabel": "Short-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r69", "r181", "r304" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Long-term investments, available-for-sale", "verboseLabel": "Long-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r421", "r422", "r423", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r469", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r123", "r124", "r469", "r647", "r648" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r471", "r679" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r128", "r129", "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "terseLabel": "Business Combination, Contingent Consideration, Liability, Total", "verboseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Contingent consideration, measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r128", "r130" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CanadaRevenueAgencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Canada.", "label": "Canada Revenue Agency [Member]" } } }, "localname": "CanadaRevenueAgencyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizationOfInternalCostsPolicy": { "auth_ref": [ "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for capitalizing internal costs associated with exploration and production activities.", "label": "Capitalization of Internal Costs, Policy [Policy Text Block]" } } }, "localname": "CapitalizationOfInternalCostsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r589", "r590", "r655", "r669" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "us-gaap_Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r51", "r180", "r620" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r46", "r51", "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r46", "r51", "r53" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "totalLabel": "Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r46", "r142" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Schedule of Non-cash Investing and Financing Activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperAtCarryingValue": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "us-gaap_CommercialPaperAtCarryingValue", "terseLabel": "Commerical Paper" } } }, "localname": "CommercialPaperAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r155", "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (Note 16)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r92", "r320", "r321", "r594", "r704" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r685", "r686", "r746" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r98" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r7", "r655" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2022 and December 31, 2021; 236,895,440 and 235,218,552 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r30", "r198", "r200", "r207", "r571", "r578" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r59", "r60", "r140", "r141", "r283", "r593" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r59", "r60", "r140", "r141", "r283", "r588", "r593" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r59", "r60", "r140", "r141", "r283", "r593", "r770" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r160", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r59", "r60", "r140", "r141", "r283" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Percentage", "terseLabel": "Concentration Risk, Percentage", "verboseLabel": "Concentration risk, percent" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r59", "r60", "r140", "r141", "r283", "r593" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r131", "r626" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r367", "r369", "r382" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract Assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r367", "r368", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r367", "r368", "r382" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-1-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligation": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.", "label": "us-gaap_ContractualObligation", "totalLabel": "Total commitments" } } }, "localname": "ContractualObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInFourthYear": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "order": 1.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_ContractualObligationDueInFourthYear", "terseLabel": "2026" } } }, "localname": "ContractualObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "order": 0.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_ContractualObligationDueInNextTwelveMonths", "terseLabel": "2023" } } }, "localname": "ContractualObligationDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInSecondYear": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "order": 2.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_ContractualObligationDueInSecondYear", "terseLabel": "2024" } } }, "localname": "ContractualObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractualObligationDueInThirdYear": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "order": 3.0, "parentTag": "us-gaap_ContractualObligation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_ContractualObligationDueInThirdYear", "terseLabel": "2025" } } }, "localname": "ContractualObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r644", "r646", "r769" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r36", "r554" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of revenue:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r710" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r684", "r741", "r743" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r684", "r741" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r684", "r741", "r743" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r57", "r283" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r151", "r153", "r162", "r220", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r496", "r635", "r636", "r637", "r638", "r639", "r682" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r682" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "us-gaap_DebtInstrumentDecreaseForgiveness", "terseLabel": "Debt Instrument, Decrease, Forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r21", "r220", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r496", "r635", "r636", "r637", "r638", "r639", "r682" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r694" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss", "terseLabel": "Debt Securities, Available-for-Sale, Realized Gain (Loss), Total" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r684", "r742", "r743" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r122", "r684", "r742" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r440", "r441" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Net deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r4", "r5", "r152", "r161", "r451" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Net deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r50" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred tax expense" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditCurrent": { "auth_ref": [ "r174", "r671", "r753" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current.", "label": "us-gaap_DeferredRentCreditCurrent", "terseLabel": "Taxes and other assessments" } } }, "localname": "DeferredRentCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r684", "r742", "r743" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "auth_ref": [ "r120", "r740" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.", "label": "Capitalized costs" } } }, "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r452" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Deferred Tax Assets, Gross, Total" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r739" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax asset (liability)" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r739" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r120", "r740" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Fixed Assets" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r118", "r120", "r740" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Research credit carryforward" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r120", "r740" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "verboseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r453" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation Allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r120", "r740" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "negatedLabel": "Purchase accounting intangibles" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r120", "r740" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Fixed assets and other" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r49", "r87" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r709" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r396", "r427", "r428", "r430", "r435", "r650" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-1-description-of-the-business", "http://transenterix.com/20221231/role/statement-note-10-leases-", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-", "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20221231/role/statement-note-6-fair-value", "http://transenterix.com/20221231/role/statement-note-7-inventories", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property" ], "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r208", "r226", "r227", "r228", "r229", "r230", "r234", "r235", "r237", "r238", "r239", "r243", "r479", "r480", "r572", "r579", "r631" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r240", "r241", "r242", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r487" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r443" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Income tax expense (benefit), percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r218", "r443", "r463" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r737", "r744" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "terseLabel": "Change in valuation allowance, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r463", "r737" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "terseLabel": "Change in enacted tax rates and other, net, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r737", "r744" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "terseLabel": "Foreign tax rate differential, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r737", "r744" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "terseLabel": "Nondeductible expenses, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r737", "r744" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "terseLabel": "Research & Development, percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r737", "r744" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "terseLabel": "State taxes (net of deferred benefit), percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r429" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r98", "r175", "r202", "r203", "r204", "r221", "r222", "r223", "r225", "r231", "r233", "r246", "r294", "r366", "r431", "r432", "r433", "r458", "r459", "r478", "r488", "r489", "r490", "r491", "r492", "r494", "r514", "r582", "r583", "r584" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r49", "r97" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Change in fair value of warrant liabilities", "negatedLabel": "Change in fair value of warrant liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r134", "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r343", "r387", "r388", "r389", "r390", "r391", "r392", "r481", "r524", "r525", "r526", "r636", "r637", "r644", "r645", "r646" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r138", "r139" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r343", "r387", "r392", "r481", "r524", "r644", "r645", "r646" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r343", "r387", "r392", "r481", "r525", "r636", "r637", "r644", "r645", "r646" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r343", "r387", "r388", "r389", "r390", "r391", "r392", "r481", "r526", "r636", "r637", "r644", "r645", "r646" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r137", "r139" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r484" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r137" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r343", "r387", "r388", "r389", "r390", "r391", "r392", "r524", "r525", "r526", "r636", "r637", "r644", "r645", "r646" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r291", "r292", "r296", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r351", "r364", "r476", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r634", "r696", "r697", "r698", "r771", "r772", "r773", "r774", "r775", "r776", "r777" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r184", "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r85" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r85" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r85" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r85" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r85" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r313", "r314", "r315", "r316", "r555", "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r83", "r556" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r80", "r82" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r83", "r555" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intellectual property, net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period (Year)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r49" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r49", "r95", "r96" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on extinguishment of debt", "negatedLabel": "Gain on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r37" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r58", "r593" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r78", "r81" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r35", "r216", "r260", "r269", "r274", "r277", "r293", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r486", "r633", "r705" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross loss" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r680", "r700" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "us-gaap_ImpairmentOfIntangibleAssetsFinitelived", "terseLabel": "Impairment of Intangible Assets, Finite-lived" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r49", "r86" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Property and equipment impairment" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r217", "r462" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "terseLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r32", "r147", "r156", "r170", "r260", "r269", "r274", "r277", "r573", "r633" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r217", "r462" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r218", "r444", "r449", "r456", "r460", "r464", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r219", "r232", "r233", "r259", "r442", "r461", "r465", "r580" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax expense", "totalLabel": "Total income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r201", "r438", "r439", "r449", "r450", "r455", "r457" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r737" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance, amount" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r437", "r443" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Change in enacted tax rates and other, net, amount" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r737" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Foreign tax rate differential, amount" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r443" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "United States federal tax at statutory rate, amount" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r737" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Nondeductible expenses, amount" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r737" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State taxes (net of deferred benefit), amount" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r737" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "us-gaap_IncomeTaxReconciliationTaxCreditsResearch", "negatedLabel": "Research & Development, amount" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r48" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r48" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r552", "r679" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r48" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities", "terseLabel": "Accrued employee compensation and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r48" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r679", "r750" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r48" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherOperatingAssets", "negatedLabel": "Other current and long-term assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r48" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r143", "r158", "r205", "r258", "r495" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r672" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 0.0, "parentTag": "asxc_InventoryCurrentAndNoncurrentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods, gross" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r77", "r624" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 0.0, "parentTag": "asxc_InventoryCurrentAndNoncurrentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods, net" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r674" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 3.0, "parentTag": "asxc_InventoryCurrentAndNoncurrentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Current Portion, gross" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r190", "r621", "r655" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 2.0, "parentTag": "asxc_InventoryCurrentAndNoncurrentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r670" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 3.0, "parentTag": "asxc_InventoryCurrentAndNoncurrentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventories, net of current portion" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r179", "r189", "r245", "r308", "r309", "r310", "r553", "r627" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r673" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 1.0, "parentTag": "asxc_InventoryCurrentAndNoncurrentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials, gross" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r77", "r625" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 1.0, "parentTag": "asxc_InventoryCurrentAndNoncurrentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials, net" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r76", "r674" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details": { "order": 2.0, "parentTag": "asxc_InventoryValuationReservesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "negatedLabel": "Current Portion, reserve" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r38", "r257" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r75", "r148", "r159", "r171", "r609" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r751" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r752" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r507" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r507" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r507" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r507" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r507" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r507" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r507" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r507" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: Amount of lease payments representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r749" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r749" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r509", "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lessor, Leases [Policy Text Block]" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r510" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "terseLabel": "Lessor, Operating Lease, Payments to be Received, Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "us-gaap_LettersOfCreditOutstandingAmount", "terseLabel": "Letters of Credit Outstanding, Amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r216", "r293", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r473", "r474", "r475", "r486", "r632", "r705", "r755", "r756" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r12", "r154", "r166", "r655", "r683", "r699", "r748" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r178", "r216", "r293", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r473", "r474", "r475", "r486", "r655", "r705", "r755", "r756" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r134" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "us-gaap_LiabilitiesFairValueDisclosure", "verboseLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-Lived Assets by Geographic Areas [Table Text Block]" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LuxembourgInlandRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Luxembourg.", "label": "Luxembourg Inland Revenue [Member]" } } }, "localname": "LuxembourgInlandRevenueMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "xbrltype": "domainItemType" }, "us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Italy.", "label": "Ministry of Economic Affairs and Finance, Italy [Member]" } } }, "localname": "MinistryOfEconomicAffairsAndFinanceItalyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "order": 0.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "us-gaap_MoneyMarketFundsAtCarryingValue", "terseLabel": "Money Market" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r213" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash and cash equivalents (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r213" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash and cash equivalents provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r46", "r47", "r50" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash and cash equivalents used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r33", "r50", "r157", "r169", "r176", "r196", "r199", "r204", "r216", "r224", "r226", "r227", "r228", "r229", "r232", "r233", "r236", "r260", "r269", "r274", "r277", "r293", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r480", "r486", "r633", "r705" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total Other Income (Expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expense), net" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r689" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r260", "r269", "r274", "r277", "r633" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating Loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r501", "r654" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "us-gaap_OperatingLeaseCost", "totalLabel": "Total Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "us-gaap_OperatingLeaseLiability", "verboseLabel": "Present value of future minimum lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r498" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities - current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r498" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r499", "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r497" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r506", "r654" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r505", "r654" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term (in years) (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r118" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r54", "r55", "r64", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-1-description-of-the-business" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r192", "r655" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r185" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r25" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation loss" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r31", "r98", "r197", "r200", "r206", "r488", "r493", "r494", "r570", "r577", "r675", "r676" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r194", "r195" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized loss on available-for-sale investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r40" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r45" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details": { "order": 1.0, "parentTag": "asxc_ProceedsFromIssuanceOfEquityNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "us-gaap_PaymentsOfStockIssuanceCosts", "verboseLabel": "Commisssion earned by Sales Agents" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r212" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Taxes paid related to net share settlement of vesting of restricted stock units" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r42", "r68", "r210" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt", "negatedLabel": "Purchase of available-for-sale investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r43" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r6", "r352" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r6", "r352" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r6", "r655" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2022 and December 31, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r191", "r311", "r312", "r622" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r668" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r44" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details": { "order": 0.0, "parentTag": "asxc_ProceedsFromIssuanceOfEquityNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "verboseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r68", "r210", "r211" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from maturities of available-for-sale investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r41", "r68", "r210" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "terseLabel": "Proceeds from Sale of Debt Securities, Available-for-Sale" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r678" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "us-gaap_ProceedsFromWarrantExercises", "terseLabel": "Proceeds from Warrant Exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r91", "r595", "r596", "r597" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r88", "r182" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r90", "r167", "r575", "r655" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r90", "r595", "r596" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property and equipment, estimated useful lives (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r209", "r298" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense", "terseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r690", "r691", "r692", "r693" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r393", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r173", "r517", "r518", "r754" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r393", "r517", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r754" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r515", "r516", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r113", "r172", "r763" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r669", "r681", "r764", "r766" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "us-gaap_RestrictedCash", "terseLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r51", "r53", "r149", "r164", "r180" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_RestrictedCashAndCashEquivalents", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r51", "r53", "r592" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent", "terseLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r592", "r670", "r681" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r9", "r99", "r165", "r585", "r587", "r655" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r175", "r221", "r222", "r223", "r225", "r231", "r233", "r294", "r431", "r432", "r433", "r458", "r459", "r478", "r582", "r584" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r255", "r256", "r268", "r272", "r273", "r279", "r280", "r283", "r380", "r381", "r554" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r370", "r371", "r372", "r373", "r374", "r375", "r378", "r379", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "us-gaap_RevenueRemainingPerformanceObligation", "terseLabel": "Revenue, Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r504", "r654" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Lease liabilities arising from obtaining right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r283", "r688" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r80", "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r13", "r14", "r15" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-7-inventories-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r103", "r104", "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r653", "r738" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r252", "r253", "r254", "r260", "r261", "r271", "r275", "r276", "r277", "r278", "r279", "r282", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r262", "r263", "r264", "r265", "r266", "r267", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r48" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Restricted stock units, Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Restricted stock units, Forfeited, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Restricted stock units, Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Restricted stock units, Granted, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Unvested (in shares)", "periodStartLabel": "Beginning of period, Restricted stock units, Unvested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Unvested December 31, 2022 (in dollars per share)", "periodStartLabel": "Beginning of period, Restricted stock units, Unvested, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Restricted stock units, Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Restricted stock units, Vested, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Options, Exercisable, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Options, Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Options, Cancelled, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Options, Forfeited, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options, Granted, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Options, Outstanding, Number of Shares (in shares)", "periodStartLabel": "Options, Outstanding, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Options, Outstanding, Weighted Average Exercise Price (in dollars per share)", "periodStartLabel": "Options, Outstanding, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Options, Vested or Expected to Vest, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Options, Vested and Expected to Vest, Exercisable, Number of Shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r421", "r422", "r423", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Options, Forfeitures in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r400", "r419", "r420", "r421", "r422", "r425", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r651" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "terseLabel": "Expected life (in years) (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Options, Exercisable, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Options, Exercisable, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Options, Outstanding, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "verboseLabel": "Average price per share (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Return of common stock to pay withholding taxes on restricted stock (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r502", "r654" ], "calculation": { "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Operating" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r54", "r214" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r24", "r98", "r175", "r202", "r203", "r204", "r221", "r222", "r223", "r225", "r231", "r233", "r246", "r294", "r366", "r431", "r432", "r433", "r458", "r459", "r478", "r488", "r489", "r490", "r491", "r492", "r494", "r514", "r582", "r583", "r584" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-note-1-description-of-the-business", "http://transenterix.com/20221231/role/statement-note-10-leases-", "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details", "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details", "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20221231/role/statement-note-10-leases-tables", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-tables", "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-tables", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-tables", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-tables", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-1-details-textual", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-details-textual", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-tables", "http://transenterix.com/20221231/role/statement-note-6-fair-value", "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-tables", "http://transenterix.com/20221231/role/statement-note-7-inventories", "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details", "http://transenterix.com/20221231/role/statement-note-7-inventories-tables", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-details-textual", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-tables", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-tables", "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r221", "r222", "r223", "r246", "r554" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20221231/role/statement-note-1-description-of-the-business", "http://transenterix.com/20221231/role/statement-note-10-leases-", "http://transenterix.com/20221231/role/statement-note-10-leases-components-of-operating-lease-expense-details", "http://transenterix.com/20221231/role/statement-note-10-leases-minimum-lease-payments-details", "http://transenterix.com/20221231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20221231/role/statement-note-10-leases-tables", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-components-of-accrued-expenses-details", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-tables", "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-tables", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-tables", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-tables", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20221231/role/statement-note-18-related-party-transactions-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-1-details-textual", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-details-textual", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-tables", "http://transenterix.com/20221231/role/statement-note-6-fair-value", "http://transenterix.com/20221231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-tables", "http://transenterix.com/20221231/role/statement-note-7-inventories", "http://transenterix.com/20221231/role/statement-note-7-inventories-components-of-inventories-details", "http://transenterix.com/20221231/role/statement-note-7-inventories-tables", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-details-textual", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-tables", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-tables", "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r6", "r7", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock, net of issuance costs (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "verboseLabel": "Total shares of common stock sold (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Award of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r6", "r7", "r98", "r99", "r406" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercise of stock options (in shares)", "negatedLabel": "Options, Exercised, Number of Shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r6", "r7", "r98", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r6", "r7", "r98", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Award of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r24", "r98", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r7", "r10", "r11", "r67", "r655", "r683", "r699", "r748" ], "calculation": { "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders' Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r102", "r215", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r366", "r477" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-14-equity-offerings", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure for Cash Flow Information" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_SwissFederalTaxAdministrationFTAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Switzerland.", "label": "Swiss Federal Tax Administration (FTA) [Member]" } } }, "localname": "SwissFederalTaxAdministrationFTAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-10-leases-tables", "http://transenterix.com/20221231/role/statement-note-11-accrued-expenses-tables", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-tables", "http://transenterix.com/20221231/role/statement-note-13-stockbased-compensation-tables", "http://transenterix.com/20221231/role/statement-note-14-equity-offerings-tables", "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-tables", "http://transenterix.com/20221231/role/statement-note-17-segments-and-geographic-areas-tables", "http://transenterix.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://transenterix.com/20221231/role/statement-note-3-revenue-recognition-tables", "http://transenterix.com/20221231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-tables", "http://transenterix.com/20221231/role/statement-note-6-fair-value-tables", "http://transenterix.com/20221231/role/statement-note-7-inventories-tables", "http://transenterix.com/20221231/role/statement-note-8-property-and-equipment-tables", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r118" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-9-intellectual-property", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20221231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r291", "r292", "r351", "r364", "r476", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r696", "r697", "r698", "r771", "r772", "r773", "r774", "r775", "r776", "r777" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r23", "r101" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "auth_ref": [ "r7", "r98", "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.", "label": "us-gaap_TreasuryStockRetiredCostMethodAmount", "negatedLabel": "Cancellation of treasury stock" } } }, "localname": "TreasuryStockRetiredCostMethodAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesRetired": { "auth_ref": [ "r7", "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common and preferred stock retired from treasury during the period.", "label": "us-gaap_TreasuryStockSharesRetired", "negatedLabel": "Cancellation of treasury stock (in shares)" } } }, "localname": "TreasuryStockSharesRetired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r745" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r630", "r644", "r765" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r436", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Unrecognized Tax Benefits, Ending Balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Gross increases for tax positions related to current periods" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "negatedLabel": "Gross decreases related to 382 limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r61", "r62", "r63", "r247", "r248", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.", "label": "Valuation Allowance by Deferred Tax Asset [Axis]" } } }, "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes", "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r454" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-12-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://transenterix.com/20221231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r234", "r239" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://transenterix.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(2))", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=123726384&loc=d3e516343-122869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r659": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r661": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r662": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r663": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r664": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r665": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r666": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r667": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 105 0001437749-23-005222-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-005222-xbrl.zip M4$L#!!0 ( /.!8E;&]5 -MQL *]B 0 1 87-X8RTR,#(R,3(S,2YX MV&T]_??_ON_/OR/Z_Y.0\I) M3'UG_.#P']'KOO; MAWOAOQ?>C,Z) QR$XCU\^+@WB^/%^_W]N[N[%W?'+R(^W3\Z.#C<_^?YUVN9 M=R_-3,2]E^>..0D%#6/*V?T++YI#F:.CPZ/CPRRW%R5AS!_R O=C'KP0U'LQ MC6[WTT19*"^0< ZM4%#WGLS/0U,J1 )6/A#7S^TY_$^)H^)H%GVD#!/Z*N6296Z!?/T62&A MFI''><8)$6-)'SXN9UIJCG)6E50M$"]X#7U(J61-A#LE9+%:Y>7:N%_17MH7#M^]>[28\"F-OY$Y%0OB48/N!)W> M<63/9?-%Q&,G7"F\3CK5W;]&'HGE8%-;!/]RLW(N?G(/C]SCPQ= >F_?@(M: M!.M8$/4%U$\7?VY&NSJX&%$O%\G^:,>!IJ^MI;R2?Y\&L9#=;W/)BV'/2.HL M._[8@FHQ!!E1S;+CCPW;>&EP,&OH\OBC&CNK9@/95T8=PWZ6%< .]FK#YBY& M7+/VSO++7UOHN33A&1'.\\M?VW3HZMQOUJ/+9?*_VC'1;"/4L=)44OXM-AI< M-D#^ZA"S >QKYO$M^AY^V4(AT(/>[?,HH/LAG:(Y;-8) \XKI; GOL.I[O#U M,A\D#*-85B6_95\7"Q9.HO03?$3;X'UFW5W1B2.MA?>$>TAGO4VQO^#1@O*8 M@4I+!J*L8,;IY.,>6MUN9@W\*R#C%V"P9%E6"%3G="DG%*'!UX*]K"QBX..> M@,8.:"KUDXOCD:"M.%#$2P*IE8X*Y=-)6Z&@" M9AV5:<-I6)BB"%NU&FL(* M;B"#PV!]"B9I+(UJUX^\1/Z =;$+_[+XP<6^R.>2RIZ#Y;Y?G36;U8I%\YIS M_C(."XVI!83)PN^W@X,#6)]_3FF5?XY"WSF59)VS@NR'_25:*VPD@OH7X6_R M]U+/2 NG.=85K*+/O-RRAO4ETZ^92LTT[46AB +FRQ%Z3 *Y*!$S2F.QA9;7 MU6I+PX>@UNN,(OP^*=%T/BF:SK6D.:A7HPAW0::& 1B/._;\J"^"T8.97N:RXRKF1&78<(J_ MAK^%%E%&&[DE+"#C@$XB+J#1MD5%0^V6@'!XH 4"VHIG!?E?G5%&WP4&7.1@ MQY7_VIT0QEWH'LG6JJ[494NQAUK%HC7X!8@Y_T!B.Z[#-[*+A7'$+=AQUVX&M^ZZ8;5@]JA@5EK@:G;:K2V7EO*/=8J%ZVTRY2PG'5/ M,\([KN=WT,-B&@34BQ,2Y,K95LUUU=K2\DNMEM_)+ES0S56^XTH^/' #"BTG MW*W=*T5-ME3Y2N]+01OJJR2UZ\H[1*\%3V"U0N\7-+2B1EV=MA1:XQQ#VVFD MB#JG*=%=5^T1#).@+.K&Y'Y[:VFY.EL*U3NVI!EU)NDY-TAOUY5YK/:>L-74 M#B9 ?-LPF:::;:E8[\4Z5)NE0-J5M.46:$9[U]7],MU==*/)!/083K?OOYHJ M;2E8[YN2=I3:D70N,IJ[KMA7"';FR?6)SX($_80AC648@@OFI"MFA&_MGS E M8PD 1WJ?E+2^/B$?=,B"5_WO.@#-"!G9=_V]=3@,94[(@Z+R2ZB6>C [;6OEK M*[>E>;UC3%I^5XJZT/4@(U0!6,2MB"PXC5KB$9P?LE^[7"P M;.N $EA]CX.GC6')2-H"BMXGURZ4Q?GE1C*UZ]#1AI]8PLC:NFV!0>_/JXEP M&;3>.O[$$A8VH&@+(7H'818-XF $3J\$LEA"@ MJ]*6OO7.QFJ8S*!:38B+)=UJZ[2DW&.](W$I>F;0[OIP%TN*;JK>EL[U7L/Z MH)I!_6O#8"QIOZ%V6\K7NPQK8VT&W2^'RMC1]DI]MO1;XQ@L G &C=9'S5C2 M;7W-MK2LCYC31N4,^M;&T]C2M;Y66WJN":=;#M89=-P46V-+W8T$;&F^)NYN M70S/@(+:R!M;ZJ^OV9;>:\+S=*$]@[Y;!=_8PD [:K9P41/39QKQ,V#%+#3' M%D@,R=A"1TU 8&,@T +LX@=6[ P)&,)%B]KP@0;XX,&6&RP:^_3F+ =$CO MT87RI!$#R[1M 4CO*FP;.O!9<>?<*.X&5+70+!4QF\MH,J _20(W8+=47H!$ MA,"[^%+5/RGV MQSA3,K9@I'>.U@6_' XCEY&^CIX&%JMD;,%"[TVM@\71 LC??E,D.F4XSWQ M3-W>EN6R-&5M2M86;/3.V3K8R+PESG#6R?(-T\XZC>+*F1,OSHP+7#D%C(Q9 MP.*2\?LX<#(E;@M4[>(SY1V5DK_,@L'EW->"OP%:&P146I[.MB%M"U:6@CJ' MB6]CS;;&P%/"KCUSMH"I]VNW!>9F,-YU^#;$#5L>!EM2LP4PO6O<*%QY&.W: M*+#D/RKRN8)Z";=JI]EBPQ+ 7FU\/V35>U5D=JYS9H>ARDSIF96.D9-S$C\M MXAJ(V\*9WA=OAK.3@D7G/&=Q0)?N^$1I *E9\\TI017X+HG+!6&UR+'G8G"& MC!&P!L!'Y\\61O5^^J6S(I5AKV;9>IZ*X)"X7!38N67V%PRCI(8OBR2%#>87R7-:3R+_"B(IH@AY$N.(*5:4URI8= + 'UR MNT6YW1X!Z3]/"EO]0;_AL-(?_J\D:/D%.T<*"E]04-E'_I$)"CVD)"CN9_D. ME"O7>UX2U#FI"#KTFH:15;U!A$\0E=(12'>$ Z"78WK42S7,3Y^8>NQQWQ)W MME"NWS]9-^JK!Y7P/:52#H3O'ZD U5"E6#[%DPLPH%=[-!##D:.0IN\CE5,L MP;$M.5OXTF^T+!]2E*%N*4?9@BH_P#@ 9OT10\N^'F,ZMB"BWS99=Z9Q<.Z8 M::PT[:S7Z:-AQIP#6VC2[Y:L05-EZ@J^4AR)2,+)E5F=\3H$S=:=Z:\NC=+GL,.I2LX5;PEL MFY*U!:V:2XA+-PXLK\PN,LY4AAQ= Y"6-2J2Q2*0*3",C$E 0H^Z8D9I7/&' M6D=22[JVH%1SGW$92M!BUUW4AI0M(-7< M)Z,#4LJ-', &E\]:S25A>G;LKU1[BTBP1QV8#"C:@DS-)3,:R'PO,25A&NB6VS#8BJ'' F;7S;,%:4M8>E-S,XT&2Z<9=V4[ZJK"W0"J MYNL);2_%S"G9@DR-GWG]C8C#"LU4;?([F*XJP!9['+.WS[HQ75O@J?$LKP5/ MF@3&L?QSE/(VC#;ME J+HR2&HJ&/>U%/"R@];5N@JO%!MP"5<"X*_@9@M1PM MBJA_6"0E\X5=0]L*$[:@5N.N;C-^%4<'1@6C ^::U(52D M^49RVTL] Q*V8-/J]O-A;=>HI_*=GB20[D*?\CR#M0%H"]*VH%/CT-9"IWIM M*'+G?$?N\BS#^-+RMGL\ORJ3T8U8NFR#WGM!XN,A7-P8PZDGB?.+^2CAH<1* M48\M0/XDMFV!N<;5;GS;O^N,2I*5+Q0Y3253^WXGA638%4Y3RQ& M_T7"O1F&O$4<1A)1R6T+U39XL 31MS4>_.8G!USG,F73N9!L5O(/>#-\*@"/ M=$GW\=/RR7M@;()V'2%F)K-A":7T.0]^?DLM<5Q*V*VX%.S\8!+H"O%C7.)W#@W)6YV:L'\8?]>^._)8H'' M5>2W]$L(:B.YK!_P&U7G2226B+CW_I7&=Y?NHU)6,]@PI_-%$#U0FC9S*$9$X_[FU9!POD'6X?]V*H9<\1R5C$+$Z0\=]YE"P^[B$ZV'L&8-QS M8A \^S*/8)T#2]LS2,$&V7/4]_04S\<]CU.?Q=EG6,.PR+^1%; 0MZ+BO?U6 M;8-H^A1$WH]ZT\YL&2/$VY M^B#;6>B-H "L9$>ACQ?\8E>"CU 'F&-EG_$EX'YM VQ8U<]LI;Q5/B6"A50( MX'+,0IF_N#6II^\N11 M:: E<=*QHY"H,-"T#;)9\DS M8_1FQFF-#-6D;DMQ%]7(4$KHQ 3]F8[CPOT^6KH[.KUD WI\).+T8N:';P!C MP---!,+\/R5<9$):JNL1YQV?CC=?6JP7#R^*E/=$;ME,1O5TMXG469P;JCU-RQ9JP=5CY'7H(Y0+)3 MO(CWH7251-Y Z_-L+BI.^N%TZX$F/R>ACDF ^J[ X*P>E%#7KIZ%V ?."?]! M8]D3+B9UAOX4>_1Q&[8@L=TTN%#U/ D\;X#!9'$3 MR0BQ\KK[!!49*-^C: _*EO7V&HIFLFX P+85]P=VY=.*D"$]FK\!SIHJZC6P M:H3; $F--?4'.NEUY5>T]*@ & A?6 AJ@5$93?$-@-2NVE[#RDC4#4#6LMZ. M0$[M#/$K&J/S&09=JTE?Z9(OE*4;P/(PDM;Q;8K[>S>L1U!OX') M^1@-6*FWNVV(H114AIP5-_$JCTUZR8\2 D8'C/U09OG9? %],V^NK:KH6LO4 MCCR*XXO)\=NCB[N02R#/5BUV7OH\2K2PC3S)T#=_TD M!Q,CE_L2Z;8,%2):#6%KSM:1"2X=;%-##'@M]I. #5'JL 8YN[H47,O\-QH; M":GR=5Y$-#;%C/J_1Y$O\BLH1D$0W2&9%5&;\W?- %V5N0FS/43J%;D[)Q@3 M3P(3+39F[[X2<[:S;6]=)UP1W+14#^5O(W6G9:V=3*6M6YTXJY\Z,4E^A;F; MTJJ!7@H61 977(DMRW35F?B5>1B( IU)/@/R,)IR*HLL*:TQ6R>#V_ PH?3* MJ$76DDPUB=V )# 'H_U1(T',( MJ/I,@1,LA%7F#SQ6];5IX4XBL^17E7[4S#]X>J]>HL;MMR7QVY3HI,QXI.XF M2O<+27"=G?M+#]'=9.<'E;S&N7]6G-A:.86.=5&6K39'C^09I46:Y2KE_.EQ M?=\2["47DW/R[XAG8-;D?/?;#9-U5 M[V^&8>HZ&?^;>O%-='J_8+P2EKQ!N:XZ&^I%V4C^7@A?WU_C&>7YL>.S\'1. ME\>==3FZT5^10Q6C51^\4Q''('/G?/.%N+Q''5#LG'NKKETM/*>"9%@G7AD9@YT M9??5HG9MHKZ@5$"#9AGLQ\,4DAFP>NWD2E\0DC.WQ?7K1%@DO" M_+/PA"Q87'@I;5;8&^U?T2D38$U3_S/#4'H]#AIS=0,13/R0*P(/^B]4B)&7 M:X^&M"G0E4,AUV#U^TF DZ_!/2GZ#<\MZ^A>4]2.V=\%G23!5S:IV?K=KHKN M-82\_U(NB>6O$5XK7.SP-K5!R])=W0B_IN$,Q\KL"K.K:!S%S+M^@"%L/O) ML>J]S>H8U[I4)]?5V9IK701 0YYNR@5S8IPLU-G.T$_]8=GYC"5GO6GF3LQ: MTIC M09,KG(;7"V?Y07SPM20W[:2+3;R)(G':@5Y]FC+1C"MH[N^4\5\:G,5 M'9;R:/):*W5W:6V M0;G.SF)RXED>V98^=G*LOIG1HX.C@]'-N7XUL2:]P_(<-LBC3>^T/*%OH*9U MV3HLW=$HGJ\32YO>47E@ ,^#5Y9ET:9UPJZ1QV,G&'Z31T+?1-DJJ[S RH5I M4: W_I6;NZA.=[J43FANR>V5.T569EN3C%U9(_\1\1]H!E1]?BM?^[);7+RT ML/SFPH$;8$B/?-]H 3SA>Q[1Q(VR4!"5O/K*IFJ01ZBW-U:2C=&R3=7];D%3Y*PKVJ,6.().CQ%OP/R]U**ZOUM:YI= MM%?Z[/+*/7L;MVN[NOO;AB7I,L-QK&Z\W+CIC*KL;XN9S@%UQ?HK>5*Z&56J M=Q&I';G-AR^C*GO48L?P!1;+^!*>+X?A[!IB2 \](F;J169->NOEH$U2SZ*% MN4AD'_8;+2FBI]?Z]UFMTN@&9O,%RT'1$M4 MGEV[@NF:Q.B6PX!/V\U95_FS:$53 \6@AAZUQTN7RB!Q6/&H325T9LWGA..7 M].GD!".K\@SFH-JJ[GZWH2F8UA7M40N\Q3B7K.%W%""0]EPQ3U&"/PI_'U_'1GBNBV MU?6HI5XC!.9,/68I!?2R9WH\A,LB/5_A1AS/=E9R&T/6#I%GU*JFP#.NIT=M M\P9&HVDAT)3B2=G%#+L77G6*$HHH8#Z>2\SI_86V^T[/1;59]KNAOC^ZH)PW%?7Z8_,K^1\Q:>SE M%%,XM:^OKVUE")":0OV1^JV[2(\_RAY/LP.0Y<&B)H 8M:@BIYO+] M:8MW+EYF'P14K=,*P>81C]E?U6!-.89D-ZBT]8+;I-3_]M5_W;8MFVKM?[L9 M=M'&XKUHB:9=C>S'NN9H4<>3MMSV[JQ M_]Z9_@^^[F?&L9/3GIPY:/#,A$YY]/CQ^]_[P@&41CY/LZ?/A M]_O@]/[\^OKP0.9A%HK M"O7"/QU5?UP5W6KZY4-9]OC3IT]'Y5]716725! :/3[ZQ]>;^VC"IF&09(HC MD:)%)K_(\LL;'H5YR<9." ?:$NI3L"P6J*^"XY/@P_&[5QD? M1!.NJ=)@])8\I"T(I62Z# MF.5ADDK@0TG61+#QY\-0OD;!LF-%^1]VW6\^G\',E,ETEK+#HQJ?HC"-BK1L M\ 8^+XHK7E!A644Z>\T9K)[%&"^I3WFTQEA%L5S.]7$H'\N)4\C@*0QG)=U' M+,WE\IMR#$K^+[[XUU62)3F[29Y9?+TB[+2DZ[0&X+*B_QM0]?#"TF?VE6?Y M9$5R&CZR]/.AVT8K/J1J$7&Q&$,B?/@G"\45E'6"?[,QZKAY(=SAKC5&'/<# M].QNP-=:HX[\A;O#_=86%=3?6&X.KU:I#4=MMSD5T0$7H ]]/@2=ZH4E3Y-\ MH6!5[80B6MN&MG6!18DC64RGU;X"Y$V7]<>"3XUIYVY7+U"(XL#QC\*!+;F- MY<#)#\*!K06-9<"''X4!VY(M2D?CLW8([?!RD#2TD& M4X Q+:;5QV 6SE4A6_O$M%E_YH<=99ZLBQL&TX:-9LHGD&1/-XJRFR1\3-(D MG]\N*+PH=&J5:76O&@66N-,QC&2'P="K+9*HD99BW^9(8G2)QJ%I[6L5P6ND1)8/M>9TB_RB1(F M)B T58E@0AJ2Y@T0P7?/8*W$5F.V794(IH=)(NP@;=6D:3"T"P/>?UI2L@L< M@-5)%TJ*OP.8N@5)2;5W %.S2'TJ:,!GR=,D5JEFP6.8JM2K0$X8RPU4+D0C M7I0H-!TXM6@;LOKF7Z=1) H6+Q5OT,LN7Z.T4(E]EP"/SQD,2:IHJ!4Y+X0 M$C?DN+/V3/8K#:Q%7^*. 6_4<#R$K^>"Q4E^QR*6/(>/Z::_SKB>UVT5^,H+ MT(S!,%(T-(\ KO @=+^Q[QO+<=2W5?&-H9@6Y:0=Y1,FSOET)MB$91*,\^L, M%C&[X5(%3D=CF"]Z6#:M^$4:PTR'61^FMV$27V?GX2S)PQ1(G?+L/N?1;SIP MZ(I^\93Q:1W-:W\<@*Z.9=!4QB^5SV"#J_5WQ<5]F#)09 I1"NP+]IB_?>K M8=<*2:3?>!8Y ;O=D%>\9X5,,B8EK,_')"OUE?.E;R:'WV02EVXYI<8L/'*= MT)VTZ==4#>7D-(O5C\O_%+#5I,KW=)J?AT+,@>Z_A:DV"<&HKF<#?"5S6P%H MB@WB+/A[DD_."YG#'BA6LZ-=K)A4]8KI@HT9]!Y76SKLY%WYI-T5O-)OJO8; MU_N_D.'K',=U]@PLY&*NI[JIR$ T=NT5+27]9CV\35)=1L-VB:$HA.VF%-<3 MGJIXB=IV\GDWV:W5AL+2+DJ(R Y-;+*==EPE"C@Z5RFZWH!H[I1C=#3^+BOY MC$*BJ>,7A7(!8,Q ?<&AZ.V>-VUEO5)]*Q:Z5:JJ^.MMVF8Y;#AJ$UFIKS8>FT%4\4KACLF?8:3;#A8B;!3G'*/&4@K^=,/ ^?$K! M7BTLR]@0I0AOYY A=A-*69B=>+H4)TIYE-WKJ8\3'8OTCQ206CA6L?C\"?CF M]855>.A)^O:=2J/[T)/L33"PWE=ZLKP)C8GGDIXT;Y1\^R3!._:AOBO%GX!N M!()WHF !_6G8J=4S6(M%^?.@*'&&*J4]M,7]6\-E&&^BM*GB &*RN"CML3A4 M)OYQ2GMN.SK'N8^4MF;6>A8U3Z\:0]?4)J3.$B]\F4IS5L<8*<0 M2FN[8-7/ZVQ;3?_&JDWM?*)^O5;C!..B MUD^[/7JL88CGWKT?PMD(]JY[K&$VKW]1*WD+Z@:/MX7JW,%>>SD> MLTA[F&00(H8]EE(JR*O=1[<6L=4\8YD)%B5M%_,T%?%[C*8LLG=<4M'&@+K+5[63%(F<5!Q7\=(62*AZ?H\J36SZ(U6"5UF.).E38>D30:&TMFZH#8VH-H*'A MH5H9&"G:P]*GB8$Q+ETG)J :Z@R,0A/W1"/JJ#\T.A556I'8:I&:51X8UWHB M-QI1MY!O,T/IM_E\KRN *;-XL4FZ,\>6Z3%.8-4,!7.6EZ MX&MI@ *^MV5BB:^E =_XW@+/>@C;9?P>QEO8@9P+7CSFXR)=FC1Z ML)U5_![N-)$^]K*E,[DBV%D2@L4VQOLY@2BE8/1#;^E9H93PU8\!@P1[*.67 M]6.?@4>84LJ9'>B=YJ!0.E[5;TZ8!;$HG<;J*4NM'6<6![@H;Z<& 0A*A[I< MCS[*'X=EP"?R#,!KOFCUR4=NKNM1-X@)H/EP3'?=6R4SHH&?[!UP9[>4'--7 M_DPRQ]"P/](=P);(FEHE/NGKIF<84&SX0-=-ECD MPU@\,'9#!R#]S^6 ZXCTE2.G!LD9G#>Q_NVH<% MTL$!MUD8>[!<3&<$[G0BI:4PT&$CWHOUY*+,9+G8F:Q&:1$.S\6=GUZB%-H> MGMVV&:1O7-S]'1@9SUGP+>\NVOJS MW2;4OR-_FX\K6OUM.AM)<9W/D+>7]WZ!#%#S-12_,:6GG7/9^8 THLH0&&"1 MCYF4YP1#-3)!VUAD!RKR846*J\B"XUJ:2'3J3)GS?:F( IP?EPRGW740WJ/8FDY&2 MGF\ U6@#HZ3F6V!$;6V4]'QSC";;'25EWV)QFLM2+& ?QS!LI)'!EC^XJ1/# MKS)/HC(*.JY6WH:W.N52!HHK 9\MCLM;N_%WT_MP1I)3 )XLJ+?D<94G5EV( M4"39TVA%WAE34&JGPB\6,%OUC%XM#J!%&=%[^0H3!>1.DH5B?@U3HGS]4IT@ MY2F0]G2M9A @EHR918V"[/!]W96 M9KLESZSNRQ,,^! E:95PX&@?M^AIN#W;FMA>[RU=+GM=S1N5D'BWUNWRLB)U M5T\5ZBAO[-'>6E1=:K0A43WUYN!UFUT0>YO37 M3S6,\&J$T\,^)XI0XEKU!'%Q1.L.-JI0%J+'76I(QP]QM1BRXH@>\YVC9]#/ 2SB:( M)H538S.9-T W_H@G2X]VLI+6*AKB-8*&P&W:ID<1Y8:R-*;"(6J(^Y*$:F0 MI2E_49M0#^Y8]$*64Y=9J$X%]9\R[0V2P[\9]5(E+A*HJ (,29CVX 2V:7(\ M 3,?#+0"BCVFK/VEA[[-[05V=:E;*")U?NZ"/;.4MYT/VDTGY/C4')#27HKN MHLD?,T=@=Y2[WA+=-4R)'ZB-SZH-"B@MM[>>K5% KEF2=KKR3OJ@P"6#K=ZB M!0H(#3G'!5$997L%R)KA(94!K0_NA()H9O)3N ;0(:VW=F^8P-D1) M2[9CC8>0*27-><=,ZI$80DF;WOTJVYFVO<<\L0V?4%+2=\^E?5/BAYDW=)7\ M'4M@DSPN2HJ_OX6SUX;!CF>/DQ1?4L;"[N>5K3'AZ^##Q_("UUS=ZPHT 619 MO^E5ABF300$25*P*V!Y\Z-^3QX,/KHCM=?"A^5+ZRY*P[3M/3:KXO;=U\=# M:%PJ_DNR2I-($ZS"5/%]]^PV7T7UFGK%71T2=$5:\3:CV:1Y= 2#U\)'X#YD M8 T6/4U]"G;8?B1/DUA=D1NLOBY/5-?.4:MCU]#*3+ )J,3J3%=:NRBX6ZB[ MZ,6+0'=':"]A7EXV6*D!BR>SQ1W+E1)0"S0UB72CBGYO+46]C;IY>:G!@ZJ> M<)P5,LF8E.=\^IADE:JK\7XK+]]3-8&6VG#E$=HK MJIK#($I'8YBW&FX@:GA&(*'W+YS'ZG6H>R:>DXC)>Y[&6@!=%;S2KVRUTDH[ MC?]=5*];CL;+1ZXT$%!UO*+X$B:95 ?+F1QEEZ]JIA>)G%24U9^QVT""KN<7 M#,A:?I&HQP74O:O:).F&$G[3YJ8SF,W5@-_P M[.D&.!97>\T#/P-37,ZX9/%HK$N;,ZU/_3*1_[^.Y8=)^:_8UI7 VUC*,Z7+ MAY4K_G5.L?;B7FEO?#)X@^"69X5]4OBQ4>EV,*_6#]) M>[3D%?$]*W5+&(+5RQ?M@]9=H9>#?G=Y[DT6%C?W1U!*UNN U'L.4LK9U"LU M?& ?(:49@>*2B6N94MHE"IRE(X)2XB0*I\'F22D!$H7-R(5'*7$1A0Z[@UI( MW]WMGFTV&D>;GB1%93LBK6.6U/!T&P-KYSE:?%V4AL@0%<8=1FD_,X)G8O-1 MVLQ0(&T#^!8[&Y$U:! [I+3!&6$TC"I2LC9\A&^X"5O)R6;/'.KT$5.:/4/^3WXQ%Z!A$J_IQ^<:ZT_P?T=^.U0M&$#M(XAV0DF;CFJ MI'1,6\3;&P\I)=,:EH&<(65*#;%K\%Y;.K5E,"3[; 6H=[OEIR!9!0I 47X& MG3A\3)6W19U6#J)%HD01I@$P?6&&6=HE3OKR9W M\?($] :(^KB>R2%UN-$N+#VR*=VMGF@NCL'5E4E\G+"X/)72^1&55UR6Y M)L/L87#OPA>04;!;BJ+HE=]:+2N@48X4W3K)5FHQ9V2KHMP?W(='+Z M>GOI:/3M]L($Z"ZS!):<-0+16',81$URI+W0,'1N[QEM10:BL2L$UE)R&(KK M4KB+YJ:RPU-MM @[*PZ#9TM,=^'05J#EGN"-[ 5Z0]]EE76NWA:)2V^L;= BMQ<*.1 68-N(I2V[B-Z 6L&BDNYR_#Y(62BWG,"KXV;5 MGP-6G;BQ?;2@7R\>'RQP06@O_[BZDP*(G=ZH?AKB^>V%AKG!34=K=T&_=QE- MN,@?6GC;79"6C8K@+\?-& HZ+ X-=HS\2]*3("D/;@6Y.H\)HJ%Z 4E]#,+R M@AE;Z6G>LD>):4M>EX)?E=[5'[91^I&Z)B2)1@%U3_F3Q\J*FI"L6 ML;M>O,J])INI 9)F"/>;B)13:@(QQ_6'1 MM44VV@L/2W=]TFN#'LA:PR(Q()\,S6\[I^VJZ&YA6(2W0FGB^?PV#4N+2YT@ M6'NLM M@9P/#XEO=8[/&^^5=;EB0N%8&1[JQE=9?,H:163ZJ>3\)!3L#'2]> M>^I8K[WOLJMA>=:9IF)1(,VF% MIB7;H=OP_I*=DJ7; ZV)B*?@"78 &:>Q4_ /.P"+5<2P<'WU#3H61=Z@9K OUC.(6WH\5CG47 M+U<*8[TX#>"[O8H4A]@"J-Y%A A/+/Z@_GL$Z0[?_"]02P,$% @ \X%B M5I2S&B;G9P H-D( !4 !AV5696=<=N\\)^5;;YSC3#MO9=?:\5- 4)+&+(E0 Z;3JUP] MZF:9 != $%Q4(J*[TI( <'W@ K#N^,__^;+,OGDFC*W[_[Q_;??D#RA MTS2?__/;SP_1Y.'\^OK;;W@1Y],XHSGYY[5R4^92P"[HDW_R?L_N;;Z)OOO_A/W[X?O+QF\^/Y]^\__[]A^A[ M\;_W4?0__C-+\S__0_[G*>;D&T%$SJN/__QV412K__CNNR]?OOSCY8EE_Z!L M_MW[[[__\-VV];>;YO+7:;'K<-CXQ^_J'W=-WPS]Y4/5]MVOO_[Z7?7KKBE/ MFQJ*0=]]]W\^WCPD"[*,HS27,Y)(6GCZ'[SZ\H8F<5%-8RN$;Y0MY*=HVRR2 M7T7OWD;/S_?7;^S_]Z!GL5X)-N#IG+/Q*Z%,][__[=^P_OOJL(%AM!0<2SBBBG M!8G>_1QQ,I>?>23VS&A.Z)S%JT6:1#$C,7\-)^8O2;0=KZ+;\=4$D9>"B$-ALW5M:2_?-;U<\U-9GJ;L@\SNIG M3UY2WD"8HH4U3;.8/U7+L>31/(Y7-6$D*_CVFSV%FR_^N$AYDE%>,O(H..5, MC/_GY(D+ADR*(XH->GA%\%"OA7NRHJP00E,#?0HD!CW](MJN=[%?D&OQYS'S MM#<1U;MI/M"Z(MI\285(\E)<9M6\"MFFWB^-$1\H+C9+3+=S>%Y5[;L& M9#^@'8Z@/>#__*Y!NG0O3/\4B3;+M-C+FY(M!*DD3U)B+$P#A_,G3!L1%(3I M($QK!*'S/2=-\NGY(1_!I5*[08+2$$3L(&('$3N(V$'$#B+V(;8NYZEW:?O' MZ"GFTI KY-!IFI4%F48Y*2)!)8_$,HWX(F:[684*W6:C^I.];>@*(G@0P4]: M-+V,62YV*'Y'V(-D_S9]H;5]$*R#8!T$ZR!8!\$Z"-8N!6O@P>-=AGX7Q4DB MIF@:D9>58%?"(U.!63.$/^FXE0B8*/P6K?SFCTD]]DT:/Z69()MPE: !;8Y# M(L9%39#/3TX^#Q(NAK,J2+A!P@T2;I!P>Y%PS20>[P+N]U%&8ANQ]DU'?\*L MXM'!FANDQ9.6%F\(YX3H/4&Z3>(/4&J=>E M7=?D]/$M^_X>QQ8U]O$K#FZ4$(#D+P20O!UQO.7\.CH"%=@@ < M!. @ 3B57'C2A20L?S%1\"I"1)SD)A/6F*^9?,X3_^N*KF>TYS3 M+)U6'\YBGO+;V9W8D,3"J;_:+)&+_>J9Y--)DM"RRO.]$YT336R[UV<&B3U( M[$%B#Q)[D-B#Q.Y28O=X>'F4^*X]"]:2H%KFWG@;Y'*0148D+K"E(2.LH.?>S?P3:93(9GRS3^2\]\IK7V:MK[HE&?;+7ND7]0V265+7S3> M42%L9O]?NE*BT7!XNQ:".(O_YNL ME60JVO5/'UTN:?Y0"$VM*L+";\NBNBI,Z')J8@&=^J>\%LAVI<_E&VX\SB'- M<3@C<%'CT352/_9R2=A)G3#USC:UZI^TZ3R@3BZ\2_JKM^%S:C-A:>]2 >GF@O2#2>I8^ M$R$5QIN]1$.TKGGOU-Z53UF:7&4T5I/8T*9WNN[)/)56R+Q0F")TS7JG[F%! MLJQMTVEJU#]ERSC+SHZ<^6]):VK5.VV/\C85[7JG[W?!7_\[%Y+_ XDYS &BBT@"V$&],N6!437JDZH$D)1.3\.[]TV-:-%IR5$T\ M4'7YDBSB?$X4IX>N68_4/;)8ZCT/Z^43S1K(:OQ]L)"#K\8E#[(Z!L>\S9OJ MV3&O>',W3>YYN&W9\VM4.^E-X0'L0T!L[Y%BTPG\0&@?T$'3.,*!F'Y APGF M P7"^Q$=/*!W$HCO)^3X%'Y-(+J?T:)[ZX("0OH%+22U1Q\([5>TT#3>5NB) MW7]"PRB:0L"LH1JP""B3< XH1 MJX"BB1F"0L,GF;0&3D"AX1-0P#%R4 ,[/ED%&E, 18A/:FF+.8(BPR>ZM 2A M08%AE5O@ =)0I/B$%V7>(!02/I%%FYH)A85/2M'DP.Y!]9Z/G>PRR\DT>HJS M.$](Q!>$%#Q:Q5)B6I B%6JU024F\S%]9&G;4A4J,PV4?C".RDP'A\I=S&Y9 M91"=5J76MEE7)WX M9=+%*X8[,0P1RO;49E&8=1X0%W!IP#H-CD.[0-H[#$Y_^S(!]@K5W$ZLFMM7 M$UH=JIV-+ZC:>[6S_JUI9I",96"H[1X0.ZS&_OV#W>$!%J2?4O;O(UXNES%; MRV+O/)WG50BGK RY*\49K3:U..'V5.NAO16ZMR<.9EU].SORFS_.2U[0)6&W M.?GXBK$V*HF^D8GJU$+ HV@%(*&AF4LBOE "<>-'! @9G8[O)H 92,'!-S% MZV1!Q-'%!#,FDJW%7W,6+\^K_3TIU&09=G5 [ /)%]+W\%"RN70WW-,G6J3) MPYJ+%35)_BK3.CE!3;/=" Y(K_AW^Q:YFD!=.Q=D?*$0(I2M<'A2<%'S=?AU M."L.[%SBTYXR\>&/C_&_*=LQ30-Q^D8>Z'M)E^6RD>>5O_=/E1 EM%0U_=X[ M53("XG;VZF4U+@10VW%0ZVP-0ZF^E_'-BF7RYC<_U"BYL.%7/!2Y?W,&5OW- M-0'\GB0D?9:FQ4:2HJH_A?S1N'Z,^YT&FD'YJXFZMWL&L+5G M;[R0LF6%CRI9..5_GI$\60@]]T_MZX!V.P4L@W+66^+6._(T+ ;M-C0663/! M#,9QCV$12&K,F.MMC_$B&'9E,#)-BZLX2;-F-:N]X8#TZJ=1"<991I*BC+,[)C8'5JRUFTA[ M!Z_TWY"B(.QV5@LG6LIU3?W&_L:%.$KT>W5C&[]QLG%&^+TX,O*2?"+ZJ=6V M]4OUWF]O?M6V6><097UB4=;ASNQQ1)'K@33[;6B+ P4; HV#EAKY^S !,S'Z M40L+VTBP-MMI=8"UMG>,J-L<(%3?5./%PHC61H&CCC0CC/.AL5)14ZL01GP: M>S,UL?&.+OG*SOGD^16VBW'@_?4 ,BQB %7R69]'4*=,-4?P^V7H9C=I2]&IL&I'%ZKC?1A;#W*IP"$?& 6G^#V1',GHBF02-(M: MY1^AK1E0J!8JU/^#?&FUO0UUEAP:T=KA[@"-.O$KZCB4"=H".]'L$F#K_5:, MLTI.1[6CN'%K=-IO')6@<6DQ;8FY1\>P6G?, ;#V,#&4S&GOD^K$F(X*!SED M3%#N'3KNA'O!M_MJEP(:*#G89 BU@$*MG5 ' M9FB*ALV,''T^X<:7=R7.YG.:5W3\GA:+G3>S)8?%M'O(8@E9+"&+!1V0,62Q M!+]8\(N=GE\,3W!RL/X$ZP]6ZX^=F.G;_O-#E,1\4?^'_%6FSW$F@XVB.)]& MC AT:2(OTI2_&UJ%+$;V9BNRIJU;'7LQG/S_Y?Z)DWQZOWN>_*V!R8Z$:A=# MX3! X:+FZS"'?56&@J!,8S@W@S*-09D.TG:0MD]0VG8G#?F6O'^,TOQ9D+BL M)<_G.,WD:YE1QN/]VP$*V[#!O,G7)N0$IVR00D]:"KW>+X7K7,:^BKWI8\S^ M)(5<$W+/*M8/)"F96(!$;ESGA!6"%1Y9+*^ZJ\/ V_5"7X\+$GR0X(,$'R3X M(,$'"=ZEO=S/N>5;RO\E6FV2L2KCLC0VKPXY!RC?MPWC3;*'$1)D^B#3G[1, MO\VPO,MD<'<^O=RN [B<;C-$D+V#[!UD[R![!]D[R-XN96_[L\BW//UKE!X4 M.M@)HX;B=,LHWJ1I$!U!F/[ZA.F0B3/63)P6RGXGLF03F4Z>"8LU-&K;^576 MPDUJ:-3.<)-:N$EMU#>IO2+0Q*<)[AE,)/Y-),[IW!\:9S%OX&S=R6/4-QA^ M@N'GQ',0PP4](2?S;18@0+] 98\<4VYF*(1MML$,60 YE,8^A=+8%C(?O2,SPI@02>.7:NO3&FOUC<=&=ZABUPV!V,]YD2;GLC L MT_.\MJU?KP5E))WG$*)U33W['>39*9FW+!:4-6^'L,8#TZU=I6W-QTC[P/ZJ M8Z*D%FK$.\<=$-!O^!X&]I(ZQH"#GTP@\9FP]H^Q+S*8:$:.U_?#4 MMQ[0P%[C1S*HM/&O."LK!I]D&?TB3Z.S];$BKV$TT^XADB9$TCB(0S%F.VIF M7L.(&: V4AL5;1Q8X3C'@K']C*:6A^'H(J5,K&KHG*"M''BX][1;:%'YY]VM M1PQ1)@XYU4[N0<>[+6#5 M]0)JJQW*9>I2*NJT0!VQK>,%VNXM!<+[@&Y50MUBZ)8E2-4Z -K%(X!RS;K3 M3$=[I.K?N(%K:P2[DQZKC17=[Y[5 VA@M!D0YP]H]N8036Z,*$23>XLFAP8] M> \C_Q#Q0E#Q)+-,(M%\);@VMK@RO7T@?\'E0%(ZQ9E/!#V\Y _BH$R% BK> M\&19C;:YIT%0-!5?"J+29W)^0(.L2*6.1')G M(;/P^X?/;:&([7W\QIWM=K3#/6_"F/215#OBXM=<]E!JKKRB9>9"#",.:0,0_!@KDZ(*<@LO. M&%%PV7ERV3DU#GOWZOU0W6-7K",ZFXDN^=RX0)1Z!']^O#8:.CGP[LJG+$UN M-R.K/7*Z=B:&"049]V2>&9"C;NN,G/>38@DE1]T6AW,4%S7!57MRKK^'.!.G:27'2J'W=O8HSX.X MBMK7&\7!'4\%3S#9#V^R[X%.\<(7-!.2+Z^O?_XDY!QX[1SC_G[1E4\\G:8Q M6Q^PM\9/WMH^N%.".\6!WZ"=SZC]23-:QP)P]:%3XPU>$#7235#9FGKBW;'8 M5LW?<;N6CBY;Q0*EB>J/+E'%>N6VJ?%^4U7Z1-IF(1B=9S!8^(T1!0N_)PN_ MI3;EW9;_2\1JGT.TBEFQCHK]9F)LU8>,Y<^^#Z?&9:K.92DO)7]@&3@+1]'# M@1'Y-BTX3\E"N5MEZ,F>D>C-J0B#M<5B.<5$3[-@G M9\?>^(#OY*:EM?.J&XZ%WH$3+O;D'(C0&ILBH <&!."7@,//X1P%1J[B9^O# M7\R93#, "GQP/X/%",$_%5)*@@\$'9 .6Q:%BS$C0@R!>&HN'U=&N/ZW%N7" M4B21:!7S8%H/ MZ8@^W#QV-'5R]IS'?#')I_(?Z=1[CC.9E[//HMO\?IT_BZ^JG)T[2<2Z_J_* M,M+'T Y\..>TFE#Q*/$73V4ATRIC&H#%J*<#4C=YL.R>%#+%F^:[@MC@^;<< MP@7QC%%V3IF,N9&;8%46-Y6'$H?0;=S;15Y1RO\43_J<)X058H,MQ#(#S[1Q M9Q?^R%)LZ6*C2./L@I9/Q>2)EL5O5#"IX%!!!X2K;<=P0/[OL4S]%8=N_)1F MZ7["M/2".^%P9>*B)CA6CVLY[D[8N\VYVN)7;>_@E?ZSF*?\=G9$5)46<9;^71VQM[-K*3GE<5;E$-<$*D 9]/2+B"Y7C"RD7O9,ZN+&)N_* MM+MG;%41FEH>D@=A+6+(OY1P6GOX1L#%1$X!LJ!)%\\8>'$[DX&T+> MWA%09HJ@I8=7!)_(EP.QC]%<_)D0L&VGZS!^:R:_IJ%%P&]I[9=REE)V1\1_ MI_U7 ,R7(8SUCIBK!B++$D.;" MU?Y ;.-$T^Z>P\L2DCY+KP%PNVCOX+N*=W7-H)C7"_),,EK-[.6+K/!$M-J8 M04_/B*J[G,0\TWEMN(>^&& _O\%RM4/LGJPH,S4"&/5%4$&\K@=9B92;PJ=R MR>MM AU&"D&:)U!$Y#,GM[-+7J1+08IJ3IL;C3Z8%"3/8(I&'%$@*:) PZ\H M)"\$A5B7&V_9"ZBYGP,=1@#A!S!M7"#H:G_ (#OP]J*K!V+VLN$6>W2%0,R M=E/XT=4&,>!OV[@1(.8?,6*VC#P!0OX)&62(N Z$]C,R:/U%S $GY!=D$]+1 M3P9$_2M2U& ?.50@P2J$0:V=4)S8)"\S+QP4)58IR];K"\6-5^BR\4! 46.3 MMHQ=LU"@V$0LZ[@R*&!L E;WN'$HZ>A$X!5M()% M5D)18I.G]NO7)H(?BAJK+&417@*%C$VZZNIVIK%3 O9#LB#34A9 5QH1/G,R*[.;=$8J1[,^I;/[ M<#C2%7%1$Y(G0[B:%SJU*US?:/3A:CI8GF--0I3:*S@A2BU$J7G9*!1; '4M MW?B6M#]$K#;-B7]WMCD[D1HRE#?9&4X,3$@.\N17*D]*SX14JG]/B\5YR0NZ M)*QR'(NUO;7>KT'"48>1?-_K$,_G3,Q][53GI!AR/1,X.Z0-E9N/&M^/P0)3%?U/\A^YCF*,ZG0F78!C;7OUNI0_8/ M\*8D=271D7]!1H\?A997.1*'T>4F#@;[\7#H8+BH"1IAT"2")A$TB:!)!$TB M:!((/ Q=Q1O?DO:/4;K/"XSBYSC-)'4SRKB@WDZX-AK3FSQM057P/@19LZ7\ M[ -)2E:E"$RV''5%F8RYAIGD+8;P7C9TLV;.-V4!R/1LO;4HE''V,2XD^>L+ ML=I F%T,&72*H%,$G2+H%$&G"#K%Z>D4W:6#$3HIW(D%OG6HGZ)9G++H6=8; ML=.8-"-XTX]::0C:4-"&(%=;U)4[#ER+8N_:E.&9WN;W_E42#A(2O3Y[R%EMP%(1;SA!X&&&P:I_>16EGW/ZQ FK M:@!=YZNRD-GK>2)Z;=XA<#YZ>%3038-N&G33H)L&W33HIJ>KFW:3*$:HGPX@ M8P)GR5_]&8-9ZDVP\JW=_USY#6451NMZ!KHAO.GW[40$!3\H^#K1?1?DL"M+ M>BY6\_9$:[TVR+![4*."&A74J*!&!34JJ%&GJT;9G8J^9>!?HM6F7)T'YL M/-(@B*F.SJNR*!F9+&6)\_I^H,UU!493X?(10:L(6D70*H)6$;2*H%6!2?]*";YWKW?=15EW;9:=EJ;I[TZOT!'0JV%7?JGF[JN[FR^?5[687 M*9?<)]YK>X$NF_XX5"YFJ9:!C?T2J5T>1>H1Y'YU%'.^ZY#MY4Z.8KVE$ M:DW75JML'\Q66^ MEN2JQ_AEXR@]([E@7=-<:.L1!YJ!"S(CC)&IH+*I#H8A>JO1!D)^.9N1I$B? MR>XUW8N-YJADA1E\^R$'2_R7=)[)HOE[FL6N07B1)N+=78GOT[GI-'0:=:"9 M^)QOKB[^N^+>S5+E]S3+!+E?8C8UG 3; 8/F'#3GH#D'S3EHSD%S_AHTYXX" M\XB<5F M)3:FBDI+*QIT/'\&-3.*@FTMV-; MK4M)\E0('G+R2)FY$SRV5V\EAPX88)5 MYQ4S\DE6D9C*:]OW#8]'X6=5!KF%5C.U^_LJ'^12_RSV#SZ1Y\Q$ M[L70L.>>GH)JIBK*;U?R3^YTI\:4>[!EGZV9L6UAB;9"IK'LA5!NY1!ZI_.KR12CV*:_P@69R(#*"53)8 M)8-5,E@E@U4R6"6_!JND&QENC,;)006,45LSWJY'*QCNAL1N3M,+81AZT#^3.2 DGI5//A8.W$8N3/8J#J8F ^F9,\64_F MC.P/6VWUAVXCX3"MXJ(F&'J#DAZ4]*"D!R4]*.E!21\L!]^%8.-='OXQ>HIY MFE27D4S3K!3*3Y23(A)3R2.Q/",NQ7M+&=EJ<']RV"D(JW MTF?R(&\DK:+'+E^2K!3L^.'Q0$]B"P M!X$]".Q!8 \"^^D)[+[.3^_R_$\R2G:9%I69OI)L)>,(2H4*8GVGN.&H_B1X M&[J"Z/[UB>Z<%0?BDOBTITQ\^.-<, V+JPN(;I^R=%ZM\:N4)W'VWR1FVY)R MV\U"*U4Y&R\(X$$ #P)X$,"# !X$\-,3P!T?D][E[)^CS?NOQSM(D%K_&24++RIX?K6B65B;]*2GB M-!,JAZ!=*(Z&&I:+1WE3N]P1VRGT_ZSD8M/@_)PNG])\D]VQ\;(4XB^>3JN; M6%ZE8@D&8W-2;'CR2#AQ/:R)V-49Y.ZFF7N2B=@>4>0K<,Z +G= M#FYS\O'55G-(LK*10P(>12L "0W-7!+QA0)(.&[D@(!+L7/0-6'W1*S*NJC4 MRSDCTU3P=4+2YP:UP[B? S(_E1+W[>QC_&_*=B=)$V'ZE@Y($;RX'5;]RI2- M7!!0+ BKRX*IWT(C428=71#Z+&9>'B/3^_C+QUB>-'$F:]=5XYK(;/-_RK3E9PBL0UDY52<_7UES( ML)-$$,K])B MKS02#&WNE_8LHU^D&'9%Q2(HGXI9F;TE4(7$J+-77%O3VX$@6?TI M1+K&?<&XWVF@&73=-%'W=B\$MAZ$<@/#;@LJBY&\(A:D)$0&[%6ELE+^YQG) MD\4R9G]J&1#:[12P#+J6WA*WWI&G6530;D-C>13/-X-QW&-8!'>$R2_B.7D' MA=#095@,/A,IV('(U_0; M$(VTDVC705OS,=(^Z#J61.W3SR?/<9I)#5H69(UEK%6.Z%L/,ESAX)6RI 'L-CD02(VNIUUFM!F":.WK'0]EKLC:%W_DC/2.U,5^Y M:$R[>\96%#(\L5;:M.M%UW0 FOF6DMNRX&(KDD$^C0%[IMW\8DESLJ5HJS+? M$WE,"+K.*&/T2QUA(GY3FLGM!O&*J;^+94R<7OYN M;..72D:?4YG3U>!P5!$-Z.(Y)7A[S\AYS!<*JIL;>::S$,N+3+>USL2DE1-O:=[1;V*O+,:\21WY1/0'@;9M2)_VGSX=9JEH-C\U!Z0OC30UG407P_GH &1;-BJKT1Y]' M4#]U0C Q='-@%7Y>;A".#H&:Q$*,A9LMA<=./.SH!EP'/ S)-4+#MC#-97O9 M5$NR.RK^[*BU8=A0G;VW]I12OZO,&;"6LB% 5/U?%VV'2E$&!(BJ_TN?+5&I MZJN@65Q=Y%* "1>(\T=D[Z\M)=SO8G,H;%I'#:$YQ;M:+@XF0^-L0W6\#V/K M02X5..0#HZ!'OR>2(QE=D>B,9E&K_".T-3L?U4*%^G^0+ZVVMZ&NX(!&M':X M.T C_/R*.@YE@K8T#S2[!-AZOQ7CK&J4H=I1W+@U.NTW/Z%CV+8,/'0,JW7' M'-93;@V.1,F<]CZI3HSY,SK&!-5/0,>=<"_X=E_M4E<.)0>[C!GHQ-._H.'I M<-6 \)S4.$;C!3#E5W6$.1K# MN!FD+HG/?O4--^P+*;SN5UQU]BKAU7#\RB[. -J4S@-"_1495'@&#O3HQW8? MF7DF/Q0I-BG'*CT:"A:5K..^WCIT&K"(2+8YRU"SJ@50E-@D MI[.NA7ZAP%%)41:H]3?@06 RK-NRA^?G&MT/$:MW"O%O0N?UDZ)W'6_,-1RUAN[AYK;OM;60K-;I!04B:4E-D= M-)A*RH18C1"K<7JQ&ETV:1QRW?M>Y#KEJ /+=2UT!;GNZY/KPD6?SJ@*EU"> MPB64NV-KXRRX(VQ&V5*&F-P^9>F\,B\JA&>COOA07;ZLB QD>TR7HLGM[$%\ MRV=QG5-3V>14EVZY'GY<HP8ZC/ MM>]7)(W>Z@S6H.-].NSD1K9$@ZS 2=Y]<_EGN$^ MT3PI&2/*JZ?,!P@V@& #0&D#"/)PD(=/41ZVVZ!]RX$_1FG^+&A=UG+.-HE; M2+1<$-I1]+,;W)NTUX6\(. % 2_<+/\J]4\2=3L[)G,/0,)1(+4=)@BU0:@- M0FT0:H-0ZZNT2(=M>J3V7C=ECOQ(\[]$JTT=CI/@[0@+ MLGN0W;6R^XJ1)-5%\#4U";)HD$6#+!IDT2"+>A++5%NP;Z'KUR@]N!9B+Y%T MD[D,1_4FD%A<^W:$ROK6O^$1ZFYI@J/4WO5T\D@'39K3T+H+IYPL*2O2O^/V M;+*.HP5]W;^^[IS._=9\)DL#OUD!NOW=J&^P0GSUJ5YZ!%W.5_N+64=N5SJ! M+"^ E(O*.#:F;*]PV;79!C/D)$=_!W T;WX.(WI@_HVWS#+^]O MO^2$\46Z.E](2:Q9?S7K9**.JPC,Z^L?MM= 7.?[XM.4\_.8L?6,LB\QFQZ; M-:S[]T+V[KJ.PT?"*-9V=4"L>D8^T>*A?/HW28I'>OFR2EE38$JG,7HEOS/M MC@@/SL53QINL__9=34C3&P\8O^IY &M+T#? M>&QT#^JJ$"007J3)N;P2A^DY1MO6*]67LYG8*H486=\Z)N;S7@@ULK9N+B\W MJN\\*:Z(O/\DDZ)I*8A:OVJLP.AP9+\N)\I(.L\AKU'7U"O-NUF;E,6"LN;M M%=9X8+JUJ[ZM^1AI'W3/>DN4-/88\7XK"BRS29S&9QRN3%\U=I+NLV71=Q MIC\;[ ;QBA.LD\,[^*Z)0V*6++3OH;F1_] (\=IOQ..R_U6RE$_3JJZ7EG!@ MKQ"4<@)!*0]?4LXWHK#O>HA.2KQXF>48PZ^PVV:;*!O;XT]#C$IKT' M @1J :FU_?#4MXH7P%[C1S*HK/0Y9[L;; 2=9R0GL[10\55+:PR4[Z32.Y+' M697ZG$OG%)%U$"=)PDKEI6P.1O0Z _^*L[(V8&09_2)EN;/UL4E*LTF8=A\8 MVS%IM=?H.M=NY+;#A+!)+T&'QBQ(S8S&&#$#C!?4QE P#JQPG&/!V"YK44NA M9G1AL2:V773QB:T<>+CWM'M.4 5CN5N/&$(*'7*JG0R$CG=;SD)J%WR#DH7= MBPP86-KQ_F1DM1M=(*RAE0/=:H4* :_+\BKMQRB7J4NIJ-,"]5>6S62!MOOL M@? ^H%N54.J?HW;N D'L'NI,=JX\_QNV?U M !H80PG$^0.:O3FD#AD?+R%UJ)_4H8Z9%>CV5=@+[.:'0+>OPD [?J>.ME,W M'-PA[P,(]\=QP(6DZ 1_X0$L7$4"!#?STCPV:>* 8'^@@2H4=@"$-NOX\!F M'K0 E2/\*>2P"7">X;&?"$_YR!\B7M#DSR=9N2 2S5=".*[([IJ:;#RPORQE M2](Z)2Q/!'V\% R MG:I0Y3!$##//\C"Z7;6F0[2V]TJ]/$!:4N6:F@Q"HS9"NKD1=CH'#=S>7]1: M\>)GL8KX_=^/PS5W7(5F+XWF M4] ^V^>CPIS!'S7H"5<1^]2^>)Z.\>S-T+6@J9LPE^.')-APD]K./#F^9)QF MFP'UN2MCG)9K"=!>_>!P&\:G51G1A>XKYIWU99U&%RM@Q*8;P/(?,JC%V MHN/67O=0:FRH0LG,@QQ$&-8$(OXQ,!7Y#@[IZ?8>;O9#1/XJA;P0T=E,=,GGG:_ M@(_H+\#,E*9.D65WC":$3/F5X+UKSDL9X'\[$\RQI'DE/W\BQRXBXWX.;CNX M*Y^R-+G=3(@ZHDW7S@$9]V2>/']AEL:^N,G'<&Y*C;.B/G_:18 M0LE1M\41"8F+FA"7>1Q!=+"9_QY+.;.X?"$L23E11F MBC\?Y:D;5[5#]-YG<,=3P3.\;YQ+D4'(F$R(K$+0K+Y3P6EK'WS7IU# 6;)K M_9(O2GF*U>I'_?(_D2_53^JY-NGL%U?YQ--I&K/UP;+4!+VVM@\1!5Y2YNQ_?DO[:ES M62/CLF1T11Y8!BY_H>CAP*%SFY./9/H0JTEI;N'"+;B)"RA7JVR]/[R4A$#: MX_#BX*(F^)3>9'E7>\"=W *T_@IUP['0.W V_9Z< Y518V,&]," /P2T6!QV,<-K.BJ&F>!GZ\-?S)>;9H#@T0S9N$H# M$G[?F07#4[@X,"+$$(BGYBIT9;SMWSFH7%B*_%NM>OC5FJ3QN VZGK=H&!.P M$U* V0 52_9U-F"X8*E_WAT9L[9[+N%6IC%QL=5Y'QR"8W((]J+)>O=-?!]E MLG ^C[A<@-4O<18]Q9ET%$5\04@1I?F,LN6KPM:F;HJ.C_'GL7!":"?GQ?Z6 MBOI&@X1MJ#BCC-$OXH?#:N^O/ =&/7$8RW%1\W68[CDK#LPKXM.>,O'ACTTX M0Z-C2/E[_U2)=:ZEJNGWWJFZEWG8#>^O\3<_U"AGJ.%7/!0-:N)^O7'^3M+Y M0F9(/XMOY^0BY8F\+4?NG7="NB?*0JFVP^#!>D_D+KC]\9&PI:JLNNTPP: = M#-I*\Q->\V[S?DY;-M;1F6PUQQ8:,X-JQFFK'(#*@ #E* PFV0YO0RTKCLZJ M'(+1@^T)F>VIFQ0VTL#T;F+VR$+4K0T[OBV)OT8".\DRDLA@WF@E/:0RY#=> M4E:D?]?6,E(;12,ZDZW%L9&*E1C%\NI@;FE:=/Y<;[;&GBB'&1^#1>^4+'H& M.N:5Y&%RDS[+BN%;AJHN[^:3 \;;N"\^"6YZ_$*R9_)1'.(+E?[L9E#$\_#? M)&97HJT3_,>#8<=-2]5=7-T&0X[[43S9W0M_-1IVY%^H.]S[L;"@/EM_C/]- MV7DFCE%-M*[%"%@0[JEKO7')#T*74X4ZVJY'YX_H?!2C\5IT?7_4?(M$98X>AOTQ.$^" MYR%X'D[/\^#2XC-2/X0#77ADS@BGU@\@=BS5=%R:O(#0L978<6'E!$+'=K>* MB6H]7 S_LHY]J3]&J_HZ(%O'FNFP \3HFQ 6W&+!+:8QG-P0L9C):T?[31H_ MI9F@:G.Q%K]X4V"8SL0);/%V=QD*)&NCB[#H<2NR.7O8HWG.+*]-V M&+18=>Y+ZW'PHE6Z+"U'P8/T5+(IH*:;M49J%T&FO 5)0=C0I< M+:V#6RBXA90VQI&[08+]-]A_D1E$W(C#([7\=A(I1FKS[2@RCM3:VTTK&*F= MMYO:-U(+KP/#!A#YSR-%;@7VES&!A6E'0.2_(D,.TI^\^RX^1%S>0O$D[ZF/ MDH.+Z.OO([JJ/LCB2<_R(G1+7T;'Q_CS;3@A-/@Z@J^C[=[=,\EAYP<,-I%W MILPK7CQ;[YML#H#)EYA-;ROFXYD4, M=;:.,LBWMT95%X'U/X>0I^.:6=ZZ:6^NW=JNJ3XFN!Y4%RK%!-9..:] M;J:'H23X>_W[>WN@4W/';'W9[NOC7*DV60\4_-O!OQW\V\&_?0RI7RUYI([O M0?3>D3K,!Y>-1NIR[]V>-U*O_&!:S4@=^KU;TD?J[A_6"#'2L('>'5DC#2H8 MUGH(E2W]E?> RLO=M%4H[M$)U3U:]9%&MO"([N6\?J-;M(_"%N$"(#9$N80H MEUZC7*J]1%HT>O6G*Y\SUMD:P)]N^/11S>R_")=P\JFLJY&(/Q^I_.H \F0^ M9V+!%>0Z+X0TP=/D7W&F3%4?G)X3F_U>-P?3QY_8W ZPE;@A:E3^X -LKU>L MZO*W_A\XUOD#6FH]3*PI):.:<>-%ZOM%N"GQO11;0Z/XHF:F^P:VWBE\E[L4>)( M%/M5%=[R6:PN?O_P67L5&*C/.!P>EW^5@D>NK MR_=3'L">@M.:81FU>"1P5'&Q%V+#OHI3UHOGM!?B3N2]O(Y*]C[SS8\_R;G% MQ_:6])W(V_E$\^=*FN\G@L#V^:1KB];J MS8(QYE N[^;G,<=OX3,7?VWA7IVL85];N%>_UJLQ1WX-X6O^VD*[>G0/>X_S M^DF&-RW3HL(1Q;D,=\KEK3,D3U+"HU7)DH68@*AZB?Q5:\O@+X>/]!<1YIQH M6)C8V]F4W_QQDR:"7Z4F^U"N5MEZ,F>DHK8Q0,>DBXE]4D'< \G%4DC(0\GF M:1)G]_2)%FGRL!9;\G*2B,7#JS>CIM5N!!P!;[BH">%WQ^%W!Y8BL1:$8A3O MOWF4>X*,[A1[N#;4S7*4TTH_A0;G=9/!>YW&FC0O2-U M(&Q+:Z^4'Z0WW#YEZ;R2%A5T:]L.3_5%2:YS>?UIL9 W8YJ 4'1%@DEU>S$8 MF?[ZX\'Q/1 A=4ZMWMG;KD@P/2Y29@?I3<\0#' "=TQ(%]WM[$#NT)P/VK8A MA,%+"$/;&4VM!2V,:/4<1QVI"*.-R0 L2'2Q&;9OBMI85E#YX/MFZA,)K##2 M1M"Q-WS3I0[,;RCYV^41U8FG'44L%"MEKY2*-]S%7UD4;C&"OP M(PVD,;>7C33&!6#=].W'?A_Q:?#FZ?: HI/K^V.<+ 1SLO7' M."]GD@OEA2Q"&;D@2RI#,BINE"$:*[U#O-- #MSDMT*&B^5TWI!8:(_5?*FI M;6^-P^&,BYJOP_W-67%@6!6?]I2)#X+17])EN6SD+>7O_5,E=BTM54V_]T[5 MO31F-+R_QM_\4*.$=PQ*H[:8BU3Q I9MV_+%6?K MEJI=!CUQ())4:4-)#'J>#J)!=RXE?9\K^?HFG:D\MP8]@YL\Y,PK;:=X7;#- M,AAM$88P(; Y*6B'[7BT;F3CHQ2=U\WD75%#'1^5:Z9_GL;@1>[IC3NP08W. MFZY1I=&L8M6)0EMM$ZC6)O3$1+["VMZ&VGZ%SC5HN$D8F2C0N0/1DB[?.:99.*X?J4YS)&+R(+XA0 [8T MM;NB 8/X\"6#R>CD#)XDB>"FZ4T:/Z69()SPRY221H. MFIR7C!TLID,OJXOQ'+B&-\]B]T3,C7P=C_'+.2/3M+@G"4F?&RQ3QOUP.&AQ M4?-UN(L-C*&3.N:#W\5KR3O-*P?6>!"Z]VS_B10PZG5=?&,HEV6UV53U1:0. MP,A"2C#/Y#H7FR^YH9P+*F]G8IVK8=F,XA?I=%H=.G%V%Z?3Z_P\7J5%G E2 MES2OZEBJP($[^L536>Y4-+_Z<0"Z6I9!4YOAJ)P\\2K4$$+M<5N_5#_':29W MC2O*'N*,/)"D9)5X<$&>BOVGEMFW&P4ETD\T3YR ?3O0(!4+Q*[RE.:50?9\ M6_JG$'_Q=$IJ.^U6)ERW0GPSN"S5FG?06*9H/4 /@]+1;G)2^$[,%V_*W? M&$VZ>L5T069$/'U:BU)"@JJ/)"%/*9"T=_!*OZF:;-S/;_B<-%^0&R':BODM MXGR>R@M6JPD^6W^,_TW9>19SK@GBLA@!"\(]=:TWF;XE6<3B]?9 GV%A>3MBV.1 VUS CIXA7#_K(P M:9IK9?*VYIYI+X2Z1J:7,XU@L)V"B=!E3L%A@P,YT25,@3&JW4_H MDJ+ F "V'2 X?_426\%9AN4#@?J[SQ/\%MN,MT!D_N[6A.\KG4'YNP 3# IF MTP/B^Q4?OJXQIM#3'Z<^KWAV)#*-K 3>E0D @%&9/('BA,A+(,-" 2"A&A M:&/@C(6B1"3C&#A!H>@0"C9->3OHE"28B@\-G4&GYP,(;U $=?F(Z+1[,XB& M4=CH^!6&UG%J-CJUW^R=FX1;H;,&F$$US_I 9R$P SPZUC4^<-H"'3&?.1K: M&VZ0W6A>\,L7PI)4G"!MY$+[.R!;O#(9!EO=R"B?=SO;/&VG6#_2 M@SD3U"CDQ29,S@=W +BZ4EX(]+>SW=[P2+?.WT._;Q,@X\XXBE#BHB:4Q'Q; MEI&12NA<4E:D?V_6RD7*:V^38"RAA"[3!-Y8LQK$?M\(?^\EKPM>%F>YGHK^#O%A'A^NO>R>D?1 MZ*]#\L0.\/J+@Y:*^7(RYGAFX4ZH@'3Z5M#=:D O2<4)]T+_N9S-B'+7&88( M[_-\)?1=:>\7?]9'2GWAT)5866*;/=PZY2F442XOXM#OUZZ&';9P7V68V6E' MJL4%[>89RXJ1)*TV-"7=;YOX+318L?WM[' IW.9]['\]/LEO.;@X994'8R\/ M[70R9?E"2!^O*'X32H24V&YS&7]].WL5NJO2W^PZ>\?%)6U$4'?Y(O>[,N6+ M>L9E<+D&$JB?WW)RRY7@G)J(&YK/JZCC6N)\I&=$[-DK:4V_G2E0&??W7"QO MMUE+2X6NK)^JH6]ZWUIY#V,9U>3#^B%!H[1=VG0=&),V5@T,#S3*P$C!'HLN M0PR,<6LQ- '5T&=@%#M[R,8RVR+'FP^ !=_KZ#)S>,W]AT8G0P#V)BV=SY^ @3#@;7 +F.'4#( 4G]W[Q.8_>>7R44-YVV; \KQ"T])Y_/2-_98PW3Q\ M(X0_4J'W2KU#QJ4) F7&_")FY$S0.961B.+8U5D8NPXW"/9'.DG^*E-&](4" M6B ;CC(L4F7N/!1DZP"^"_'N0G$^QL5FNBMA<;W+58BSC-_.U&]'!=WEV+YG MY3F5E=P$.1>T?"IF9;8UG:C!MG;Q6^+W=3S=[5,="WZ=;PW[@E S#=#!B'Z+ MP9KLOXAVUU#,N"E M$5W>9 = %*2 (DPV!)6 [3W^$ATK] KY5;$K51@.NDW!UY28Q+NB6U#>)LE! MH#BZ7&!?DP?1C-!E#ON:',-X)'19QOYV;I/ 3W39RGU/DU5*)W"6/!8#]L1, M<%L;<(H\EA;V-$66$87 ^?)8JMCC/FX:*@N5.4]/#C>(DX9.TNE)YH,D7J&3 M4F$ZLVWL'#I-V *(=AK: G;1Z;VN)T 9%HI.F;5#[J V!KHU[YH'=+&+Z#1/ MIVS@ZJH3?PJEZW??'HF+3EGLZPQHS$)!IP2Z1@]-=D"GZCG="-S4J4*GWKEF M%H,$('S:F_.M$Q*+@T\_ZS8-MC'(Z.2(3EYE<&@Y.@6J Z!#"V&7T%)T.I6C M.7$?CHE.!^N)>X QN^@4,3?389NF@TXWZ;2E@K.OQK*E0@!M!5+S I-CV42! ML^ V36,L^Z8MBY@5]1S+MFG(*K;9JN@D43?3T7M=(73'C9MY&[*P&CK3&H(I M13Y#P/AJXWP&=%*-$03EG4K-*:3HA!=;L&T5F=!9CV'LZ[9D(CK6=@9O*YM9 MUO)&MPR<3TQ/5=O1R??8BX?)M/4DF+D@,MK?X^ MHI7F$HD#OZR_%BQ2+FMU)IK*2Y4R@SM=W#_3Q\4O?5$-NQTFW ]P2O<#<%8< MY.>*3WO*Q(<_/L8OZ;)/U5B)6FI:OJ]=ZKNY<;:\/X:?_-# MC7*&&G[%0Y&SE>>N,L%!&.C9>M]DHZ),OL1LN@^\W>^S,BQ*ZJD7J=2)A>8J MMO C[-Z?._[9_!?-Q#!26/$]G\U/'N^,WJ?\SRM&R+64.H38Z6L^=<_U/YM/ M[:B>3+CDD;"EZLJ/_A\8ZJ'XKX<2:H=T!M(L)=$6<<4O @?53S3"(!I;EVK& M::MT[=DJI2_= N6H3C5;^C>PM;T-M0;F%T(H#11* YU>:2#/:ADZZ_2 LZ13 MMM#%I0PP3^U*%+IP%8-9\J C>71NZ.YJKQPR/$HWAGL9KD88C\A?Y8$[IMO] M]*!'^'!=."*RTSWVE;M01DJ*C;AD:3ZO(W$JEN(V=V8[&=!$#38#5JT(A[B, MQO-]@W&Y+*OHSRHW46X?C"RD$/=,ZGB+1ONS=7_/]Q0WNK?UB"!]AKIMV5%Y M=@CK),QK_?G:FFV3U.OC_5[[^L^ M $2[#I3M_-X46AUE_5>Y)'75T&;-<;,)AAO'B'&TWO"'ZPJA/\)V=PET".G7L$_E2_:2>:Y/.>'#MX#8LVSZ.?[0;N]WE M*[-=$YS&AE[I?90I=R5;M^N/FI;#42QDYI1)<8P7'TFQH-.Z,"4$0DO7X3!M M#Z"*/ B2Q@Y#Q>HX\(%;R*MH D=@M@L*-LL,%I_4Y.XW>S'4RB:"SDD.?I.M M&R0ZSS88FH$-'9U;&@P28G]!YTZ&OT([Q\Y@X48-\9%NMY\0A(1C?S4(B%!; M&M%MK= 7I5<"T&VF%G>,]>YG0[G_%DAVL:*!1#@C=7PWD[BO<+7*/%8]-)),N+D,H>4AK_RK=.G #Y:1>G>LKOOR(XO_$JTV]74KL9)L*^Q&O%PN8[:6V:B*%G8" MN;L'>I/*79/<*6/W8YPL!*^Q]<"J2J%;Y)/+\A2J'A%?>_RKE)R8R1? M]X$<9.B^KKE;WYBIIK:]-0Y% QU19T5?D)50LM.*R\7?&:D.D5Q:,UF1 M_EU]WWJAECIIVLGPOO-'5Z78$O5[!["U;T50[%=E(N=47L-,YXQP?8X=I(M7 M#%6K&4N:YV_R+_T"-H[>*6_VI>EM^=Z*<["Y[J6A18 H(=7!,K5>+9^ M%'1H\ND,>N) I$LH@77"@4-MK()TP8%!$>!K:.DT!(Y[NHXS,!^I6GNE_(+,B'CZ]%X0<"[^30L][:WM M_9=Z-5W&L$[!81 MFR)IZ34$DFKKGN33&_%4TS<#ZSN(,67#-'5Y#"@LL\[#X*I9R!(7J/,@N%ZQ MDATZDR&\8C2#@XGR8!0+1K%@% M&L:_7*&8D@X[4+F8AS8W4/&8DAX_43&8C MQ([<7&8N^8W4@F8CR .A8BN(9XAM&%.A0$MXD295R8A9_5*.PJ3$9/)(3D!$ MZ^0 FEN'C_7S],&,C$[I#Q;(8(%LU<%EG=0KP4VRFD^:EVD^O]VQU1F1++C; M=@B_V+"G5D_O-"+V&;A\$0MNE1=X0\83#LU)3$HH$$!#<*S=SH_'RQ3L>-NS(2JR6UI MC8%R<7C(JWJJ6\;$ I(W+\G#IO9"B-9WV\W(#*CEX!CFY9Y,Z](,KVF_ MB5>%!3(H$ &!3(HD$>00.?/2)7# M/HZ.-$6+)PVF,EK3VNDZ@W%PX:=%B '5\I;%1/$#<7LM^+@TK>^%N=5U7)RESP MUS:ON]L;M7@$)O =W[;-,W!897%1$VS$1Y:O9N9K\C,I#%KF R# ]WIQ3;:Q M]K421-GZ56,CX%8CHYN1K>2X#?X5C>K*TE* K)%E&?TBA8<.LV/Q%+0S=9G' M25%!Z,@R^@'1X3\."Y%!93D*!J3BB[H M&M_*$F88U?U#U%=(F:@)#A$O*D0AXB5$O+C.XW8O;8PT3L:YK7*D03*=I).1 M%N=P9SH8:Q38YU )4 MBO)WZ;#/&>G"(^]&(EFV:?Y0N&,4&VU],= YP2)"]A%Z!IT#+")E+\%IT$D8 MB5AI9N.'@A^CC-G/3(Q.X+2//89.R>CDS [AR- YP2)>.O" 0FU.6.1'U]%. M4/PC$1:M_?W0>1BC%-G[I& 1(XTB7J#@L,B'76."O:<8_A"1O\JT6$=4BB6" M,A[Q: M!"YJ0M+&4LOKE;WMB&23+GXQ-"U6]B VE^V252$!=_0; MQE(14$WNIW@I_GR4FVYDX2<2V4J2R6MU+DI53 MT:>Z7TL\;E76M0:E89G$+*^,S?MQ+(WMPU+ISU"/ 6>H01],U1H#Q.2 ]QYV MK'>YX;SZ3HL=WXE];L-UVW.YL698+V./:5;.ULT#: P['IZ(8 :E[J@U3D.[ MG0*60^(2S2F!SL)J@\] )@J>G.#),4,&76 MG!,Z9_%J(:V<\DZ?2' /IUDZC:6Q,ZYR!*J&&&3+#N7_,D$2ZO#K-6M7-P&4#*Z(A_3Z30CES&7R>Z3F3C?8C4] MP"X.B+L1K^5&OI4Z<49-DK:A T)NBP5ANY=PG5\NB6:"VEMWMJ$GU>CK6K7? M?-AK]9LO_CC_KR/RWO[@B9+K1P4E^Q\\4?+Y04')_@<\!:*-Z*V(V\4GM.HR@W4X! MRZ#>K[?$K7?D:9RTT&Y#8WD4SS>#<=QC6 2;RA+QG+R#0FCH,BP&.:-F"^1M MC_$B&'1U[P^L-Q1JSPYPO^ E#O7"E:99O/Y7F%1'C41L3/A,SC=JL1&/!&NS M2*(#K!4S1^L0-Y/6T'FUP6^)PNV&J%Q>?;(P!I]TOZS<++'CY^*&S95:BV!C MX6?+XZ<3%SN*/'# Q0;6)#3\"Q.!J-KBCHHUW4A^_QPB2?XT@V?D3T>3_PG&J/.- ='T7RK:[(VU163X M76X!_<7>$QGN]5_-CN:RZ3B^FN &P54293CQE92#9^)E7V\I;H M]@@]%T_Q$7/GCLY.470W).9$$QOV]F=7$6%U+>!-7@2[)P)$50M^>W=*$SE& M'7'$_N"B)D0B"5GECE%Y0R#L.4V:7-=MS7S1R(4\NWD\5\;[M+8=![6# M^G G2\J*].]-)/RU."KSN;S!J%;4CV"8=?**XZSD0C#@_)PNG]*\KJ6ON,A. MIAK-ZU-G6VZ_COA7WN]VD\9/:2:6JRI,PO/3/</).\)*WO0-/6 M.]5R^C9757 X;KF?NM0'">GRH))"L*U;;U2+2_@K*[>G$S_7?)"[IJWLTVR MJ.IP O7Q&RYQYD8N M4KZ29I?;F8)^X_Y^T54'JF3P.B7S[;4X9V1&&3FXB%NL A93-A5"%EM79J!/ M-)?V-$8S0=K\6EH@"%>]3P]/'& &E;>OE<7TS;W2+H35/TML=!?8MX".[G%;'U3<82D7/QU6];:<.5>/ M\S]WIILLK)-7'!L+JC:WI+&-[YJ)#9>^ZR<;U,LA63Y7GT>UHLSL5> M(+B U;54!%=(94+\;ZI>2AU&&@)QFU5'U19'"US\JF4;_AV5E]*<5L6O(ASN2/H M;)168X2\M][SWK3.8VKDMQU=0A3,>8XJ]+[]55"0;(4JU*\S'R(/P#=^<9JC M%%6<.@B4/CYK=*EG(8K6> <,4;3]1M'J51PTYUV.EE [!&OMI\#/O7L_1$G,%_5_R%]E^AQG9'LS'-O=XGG0"-32[KX] M+[3XJ/GC&PVL,E"H?7-*M6\,XD_/!>,:A)@D_[GOC. 7O/7 M$5=)(T>E)*ES3$P'"'D1X::W'*-T%.? H?H[3 M3!X7,\H$X21*-E'[99Q%R[C86,DM#6M.GN7-<.:0VDXELV4TT8&#XHB.30"I M8$+*BX\U'>M/XH&W.7FDCU_H?Y.8'2L*SL=U4*1;3\XN],@A1/B8. R*N*@) MYLWCDLY;]KJB[$&PUQ'S':XGZ7!1%GFV'&90K'L");D?=]NA3/9*<[&FY')Z M13L0O?W ^.=CM_^XG(LW@R*:A_TG*\1ONP?S6S"_!?-;,+\%\YL7K=CUX3Q2 MXYW+%,>1F?]ZT"U':A;LIJR,U#AH)Z7Z-NS]%,T$#T;/D@DC7BZ7 M,5O+V]Z2*J4V$C-Q\+O@VNC+)I%K2Q]SND3)^Q95O:[S?!H'R74%UU/F^,FNCO 0ZL MB6[H^D3SWK&_?08.^QXN:H*U475%S]EZQT_G6GQMFT\5S![VJT6B;/X"BV/2W64>UEYA, MK_-M1DK;[/IZ_BAF5WNF.IY)T+."+?H42F370 M+C5&+U^/EMTQNOOZ-?;Z=@[]7,4VYT)7D3'+HOF*YE68,YV]^L7.VV,YNC?W M32?Z.OECKC>CKS=<,,FG^\R)JNIXDZ,!WLN!YT3[L$^DT1,"[>.2O"M9%WI! MIE4=>KFXZB)'64:_Q'ER;&.PZNN27)/7[.'EWL=?/L9RN<29Z>3!NKHD=O<4 M6>2=/1/>Q&9:FHU&Z)5T6X(=YIX'-Z$+JL;A)FS>\A2637UC!'171:^V*\(( M1&//81 U[?_Z1L/0^?:LUS49B,:VDAZ:EL-0?'AZMM'])6BDN1ZF@BP0IK\[)4S>)]"\#,3H[R(($XP6ED @7G^W071]IV_4 M=J@PX"^FQW!UVG/I.[023HO*"<6'1//5.Z"R6P:E1$.JNU>/ M;^=MNGBGOFI'7MV:-#KX' R'P].&BYK@]SNRO&[N0"?31Y(L7@;# MM:D-P%Y^$X34*V:2).6R%&N$3 _OT5: LQ\("]ZS]PQ-(%MP?DFDX7$$N6[#=D^51Y M+*A-[X >&!!H3;2@/N-&,:A9^7:[\:OVX_:&?LVQ"R$X/FK.C_:&P=P=DF24 MFC5^PS!D5Z=6&^AHS;[@@PZ=F1?V=F@G^025H:L/+L9@N T6RV"Q/!V+)40) M'ZE]LDTN')G]$2J>>S>[O8_2:L^.BOBEJEXU(XR1J?P8Q95IT-;49CZR/_.: M+6T=[V2NG_(8O]1&5_'']KN-7+"-E9=R0Y*P,LYX]2^9'A14U5<#ZN\I#DH< MB47"BG(E^5X^_;98$+8W13='OYAWQ&'OPT5-L#Z^"7:NUT0MLHI%0$'"1AD+\N;?$DS:4(\#M8X_MR.M]NX"&:CPQ9G,HI7I-NM M1^OH;FX4?&.GD K2="!IX@1:VP]/?6LJ%[#7^)&8Z-O!Z^K,Z]J^1J@E,X[6 MZPK<-M#Y7*%OA]J;"%%YZOI@80PN5[>O&B(7!9=R<"F;(0XNY6-(_=L+1N:8 M]N)<&ZE7NY.M;:3)-+9&5"!<;-7.+%U%0+38*KA:NP" >+&4+$4KD5[H"#2B+8"K9VLN5"02.6OUP8[Z'3@$7:,@^Y@")$+SOI_/[> MPP,_1+R@R9]/4IRO*2RL"C>*+&@=?8QBN5EV+WHVM"JA5\NY*3IO4^M[;W[3 _WH'X M_Q_/J;%-O#MAXI"95\<(/UOOV]S%:_E=Q3I[_LFG4NQM]5'V^:@P M9_!'#9HZ'L(WU-I <++;.-F;SS'J<]\9K3=>(P.@\\#W^AJIL92!R@DZZ%H8 MB5O?%_\8R'CXG(X]SY&E%A]"*$((A1GB$$+QYJBWL%;X-O#^%,WBE$7/<5:2 MZ*\REDQ7%2J)TKS:,BJ[9/Q$RT)\LRH+'L7YM&I?_[0DQ8).99'BE/"HE"9- MT>]PU"6)>2WFWUU<'W!1]2I,7N-]IH!G4&M=$G=ICT-)Z$,J% M#/.4YIN@SES&1(D=6/S%TVD5(R6/N]J#O3[>HEM0.AC9ZXQN@O7C#H/@ZN:6EX1\T'K90'T& ;! 9_PM].LOW7,9HS3 M1CGHSGF\Y"]2GM R+Y12HGG'0?']@YCI3]X+(/'\H0\EH;"%G4B!6"N@$_T?QS\^&G:>$Y?[H2 MAJZ$^"QE7Q8GQ>]IL3@O>4&7A DU-"NG0B*6=4C$_V1)$@62#B/Y]9!AL^8Z8$2B"H>+(]LV!JLT#Z#BQ^YZ(@1V=;2)&-C8TSB0P1H#0ZM=; MY.S%*6V2J!@1M'>TZGNCBSH(#CWC(RLX]/IUZ'4V0?AVX/T8I?DSX46=7!T_ MQVDF7\:,,AYG).+EE35\3_GC,19^K?X*";S3+(F M45M,G8X]BEF1-R7T-2N-8V.:E25EA2147GMS%G-U25C+80;%NB?P-;E C&W= M46([?WU=CR7$\Z9+?Y A?7LWD258U25'GO">TZ60 Y,TSNYBH0!I?4#:MIZI M9BO*Q);W>BY;J ?T\9N9GN9Q+J=S;X[1E4+0MPZ^N%.X[%A*_S/"]I8@H9O= MSAI>/9<1U+SY)_V-O#T\(LR1^A&#YHA_?OB-/A.65YO%G @*CX\?[99IVCWX MK?WD:;>QH=#<'KU7%*ZD[D0W4;E!+2-Z1Q-C(2?F="8RX$S@>WV;3N; M,A LMKNW.UF7@9BQW<#=U/OF.*.R7O3K+LO KPU.;KJEN%I-40V#!T8$-+(MV$IW$C:S?_ M.(YTQ'%1&Y(G#=R>>4)D%)\\;^Y3_N<9R9/%,F9_:MT9T&ZG@&50=\M;XM8[ M\C2>76BWH;$$R2_B.7D'A=#095@,;PMGM4%0E6@=(X)! M5_?EQ\N)_A[P-PV\TK<_HM[,H)9L<#^_(1M2S]F$KW\BA1:!MFT(C E)ZCO# MR7B<_>//Y(8%,T"D!FIQO(T$:[.@IP.L%=Y'%Y41TJ/52$)ZM'=VM%/)T'"F M\:9!C80H5'S;YZ9Z8F70P9HY?D9N..ZIM2HS%GZV%(@P[,DN*P6H]<$1M@ M1#KO IJH"S :D!O0+ZP0V!8"VTXOL UNGO8=V/%3-(M3%CW+*V4.RP[$G)-- M)$.VJ1@OZPXLZZ+QTR@N#CL*YF8R9H6E^3QZDJ%YEG$?OLCQ%A;B%U"H /'U M!4H8&(TG%=/MKI"2]PV)[5'PF\)^W-H>989WR&4?6RZ[Q>TE"L =1O+K7(WY M8I)/Y3^7?Y6IV.5);K(RC?O[S8\WNO-.=66[P:6'OG$=W$3X3NO@!/08',%[ M8P3OD2'X8(R@\?Y(WPA,+L1483*_M_E440X:8G*SE^'AFSBLDU<<]X07+$T* M,FT^811(H-U"2$<(Z5":M@;U:,#J-_BYRW?(B0BW5WNXO;I1 D1EE?;,\<@= M7KTR0Z,PC<8SUBMT!+>X!W]3\#>=H+_)SCR$;M>!UDHWT3[0N.G-0/K(DA]K M&83V+/EQ%42 N5V Z+"5/NALH@?B_AD9;A-K3WL4P.9[^9^GF!/QS?\/4$L# M!!0 ( /.!8E;^&>^F09$ )(N" 5 87-X8RTR,#(R,3(S,5]L86(N M>&UL[+W_<^2XL2?X^T7<_X";W;TW$U&:F>[QV,_>]W:C6JV>56QW2R>I/>OM MN'!0)$JBAT74(UEJR7%__"$!?BL5OP");U3;$?9TJ8I$?I!()!*)1.:__??' M;48>:%&F+/_W;UY]_^,WA.8Q2]+\[M^_^71]LKX^/3__AI15E"=1QG+Z[]_D M[)O__M_^S__CW_ZODY-?:$Z+J*()N7TB-_?[/*'%6[:EY'^]N7I/3LB/O_O3 M[WYLN/OA]8\__O1#\_0W]>/P:U*U+_0?_OD'^6/[Z%'3 M7WX2S[[ZXQ__^(/XM7VT3(<>Y(V^^N%_?7A_'=_3;722YL"1&+"4Z9]*\>5[ M%D>58.-L%\CH$_#72?/8"7QU\NKUR4^OOG\LDV\XUPF1K"M81J_HAL"_GZ[. M1VG^\0=XXH>KWP.._S346O6T MX[)1IMM=1K_YP1CI)2U2EISEEB$/-^L$^W45%94+],<-6\9_PZHHLXO\N$G; MF+D*HY8Q'S5I&?-':ED^GC=H#R\":'4,4A%=!D^]YY_J!Z'!":4JZ-4JO-

*#3D3E8\R!OG[]ZK54LO\)OOGK6Q;OMS2OUCE7%E5:/9WG M&U9LA7YOR B8L@6EYR6L#%8)5M0=/NBR9KLG69^;2DPZ9G]!2[8O8KFHC!OCRYBZ+=#R!#/]"L*IMOA%0) MB:J_^.OU?530-WQ=3T[9=D?S4H!9%P7G.@6L;YZZ1RZC)P'_2U0D[Z*T^'.4 M[>FZ+/?;';Q5GCWN:,SG_-OT(4VXH%]Q!?!,,KW3U91P;_A)5"?F?3RS8,*HJQ9'U\R.KZ U[E^9\DY1&&3=9 M*P'R+:VB-"MO^.*\C[*AE53O3]3>I>GFS2.^.K__YWB>MWA(.L6![FLR?L73RN#Q*QSWH$HYWQ&G;P^X8I[&Q5/)VPS"ZV*;C-U MT39MWY:H8W%XT=*OR0FYEL@(VY 7,1V,!W9J>M@9+6_[KO,\9EMZ$SU>46!E MFJ7"=FJ_!FLH+^D;FM--6JVK=S2AA5R^]ERLG[KWQ_=83F@@]U-6L;B>89_R M%,QZ82N49".AD"IZ)%$%QPX2$H%3AA6)MB!908Q^-P/,O(R:MYFV?N!V'DSU M=ZRXCC)Z3>-]D59< [REM]4'CE3^]6M:W:?Y14[_0J-BO65%E?X=-C9E-3*] M[#6,G%/F %Q/)(&!DC0G7-.6I+J/3-'_@,.*DB/&K!A:+5I=))0H>UD7?N;KPGF'945: M43CA:$X SH+6 KT1FU7_B&%P)=V_/P&E^YG(+" M(7_VKG;QC)\5P%ENNA*W/PC)S[E (,\ZIQJP*G!#A+Q(W!]JS5B37I#(3?)^ M5N;F&>K-JGV?1K=I)BR+CYP9^Z* G>LMM[NC>.P$0^D=I$TZV;9KH7O/\KN3 M&UIL20_&GX(8F&H\9BC&N=)H_WJR*]B.%M63V+W!;FXG?D4H-\6VK.JY&9I> M5-Z_B%> %B:SBR,Q*K Z[_4<%O4W+.&/EOJ 0H/J&$_IM9 U7 M><4T9F>@:=?R*&D33IQTU,EGH$\$@/\W;,3-%+>' FAF6>A**;[Z\22C48G; MF8R];%7Q/2?B1=6]^I'KNO>"[(*4VRB_9]79-!.="= XT0 (?VXJB5)J_(8S0NN'N-?9F!L0[F\,PY24$QPXC?)'AL<-="1X@:XO#)ED='EK:+S\\=F9.N<[I M,#6,SI;XWXECB KN@FXH6+HX.W.V&;N+^B@Y/ZLYQ+:>"0#DH@&PI%5\?C3F MEV]%%HT(&(%7Y):QXWDO*HW&!YG$^+W ML&7=FC$##CMHUF2T&L.VKRT M8T;"F9C_X:2D=QV2.\KNBFAW#Y.QH!%.S/7:M"OF:K3]B#G$TU[7:(2,_]*B M(6M LR0QUQRT>3''C,0B\F#1LDJW$:Q!^Y)N]I!4_8%_S=^,RI+R[B0R*9W6 MI'"*(%PN+56D"\RV!5OH!CWY)-#S30)'#^^N!7KR;9U_\+L%S52WDF0W>1=. M//RZXF_GO6BW.EXT"&A_->6!=TK0Q/'N!)A7?[N3'J#=[ OAIXEW/4LWE'R; MYN(:+?OCW !X9'\]P2+0_3\4:FL=(<1+\S"K;NXLI7;=# 5B?KG+@6 MYY4F)0^S2Q%1X#EV6J-L;'K8B/?<["]HINE* '*^H89U"2F4U)_$S$HO2((E M9M)&O,0<3II/+W'F^Y$RJVFB#$4G4/:C>^ZD;*.O43K",DV?&7A4L2TE M1\^AKZ][F'0!](N7BZFJ1LGG!)U&M*!I M>=H!)5TBM9CD+G.;MF^XM_L]G7/'AHUR/M5W;.$9>P.>KF'6W5@]?5: MK7LNS9PXX_P1P0'2BV^J;8)#=J>3@G4MC.;Z?WK=[=<%)Z*[_!OHKM!FG;GR MH=]="-=)"'^OW^Z'7G?)Z4%WEZ_?P@NWGA9SC^Y]WK_PZ=X,9C M$1V%\U;PL4RAVIH='>@,BA=[RP[DX-;6J>@&9,KO/0'*Z->Z&X?Q[!5\[+JQ M?%WD3LC0EI8+R?&3:!KR#K!<*+3:P]K\@E$&R+8=IJ>>Q1 B<[6\7E+C:HX' MFM^6./^PXZJ9^EISL+PG+N[-^)$G,)/&'CD_Z8^5807.D'RX*HX\L\399E$@ M\"F7D:,/:]BBGU\/@'/?_I _OPL]7M7^_!5I MX"W9@X\_7^(:93;2Z+SJ&L/G M>Q;5=JX= O/]VAS&]UGI=5L1<>89%,]^8^RNNE_A?A^3G/96K<7VEZ=U_1 M9/U B^B.BA_?)7[@E ^.6=4V&%0./0 MRFADW9OJVS1/M_MMO6_8R;'&N=9U&W5DBD\3#["?_2 !U?O7>CHMT^^M/80: MMK7.N'P%MO0[5FQH6NVYK"S/D,: 6YP5K=.)4"9TC?&?5K0%^?-B0N.%ZBO0 M61^9N+Y.%[CUUX>V.'VEWH7%URZSV%>OQUG L:+B;*L]4'O]\/#NZ&?4YMN8C-WM.!J.GPWZ*PA1DPB:$^7CH^>C M!Q:Y93PB80=Y%EYAIR//AT68T/NS*QY?9+F? V :GV/7-]W?[3! M1[8/% M<-Q\S9J$?RRKNB+FAA5\RY(_LZQ$;4S@9Q/DQ^>\E2EEB;;3^6:(,=AD?%OC M%I>DWTG:V7S>Y^L;DA3(2[]C^>K=L8YK+KX-Z:%R]+4L" M%72MH/>\=^D#E28,F"6UP7*Z+PJ:QT\WO,]E%(O^YXGX*Y/<2/ZVE\G./]+J M8L.-GY$UR"TQY(+C!I3KU:4Q)N,:&JDZ- 3,GR!3U?$ ,[^CYFWW1S>T@ 3" ML"\UR&F :-?MKFVL3.WY M6;=[IPS,,(MGY\ZD$3:\AE ^U%+",: ZR] MFNB.FK=%Y;)@,:5)^8XS[#J"*SIM'2MN*L(W70VYM_1V;*W!-H-<@G3)^5J9 M='%A%BSW?4>L8PTHZ:T'$.!@ O*]&H3/:Z3!8T%6.;2T,EO#X->U?COOH[E] M[J,YN"[+]X9P8 HNPAL&7YT]TB).2^CMLQC"*[J-4O P]DK?W=!B^VK*][XH M@";.^45TQ+6VZRJH22>HR')<@R85$U^O2 _XBC3028V=M. /2B0"?/+M7VA4 M!'2G+F(,1_VMBT 7QL"GFPV-ZRHK;:P"V%5YG&:I0;X<K/'/UW_ MPOCBFHNU^8[R"2^W!]UFX0.=B%31?1UIRZJ2<3T;/EV3#@AID#S?5Y+/$DV8 M_"G:0\),^1QX%2A/V+[BK^8))%-TN!),$@JQ&@P"6MR*4)*+#N5+7A6FQ]_6 MRJ PJ%]!(.1A?F'O<9##Y!<7!GD(,W#V[J\XN&Q$' )DVE[ L565CB+,6[;P@$-&H/K^7=X:+%M8<+1171P4E'"@48J8A+# MG1HPQ+@_45K)B'B4*]KYC#Y!>W8A["?/GW!@[[LZQH=S2O75Q;_O/7 M'@ _,@$#)"E>U.Z_5\0^*LO]=F<086638A#O\"2RQ3D&1'EV^<.Z@_N2/02* MHF'-B:PQWMXLH%-6[%C!NZ/A1E9Z!VEK3+;M>DZTQ)?E(U;C-T,Q,4!.^KZ. M.65E!9N!HX6N6P;+=2:DB#\]E@$<6BG?/%WRP=3,7!\ BW%^>X^8@V?!!V3D M]HD M.6EO \A/8.)\8.)1 !SLBCWSB()IMKV92(.85B$,7AU_>G%A@M,#JR) M@3<_6LMW9BD'^+E)@X$D[]N9I0ES@6&T$ACXIT4/RY?K?L&*C WWBY$_&Y5?M4[6URJK"6\1"_!'C@M R^D[],RB2[?:EQ63A=M( M +ZB-?U9T'[]"[TLTMAZ#0JKH!:[_D^!7Z!5<'2YI@%,!.*O(M>^7<'S:D6H M2Y,SV^)W)U0<.9VPS886:7X'97RWVZB ;T1T UQ13KBMTSR ,R;,Z=BU'O!X M_)@+OX.;,P(AN6@0@@4A,0H['S"23X"Q?629QH&%L9^W!FP-Z%>T_*_O[@IQ ML'^>5[S#91H[J3YE"\]B%_T1W+[7>U8,+/X[P)*>53./+K3FY_>$_5ZGX&6X5EEU4'GV,LWW"WQ$9 M?V%_M*_D]HCK2QH5N="A73NH93\L1KLF0YB^^#$W?N:VQ1OHG=A5O)6](Q]I M)3-M7W(;0\P5*/S3ZU__&/VL[I^,F3WM^@?®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᭞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ɰ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end

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